84th EAS CONGRESS

Transcription

84th EAS CONGRESS

84 EAS CONGRESS
th
May 29 - June 1, 2016
Innsbruck, Austria
k
oo
B
e
m
m
Progra
www.eas2016.kenes.com
EAS 2016 AT YOUR FINGERTIPS
Download the App for the Full Congress Experience Search “EAS 2016”
Your all-in-one guide for the duration of the Congress:
84 EAS CONGRESS
th
May 29 - June 1, 2016
Innsbruck, Austria
· Access the programme and venue maps
· Bookmark your preferred sessions and read about your favorite speakers
· Receive important notifications from the organisers
· Learn about exhibitors and sponsors, accreditation, and much more
k
oo
B
e
m
m
Progra
Organised by
Rue François-Versonnex 7
1207 Geneva, Switzerland
Tel: +41 22 501 7420
Fax: +41 22 906 9140
Email: eas@kenes.com
84 EAS CONGRESS
th
CONTENTS
Welcome Letter
Dear friends and Colleagues,
3
Committees4
The European Atherosclerosis Society
6
About Innsbruck
8
EAS Keynote Lecture
9
The Anitschkow Prize
10
Young Investigator Awards
11
General Information
13
CME Accreditation
16
Information for Presenters
19
Poster Area Map
22
Programme at a Glance
24
Congress Floor Plan
28
Hall Name Eulogy of Distinguished Scientists
30
Scientific Programme
Sunday, May 29, 2016
35
Monday, May 30, 2016
41
Tuesday, May 31, 2016
57
Wednesday, June 1, 2016
73
Science at a Glance Presentations
81
Poster Presentations, Monday May 30, 2016
99
Poster Presentations, Tuesday, May 31, 2016
137
Index of Authors
181
Recognition, Acknowledgements and Commercial Support
217
On behalf of the European Atherosclerosis Society (EAS) and the Austrian Atherosclerosis
Society (AAS) we are delighted to welcome you to Innsbruck for the 84th EAS Congress.
The congress committees have been working hard on preparing a programme of
scientific excellence that will excite and inform the European and Global Atherosclerosis
communities. We are particularly proud to announce the certainly inspiring Keynote Lecture
by Nobel laureate Michael S. Brown entitled “How genes control cholesterol” and invaluable
contributions by outstanding plenary speakers. The comfortable atmosphere of the
congress venue and its impressive setting will provide a unique meeting place for high-level
interdisciplinary exchange of newest research highlights and effective networking among
participants from more than 70 countries from across the world.
The congress will be held at Congress Innsbruck, located next to the scenic river Inn and
in walking distance to the city centre and all major hotels. Innsbruck is one of the most
beautiful cities in the Alps, surrounded by impressive mountain peaks. Another attraction,
of course, are the superb Tyrolean culinary highlights that will be offered during the unique
Social Programme and throughout the meeting. Finally, for those with a few days to spare,
there are many interesting opportunities to visit Innsbruck’s cultural highlights before and
after the congress.
The 84th EAS congress is accompanied by an International Satellite Symposium on Lp(a)
two days ahead of the main congress, again bringing together world experts in this small
but exciting and emerging field of an extraordinary atherogenic lipoprotein.
On behalf of the organising committee, we welcome you to Innsbruck for a memorable
and inspiring congress.
Acknowledgements219
2
Industry Sponsored Sessions
222
Educational Grant
228
Exhibition Information
229
List of Sponsors and Exhibitors
231
Alberico L.
Catapano
EAS President
Geesje
Dallinga-Thie
Chair,
Programme
Scientific
Committee
Seppo
Ylä-Herttuala
Co-Chair,
Programme
Scientific
Committee
Hans Dieplinger
Congress Chair
Florian
Kronenberg
Congress Chair
3
84 EAS CONGRESS
th
COMMITTEES
FACULTY LIST
Afonyuskin Taras, Austria
Alitalo Kari, Finland
Armitage Jane, UK
Assmann Gerd, Germany
Averna Maurizio, Italy
Banach Maciej, UK
Besseling Joost, The
CONGRESS CHAIRs
Hans Dieplinger, Austria
Florian Kronenberg, Austria
EAS EXECUTIVE COMMITTEE
Alberico L. Catapano, Italy, President
Olov Wiklund, Sweden, Vice President
Netherlands
SCIENTIFIC PROGRAMME
COMMITTEE
Geesje Dallinga-Thie, The Netherlands,
Chair
Denmark
Petri Kovanen, Finland, Secretary & Award
Committee Chair
Seppo Ylä-Herttuala, Finland, Co-Chair
Boulanger Chantal M., France
Brouwer Ingeborg A.,
Eric Bruckert, France
The Netherlands
Jan Borén, Sweden, Treasurer
Alberico L. Catapano, Italy
Lale Tokgözoglu, Turkey, President Elect
Christoph J.Binder, Austria
Jörg Heeren, Germany
Geesje Dallinga-Thie, The Netherlands
Dimitris Kardassis, Greece
Børge Nordestgaard, Denmark
Florian Kronenberg, Austria
Arnold von Eckardstein, Switzerland
Chris Packard, UK
Michal Vrablík, Czech Republic
Erik Stroes, The Netherlands
M. John Chapman, France, Past President
Arnold von Eckardstein, Switzerland
LOCAL ORGANISING
COMMITTEE
Counselling Members
Hans Dieplinger, Innsbruck, Congress Chair
Wolfgang Schneider, Austria
Florian Kronenberg, Innsbruck, Congress
Co-Chair
Christoph Binder, Vienna
Benjamin Dieplinger, Linz
Christoph Ebenbichler, Innsbruck
Bernhard Föger, Bregenz
Gerhard Kostner, Graz
Dagmar Kratky, Graz
Gerhard Kostner, Austria
CONGRESS COMMITTEE
Marja-Ritta Taskinen, Finland, Chair
Wolfgang Schneider, Vienna
Herbert Stangl, Vienna
Ernst Steyrer, Graz
Gerd Utermann, Innsbruck
Rudolf Zechner, Graz
de Meyer Guido R.C., Belgium
Després Jean-Pierre, Canada
Dieplinger Benjamin, Austria
Dieplinger Hans, Austria
Ebenbichler Christoph J.,
Austria
The Netherlands
Andreas Ritsch, Innsbruck
APPRECIATION AND THANKS
We would like to thank the reviewers of the
submitted abstracts for their valuable help
and assistance.
The Netherlands
Mach Francois, Switzerland
Maegdefessel Lars, Sweden
März Winfried, Germany
Malik Vasanti, USA
Mangelsdorf David, USA
Manolio Teri, USA
Marsche Gunther, Austria
Martinez Laurent O., France
Matsuzawa Yuji, Japan
McCormick Sally,
Suhre Karsten, Qatar
Stuling Thomas, Austria
Taskinen Marja-Riitta, Finland
Tawakol Ahmed, USA
Titze Jens M., Germany
Tokgözoglu Lale, Turkey
Tschöp Matthias, Germany
Ulmer Hanno, Austria
Utermann Gerd, Austria
van Gaal Luc, Belgium
von Eckardstein Arnold,
The Netherlands
Chris Packard, UK
Ruth Prassl, Graz
The Netherlands
Netherlands
Danilo Norata, Italy
Lambert Gilles, France
Lamina Claudia, Austria
Laufs Ulrich, Germany
Letourneur Didier, France
Luetjohann Dieter, Germany
Ley Klaus, USA
Lichtenstein Alice H., USA
Lutgens Esther,
Pechlaner Raimund, Austria
Piepoli Massimo, Italy
Poirier Steve, Canada
Prassl Ruth, Austria
Ray Kausik K., UK
Reaven Peter D., USA
Ripatti Samuli, Finland
Ritsch Andreas, Austria
Rudling Mats, Sweden
Ryan Robert O., USA
Sanjana Neville, USA
Schmid Johannes, Austria
Schneider Markus, Germany
Schneider Wolfgang, Austria
Scharbagl Hubert, Austria
Scheja Ludger, Germany
Schunkert Heribert, Germany
Seed Mary, UK
Stangl Herbert, Austria
Steinhagen-Thiessen
Elisabeth, Germany
Steyrer Ernst, Austria
Stojakovic Tatjana, Austria
Stroes Erik,
Brown Mark J., USA
Brown Michael, USA
Bruckert Eric, France
Bujo Hideaki, Japan
Caligiuri Giuseppina, France
Carmeliet Peter, Belgium
Catapano Alberico, Italy
Chapman M. John, France
Colhoun Helen, UK
Dallinga-Thie Geesje,
El-Osta Assam, Australia
Farinaro Eduardo, Italy
Ferri Nicola, Italy
Föger Bernhard, Austria
Fu Jingyuan,
Jan Borén, Sweden
Bernhard Paulweber, Salzburg
4
Binder Christoph J. , Austria
Borén Jan, Sweden
Bossano Prescott Eva,
Hoffmann Michael, Germany
Humphries Steve, UK
Hunt Steve, Qatar
Jauhainien Matti, Finland
Kararigas Georgios, Germany
Kardassis Dimitris, Greece
Karpe Fredrik, UK
Koenig Wolfgang, Germany
Kollerits Barbara, Austria
Kostner Gerhard, Austria
Kotseva Kornelia, UK
Kovanen Petri, Finland
Kratky Dagmar, Austria
Kronenberg Florian, Austria
Kuivenhoven Jan Albert, The
Gaetano Carlo, Germany
Gaudet Daniel, Canada
Gordts Philip, USA
Graham Ian, Ireland
Herz Joachim, USA
Heeren Jörg, Germany
Hersberger Martin, Switzerland
Hobbs Helen, USA
Hoefer Imo,
The Netherlands
New Zealand
Moschetta Antonio, Italy
Moulin Philippe, France
Müller Thomas, Austria
Nicholls Stephen, Australia
Norata Giuseppe Danilo, Italy
Nordestgaard Børge, Denmark
Öörni Katariina, Finland
Packard Chris, UK
Parini Paolo, Sweden
Pasterkamp Gerard,
The Netherlands
Switzerland
Vrablik Michal, Czech Republic
Watts Gerald, Australia
Wiklund Olov, Sweden
Willeit Peter, UK
Ylä-Herttuala Seppo, Finland
Yvant-Charvet Laurent, France
Zambon Alberto, Italy
Zechner Rudolf, Austria
Zelcer Noam, The Netherlands
Zimmermann Robert, Austria
Paulweber Bernhard, Austria
5
84 EAS CONGRESS
th
The European
Atherosclerosis Society
The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of
“advancing and exchanging knowledge concerning the causes, natural history, treatment
and prevention of atherosclerotic disease”.
For more than 50 years the Society’s expertise has been used to teach clinicians how to
manage lipid disorders and how to prevent atherosclerosis. By offering to our members
access to educational materials, and opportunities to take part in Congress and courses,
and by providing a forum in which new developments can be discussed, EAS contributes
to the development of knowledge in the field, and ultimately to the improved treatment of
persons with cardiovascular disease and lipid disorders.
In recent years the Society has made a particular effort to recruit young scientists and
clinicians also from other related disciplines.
The European Atherosclerosis Society’s goal is to provide a framework for concerted
scientific and clinical discussion of new developments in basic research, diagnosis and
therapy of atherosclerosis.
What we do – at a glance
• EAS is active in the publication of Guidelines and Consensus Position Papers, and its
official Journal is Atherosclerosis. Through a regular series of Featured Commentaries
EAS puts into perspective topical issues of relevance to our members.
• The Society organizes an annual Congress for approximately 2000 delegates, and runs a
programme of Advanced Courses for both basic scientists and clinicians.
•EAS Academy is the Society's online e-Learning resource, containing a range of
educational material and self-teaching programmes.
• EAS is co-organiser of the European Lipoprotein Club (ELC) annual Scientific meeting.
• EAS coordinates the FH Studies Collaboration, working to establish an international
registry of observational studies on FH.
Why should I become an EAS member?
Stay well informed with EAS publications
EAS membership makes it easier for those working in the field to stay abreast of the
latest developments in the field. In addition to access to the Society's own publications
of Consensus position papers and Guidelines, EAS membership includes complimentary
access to Atherosclerosis Journal (worth ca. 300 €), and members receive by email
newsletters and featured commentaries on topical issues.
Interact with leading experts in the field at EAS Congress
The participants at EAS annual Congress are world leaders in atherosclerosis research
and clinical practice, and the size and format of the Congress lends itself to networking
and interaction. EAS members are encouraged to submit their findings as an abstract to
Congress, where they can participate at significantly reduced registration fee (savings of up
to 100 € compared to non-member fees).
Apply for grants and prizes as an EAS member
EAS members may apply for the Society's travel grants to attend Congress, and, where
eligible, may apply for the Society's Prizes.
Great value membership benefits at affordable annual
subscription rates
EAS' aim is to provide access to learning that will help our members to manage lipid
disorders and to prevent and treat atherosclerosis. We keep our annual membership
subscription rates low – 40 € (persons over 35) or 20 € (persons 35 or younger) – so that as
many as possible can afford to become members.
How to become an EAS member
If you're not an EAS member and would like to become one, you should complete the
application form and pay the annual subscription fee. Once your application is approved,
and the subscription payment processed, you become eligible for membership benefits for
one year at www.eas-society.org.
Continue your professional development with EAS
educational activities - Advanced courses & EAS Academy
EAS membership offers opportunities to deepen your theoretical skills and/or practical
knowledge, which you can then apply in your own research or clinical practice. The
Society organises educational activities such as Advanced Courses (many CME accredited
by EBAC), and offers a wealth of online learning material, such as webcasts, videos and
quizzes, on the Society's educational platform, EAS Academy. As an EAS member, you have
access to the very latest uploaded material, EAS Academy's Premium content.
6
7
84 EAS CONGRESS
th
EAS KEYNOTE LECTURE
ABOUT innsbruck
Innsbruck is the capital city of the federal state of Tyrol in western
Austria. It is located in the Inn Valley at the junction with the Wipptal
(Sill River), which provides access to the Brenner Pass, some 30
kilometers (19 mi) south of Innsbruck. Located in a broad valley
between high mountains, it is an internationally renowned winter
sports centre.
Innsbruck serves as an ideal place for skiing in winter, and
mountaineering in summer. There are several ski resorts around
Innsbruck as well as nearby, which include the Axamer Lizum,
Patscherkofel, Igls, Seefeld, Tulfes and Stubai Valley.
The city of Innsbruck is suffused with the spirit of the Habsburg
dynasty.
The Habsburgs’ legacy in Innsbruck is sumptuous and palatial majestic
and has left many architectural landmarks in the city.
The Keynote Lecture at EAS Congress 2016 is given by Michael
S. Brown, Paul J. Thomas Professor of Molecular Genetics
and Director of the Jonsson Center for Molecular Genetics at
University of Texas Southwestern, Dallas, USA.
Dr. Brown and his long-time colleague, Dr. Joseph L. Goldstein, are recognised as the
discoverers of the low density lipoprotein (LDL) receptor, which controls the level of
cholesterol in blood and in cells. Drs. Brown and Goldstein have received many awards for
this work, including the U.S. National Medal of Science and the Nobel Prize for Medicine or
Physiology in 1985.
Working together, Drs. Brown and Goldstein showed that familial hypercholesterolaemia
is caused by genetic defects in the LDL receptor, which disrupt the normal regulation of
cholesterol metabolism. Their studies led to the elucidation of the mechanism by which this
receptor carries LDL particles into cells through coated pits and coated vesicles. These LDL
receptor studies provided clear evidence for selective uptake of macromolecules into cells,
giving rise to the concept of receptor-mediated endocytosis.
More recently, study of another genetic disease called Niemann-Pick C (NPC), has
provided insights into how cholesterol is transported from one organelle to another, which
underlie the consistency in cholesterol concentration in the plasma membrane. Extensive
studies showed that both the NPC1 and NPC2 proteins have the capacity for binding LDL
cholesterol. Whereas binding of cholesterol to NPC2 is rapid, occurring within minutes,
binding to NPC1 is extremely slow, requiring several hours to reach equilibrium. However,
this process can be accelerated when cholesterol is delivered by NPC2. Based on these
findings, it was proposed that NPC2 extracts cholesterol from LDL in the lysosome and
then transfers it to the N-terminal domain of membrane-bound NPC1 for insertion into the
lysosomal membrane, currently being tested in the laboratory of Professor Brown.
The work of Drs. Brown and Goldstein has not only been the stimulus for new thinking about
cholesterol homeostasis, but also has led to the development of new concepts in biology.
Specifically, these include selective sorting of proteins within the plasma membrane, a
prerequisite for receptor-mediated endocytosis; receptor-mediated endocytosis and receptor
recycling; and, finally, the concept of feedback regulation of receptors.
Michael Brown graduated in 1962 from the College of Arts and Sciences of the University
of Pennsylvania, with chemistry as his major subject, and subsequently obtained his M.D.
degree in 1966 at the same university. He was an intern and resident at the Massachusetts
General Hospital, where he met Joseph L. Goldstein, a fellow intern; the two established
the friendship and mutual respect that led to their long-term scientific collaboration. Dr.
Brown subsequently completed a postdoctoral fellowship at the National Institutes of
Health, before moving to UT Southwestern, becoming Professor in 1976. The remainder of
this story has been instrumental in changing how hypercholesterolaemia is managed, and
paving the way for innovative new therapeutic agents targeting LDL cholesterol.
8
9
84 EAS CONGRESS
th
THE ANITSCHKOW PRIZE
YOUNG INVESTIGATOR AWARDS
The Anitschkow prize recipient 2016 is
Professor Peter Carmeliet, Professor at the
Katholieke Universiteit Leuven (Leuven, Belgium).
These annual awards are presented by EAS for outstanding
publications by young scientists in the field of
Atherosclerosis
The Anitschkov lecture entitled Endothelial Cell Metabolism: A Novel Player in
Atherosclerosis? Basic Principles and Therapeutic Opportunities will be part of the Congress
Opening Ceremony.
p r o f e ss o r
P e t e r C arm e li e t
Peter Carmeliet is a physician and professor at the Katholieke
Universiteit Leuven (Leuven, Belgium). He is former director (20082015) of the Vesalius Research Center, VIB - KU Leuven and is
heading the Laboratory of Angiogenesis and Vascular Metabolism at
the VRC. His research interests are vasculogenesis, angiogenesis, and
vascular endothelial growth factors. His research group has sought
to elucidate the molecular basis of angiogenesis with the aim of
translating their findings to therapeutic concepts and ultimately novel
treatments. Latest findings indicate that the efficacy of current antiangiogenic therapy in cancer is limited by intrinsic refractoriness and
acquired drug resistance. To overcome this problem, his research
team pioneered the study of endothelial cell metabolism during vessel sprouting. Professor
Carmeliet is the recipient of numerous awards, including InBev-Baillet Latour health prize
(2010), Ernst Jung-Priz für Medizin (2010), the Blaise Pascal Medal in Medicine and Life
Sciences by the European Academy of Sciences (2011), the Münster Heart Center Award
(2015), and award of the Noble title of Baron, granted by King Filip of Belgium (2015).
10
st e v e p o iri e r
In 2003, Steve joined the team of Dr. Nabil Seidah at the Clinical
Research Institute of Montreal the same year the laboratory
published the identification of PCSK9 and its link to familial
hypercholesterolemia. Over the years, he actively designed
and performed key experiments as well as collaborated with
international researchers to accomplish important studies in the
highly competitive field of PCSK9 biology in cardiovascular diseases.
Cited by more than 850 publications, those manuscripts have
questioned and revisited published papers that supported the fact
that PCSK9 had only one target and that it was acting exclusively via an extracellular route.
He was the first to show that PCSK9 has other important targets towards LDLR family
members and revealed the existence of an intracellular route for PCSK9-induced LDLR
degradation. In addition, he also made many other significant contributions in the field
of PCSK9 such as the identification of the two known natural inhibitors of PCSK9 namely
AnxA2 (extra-hepatic) and GRP94 (hepatic) now used as precursors for the design of
lipid-lowering agents with high therapeutic potentials. He also showed that the cytosolic
adaptor AP-1A is directly implicated in the intracellular trafficking of Niemann-Pick type
C proteins and revealed the first evidence and mechanism by which the cancer drug
5-Azacytidine favorably perturbs lipid and cholesterol metabolism. Together with his great
scientific partner Dr. Gaétan Mayer (CSO), he is the co-founder and CEO of Monogenic
Pharmaceuticals a Montreal Heart Institute-based biotech primarily developing 4 distinct
unprecedented and highly innovative therapeutic pipelines to lower circulating LDLCholesterol and cardiovascular diseases by specifically targeting PCSK9.
11
84 EAS CONGRESS
th
GENERAL INFORMATION
YOUNG INVESTIGATOR AWARDS
VENUE
Congress und Messe Innsbruck GmbH
Rennweg 3
6020 Innsbruck, Austria
www.cmi.at
J o o st B e ss e ling
Dr. Besseling started Med School at the University of Amsterdam
(the Academic Medical Center) in 2004 and obtained his medical
degree in 2012. Subsequently, he started his PhD research under
the guidance of Prof. Kastelein, Dr. Hovingh and Dr. Hutten.
He worked on studies focused on different aspects of familial
hypercholesterolemia and published in highly cited peer reviewed
journals, such as Lancet and JAMA. He specifically focused on the
diagnosis, consequence and treatement of FH and as such showed
that FH patients are relatively protected from diabetes mellitus.
Moreover, he developed a new prediction model for carriership
of an FH mutation, and investigated the consequence of CETP inhibition in these
patients. In January 2016, he started his residency to become a board certified specialist
in internal medicine, and in October 2016, he will defend his PhD thesis on familial
hypercholesterolemia.
OFFICIAL LANGUAGE
The official language of the Congress is English. All presentations will be made in English.
CLOTHING
Clothing is informal for all occasions.
REGISTRATION DESK HOURS
The Registration Desk will be situated at the North Entrance, ground level of the convention
center, as follows:
Sunday, May 29
10:00 – 21:00
Monday, May 30
07:30 – 19:40
Tuesday, May 31 08:00 – 18:30
Wednesday, June 1 08:00 – 12:30
EXHIBITION OPENING HOURS
Sunday, May 29
Monday, May 30
Tuesday, May 31
Wednesday, June 1 17:30 – end of Welcome Reception
10:00 – 17:30
10:00 – 17:30
10:00 – 12:30
CONGRESS NAME BADGE
Upon registration you will receive your name badge. You are kindly requested to wear your
badge during all sessions and events.
EAS 2016 App
Install the EAS 2016 interactive mobile App to your smartphone and portable devices to
access all the Congress information you could need during the Congress:
• See the overview of sessions, speakers and exhibitors
• Create your own programme for the event, including bookmarking
the sessions you wish to attend
• Receive real-time updates
Download the EAS App now to enhance your congress experience!
(available on the App Store or Google Play).
12
13
84 EAS CONGRESS
th
EAS 2016 E-Book
Cloak Room
EAS 2015 Final Programme E-Book is available online and can be viewed and downloaded at:
This e-book offers a ‘green alternative’ to the printed programme book, provides delegates
a convenient and enjoyable way to access congress content on the move and is designed
to provide a user friendly interface on any mobile device. EAS is dedicated to implementing
innovative and environmentally-friendly technology. The programme book can be
downloaded as a PDF file from the congress website.
A cloak room will be available for participants on Wednesday, June 1st at the Innfoyer.
REFRESHMENTS
Please do not leave bags or suitcases unattended at any time, whether inside or outside the
session halls. Hotels strongly recommend that you use their safety deposit boxes for your
valuables.
Coffee and refreshments will be served to Congress participants in the Exhibition Area from
May 29-June 1, as indicated in the Programme.
Cash Bars will be available next to the Exhibition Area.
internet access
WiFi is available for congress participants throughout the public areas. In order to log in
please use the following user name and password:
User name: eas-2016
Password: eas-2016
Free internet and email facilities will be available in the exhibition area during the exhibition
opening hours only. Congress abstracts will also be available for viewing from these
stations. Please be considerate of fellow participants when using these facilities.
CONGRESS ABSTRACTS
The congress abstracts will be published online in the Atherosclerosis Journal following the
congress.
MOBILE PHONES AND PHOTOGRAPHY
LIABILITY AND INSURANCE
The Congress Secretariat and Organisers cannot accept liability for personal accidents or
loss of or damage to private property of participants. Participants are advised to take out
their own personal travel and health insurance for their trip.
SAFETY AND SECURITY
WEBCASTING
A selection of sessions will be webcast and will be available on the Society
website after the Congress.
CONGRESS ORGANISERS
84th EAS Congress
Rue François-Versonnex 7,
1207 Geneva,
Switzerland
Tel: +41 22 501 7420
Fax: +41 22 906 9140
E-mail: eas@kenes.com
Participants are kindly requested to keep their mobile phones switched off in session halls
and refrain from taking pictures during sessions.
SMOKING POLICY
The 84th EAS Congress is a Non-Smoking event and participants are requested to refrain
from smoking in the venue.
14
15
84 EAS CONGRESS
th
CME ACCREDITATION
EDUCATIONAL OBJECTIVES
EBAC Accredited Educational Programme
After participating in this educational event, learners should be able to:
EBAC Accredited Educational Programmes will be taking place during the Congress as
follows:
• Address individual needs in compliance with their Continuous Professional Development
(CPD) plan.
• Exchange ideas and knowledge in the field of Atherosclerosis and related cardiovascular
conditions across continents, institutions, and individuals.
• Discuss the innovative new therapeutic agents targeting LDL cholesterol.
• Identify possible programmatic collaborations to more effectively address regional,
national and local responses to Atherosclerosis around the world and overcome barriers
that limit access to prevention, care and services.
• Discuss the latest scientific advantages in the field of Atherosclerosis and related
cardiovascular conditions.
• Summarise the latest research outcomes in the field of Atherosclerosis and related
cardiovascular conditions.
TARGET AUDIENCE
Specialists in the field of atherosclerosis, clinical chemistry, diabetes, endocrinology,
primary care and more.
ACCREDITATION STATEMENT AND CREDIT DESIGNATION
European Board for Accreditation in Cardiology (EBAC)
An application was made to the European Board for Accreditation in Cardiology (EBAC) for CME
accreditation of this event. EBAC works according to the quality standards of the European Accreditation
Council for Continuing Medical Education (EACCME), which is an institution of the European Union of
Medical Specialists (UEMS).
American Medical Association (AMA)
Through an agreement between the European Union of Medical Specialists and the American Medical
Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1
Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.
ama-assn.org/go/internationalcme.
Royal College of Physicians and Surgeons of Canada
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC
credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance
of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more
• EBAC Accredited Educational Programme: Diet and prevention of cardiovascular disease.
Symposium at EAS 2016 Innsbruck Sunday, May 29, 2016, 14:00-15:30
This session is supported by an unrestricted educational grant from BASF, Raisio and
Unilever.
• EBAC Accredited Educational Programme: Gene therapy and lipoprotein lipase
deficiency.
Symposium at EAS 2016 Innsbruck Sunday, May 29, 2016, 14:00-15:00
This session is supported by an unrestricted educational grant from Chiesi.
• EBAC Accredited Educational Programme: Gene therapy and lipoprotein lipase
deficiency.
Symposium at EAS 2016 Innsbruck Monday, May 30, 2016, 13:00-14:00
This session is supported by an unrestricted educational grant from Meda (Rottapharm).
• EBAC Accredited Educational Programme: Low HDL high triglyceride, diabetic
dyslipidaemia.
Symposium at EAS 2016 Innsbruck Tuesday, May 31, 2016, 13:00-14:00
This session is supported by an unrestricted educational grant from Mylan.
• EBAC Accredited Educational Programme: Lysosomal Acid Lipase Deficiency.
Symposium at EAS 2016 Innsbruck Tuesday, May 31, 2016, 13:00-14:00
This session is supported by an unrestricted educational grant from Alexion.
In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in
this programme have disclosed or indicated potential conflicts of interest that might cause
a bias in the presentations. The Organizing Committee is responsible for ensuring that all
potential conflicts of interest relevant to the event are declared to the audience prior to the
CME activities.
CREDIT BREAKDOWN
Day
Maximum Credits
Sunday,
May 29
Monday,
May 30
Tuesday,
May 31
Total Credits:
2
1
2
5
information, visit: www.royalcollege.ca.
CREDIT BREAKDOWN
Day
Maximum Credits
16
Monday,
May 30
Tuesday,
May 31
Wednesday,
June 1
Total Credits:
6
6
3
15
17
84 EAS CONGRESS
th
INFORMATION FOR PRESENTERS
TO RECEIVE YOUR CME/CPD CERTIFICATE
ORAL PRESENTATIONS
The CME/CPD certificate will be available after completing the online evaluation and credit
claiming procedure. The process takes about 5 minutes. We thank you for your feedback
as it is an important part of CME/CPD accreditation and helps improve future educational
offerings.
Data Presentation:
Before June 29, 2016:
1. Access the online system via any of the following
Please note that web browsers Mozilla Firefox 2.X or higher, or Google Chrome are
recommended
- Visit the CME/CPD Accreditation page on the event website
- Follow the link in the email sent at the end of the event
2. Complete the anonymous online evaluation
3. Complete the credit claim form and submit
4. The CME/CPD certificate will be available for download; fill-in and retain for your
personal records
DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF
INTEREST
In accordance with CME/CPD accreditation criteria and standards for commercial support
to ensure balance, independence, objectivity, and scientific rigor, those in control of the
educational content must disclose potential or actual conflicts of interest. Disclosure
information is evaluated and conflicts of interest resolved. Disclosure is made to
participants prior to the activity. Participants will be asked on the evaluation to assess the
objectivity and independence of the event.
INDUSTRY SUPPORT DISCLOSURE
This event is supported, in part, by funding from industry. All support is managed in strict
accordance with CME/CPD accreditation criteria and standards for commercial support.
Appropriate acknowledgement of all supporting organizations is made in the Programme
guide, on the event website, and with signage during the event. Disclosure is made to
participants prior to the activity.
18
Aegerion
Pharmaceuticals
Akcea
Therapeutics
Alexion
Amgen
BASF
Chiesi
Denka Seiken
European FH
Network
FH Score
Fuji Film/
Sonosite
Merck MSD
IBL
Kaneka Pharma
Kowa
Meda Pharma
Mercodia
Mylan
Numares
Pfizer
Raisio
Randox
Regeneron
Sanofi
Unilever
Wisepress
A speakers’ ready room will be available throughout the entire Congress for speakers. The
room is located on the 1st Level (Maximilian).
If using a PowerPoint presentation (or any other PC based application, such as PDF),
please note you need to bring it on USB Memory stick and load it on one of the Congress
computers in the Speakers’ Ready Room at least 1 hour before the start of the session.
The recommended format for PPT presentations is 16:9.
Please make sure to prepare your presentation accordingly.
Please note that the Congress computers in the session halls are being supplied with Office
2010 (at least).
If combining video films with PowerPoint, please make sure to check it in the session hall
where your lecture is taking place during the break prior to your session, at least 30 minutes
before the start of the session - even after checking it in the Speakers’ Ready Room.
Alternatively you may supply your own laptop computer. In such a case please confirm
that it has a VGA socket for external signal and come to check it first in the Speakers’ Ready
Room as soon as you arrive and later on in the session hall where your lecture is taking
place during the break prior to your session, at least 30 minutes before the start of the
session.
Important note for Apple Mac users:
In order to use MAC presentations on a PC compatible computer please note that you need
to prepare it according to the instructions below, before bringing it to the Speakers’ Ready
Room:
1.Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might
be changed to a default font on a PowerPoint based PC).
2.Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on
a PowerPoint based PC).
Alternatively you may use your own Macintosh laptop computer. In such a case please
confirm you provide it with a VGA adaptor for external signal, advise the operators in the
Speakers’ Ready Room about it as soon as you arrive and later on test it in the session hall
where your lecture is taking place during the break prior to your session, at least 30 minutes
before the start of the session
19
84 EAS CONGRESS
th
SCIENCE AT A GlANCE PRESENTATIONS
EAS is proud to have Science at a Glance E-Poster sessions that will be located in the
Exhibition area, providing the unique opportunity for convivial scientific discussions and
exchange. For further details please refer to the Overview of these Sessions.
OVERVIEW OF SCIENCE AT A GLANCE E-POSTER SESSIONS
Session I, Monday, May 30, 2016
Session Topic
Session Chair
13:00-14:00
E-Poster Station
14:00-15:00
Session Chair
E-Poster Station
Poster #
Experimental Cadiovascular
Medicine II
Matti Jauhiainen,
Finland
Station A
SaG097-SaG104
Immunity and Atherosclerosis
Giuseppina Caligiuri,
France
Station B
SaG105-SaG112
Emerging Aspects in
Pharmacological Treatment of
Primary and Secondary Dyslipidemia
Benjamin Dieplinger,
Austria
Station C
SaG113-SaG120
Vascular Biology III
Joachim Herz, USA
Station D
SaG121-SaG128
Lipids and Lipoproteins
Jörg Heeren, Germany
Station A
SaG001-SaG008
Vascular Biology I
Guido de Meyer,
Belgium
Station B
SaG009-SaG016
Genetic, Omics and in silico
Approaches
Neville Sanjana, USA
Station C
SaG017-SaG024
POSTER PRESENTATIONS
CV Risk Factors and Atherosclerosis I
Yuji Matsuzawa, Japan
Station D
SaG25-SaG032
Posters will be on display in 2 shifts. Please check the Scientific Programme to see the exact
poster board number, date, and time of the poster discussion groups.
Session II, Monday, May 30, 2016
14:00-15:00
Session Topic
Session Chair
E-Poster Station
Poster #
Experimental Cadiovascular
Medicine I
Paolo Parini, Sweden
Station A
SaG033-SaG040
Nutrition, Nutraceuticals and
Cardiovascular Disease
Alice H. Lichtenstein,
USA
Station B
SaG041-SaG048
Pharmacology of Dyslipidemia
Maurizio Averna, Italy
Station C
SaG049-SaG056
Imaging in Vascular Dysfunction and
Myocardial Infarction
Wolfgang Koenig,
Germany
Station D
SaG057-SaG064
Session III, Tuesday, May 31, 2016
20
Poster #
Session IV, Tuesday, May 31, 2016 Session Topic
13:00-14:00
Session Topic
Session Chair
E-Poster Station
Poster #
CV risk factors and Atherosclerosis II
Winfried März,
Germany
Station A
SaG065-SaG072
Vascular Biology II
Herbert Stangl, Austria
Station B
SaG073-SaG080
Insulin Resistance, Diabetes,
Metabolic Syndrome and Obesity
Gerald Watts, Australia
Station C
SaG081-SaG088
Hypertension, Liver and Chronic
Renal Disease
TBA
Station D
SaG089-SaG096
The organisers are not responsible for any posters that have not been removed by the end
of sessions on Wednesday, June 1.
Poster Shift I
Posters may be mounted from 17:30 on Sunday, May 29, 2016 and should remain on
display until Monday, May 30, 2016 at 18:30.
Poster Shift II
Posters may be mounted from 08:30 on Tuesday, May 31, 2016 and should remain on
display until Wednesday, June 1, 2016 at 12:30.
Authors are asked to actively participate in both the poster sessions on the day in which
their poster was allocated to.
Poster sessions will take place on Monday, May 30 from 13:00-14:00, 17:00-18:00 and
Tuesday, May 31 from 13:00-14:00, 17:00-18:00.
21
84 EAS CONGRESS
th
Poster Area Map
POSTER OVERVIEW
Please note that posters of Abstract presenters that were not registered to the congress by
the deadline were not allocated poster boards. Such abstract presenters are requested to
approach the poster help desk to be allocated an available poster board on-site.
Poster Shift I – Monday, May 30, 2016
Session Time
Topic
13:00-14:00
Vascular Biology: Endothelium and Smooth Muscle Cells
Poster Board
001 – 044
Vascular Biology: Macrophages, Inflammation, Immunity
045 - 088
Vascular Biology: Myocardial Infarction, Stroke, Peripheral Vascular
089 - 134
Disease
17:00-18:00
Vascular Biology: Immune Disease and Cardiovascular Pathologies
135 - 142
Lipoproteins and Lipid Metabolism: ApoB Containing Lipoproteins
143 - 163
Lipoproteins and Lipid Metabolism: Lipoprotein Metabolism
164 - 187
Lipoproteins and Lipid Metabolism: Lp(a)
188 - 210
Lipoproteins and Lipid Metabolism: HDL
211 - 245
CVD Risk Factors
246 - 320
Poster Shift II – Tuesday, May 31, 2016
Session Time
Topic
13:00-14:00
Metabolic Abnormalities and Atherosclerosis: Diabetes
001 - 056
Metabolic Abnormalities and Atherosclerosis: Adipose Tissue
057 - 066
To: Nikolai N.
Anitschkow
(Tirol)
Poster Board
Metabolic Abnormalities and Atherosclerosis: Kidney
067 - 081
Metabolic Abnormalities and Atherosclerosis: NASH and Liver
082 - 090
Abnormalities
Dyslipidemias: Dyslipidemias, Screening and Treatment
To: Nikolai N.
Anitschkow
(Tirol)
17:00-18:00
091 - 167
Dyslipidemias: Treatment
168 - 199
Dyslipidemias: Coagulation
200 - 210
Dyslipidemias: Endothelial Dysfunction
211 – 220
Genetics, Nutrition, Biomarkers: Genetics, Gene Regulation
221 - 259
Genetics, Nutrition, Biomarkers: Nutrition
260 - 298
Genetics, Nutrition, Biomarkers: Biomarkers
299 - 333
Genetics, Nutrition, Biomarkers: Guidelines and Miscellaneous
334 - 344
Please note that posters of abstract presenters that were not registered to the Congress by
the deadline were not allocated poster boards. Such abstract presenters are requested to
approach the poster help desk to be allocated an available poster board on-site.
22
23
84 EAS CONGRESS
th
Programme at a Glance
Exhibition &
Posters Area
Plenary Session
Workshop
Science at a
Glance Session
Young Investigators
Session
Oral Communication
Session
Company
Sponsored Session
EBAC Accredited
Session
Poster Walk
Session
Other
Social Event
08:30-10:30
10:30-11:00
12:00-13:30
13:30-14:00
Workshop 1.1
Novel
Aspects of
Pathogenesis in
Atherosclerosis
EBAC
Accredited
Educational
Programme
Diet and
Prevention of
Cardiovascular
Disease
14:00-15:00
EBAC
Accredited
Educational
Programme
Gene Therapy
and Lipoprotein
Lipase
Deficiency
12:30-15:00
11:00-11:45
Advanced Clinical
Seminar
Debate on Statin
Associated Muscle
Symptoms (SAMS)
- A Problem for
Clinicians or a
Problem with
Clinicians?
Workshop 3.1
Novel Therapies
Break, Exhibition and Poster Viewing
13:00-14:00
Science at a
Glance Session I
13:00-14:00
Poster Walk
Session I
14:00-15:00
Science at a
Glance Session
II
13:00 – 14:30
Educational
Symposium Supported
Session
Not included in
the CME/CPD
programme
13:00 – 14:30
Educational
Symposium Supported
Session
Not included in
the CME/CPD
programme
EAS- ESC Joint
Workshop
Sex
differences in
Cardiovascular
Diseases
Workshop 1.2
Therapeutic
and Diagnostic
Targeting of the
Arterial Wall
Educational
Symposium
Supported
Session
Not included in
the CME/CPD
programme
15.00-16:30
Opening
Ceremony,
including the
Anitschkow
Lecture
16:30-17:00
Coffee break, Exhibition and Poster Viewing
17:00-18:30
17:00-18:00
Poster Walk
Session II
Break
Welcome
Reception
18:40-19:40
24
Wilhelm
Auerswald
(Strassburg)
11:45-12:30
Advanced Clinical
Seminar
Role of Nutrition in
Disease Pathology
Break
18:00-19:45
19:45– 20:45
Wilhelm
Auerswald
(Strassburg)
Break
16:00-17:30
17:30-18:00
Carl von
Rokitansky
(Brussel)
Workshop 2.1
Lipoproteins
and Extracellular
Matrix
12:30-13:30
Meet the Expert
Supported
Session
Not included in
the CME/CPD
programme
14:00-15:30
15:30-16:00
Karl
Landsteiner
(Innsbruck)
Carl von Rokitansky
(Brussel)
Coffee Break, Exhibition and Poster Viewing
11.00-12.30
Nikolai N.
Anitschkow
(Tirol)
Karl
Landsteiner
(Innsbruck)
Plenary Session:
Integrative
Approach in
Atherosclerosis
Exhibition &
Posters Area
Nikolai N.
Anitschkow
(Tirol)
Young
Investigator
Session
Vascular
Biology and
Inflammation
Young
Investigator
Session
Lipids and
Lipoproteins
Metabolism
13:00-14:00
EBAC Accredited
Educational
Programme
Nutraceuticals with
Lipid Lowering: Who
Can Benefit?
Workshop 2.2
Adipose Tissue –
Liver Axis
15:00-15:45
Late Breaking:
Basic Science
15:45-16:30
Young
Investigator
Award Session
Young Investigator
Session
Clinical
Epidemiology and
Pharmacology
Oral
Communication
Session
Vascular Biology
Keynote Lecture
25
84 EAS CONGRESS
th
Exhibition &
Posters Area
08:30-10:30
10:30-11:00
Karl
Landsteiner
(Innsbruck)
Carl von
Rokitansky
(Brussel)
Wilhelm
Auerswald
(Strassburg)
Plenary Lecture:
Lipid Biology,
New Insights
Exhibition &
Posters Area
08:30-10:30
11:00-12:30
12:30-15:00
Nikolai N.
Anitschkow
(Tirol)
Workshop 1.3
Cellular Stress
Response in
Atherosclerosis
Workshop 2.3
Gut- Liver Axis
ICCR-EAS Joint
Session
Management of
Cardiometabolic
Risk; Where Do
We Stand?
Workshop 3.2
Vascular Aging
and Atherothrombosis
13:00-14:30 Educational
Symposium
Supported
Session
Not included in
the CME/CPD
programme
13:00-14:00
EBAC
Accredited
Educational
Programme
Low HDL High
Triglyceride,
Diabetic
Dyslipidaemia
13:00-14:00
EBAC
Accredited
Educational
Programme
Lysosomal
Acid Lipase
Deficiency
14:10-14:55
Supported
Session
Not included in
the CME/CPD
programme
14:10-14:55
Supported
Session
Meet the Expert
Not included in
the CME/CPD
programme
15:00-16:30
EAS Initiatives
Update Session
(open to all)
Advanced
Clinical Seminar
Economics and
Guidelines/
Technology of
the Future
Break, Exhibition and Poster Viewing
13:00–14:00
Science at a
Glance
Session III
13:00-14:00
Poster Walk
Session III
14:00–15:00
Science at a
Glance
Session IV
15.00-16:30
14:00-14:45
Supported
Session
Special Lecture
Not included in
the CME/CPD
programme
Workshop 3.3
Genetics in
Risk Factor
Prevention and
Treatment
Late Breaking:
Clinical Science
10:30-11.00
11:00-12:30
Karl
Landsteiner
(Innsbruck)
Carl von
Rokitansky
(Brussel)
Wilhelm
Auerswald
(Strassburg)
Fritz Pregl
(Freiburg)
Workshop 4.4
New
Guidelines on
Prevention of
Cardiovascular
Disease in
Clinical Practice
Workshop 2.4
Novel Role of
Lipoprotein
Receptors
Plenary Session:
Future
Therapeutic
Challenges
Workshop 1.4
Inflammation
Immunity and
Atherosclerosis
Workshop 3.4
Biology of CVD
Risk
16:30-16:50
EAS General
Assembly
26
16:30-17:00
17:00-18:30
17:00-18:00
Poster Walk
Session IV
Workshop 3.5
Epigenetics
and Gene
Regulation
Oral
Communication
Session
Imaging,
Biomarkers
Oral
Communication
Session
Intracellular
Lipid
Young
Investigator
Session
Novel
pathways in
27
84 EAS CONGRESS
th
CONGRESS FLOOR PLAN
28
Level 0
Level 2
Level 1
Level 3
29
84 EAS CONGRESS
th
HALL NAME EULOGY OF
DISTINGUISHED SCIENTISTS
Nikolai N. Anitschkow (1885-1964)
Professor of the Department of Pathological Physiology of
the Military Medical Academy St. Petersburg, Russia
In 1913, experimental pathologist Dr. Nikolai N. Anitschkow
showed that simply feeding to rabbits purified cholesterol
dissolved in sunflower oil induced vascular lesions closely
resembling those of human atherosclerosis, both grossly
and microscopically. Controls fed with only the sunflower
oil showed no lesions. It is fair to say that this paper
marked the beginning of the modern era of atherosclerosis
research. Dr. Anitschkow was not only a keen-eyed
structural pathologist and a careful experimentalist;
he thought in terms of function and time-related
pathogenesis.
However, the landmark studies by Dr. Anitschkow were
largely rejected at the time. An important reason for this
was that the findings were inconsistent with the prevailing
view of atherosclerosis. It was generally accepted to be
an inevitable accompaniment of aging (the “senescence
hypothesis”). If the full significance of his findings had
been appreciated at the time, we might have saved more
than 30 years in the long struggle to settle the cholesterol
controversy.
In honor of Dr. Nikolai N. Anitschkow, the “Anitschkow
Prize in Atherosclerosis Research” awarded annually by
the EAS recognizes outstanding research in the field of
atherosclerosis and linked metabolic disturbances.
30
Karl Landsteiner (1868-1943)
Karl Landsteiner, Austrian pathologist, studied
medicine at the University of Vienna. In 1896 he
became an assistant in the Hygiene Institute at
Vienna where he was interested in the mechanisms
of immunity and in the nature of antibodies. From
1898 till 1908 he held the post of assistant in the
University Department of Pathological Anatomy in Vienna, in 1911 he
became Professor of Pathological Anatomy in the University of Vienna.
He showed that the cause of poliomyelitis could be transmitted to
monkeys by injecting into them material prepared by grinding up the
spinal cords of children who had died from this disease. His work laid
the foundations of our knowledge of the cause and immunology of
poliomyelitis.
Landsteiner made numerous contributions to both pathological anatomy,
histology and immunology, all of which showed, not only his meticulous
care in observation and description, but also his biological understanding.
But his name will no doubt always be honoured for his discovery in
1901 of the blood groups, for which he was given the Nobel Prize for
Physiology or Medicine in 1930. In 1875 Landois had reported that, when
man is given transfusions of the blood of other animals, these foreign
blood corpuscles are clumped and broken up in the blood vessels of man
with the liberation of haemoglobin. In 1901-1903 Landsteiner pointed
out that a similar reaction may occur when the blood of one human
individual is transfused, not with the blood of another animal, but with
that of another human being, and that this might be the cause of shock,
jaundice, and haemoglobinuria that had followed some earlier attempts at
blood transfusions.
His suggestions, however, received little attention until, in 1909, he
classified human blood into the now well-known A, B, AB, and O groups
and showed that transfusions between individuals of groups A or B do
not result in the destruction of new blood cells and that this catastrophe
occurs only when a person is transfused with the blood of a person
belonging to a different group. Earlier, in 1901-1903, Landsteiner had
suggested that, because the characteristics which determine the blood
groups are inherited, the blood groups may be used to decide instances
of doubtful paternity. In 1922, he accepted a post in the Rockefeller
Institute for Medical Research in New York. It was here that he did further
work on the blood groups which greatly extended the number of these
groups, and studied bleeding in the new-born, leading to the discovery of
the Rh-factor in blood, which relates the human blood to the blood of the
rhesus monkey.
31
84 EAS CONGRESS
th
Karl Baron von Rokitansky
(1804-1878)
Austrian pathologist whose endeavours to establish
a systematic picture of the sick organism from
nearly 100,000 autopsies—30,000 of which he
himself performed—helped make the study of
pathological anatomy a cornerstone of modern
medical practice and established the New Vienna School as a world
medical centre during the latter half of the 19th century.
A professor of pathological anatomy at the Vienna General Hospital, he
inspired the Bohemian student Ignaz Semmelweis, later a martyr to the
cause of antiseptic medical practice, to take up the study of medicine and
afterward supported him in his struggle to eliminate childbed fever by
cleaning up Europe’s maternity wards.
First to detect bacteria in lesions of malignant endocarditis, an often
rapidly fatal inflammation of the membrane lining the inner walls of
the heart, Rokitansky created the basis for a differentiation of lobar
pneumonia (originating in the lower lobe of the lung) and lobular
pneumonia, or bronchopneumonia (originating in the finer subdivisions
of the branched bronchial tree). He made a fundamental study of
acute yellow atrophy of the liver (now known as Rokitansky’s disease),
established the micropathology of pulmonary emphysema (a condition
of the lung characterized by enlarged air spaces separated from the
terminals of the bronchial tree), and first described spondylolisthesis, the
forward displacement of one vertebra over another.
32
Wilhelm Auerswald (1917-1981)
Wilhelm Auerswald, Austrian physiologist,
graduated from medical school at the University
of Vienna in 1940. Auerswald became assistant
at the Physiological Institute of the University
of Vienna in 1944. Under the later-appointed
Director Carl Schwarz-Wendl Auerswald could
finish his habilitation in Physiology in 1950 and was
established in 1968 as the successor to Gustav Schubert.
His scientific work includes 370 publications in the fields of
physiology and pathology of blood proteins, nutrition, thrombosis,
atherosclerosis, aerospace- and work physiology. It was Auerswald’s
concern to make his research results available for practical medicine; he
provided valuable pioneering work in the fields of plasma replacement,
productions of vaccines (first Poliomyelitis vaccine in Austria) and
immunoglobulins (first intravenous application). His blood coagulation
studies gained high international reputation.
In his teaching Auerswald was anxious to consider physiology as medical
basic science with strong and immediate reference to the bedside; he
also succeded in renaming his workplace into the Department of Medical
Physiology. Its translation and adaptation of the “Textbook of Physiology”
33
Fritz Pregl (1869-1930)
Fritz Pregl, Austrian physiologist and chemist, studied
medicine at the University of Graz and received
his M.D. In 1894, he became assistant lecturer for
physiology and histology under Alexander Rollett,
taking over the chair when Rollett died in 1903.
During this time Pregl also acquired a thorough
knowledge of all branches of chemistry under the guidance of Professor
Skraup. He started investigating the components of albuminous bodies and
the analysis of bile acids. His work, however, was handicapped by the lack of
sufficient starting materials and this fact impelled him to look for methods
requiring smaller amounts when making quantitative analyses of elements
in compounds.
The years 1910-1913, whilst professor at the University of Innsbruck, were
almost entirely devoted to developing the method of quantitative organic
micro-analysis. Pregl continued this work when he was recalled to Graz in
1913.
Initially Pregl’s scientific work had been mainly in the fields of physiology
and physiological chemistry; later he turned to the study of the constitution
of chemical compounds, in particular the investigation of bile acids. By 1912
he was able, by using his own methods of quantitative micro-analysis, to
make measurements of carbon, hydrogen, nitrogen, sulphur, and halogen,
using only 5-13 mg of starting materials with results as accurate as those
obtained by macro-analysis. Later he perfected his techniques so that
as little as 3-5 mg were adequate. Pregl also contributed a number of
micromethods for measuring atomic groups and developed a series of
apparatus, including a sensitive microbalance, necessary for his work.
The greatest honour was the award of the Nobel Prize for Chemistry by
the Swedish Academy of Sciences in 1923. The Nobel Committee pointed
out that it was not for a discovery, but for modifying and improving existing
methods that Pregl was awarded the prize. Following the Nobel Prize for
Chemistry in 1923, chemists from all over the world came to the MedicoChemical Institute in Graz to study Pregl’s techniques of quantitative
organic micro-analysis under his guidance.
84 EAS CONGRESS
th
May 29 - June 1, 2016
Innsbruck, Austria
e
m
m
a
r
g
o
r
P
c
fi
i
Scient
ay 29, 2016
Sunday, M
34
12:30 - 13:30
C. von Rokitansky Hall
Industry Symposium: Meet the Expert
Supported Session. Not included in the CME/CPD Programme.
For programme details please refer to the Recognition, Acknowledgements & Commercial Support
section in the final Programme.
13:30 - 14:00Exhibition & Poster Area
Break
37
14:00 - 15:30
EBAC Accredited Session: Diet and Prevention of
Cardiovascular Disease
14:00 - 15:00W. Auerswald Hall
EBAC Accredited Session: Gene Therapy and Lipoprotein
Lipase Deficiency
This educational programme is accredited by the European Board for Accreditation in
Cardiology (EBAC) for 1 hourof external CME credit(s); Each participant should claim
only those hours of credit that have actually been spent in the educational activity.
EBAC works according to the quality standards of the European Accreditation Council
for Continuing Medical Education (EACCME), which is an institution of the European
Union of Medical Specialists (UEMS).
EAS have independently organised all matters related to this 90-minute Programme,
including content and presenters. We acknowledge financial support, in the form of an
educational grant, received from BASF, Raisio and Unilever in support of the Programme.
Chair: E. Bruckert (France)
14:00 SHOULD SATURATED FAt BE TARGETED FOR The PREVENTION
Of CARDIOVASCULAR DISEASE?
1
2
A.H. Lichtenstein (USA)
14:20 SUGAR INTAKE AND CARDIOVASCULAR DISEASE - SHOULD IT BE
The NEXT FIGHT TO DECREASE CVD?
3
10
Chair: M. Averna (Italy)
11
14:00 GENETIC SEVERE HYPERTRIGLYCERIDEMIA
14:15 GENETIC THERAPY FOR LIPOPROTEIn LIPASE DEFICIENCY
12
4
13
E. Stroes (Netherlands)
14:45 CASE REPORT
J. Chapman (France)
15:00 ROLE Of MICROBIOTA ON CARDIOVASCULAR DISEASE
Chair: J. Borén (Sweden)
A. Zambon (Italy)
J.P. Després (Canada)
14:40 PLANT STEROL AND STANOLS AND CARDIOVASCULAR DISEASE. IMPACT
Of ENRICHED FOODS AND CHOLESTEROL-LOWERING DRUGS
educational grant, received from Chiesi in support of the Programme.
14
E.S. Thiessen (Germany)
14:45 CONCLUSION AND DISCUSSION
15
5
J. Fu (Netherlands)
6
7
Break
J. Chapman (France)
8
J. Fu (Netherlands)
9
15:20 PANEL DISCUSSION
A.H. Lichtenstein (USA)
16:00 - 17:30N. Anitschkow Hall
Industry Symposium: Company Sponsored Session
Break
38
39
Plenary: Opening Ceremony, including the Anitschkow
Lecture
Chair: A. Catapano (Italy)
16
Chair: H. Dieplinger (Austria)
17
Chair: F. Kronenberg (Austria)
18
18:00 WELCOME FROM EAS PRESIDENT
84 EAS CONGRESS
th
May 29 - June 1, 2016
Innsbruck, Austria
19
A. Catapano (Italy)
18:03 WELCOME FROM IAS PRESIDENT
20
Y. Matsuzawa (Japan)
18:06 WELCOME FROM MAYOR Of INNSBRUCK 21
C. Oppitz-Plörer (Austria)
18:09 WELCOME FROM PRESIDENT Of The MEDICAL UNIVERSITY Of INNSBRUCK
22
H. Fritsch (Austria)
18:12 WELCOME FROM AUSTRIAN ATHEROSCLEROSIS SOCIETY & CONGRESS CHAIR 23
H. Dieplinger (Austria)
18:15 ACKNOWLEDGEMENT Of JOURNAL EDITOR-IN-CHIEF, PROFESSOR
STEVE HUMPHRIES
24
A. Catapano (Italy)
18:20 MUSICAL INTERLUDE
25
18:30 INTRODUCTION TO ANITSCHKOW PRIZE WINNER
26
A. Catapano (Italy)
18:35 ANITSCHKOW LECTURE: ENDOTHELIAL CELL METABOLISM: A NOVEL
PLAYER In ATHEROSCLEROSIS? BASIC PRINCIPLES AND THERAPEUTIC
OPPORTUNITIES 27
P. Carmeliet (Belgium)
19:25 CLOSING REMARKS AND INVITATION TO WELCOME RECEPTION
28
F. Kronenberg (Austria)
19:30 MUSICAL INTERLUDE
29
19:45 - 20:45Exhibition Area
Welcome Reception
40
e
m
m
a
r
g
o
r
P
c
fi
i
Scient
ay 30, 2016
Monday, M
Key journals in
Cardiology
Plenary: Integrative Approach in Atherosclerosis
8:30
30
Chair: H. Dieplinger (Austria)
31
GENETIC PROTECTION FROM CORONARY ARTERY DISEASE: The ROLE
Of ABCG5 AND ABCG8
32
H. Hobbs (USA)
International Journal of
Cardiovascular Medicine, Surgery, Pathology and Pharmacology
9:00
25 Thrombin Generation and Platelet Reactivity at
Editorial
41 Utilization of Statins: Guiding Principles and the
New United States Guidelines
Hennekens, C.H.; Gelb, I.J. (Boca Raton, Fla.)
Editorial Comments
13 Systemic Inflammatory Response following
Transcatheter Aortic Valve Implantation
Paraskos, J.A. (Worcester, Mass.)
51 Hyperthyroid Atrial Fibrillation: Does It Matter for
Stroke Risk?
Poulin, M.-F.; Doukky, R. (Chicago, Ill.)
Hospital Discharge and 6-Month Outcome after the
Acute Coronary Syndrome in Diabetic and
Nondiabetic Patients
Kuliczkowski, W.; Szewczyk, M.; Kaczmarski, J.; Sztohryn, E.;
Greif, M.; Pres, D. (Zabrze); Fortmann, S.D. (Towson, Md.);
Poloński, L. (Zabrze); Serebruany, V. (Towson, Md.)
34 Assessment of Characteristics of Neointimal
Hyperplasia after Drug-Eluting Stent Implantation in
Patients with Diabetes Mellitus: An Optical Coherence
Tomography Analysis
Tian, F.; Chen, Y.; Liu, H.; Zhang, T.; Guo, J.; Jin, Q. (Beijing)
9:30
from Cellular Senescence via a Paracrine Mechanism
Zhang, Y. (Suzhou); Wang, D. (Haerbin); Cao, K.; Chen, M.
(Nanjing); Yang, X.; Tao, Y. (Suzhou)
Review
LEADING The WAY TO GENETICS AND PHARMACOGENOMICS In The CLINIC 34
T. Manolio (USA)
54 Autoantibodies to Oxidized Low-Density Lipoprotein
Coronary Interventions: Pathogenesis, Risk Factors,
Outcome, Prevention and Treatment
33
H. Schunkert (Germany)
43 Rat Induced Pluripotent Stem Cells Protect H9C2 Cells
62 Contrast-Induced Nephropathy in Percutaneous
GWAS FOR CORONARY ARTERY DISEASE
in Patients with Aortic Regurgitation: Association with
Aortic Diameter Size
Shimoni, S.; Bar, I.; Zilberman, L.; George, J. (Rehovot)
Aurelio, A.; Durante, A. (Milan)
Novel Insights from Clinical Experience
Original Research
10:00 EPIGENETICS In ATHEROSCLEROSIS
9 Transcatheter Aortic Valve Implantation for a Failed
1 Allitridin Reduces IKr Current by Disrupting the
Trafficking of Human Ether-à-Go-Go-Related Gene
Channels
Li, G.; Cheng, G.; Wu, J.; Ma, S.; Zhang, A.; Han, W.; Sun, C.
(Xi’an)
Bio-Bentall in Patients with Marfan Syndrome
Beigel, R.; Siegel, R.J.; Kahlon, R.S.; Jilaihawi, H.; Cheng, W.;
Makkar, R.R. (Los Angeles, Calif.)
35
A. El-Osta (Australia)
15 Synergistic Restoring Effects of Isoproterenol and
Magnesium on KCNQ1-Inhibited Bradycardia Cell
Models Cultured in Microelectrode Array
Kim, S.K.; Pak, H.-N.; Park, Y. (Seoul)
Editor-in-Chief
U. Pohl (Munich)
An invaluable aid in understanding
and treating heart disease
A source of current research
Cardiology features:
• First reports on original clinical,
preclinical and fundamental research
• ‘Turning Basic Research into
Clinical Success’
• ’Clinical Trial Design’
• Topical comprehensive reviews
in selected areas of cardiovascular
disease
• ‘Editorial Comments’
The Journal of Vascular Research
publishes original articles and reviews
of scientific excellence in vascular and
microvascular biology, physiology and
pathophysiology. The scope of the
journal covers a broad spectrum of
vascular and lymphatic research,
including vascular structure, vascular
function, haemodynamics, mechanics,
cell signalling, intercellular communication, growth and differentiation.
www.karger.com/crd
www.karger.com/jvr
Coffee Break, Exhibition & Poster Viewing
KI16241
Editor-in-Chief
J.S. Borer (New York, N.Y.)
43
11:00 - 12:30
Workshop 1.1: Novel Aspects of Pathogenesis in
Atherosclerosis
Workshop 2.1: Lipoproteins and Extracellular Matrix
Chair: C.J. Binder (Austria)
36
Chair: S. Ylä-Herttuala (Finland)
37
11:00 BEYOND VASCULAR INFLAMMATION: RECENT ADVANCES
In UNDERSTANDING ATHEROSCLEROSIS
38
K. Ley (USA)
11:25 B-CELLS AND ATHEROSCLEROSIS
39
C.J. Binder (Austria)
11:50 REGULATORY T CELLS FROM PATIENTS WITH ATHEROSCLEROSIS HAVE
ENHANCED SUPPRESSION FUNCTION DUE TO INCREASED EFFECTOR/
RESTING RATIO AND PRO-INFLAMMATORY SKEWING
40
I.E. Dumitriu, P. Baruah, J.C. Kaski (United Kingdom)
12:03 CONTROL Of ATHEROSCLEROSIS BY AN APOE RECEPTOR-DEPENDENT
NEUROMODULATOR41
J. Herz (USA)
12:16 DYNAMIN-RELATED PROTEIn 1 INHIBITION REDUCES OSTEOGENIC
DIFFERENTIATION INDUCED TYPE 1 COLLAGEN SECRETION AND
PREVENTS HUMAN VASCULAR CELL CALCIFICATION
M. Rogers, N. Maldonado, J. Hutcheson, C. Goettsch, M. Aikawa, E. Aikawa (USA)
K. Landsteiner Hall
Chair: J. Borén (Sweden)
43
Chair: P. Gordts (USA)
44
11:00 POSTPRANDIAL HYPERLIPIDEMIA, ENDOTHELIAL DYSFUNCTION AND
CARDIOVASCULAR RISK: FOCUS ON INCRETINS
45
P.D. Reaven (USA)
11:30 The ROLE Of PROTEOGLYCANS In HEPATIC TRIGLYCERIDE-RICH
LIPOPROTEIn METABOLISM: ROLE Of ACOCIII AND APOAV
46
P. Gordts (USA)
12:00 INCREASED LIPOPROTEIn BINDING TO ARTERIAL PROTEOGLYCANS
AND NORMAL MACROPHAGE CHOLESTEROL EFFLUX CAPACITY DEFINE
The PRO-ATHEROGENIC FEATURE Of CKD DYSLIPIDEMIA
47
M. Pedrelli, P. Stenvinkel, M.E. Minniti, K. Emma, A. Dikkers, S. Ebtehaj,
M. Gomaraschi, P. Barany, A.R. Qureshi, G. Camejo, B. Lindholm, K. Oörni, U. Tietge,
L. Calabresi, E. Hurt-Camejo, P. Parini (Sweden)
12:15 BROWN AND BEIGE ADIPOCYTE ACTIVITY CONTROLS METABOLIC FLUX
THROUGH The HDL COMPARTMENT
48
N. Schaltenberg, A. Bartelt, J. Clara, A. Worthmann, C. Lisa M., R. Franz, H. Markus,
N. Stefan K., S. Ludger, J. Heeren (Germany)
42
11:00 - 11:45
Advanced Clinical Seminar 4.1: Debate on Statin Associated
Muscle Symptoms (SAMS) - A Problem for Clinicians or a
Problem with Clinicians?
Chair: C. Packard (United Kingdom)
11:00 LESSONS FROM CLINICAL EXPERIENCE
49
50
U. Laufs (Germany)
11:20 LESSONS FROM CLINICAL TRIALS
51
J.M. Armitage (United Kingdom)
11:40DISCUSSION
44
52
45
11:45 - 12:30
Workshop 4.2: Role of Nutrition in Disease Pathology
Workshop 3.1: Novel Therapies
53
Chair: F. Mach (Switzerland)
58
Chair: J.M. Titze (Germany)
54
Chair: D. Gaudet (Canada)
59
11:45 ROLE Of SODIUM In ATHEROSCLEROSIS
55
J.M. Titze (Germany)
12:05 SATURATED FAt In The DIET: GOOD OR BAD?
60
F. Mach (Switzerland)
56
I. Brouwer (Netherlands)
12:25DISCUSSION
11:00 ANTI-INFLAMMATORY INTERVENTIONS VERSUS INTENSIVE LDL LOWERING
57
11:25 COMPARATIVE EFFECTS Of CHOLESTERYL ESTER TRANSFER
PROTEIn INHIBITION, STATIn AND EZETIMIBE THERAPY ON
ATHEROGENIC AND PROTECTIVE LIPID FACTORS: The ACCENTUATE TRIAL
61
S. Nicholls, K. Ray, C. Ballantyne, L. Beacham, D. Miller, G. Ruotolo, J. Riesmeyer
(Australia)
11:50 A NOVEL COMBINATORIAL NON-VIRAL VECTOR TO TREAt FAMILIAL
HYPERCHOLESTEROLAEMIA (FH)
62
A. Kerr, L. Tam, M. Cioroch, A. Hale, G. Douglas, K. Channon, R. Wade-Martins
(United Kingdom)
12:03 CURRENT STATUS-PHASE I TRIAL Of CELL-TRANSPLANTATION
THERAPY WITH ALLOGENEIC ADIPOSE TISSUE-DERIVED MULTILINEAGE
PROGENITOR CELLS In SEVERE FAMILIAL HYPERCHOLESTEROLEMIA
PATIENTS UNDERGOING LDL-APHERESIS
63
M. Koseki, S. Ayami, T. Okada, T. Kobayashi, M. Asaji, R. Kawase, M. Nishida,
Y. Sakata, S. Yamashita (Japan)
12:16 NOVEL INTRANASAL ANTI-CETP VACCINE AGAINST The DEVELOPMENT
Of ATHEROSCLEROSIS AND FATTY LIVER DISEASE
64
J. Mas-Oliva, B. Delgado-Coello, K. Méndez-Acevedo (Mexico)
Break, Exhibition & Poster Viewing
Science at a Glance Session I
13:00 - 14:00
Kristall Foyer
Poster Walk Session I
46
47
Science at a Glance Session II
13:00 - 14:30
EAS-ESC Joint Workshop: Sex Differences in Cardiovascular
Diseases
K. Landsteiner Hall
71
Chair: L. Tokgözoglu (Turkey)
72
15:00 PUBLIC HEALTH PERSPECTIVES ON CARDIOVASCULAR CARE FOR MEN
AND WOMEN
13:00 - 14:00
Chair: I. Hoefer (Netherlands)
73
K. Kotseva (United Kingdom)
15:22 SEX DIFFERENCES In HEART DISEASE In CLINICAL PRACTICE
15:45 SEX-SPECIFIC BIOMARKERS FOR CARDIOVASCULAR DISEASES
EBAC Accredited Session: Nutraceuticals with Lipid
Lowering Activity: Who Can Benefit?
74
E. Bossano Prescott (Denmark)
75
B. Nordestgaard (Denmark)
16:07 SEX-SPECIFIC GENOMIC AND PROTEOMIC REGULATION
In CARDIOVASCULAR DISEASE
76
G. Kararigas (Germany)
educational grant, received from Meda (Rottapharm) in support of the Programme.
Chair: P. Kovanen (Finland)
65
Chair: G. Assmann (Germany)
66
13:00 GUIDELINES In PRIMARY PREVENTION
67
E. Farinaro (Italy)
13:15 TO BRIDGE The GAP BETWEEN LIFESTYLE AND PHARMACOLOGICAL
TREATMENT: DO WE HAVE AN UNMET NEED?
68
B. Paulweber (Austria)
13:30 PLANT NUTRACEUTICALS FOR The TREATMENT
Of HYPERCHOLESTEROLEMIA: The AVAILABLE CLINICAL DATA
69
E. Bruckert (France)
13:45 DISCUSSION AND CONCLUSION
48
70
49
15:00 - 16:30
K. Landsteiner Hall
Workshop 1.2: Therapeutic and Diagnostic Targeting of the
Arterial Wall
Chair: E. Stroes (Netherlands)
77
Chair: A. Tawakol (USA)
78
15:00 NANOMEDICINE AS DIAGNOSTIC TOOL FOR CARDIOVASCULAR DISEASE
79
D. Letourneur (France)
A. Tawakol (USA)
15:50 INCREASED ARTERIAL WALL INFLAMMATION In PATIENTS WITH FAMILIAL
DYSBETALIPOPROTEINEMIA81
S. Verweij, S. Bernelot Moens, J. Kroon, J. Schnitzler, E. Stroes (Netherlands)
Workshop 2.2: Adipose Tissue – Liver Axis
Chair: M. Taskinen (Finland)
84
Chair: F. Karpe (United Kingdom)
85
15:00 BIOLOGY Of ADIPOSE TISSUE PHENOTYPE AND ITS LINK TO DISEASE
82
86
F. Karpe (United Kingdom)
87
R.O. Ryan (USA)
15:50 FGF21 LOWERS PLASMA TRIGLYCERIDES BY ACCELERATING
LIPOPROTEIn CATABOLISM In WHITE AND BROWN ADIPOSE TISSUES
88
C. Schlein, S. Talukdar, M. Heine, A.W. Fischer, L.M. Krott, S.K. Nilsson, M.B. Brenner,
J. Heeren, L. Scheja (Germany)
16:03 OAT2 DEPLETION IMPROVES INSULIn SENSITIVITY AND HEPATIC STEATOSIS
D. Agrawal, P. Gunasekar, C. Boosani, V. Swier, M. Radwan, M. Del Core, W. Hunter
(USA)
16:16 SPOTTY CALCIFICATION AS A MARKER Of VULNERABLE PLAQUE: NOVEL
FINDINGS FROM IN-VIVO STUDY In SURVIVORS Of CARDIAC ARREST AND
IN-VITRO STUDY In AUTOPTIC SCD PATIENTS
15:25 APO AV, BEYOND TRIGLYCERIDES
15:25 NON-INVASIVE IMAGING Of ATHEROSCLEROTIC BURDEN AND
INFLAMMATION80
16:03 GENE THERAPY REDUCES ANGIOPLASTY INDUCED CORONARY
RESTENOSIS In A HIGH CHOLESTEROL SWINE MODEL
15:00 - 16:30
89
P. Parini, C. Pramfalk, O. Ahmed, L. Larsson, F. Karpe, M. Neville, M. Eriksson
(Sweden)
16:16 SHORT-TERM COLD EXPOSURE MODULATES HUMAN VLDL AND HDL
METABOLISM90
K. Nahon, G. Hoeke, L. Bakker, D. Drettwan, P. Pagel, I. Jazet, J. Berbée, M. Boon,
P. Rensen (Netherlands)
83
J. Pu, P. Zhang, G.S. Mintz, X. Ma, B. He (China)
50
51
Late Breaking: Basic Science
Young Investigator Session: Vascular Biology and
Inflammation
Chair: J. Herz (USA)
91
Chair: R. Zechner (Austria)
92
15:00 FLOW PERTURBATION MEDIATES NEUTROPHIL RECRUITMENT AND
POTENTIATES ENDOTHELIAL INJURY VIA TLR2 In MICE. A NOVEL In VIVO
APPROACH FOR PROBING The PATHOPHYSIOLOGY Of SUPERFICIAL EROSION93
G. Franck, G. Sausen, T. Mawson, M. Salinas, G. Masson, A. Cole, M. BeltramiMoreira, Y. Chatzizisis, Y. Tesmenitsky, E. Swartz, G. Sukhova, F. Swirski,
M. Nahrendorf, E. Aikawa, K. Croce, P. Libby (USA)
15:15 The ATYPICAL CADHERIn FAT1 SUPPRESSES MITOCHONDRIAL RESPIRATION
TO LIMIT SMOOTH MUSCLE CELL RESPONSE TO VASCULAR INJURY
100
Chair: L.O. Martinez (France)
101
17:00 IRON ACCELERATES CARDIOVASCULAR DISEASE: The IMPORTANCE
Of MAINTAINING IRON BALANCE
102
F. Vinchi, A. Simmelbauer, S. Altamura, B. Galy, M.W. Hentze, M. Muckenthaler
(Germany)
94
N. Sibinga, L.L. Cao, D. Riascos-Bernal, P. Chinnasamy, C. Dunaway, M. Pujato,
A. Fiser (USA)
15:30 The CORONARY ARTERY DISEASE RISK ASSOCIATED GENE PLPP3/PPAP2B
SUPPRESSES ATHEROSCLEROSIS In MICE
Chair: K. Öörni (Finland)
17:15 INCREASED APOA-I TRANSCRIPTION BY BET INHIBITOR JQ1(+) ACTS
INDEPENDENTLY FROM PPAR-ALPHA ACTIVATION AND IS LINKED
TO ER-STRESS INHIBITION
103
S.E. Van der Krieken, H.E. Popeijus, R.P. Mensink, J. Plat (Netherlands)
95
A. Morris, P. Mueller, J. Brandon, L. Yang, S. Smyth (USA)
17:30 PHOSPHATIDYLSERINE IMPROVES ANTI-INFLAMMATORY FUNCTION
Of RECONSTITUTED HDL In MACROPHAGES VIA SR-BI-, Akt- AND p38
MAPK-DEPENDENT PATHWAYS
104
M. Darabi, E. Tubeuf, M. Lhomme, I. Guillas-Baudouin, C. Dauteuille, M. Patel,
T. Huby, E.L. Gautier, K.A. Rye, P. Lesnik, W. Le Goff, A. Kontush (France)
Young Investigator Award Session
17:45 CCAAT/ENHANCER BINDING PROTEIn DELTA CONTRIBUTES TO LIPID
ACCUMULATION In M1 MACROPHAGES Of BLOOD VESSEL LESIONS
105
H.Y. Lai, L.W. Hsu, P.Y. Liu, J.M. Wang (Taiwan)
96
Chair: G. Dallinga-Thie (Netherlands)
97
15:45 GRP94 REGULATES CIRCULATING CHOLESTEROL LEVELS THROUGH
BLOCKADE Of PCSK9-INDUCED LDLR DEGRADATION
98
S. Poirier (Canada)
16:05 ASSOCIATION BETWEEN FAMILIAL HYPERCHOLESTEROLEMIA AND
PREVALENCE Of TYPE 2 DIABETES MELLITUS
99
J. Besseling (Netherlands)
18:00 INHIBITION Of The CHOLESTEROL SYNTHESIS PATHWAY PREVENTS
TRAINED INNATE IMMUNITY
106
S. Bekkering, S. Bernelot Moens, S. Verweij, J. Roeters van Lennep, J. Van Tuijl,
L. Joosten, E. Stroes, M. Netea, N. Riksen (Netherlands)
18:15 SELECTIVE DONOR ENDOTHELIAL HEPARAN SULFATE MODIFYING
ENZYME NDST1 DELETION SIGNIFICANTLY BLOCKS REJECTION AFTER
RENAL TRANSPLANT
107
S. Ambadapadi, H. Chen, D. Wakefield, S. Morshed, W. Clapp, A. Lucas (USA)
17:00 - 18:00
Kristall Foyer
Poster Walk Session II
52
53
17:00 - 18:30
K. Landsteiner Hall
Young Investigator Session: Lipids and Lipoprotein
Metabolism
17:00 - 18:30
Young Investigator Session: Clinical Epidemiology and
Pharmacology
Chair: L. Scheja (Germany)
108
Chair: K. Kotseva (United Kingdom)
116
Chair: A. Ritsch (Austria)
109
Chair: P.D. Reaven (USA)
117
17:00 PARAOXONASE 1 (PON1) MAINTAINS CELLULAR CHOLESTEROL
HOMEOSTASIS VIA The REGULATION Of CHOLESTEROL EFFLUX
110
S. Ikhlef, H. Berrougui, A. Khalil (Canada)
17:15 A UBIQUITOUS TRANSCRIPTION FACTOR INFLUENCES DIET-INDUCED
THERMOGENESIS AND SENSITIZES BAt TO NORADRENERGIC STIMULI
IMPROVING CARDIOMETABOLIC HEALTH
111
112
M. SHARMA, G. Redpath, S. McCormick (New Zealand)
17:45 PLASMA CETP IS DERIVED FROM HEPATIC KUPFFER CELLS RATHER THAN
ADIPOSE TISSUE
113
114
119
B. Arsenault, F. Tabet, W. Bao, F. Petrides, G.K. Hovingh, S.M. Boekholdt, D. DeMicco,
K.A. Rye, D. Waters, J. Kastelein, P. Barter, G. Lambert (Canada)
17:30 CLINICAL CHARACTERISTICS AND LONG-TERM CLINICAL OUTCOMES
Of PATIENTS WITH TYPICAL RESTING CHEST PAIn ACCORDING TO
The TYPES Of VASOMOTOR RESPONSE TO AN ACETYLCHOLINE
PROVOCATION TEST
120
17:45 RESPONSE TO TREATMENT AND OCCURRENCE Of CARDIOVASCULAR
(CV) COMPLICATIONS In PATIENTS WITH AUTOSOMAL RECESSIVE
HYPERCHOLESTEROLEMIA (ARH): A RETROSPECTIVE ANALYSIS
121
L. D'Erasmo, I. Minicocci, L. Masana, J. Roeters van Lennep, M. Harada-Shiba,
S. Muntoni, P. Pintus, S. Bertolini, C. Sirtori, L. Calabresi, C. Pavanello, M. Averna,
A.B. Cefalù, D. Noto, A. Pacifico, G. Pes, R. Fellin, E. Manzato, S. Zambon, M. Arca
(Italy)
E. Garcia-Vaz, A. Mc Neilly, J. Gallagher, R. Mc Crimmon, F. Khan, M.F. Gomez
(Sweden)
18:15 OXYSTEROLS, 24S-HYDROXYCHOLESTEROL AND
27-HYDROXYCHOLESTEROL, In SUBJECTS WITH GENETIC
HYPERCHOLESTEROLEMIA NEGATIVE FOR LDLR/APOB/PCSK9/APOE
MUTATIONS. ASSOCIATION WITH LIPIDS AND CAROTID ATHEROSCLEROSIS
17:15 IMPACT Of DIABETES, INSULIn RESISTANCE AND CETP INHIBITION ON
CIRCULATING PCSK9 LEVELS In PATIENTS At HIGH CARDIOVASCULAR
RISK: The ILLUMINATE STUDY
E.M. Lee, H.S. Seo, M.H. Choi, H.K. Kim, S.Y. Lee, N.H. Kim, D.O. Kang, C.U. Choi,
J.W. Kim, E.J. Kim, S.W. Rha, C.G. Park, D.J. Oh (Republic of Korea)
L. Blauw, R. De Mutsert, Y. Wang, H. Lamb, A. De Roos, F. Rosendaal, W. Jukema,
S. Van der Tuin, S. Rensen, R. Shiri-Sverdlov, B. Atanasovska, J. Fu, W. Buurman,
J.W. Greve, M. Hofker, K. Willems van Dijk, P. Rensen (Netherlands)
18:00 In VIVO INHIBITION Of NUCLEAR FACTOR Of ACTIVATED T CELLS (NFAT)
RESTORES MICROVASCULAR ENDOTHELIAL FUNCTION In DIABETIC MICE
118
N. Wong, E. Kulikowski, S. Wasiak, D. Gilham, C. Calosing, T. Laura, C. Halliday,
J. Johansson, M. Sweeney (Canada)
P.P. Laurila, J. Soronen, S. Kooijman, M. Boon, M.R. Taskinen, V. Olkkonen, S. Ripatti,
P. Kovanen, P. Rensen, M. Jauhiainen (Finland)
17:30 CALCIUM DEPENDENT ENDOCYTOSIS AND RECYCLING
Of LIPOPROTEIN(A) In HEPG2 CELLS
17:00 APABETALONE (RVX-208) DECREASES ATHEROGENIC, THROMBOTIC AND
INFLAMMATORY MEDIATORS In VITRO AND In PLASMA Of PATIENTS WITH
CARDIOVASCULAR DISEASE (CVD).
115
L. Baila-Rueda, A. Cenarro, I. Lamiquiz-Moneo, R. Mateo-Gallego, A.M. Bea-Sanz,
S. Perez-Calahorra, V. Marco-Benedi, F. Civeira (Spain)
18:00 ASSOCIATION Of PERIPHERAL BLOOD MONONUCLEAR CELLS
ADENYLATE CYCLASE-ASSOCIATED PROTEIn 1 mRNA WITH CORONARY
ARTERY DISEASE
122
M. Sopic, J. Joksić, V. Spasojević Kalimanovska, D. Kalminaovska Oštrić,
K. Anđelković, Z. Jelić Ivanović (Serbia)
18:15 FILAGGRIn MUTATIONS AS RISK FACTORS FOR ISCHEMIC STROKE
In The GENERAL POPULATION
123
A. Varbo, B.G. Nordestgaard, M. Benn (Denmark)
54
55
Oral Communication Session: Vascular Biology
Chair: L. Yvant-Charvet (France)
124
Chair: K. Ley (USA)
125
17:00 SELECTIVE HDL-RAISING GENE TRANSFER COUNTERACTS
The DEVELOPMENT Of PRESSURE OVERLOAD-INDUCED
CARDIOMYOPATHY In MICE
126
84 EAS CONGRESS
th
May 29 - June 1, 2016
Innsbruck, Austria
R. Amin, I. Muthuramu, F. Jacobs, B. De Geest (Belgium)
17:15 BONE MARROW-SPECIFIC SIRT6 DELETION INCREASES ATHEROGENESIS
BY INCREASING MACROPHAGE SCAVENGER RECEPTOR 1
127
T. Arsiwala, L. J. van Tits, M. Miranda, K. Nussbaum, J. Weber, S. Stivala, J. H. Beer,
M. Greter, B. Becher, M. O. Hottiger, R. Mostoslavsky, J. Auwerx, T. F. Lüscher,
C. M. Matter (Switzerland)
17:30 T CELL-SPECIFIC CD40L CONTRIBUTES TO ATHEROSCLEROSIS
128
C. Bürger, H. Winkels, C. Spitz, S. Meiler, S. Reim, C. Weber, E. Lutgens, N. Gerdes
(Germany)
17:45 STRUCTURAL REMODELING AND GLUCOSE METABOLISM IMPAIRMENT
At EARLY ATHEROSCLEROSIS: IN-SITU AORTA ALTERATIONS AND PLASMA
TRANSLATION.129
M. Martin-Lorenzo, L. Gonzalez-Calero, A.S. Maroto, P.J. Martinez, A. Heredero,
G. Aldamiz-Echevarria, F. Vivanco, G. Alvarez-Llamas (Spain)
18:00 LIVER-SPECIFIC ABLATION Of HNF-4α In MICE IS ASSOCIATED WITH
CHANGES In PLASMA LIPOPROTEIn PROFILES AND The EXPRESSION
Of GENES INVOLVED In LIPOPROTEIn METABOLISM
130
E. Thymiakou, D. Kardassis (Greece)
18:15 HEPATOCYTE-SPECIFIC PPAP2B ABLATION INCREASES PLASMA LEVELS
Of SEVERAL MINOR PRO-ATHEROGENIC LIPID SPECIES AND WORSENS
ATHEROSCLEROSIS In APOE-/- MICE
131
M. Busnelli, S. Manzini, M. Hilvo, C. Parolini, G.S. Ganzetti, F. Dellera, K. Ekroos,
M. Jänis, C.R. Sirtori, R. Laaksonen, G. Chiesa (Italy)
Plenary: Keynote Lecture
132
Chair: W.J. Schneider (Austria)
133
18:40 HOW GENES CONTROL CHOLESTEROL
M.S. Brown (USA)
56
134
e
m
m
a
r
g
o
r
P
c
fi
i
Scient
ay 31, 2016
Tuesday, M
Plenary: Lipid Biology, New Insights
8:30
Chair: G. Kostner (Austria)
135
Chair: O. Wiklund (Sweden)
136
PATHOPHYSIOLOGY Of INTERCELLULAR AND INTRAVASCULAR LIPOLYSIS
137
R. Zechner (Austria)
9:00
ADIPOSE TISSUE BROWNING AND METABOLIC HEALTH
138
J. Heeren (Germany)
9:30
NUCLEAR RECEPTORS In LIPID METABOLISM
139
D. Mangelsdorf (USA)
10:00 ANGIOGENESIS AND ENDOTHELIAL CELL DYSFUNCTION
In ATHEROSCLEROSIS: A NOVEL TARGET FOR TREATMENT
140
P. Carmeliet (Belgium)
10:30 - 11:00Exhibition & Poster Areater Area
59
11:00 - 12:30
Workshop 1.3: Cellular Stress Response in Atherosclerosis
Workshop 2.3: Gut - Liver Axis
K. Landsteiner Hall
Chair: G.R.Y. De Meyer (Belgium)
198
Chair: A. Moschetta (Italy)
205
Chair: R. Prassl (Austria)
199
Chair: D. Kardassis (Greece)
206
11:00 MICTOPARTICLES In ATHEROSCLEROSIS
200
C.M. Boulanger (France)
11:25 ROLE Of AUTOPHAGY In VASCULAR DISORDERS
201
202
S. Lehti, I. Belevich, S.D. Nguyen, P. Lindsberg, E. Jokitalo, P.T. Kovanen,
K. Oörni (Finland)
11:50 A MARCH6 AND IDOL E3 UBIQUITIn LIGASE CIRCUIT UNCOUPLES
CHOLESTEROL SYNTHESIS FROM LIPOPROTEIn UPTAKE In HEPATOCYTES
209
A. Loregger, E. Cook, J. Nelson, M. Moeton, L. Sharpe, S. Engberg,
M. Karimova, G. Lambert, N. Zelcer (Netherlands)
203
E. Ehrenborg, P. Gustafsson, O. Werngren, M. Pedrelli, P. Parini, J. Magné
(Sweden)
12:16 EXTRACELLULAR LIPID PARTICLES ACCUMULATING In HUMAN CAROTID
ARTERY INTIMA INDUCE STERILE INFLAMMATION In MACROPHAGES
208
A. Moschetta (Italy)
D. De Gonzalo Calvo, A. Cenarro, F. Civeira, V. Llorente-Cortés (Spain)
12:03 A FUNCTIONAL GENETIC VARIANT In The LIPID DROPLET-ASSOCIATED
PROTEIn PERILIPIn 2 (PLIN2) AFFECTS CHOLESTEROL CONTENT AND
AUTOPHAGY In HUMAN PRIMARY MACROPHAGES TREATED WITH OXLDL
207
M.J. Brown (USA)
11:25 INTESTINAL NUCLEAR RECEPTORS In LIPID REGULATION
G.R.Y. De Meyer (Belgium)
11:50 HYPERCHOLESTEROLEMIA ALTERS The microRNA PROFILE
Of VASCULAR SMOOTH MUSCLE CELL-DERIVED MICROPARTICLES
11:00 The GUT MICROBIOME ENDOCRINE ORGAN: BACTERIALLY SIGNALS
DRIVING CARDIO-METABOLIC DISEASES
12:03 BUTYRATE VIA The GUT-BRAIn CIRCUIT REDUCES APPETITE AND
ACTIVATES BROWN ADIPOSE TISSUE
210
Y. Wang, L. Zhuang, C. Yi, C.K. Chuang, S. Kooijman, K. Willems van Dijk,
A.K. Groen, P.C.N. Rensen
204
12:16 NON-ALCOHOLIC FATTY LIVER DISEASE AS A CAUSE Of ISCHEMIC HEART
DISEASE: A MENDELIAN RANDOMIZATION STUDY AND META-ANALYSIS
Of 170,998 INDIVIDUALS
211
B. Lauridsen, S. Stender, T. Kristensen, K. Kofoed, B. Nordestgaard,
A. Tybjærg-Hansen (Denmark)
60
61
11:00 - 12:30
Workshop: ICCR-EAS Joint Session: Management of
Cardiometabolic Risk; Where Do We Stand?
Workshop 3.2: Vascular Aging and Atherothrombosis
Chair: J.P. Després (Canada)
212
Chair: J. Chapman (France)
213
11:00 MANAGEMENT Of SUBJECTS At HIGH CARDIOMETABOLIC RISK - WHERE
DO WE FALL?
214
11:22 DOES The HEALTHY METABOLICALLY OBESE PHENOTYPE EXIST?
215
216
V. Malik (USA)
12:07 NAFLD - The NOVEL TREAt FOR VASCULAR DISEASE
M. Taskinen (Finland)
Chair: C. Gaetano (Germany)
218
Chair: B. Föger (Austria)
219
11:00 VASCULAR PROGENITOR CELLS, LYMPHATICS, ANGIOGENESIS AND
ATHEROSCLEROSIS220
A. Kari (Finland)
11:25 SIRTUINS In CARDIOVASCULAR DISEASE
L. Van Gaal (Belgium)
11:45 TRANSLATING NUTRITIONAL SCIENCE INTO CLINICAL PRACTICE
217
221
C. Gaetano (Germany)
11:50 PENTRAXIn 3 DEFICIENCY IS ASSOCIATED WITH INCREASED ARTERIAL
THROMBOSIS In ANIMAL MODELS
222
F. Bonacina, S. Barbieri, L. Cutuli, P. Amadio, A. Doni, M. Sironi, S. Tartari,
B. Bottazzi, C. Garlanda, E. Tremoli, A. Mantovani, A.L. Catapano, G.D. Norata
(Italy)
12:03 HDL MODULATES CARDIAC GLUCOSE METABOLISM AND INFLAMMATION
AND IMPROVES CARDIAC FUNCTION AFTER MYOCARDIAL ISCHEMIAREPERFUSION INJURY
223
B. Kingwell, S. Heywood, A. Richart, D. Henstridge, K. Alt, H. Kiriazis,
A. Carey, H. Kammoun, H. Begum, L. Delbridge, P. Meikle, C. Hagemeyer,
M. Febbraio, X.J. Du, A. Siebel (Australia)
12:16 DIET-INDUCED OBESITY REQUIRES SIGNALLING THROUGH TUMOR
NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTOR 1 (TRAF-1)
In ADIPOCYTES224
D. Wolf, N. Anto Michel, I. Hilgendorf, Bode, A. Zirlik (Germany)
Break, Exhibition & Poster Viewing
Science at a Glance Session III
13:00 - 14:00
Kristall Foyer
Poster Walk Session III
62
63
13:00 - 14:30
K. Landsteiner Hall
EBAC Accredited Session: Lysosomal Acid Lipase Deficiency
13:00 - 14:00
EBAC Accredited Session: Low HDL High Triglyceride,
Diabetic Dyslipidaemia
educational grant, received from Mylan in support of the Programme.
13:00 DIABETIC DYSLIPIDEMIA
225
226
A. Zambon (Italy)
13:20 TRIGLYCERIDE, REMNANTS AND ATHEROSCLEROSIS
Union of Medical Specialists (UEMS). EAS have independently organised all matters
related to this 60-minute Programme, including content and presenters. We
acknowledge financial support, in the form of an educational grant, received from
Alexion in support of the Programme.
229
230
13:00 LIPID METABOLISM ABNORMALITIES In GENERAL WITH DIFFERENTIAL
DIAGNOSIS INCLUDING ALSO LAL-D
231
T. Stulnig (Austria)
13:20 LIPID METABOLISM ABNORNALITIES In LAL-D AS A LYSOSOMAL STORAGE
DISEASE WITH A FOCUS ON SPECIFIC SIGNS AND SYMPTOMS
232
M. Averna (Italy)
233
227
Science at a Glance Session IV
228
Industry Symposium: Special Lecture
14:10 - 14:55
64
65
15:00 - 16:30
Industry Symposium: Meet the Expert
Late Breaking: Clinical Science
Workshop 3.3: Genetics in Risk Factor Prevention and
Treatment
Chair: G. Utermann (Austria)
234
Chair: S. Ripatti (Finland)
235
236
S. Ripatti (Finland)
15:20 LOSS-OF-FUNCTION MUTATIONS In APOC3, REMNANT CHOLESTEROL,
LDL CHOLESTEROL, AND RISK Of ISCHEMIC VASCULAR DISEASE
237
A.B. Jørgensen, R. Frikke-Schmidt, B. Nordestgaard, A. Tybjaerg-Hansen
(Denmark)
15:34 LEUKOCYTE TELOMERE LENGTH, GENETICALLY DETERMINED, IS
CAUSALLY ASSOCIATED WITH The PROGRESSION Of CAROTID INTIMAMEDIA THICKNESS AND INCIDENCE Of CARDIOVASCULAR EVENTS
238
239
240
244
D. Gaudet, S. Saheb, E. Bruckert, J. De Graaf, G. Langslet, J.C. Tardif,
S. Bergheanu, A. Steinberg, Y.J. Choi, R. Martin, C. McWherter, J. Kastelein,
P. Boudes (USA)
15:15 AFFITOPE-BASED ANTI-PCSK9 (PROPROTEIn CONVERTASE SUBTILISIN/
KEXIn TYPE 9) VACCINE (AT04A) REDUCES ATHEROSCLEROSIS
In APOE*3LEIDEN.CETP MICE
245
G. Galabova, C. Juno, J.W.A. Van der Hoorn, E.J. Pieterman, M. Pouwer,
C. Landlinger, J.W. Jukema, H.M.G. Princen, G. Staffler (Austria)
15:30 TREATMENT ADHERENCE TO The PROPROTEIn CONVERTASE SUBTILISIN/
KEXIn TYPE 9 INHIBITOR ALIROCUMAB In SIX ODYSSEY PHASE 3 CLINICAL
STUDIES WITH TREATMENT DURATION Of 52 - 104 WEEKS
246
M. Farnier, H.M. Colhoun, W.J. Sasiela, J. Edelberg, G. Asset, J.G. Robinson
(France)
247
D. Gaudet, D.A. Gipe, E. Khoury, R. Pordy, W. Sasiela, K.C. Chan
248
J. Sun, J. Liu, N. Balu, D. Hippe, K. William, A. Wang, G. Canton, T. Hatsukami,
C. Yuan (USA)
16:15 MORTALITY In RELATION TO GLYCAEMIC STATUS In PATIENTS WITH
PERIPHERAL ARTERIAL DISEASE
249
I.D. Hjellestad, E. Søfteland, R.M. Nilsen, E.S. Husebye, T. Jonung (Norway)
I. Brænne, C. Willenborg, B. Reiz, L. Zeng, V. Tragante do Ó, T. Meitinger,
N.J. Samani, T. Kessler, F.W. Asselbergs, J. Erdmann, H. Schunkert (Germany)
16:16 INVESTIGATION Of MULTIPLE DYSLIPIDEMIAS In A LARGE AUSTRIAN
PEDIGREE BY GENETIC RISK SCORES AND EXOME SEQUENCING
243
16:00 DYNAMIC CHANGES In MR SIGNALS Of INTRAPLAGUE HEMORRHAGE
ARE STRONGLY CORRELATED WITH PLAQUE PROGRESSION: A SERIAL
IMAGING STUDY ON CAROTID ATHEROSCLEROSIS
I. Khurana, A. El-Osta (Australia)
16:02 PLEIOTROPIC MOLECULAR TARGETS Of COXIBS REVEALS NOVEL
GENOMIC LOCI CONFERRING CORONARY ARTERY DISEASE RISK
242
Chair: M. Vrablik (Czech Republic)
15:45 SAFETY AND EFFICACY Of EVINACUMAB, A MONOCLONAL
ANTIBODY TO ANGPTL3, In PATIENTS WITH HOMOZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OFCONCEPT STUDY
A. Baragetti, J. Palmen, K. Garlaschelli, L. Grigore, S. Humphries,
A.L. Catapano, P.J. Talmud, N. Giuseppe Danilo (Italy)
15:48 DEEP SEQUENCING IDENTIFIES DNA METHYLATION DEPENDENT GENES
IMPLICATED In DIABETIC COMPLICATIONS
Chair: P. Moulin (France)
15:00 A PILOT STUDY Of MBX-8025 In The TREATMENT Of HOMOZYGOUS
FAMILIAL HYPERCHOLESTEROLEMIA (HoFH)
15:00 GENETIC DISCOVERIES FOR LIPID GENETIC TRAITS. LESSON LEARNED
FROM FAMILIES AND The GENERAL POPULATION
K. Landsteiner Hall
241
E. Nikkola, A. Ko, R.M. Cantor, R. Muxel, N. Matikainen, S. Söderlund,
M.M. Motazacker, J.A. Kuivenhoven, J. Boren, F. Kronenberg, W. Schneider,
A. Palotie, M. Laakso, M.R. Taskinen, P. Pajukanta (USA)
66
67
15:00 - 16:30
EAS Initiatives Update Session (open to all)
250
251
252
253
17:00 - 18:00
K.K. Ray (United Kingdom)
15:30 CONSENSUS ACTIVITIES HIGHLIGHT- CONSENSUS ON FASTING/
NONFASTING LIPID ANALYSES (WITH EFLM)
A. Catapano (Italy)
15:15 FHSC UPDATE
EAS General Assembly (Members Only)
15:00 WELCOME AND OVERVIEW Of EAS ACTIVITIES
16:30 - 16:50
254
Kristall Foyer
Poster Walk Session IV
15:45 EDUCATIONAL ACTIVITIES HIGHLIGHT- ADVANCED COURSES & EAS
ACADEMY ACCREDITED PROGRAMMES 255
L. Tokgözoglu (Turkey)
15:55 OTHER ACTIVITIES: GUIDELINES & CONSENSUS UPDATE
Workshop 3.5: Epigenetics and Gene Regulation
256
A. Catapano (Italy)
16:05 OTHER ACTIVITIES: JOURNAL
257
258
A. Catapano (Italy)
Advanced Clinical Seminar: Economics and Guidelines/
Technology of the Future
259
Chair: G. Dallinga-Thie (Netherlands)
260
261
G. Corrao (Italy)
262
G. Kostner (Austria)
68
17:00 The EMERGING ROLE Of microRNAs In CARDIOVASCULAR DISEASE
17:25 IDENTIFICATION Of HISTONE DEACETYLASE 3 AS A MOLECULAR BRAKE
Of WHITE ADIPOSE TISSUE BROWNING
17:38 HYPERCHOLESTEROLEMIA TRANSFORMS HIGH-DENSITY LIPOPROTEINSMEDIATED TRNA-DERIVED SMALL RNA INTERCELLULAR COMMUNICATION
17:51 QUAKING POST-TRANSCRIPTIONALLY PROMOTES DIFFERENTIATION
Of MONOCYTES INTO PRO-ATHEROGENIC MACROPHAGES BY
CONTROLING PRE-MRNA SPLICING AND GENE EXPRESSION
266
267
268
263
269
R.G. De Bruin, L. Shiue, J. Prins, A. Djaramshi, H. De Boer, W.S. Fagg, J. Van
Gils, J. Duijs, C. Van Kooten, J.W. Jukema, H. Van Esch, T.J. Rabelink,
H. Kazan, E.A.L. Biessen, M. Ares Jr., A.J. Van Zonneveld, E. Van der Veer
(Netherlands)
18:09 INNATE IMMUNE CELL ACTIVATION In SYMPTOMATIC AND
ASYMPTOMATIC ATHEROSCLEROSIS In HUMANS In VIVO
N. Sanjana (USA)
16:00 WHAt DID WE LEARN FROM Lp(a)? SUMMARY Of The SATELLITE MEETING
265
R. Allen, D. Michell, W. Zhu, S. Zhao, Q. Sheng, L. MacRae, K. Vickers (USA)
Chair: M. Banach (Poland)
15:30 CrisprCas9 TECHNOLOGY AS A NEW STRATEGY FOR TARGET DISCOVERY
264
Chair: A. El-Osta (Australia)
M. Crestani, A. Ferrari, E. Fiorino, R. Long, N. Mitro, G. Cermenati, A. Mai,
D. Caruso, E. De Fabiani, S.W. Hiebert (Italy)
15:00 PHARMACO-ECONOMICS - HOW TO EXPLORE IT
Chair: L. Maegdefessel (Sweden)
L. Maegdefessel (Sweden)
A. von Eckardstein (Switzerland)
16:15Q&A
270
S. Bekkering, I. Van den Munckhof, T. Nielen, J. Rutten, J. De Graaf,
L. Joosten, M. Netea, M. Gomes, N. Riksen (Netherlands)
69
17:00 - 18:30
K. Landsteiner Hall
Oral Communication Session: Imaging, Biomarkers and
Clinical Epidemiology
17:00 - 18:30
Oral Communication Session: Intracellular Lipid
Metabolism
Chair: D. Letourneur (France)
271
Chair: D. Kratky (Austria)
279
Chair: B. Paulweber (Austria)
272
Chair: J. Heeren (Germany)
280
17:00 ULTRA-SMALL POSITIVE AND NEGATIVE DUAL CONTRAST IRON OXIDE
NANOPARTICLES FOR MOLECULAR IMAGING Of CARDIOVASCULAR DISEASE 273
H. Ta, Z. Li, K. Peter, C. Hagemeyer, A. Whittaker (Australia)
17:15 COMPUTED TOMOGRAPHY ANGIOGRAPHY DERIVED COMPARED TO
INVASIVE FRACTIONAL FLOW RESERVE ASSESSMENT. A META-ANALYSIS.
274
275
17:45 In TYPE 2 DIABETES MELLITUS The GLP-1 EFFECTS ON PLATELETS ARE
IMPAIRED276
277
L.R. Lopez, T. Bottiglieri, A. Vasudevan, C. Swift, R. Schiffmann,
P.A. McCullough (USA)
M. Schneider, M. Mieth, S. Titze, F. Kronenberg, Y. Li, R. Maas, K.U. Eckardt
(Germany)
17:30 CONVERGENT SIGNALING PATHWAYS CONTROLLED BY LRP1
CYTOPLASMIC AND EXTRACELLULAR DOMAINS LIMIT CELLULAR
CHOLESTEROL ACCUMULATION
282
284
N. Vujic, S. Schlager, T.O. Eichmann, M. Goeritzer, C.T. MadreiterSokolowski, S. Schauer, A. Lass, R. Zimmermann, G. Hoefler, W.F. Graier,
B. Radovic, D. Kratky (Austria)
18:00 LACK Of ADIPOSE TISSUE LIPOLYSIS PROTECTS AGAINST PRESSURE
OVERLOAD-INDUCED HEART FAILURE
278
283
P. Boucher, Z. El Asmar, J. Terrand, M. Jenty, L. Host, M. Mlih, A. Zerr,
H. Justiniano, R. Matz L., C. Boudier, E. Scholler, J.M. Garnier, D. Bertaccini,
D. Thiersé, C. Schaeffer, V.D. Alain, J. Herz (France)
17:45 MONOGLYCERIDE LIPASE REGULATES ENDOCANNABINOID
TONE AND ATHEROSCLEROTIC PLAQUE STRUCTURE
In APOLIPOPROTEIn E-DEFICIENT MICE
C. Barale, C. Frascaroli, F. Cavalot, A. Guerrasio, I. Russo (Italy)
18:15 ASYMMETRIC DIMETHLYARGININE DIRECTLY PROMOTES CHRONIC
KIDNEY DISEASE PROGRESSION: EVIDENCE FROM A MENDELIAN
RANDOMIZATION APPROACH In The GCKD STUDY
17:15 α/β HYDROLASE DOMAIN-CONTAINING 6 (ABHD6) DEGRADES The LATE
ENDOSOMAL/LYSOSOMAL LIPID BIS(MONOACYLGLYCERO)PHOSPHATE
R. Zimmermann (Austria)
R. Laaksonen, K. Ekroos, M. Sysi-Aho, T. Vihervaara, D. Kauhanen, M. Hilvo,
R. Hurme, E. Ringdal Pedersen, G. Tell, O. Nygård (Finland)
18:00 INCREASED F2-ISOPROSTANE OXIDATIVE STRESS In CORONARY ARTERY
DISEASE (CAD) PATIENTS WITH POOR ASPIRIN-INDUCED THROMBOXANE
B2 INHIBITION 281
L.O. Martinez, G. Cardouat, S. Fried, S. Najib (France)
S. Baumann, M. Renker, S. Hetjens, T. Becher, D. Loßnitzer, I. Akin,
M. Borggrefe, U.J. Schoepf (Germany)
17:30 PLASMA CERAMIDES IDENTIFY RESIDUAL CARDIOVASCULAR RISK
In STATIn TREATED CORONARY ARTERY DISEASE PATIENTS
17:00 AN UNEXPECTED ROLE Of AUTOPHAGY In TARGETING FUNCTIONAL
MITOCHONDRIAL ATP SYNTHASE TO The PLASMA MEMBRANE: ITS ROLE
In HDL ENDOCYTOSIS
285
A. Foryst-Ludwig, J. Salatzki, S. Brix, Z. Ban, J. Grune, R. Klopfleisch,
M. Rothe, E. Kershaw, U. Kintscher (Germany)
18:15 A LOSS-OF-FUNCTION VARIANT In OSBPL1A PREDISPOSES TO LOW
PLASMA HDL CHOLESTEROL LEVELS AND IMPAIRED CHOLESTEROL
EFFLUX CAPACITY
286
J. Van Capelleveen, J. Pirhonen, M.M. Motazacker, M. Weber-Boyvat,
M. Jauhiainen, G.K. Hovingh, G.M. Dallinga-Thie, V. Olkkonen (Netherlands)
70
71
Young Investigator Session: Novel Pathways in
Atherosclerosis
Chair: J.A. Kuivenhoven (Netherlands)
287
Chair: R.O. Ryan (USA)
288
17:00 REDUCING AMYLOID PROCESSING PREVENTS DIABETES INDUCED
VASCULAR DYSFUNCTION.
84 EAS CONGRESS
th
289
May 29 - June 1, 2016
Innsbruck, Austria
P. Meakin, F. Khan, M. Ashford (United Kingdom)
17:15 A LIPID METABOLITE PROFILE In ATHEROSCLEROTIC PLAQUES
ASSOCIATED WITH INCREASED INFLAMMATION AND CARDIOVASCULAR RISK 290
L. Tomas, H. Björkbacka, A. Edsfeldt, A. Danielsson, M. Wigren, H. Grufman,
A. Persson, C. Prehn, J. Adamski, J. Nilsson, I. Gonçalves (Sweden)
17:30 A COMPLEX ATHEROSCLEROTIC PHENOTYPE Of MIF GENE-DEFICIENT
MICE In AN ATHEROGENIC APOE-/- BACKGROUND UNCOVERS A NOVEL
CONNECTION BETWEEN MIF AND B CELLS
291
C. Schmitz, E. Straußfeld, O. El Bounkari, H. Noels, J. Bernhagen (Germany)
17:45 MARKERS Of VULNERABLE PLAQUES In NON-HUMAN PRIMATES UNDER
ATHEROGENIC DIET
292
V. Di Cataldo, J. Piraquive Agudelo, A. Geloen, M. Verset, A. Paturet,
A. Serusclat, F. Lamberton, D. Ibarolla, F. Lavenne, D. Le Bars, H. Contamin,
E. Canet-Soulas (France)
18:00 The ROLE Of INFLAMMATION In The ASSOCIATION BETWEEN ADIPOSITY
AND SUBCLINICAL ATHEROSCLEROSIS
293
T. Christen, S. Trompet, K.B. Gast, P.C.N. Rensen, J.A.P. Willems van Dijk,
H.J. Lamb, A. De Roos, J.W. Jukema, F.R. Rosendaal, S. Le Cessie,
R. De Mutsert (Netherlands)
18:15 The RELATIONSHIP Of NETRIN- 1 EXPRESSION WITH MACROPHAGE
INFILTRATION AND POLARIZATION In HUMAN EPICARDIAL ADIPOSE
TISSUE AND SEVERITY Of CORONARY ARTERY DISEASE
294
K.M. Gurses, F. Ozmen, D. Kocyigit, N. Yersal, E. Bilgic, E. Kaya, C. Kopru,
T. Soyal, S. Doganci, L. Tokgozoglu, P. Korkusuz (Turkey)
e
m
m
a
r
g
o
r
P
c
fi
i
Scient
y, June 1, 2016
Wednesda
72
8:30 - 10:30
K. Landsteiner Hall
Plenary: Future Therapeutic Challenges
8:30
295
Chair: L. Tokgözoglu (Turkey)
296
In INTEGRATIVE OMICS APPROACH In HUMAN DISEASE RESEARCH
297
K. Suhre (Qatar)
9:00
DRUGS FOR METABOLIC DISORDERS AND OBESITY
298
M. Tschöp (Germany)
9:30
The USE Of NOVEL THERAPIES In ATHEROSCLEROSIS: FROM ANTIBODIES
TO NANOTECHNOLOGY
299
E. Stroes (Netherlands)
10:00 LESSONS LEARNED FROM EMERGING THERAPIES FOR SEVERE
HYPERTRIGLYCERIDEMIA300
D. Gaudet (Canada)
75
11:00 - 12:30
K. Landsteiner Hall
Workshop 1.4: Inflammation, Immunity and Atherosclerosis
Workshop 3.4: Biology of CVD Risk
Chair: G.D. Norata (Italy)
301
Chair: H. Colhoun (United Kingdom)
308
Chair: E. Lutgens (Netherlands)
302
309
11:00 TARGETING The ADAPTIVE IMMUNE SYSTEM: A NEW STRATEGY
In ATHEROSCLEROSIS303
E. Lutgens (Netherlands)
11:25 CHOLESTEROL, INFLAMMATION AND IMMUNITY
11:50 CD27 CO-STIMULATION FOSTERS REGULATORY T CELL SURVIVAL AND
AMELIORATED PROGRESSION Of ATHEROSCLEROSIS.
305
306
D. Tsiantoulas, I. Bot, M. Kiss, B. Bartolini-Gritti, L. Göderle, M. OzsvarKozma, T. Perkmann, K. Hartvigsen, A. Bergthaler, D.H. Conrad, J. Kuiper,
Z. Mallat, H. Jumaa, C.J. Binder (Austria)
311
G. Pasterkamp (Netherlands)
312
P. Willeit, X. Yin, D. Kaudewitz, P. Skroblin, A. Zampetaki, A.R. Moschen,
C.M. Ramirez, L. Goedeke, N. Rotllan, E. Bonora, A.D. Hughes, P. Santer,
C. Fernandez-Hernando, H. Tilg, J. Willeit, S. Kiechl, M. Mayr (United
Kingdom)
12:03 ASSOCIATIONS BETWEEN LIPOPROTEIn SUBFRACTIONS AND GENOMEWIDE DNA METHYLATION In KORA F4
313
L. Pfeiffer, R. Wilson, H. Grallert, E. Reischl, A. Peters, C. Gieger, S. Wahl,
M. Waldenberger (Germany)
A. Lindau, C. Haerdtner, F.K. Swirski, P. Libby, L. Hein, C. Bode, A. Zirlik,
I. Hilgendorf (Germany)
12:16 DEFICIENCY Of SECRETED IgM ANTIBODIES CAUSES INCREASED PLASMA
IgE LEVELS THAt PROMOTE ATHEROSCLEROSIS
310
H. Colhoun (United Kingdom)
11:50 CIRCULATING MICRORNA-122 IS ASSOCIATED WITH INCIDENT
METABOLIC SYNDROME AND TYPE-2 DIABETES
H. Winkels, S. Meiler, C. Spitz, C. Buerger, A. Faussner, J. Borst, C. Weber,
E. Lutgens, N. Gerdes
12:03 EARLY ATHEROPROTECTION BY SYK INHIBITION FAILS In ESTABLISHED
DISEASE WHEN LOCAL MACROPHAGE PROLIFERATION DOMINATES
LESION PROGRESSION
11:00 NOVEL BIOMARKERS FOR CVD In METABOLIC DISORDERS
11:25 CIRCULATING CELLS AND CVD RISK
304
L. Yvant-Charvet (France)
76
11:00 - 12:30
307
12:16 PLASMA LIPIDOMIC PROFILES IMPROVE UPON CONVENTIONAL RISK
FACTORS TO PREDICT CARDIOVASCULAR EVENTS
314
P. Mundra, C. Barlow, N. Mellett, K. Huynh, Z. Alshehry, G. Wong, B. Kingwell,
P. Nestel, P. Thompson, D. Sullivan, E. Barnes, J. Simes, A. Tonkin, P. Meikle
(Australia)
77
11:00 - 12:30F. Pregl Hall
Workshop: New Guidelines on Prevention of
Cardiovascular Disease in Clinical Practice
Workshop 2.4: Novel Role of Lipoprotein Receptors
315
Chair: M. Piepoli (Italy)
316
11:00 INTRODUCTION: WHAt IS NEW In THESE GUIDELINES?
318
M. Piepoli (Italy)
11:05 HOW CAN WE IDENTIFY HIGH RISK?
320
321
A. Catapano (Italy)
11:50 POPULATION APPROACH TO PREVENT CVD
328
11:00 NOVEL ROLE Of ENDOTHELIAL RECEPTORS In ATHEROSCLEROSIS
329
A. von Eckardstein (Switzerland)
330
H. Bujo (Japan)
11:50 REGULATION Of HDL-C LEVELS VIA ABCA1: A ROLE FOR LRP1331
TBA
11:35 LIPIDS: WHAt IS NEW?
327
Chair: E. Steyrer (Austria)
11:25 SOLUBLE LR11, A CIRCULATING MARKER FOR ATHEROSCLEROSIS
319
I. Graham (Ireland)
11:20 WHAt ARE The RISK FACTOR TARGETS?
Chair: A. von Eckardstein (Switzerland)
322
E. Bossano Prescott (Denmark)
12:05 PANEL DISCUSSION
323
12:25CONCLUSIONS
324
F. Oldoni, J. Van Capelleveen, M.M. Motazacker, J. Heeren, R. Sinke,
G. Dallinga-Thie, D. Hui, K. Hovingh, J.A. Kuivenhoven (Netherlands)
12:03 SorLA IS A NOVEL HIGH AFFINITY PCSK9 RECEPTOR THAt INHIBITS ITS
INACTIVATION BY FURIN
332
C. Gustafsen, S. Skeldal, S.L. Jensen, O.M. Andersen, C.M. Petersen,
P. Madsen, S. Glerup (Denmark)
12:16 UNRAVELLING The MECHANISM AND IMPORTANCE Of BROWN ADIPOSE
TISSUE WHOLE LIPOPROTEIn UPTAKE
333
A. Fischer, K. Gottschling, N. Mangels, M. Heine, J. Heeren (Germany)
A. Catapano (Italy)
M. Piepoli (Italy)
78
325
79
84 EAS CONGRESS
th
May 29 - June 1, 2016
Innsbruck, Austria
e
c
n
a
l
G
a
t
a
e
c
Scien
s
n
o
i
t
a
t
n
e
s
e
r
P
E-Poster
80
Science at a Glance
CALL FOR PAPERS
Atherosclerosis
Official Journal of the European Atherosclerosis Society
Atherosclerosis publishes original papers and review articles
reporting research findings and investigations into all aspects
of atherosclerosis, its complications and related diseases.
Encompassing: lipoprotein metabolism, disorders of lipid
transport, arterial and vascular biology, including vascular
imaging and flow studies, cardiovascular stem cell biology,
thrombosis and inflammation. Papers covering genetics, metaanalysis and epidemiology of atherosclerosis are of interest, as are
dietary studies and investigations into diabetes and hypertension
as related to atherosclerosis and cardiovascular risk factors.
Publisher, Koos Admiraal, k.admiraal@elsevier.com
Editor-in-Chief: A. von Eckardstein
If you have a specific question please contact our
Editorial Assistant, S. Negrini, Simona.Negrini@usz.ch
BENEFITS OF PUBLISHING IN ATHEROSCLEROSIS
• Seamless electronic editorial system, from online submission to article publication, with clear
instructions and online tracking.
• Improved presentation and the option to enrich your article with graphical abstracts, video,
3D images and linkage of content to relevant databases.
• Rapid editorial processing and availability of accepted articles (2-3 weeks after acceptance) as
“articles in press”
• Advance notification of article publication via ScienceDirect’s alerting service
• High visibility, with articles appearing in Scopus and PubMed shortly after publication
• Unparalleled international readership via ScienceDirect, with 10 million active users monthly from
over 120 countries. Over 80,000 Atherosclerosis articles are downloaded every month.
• Atherosclerosis available via mobile Apps for increased accessibility
• Authors receive quarterly updates of the number of downloads of their article
• Open access publishing available
BENEFITS OF PUBLISHING IN ATHEROSCLEROSIS
Poster #
Lipids and Lipoproteins
SaG001
Chair: J. Heeren (Germany)
334
CONSEQUENCES OF DEFECTIVE LIPOLYSIS IN THE SMALL INTESTINE
ON LIPID METABOLISM
M. Korbelius, S. Obrowsky, S. Rainer, N. Vujic, D. Kratky (Austria)
335
SaG002 POSTTRANSCRIPTIONAL REGULATION OF THE LDLR BY ACTH
TREATMENT - IMPORTANCE OF PCSK9 IN LIVER WHILE IDOL TAKES
THE SCENE IN THE ADRENALS
M. Ghosh Laskar, B. Angelin, M. Rudling (Sweden)
336
SaG003 TNF-ALPHA INDUCES PROPROTEIN CONVERTASE SUBTILISIN KEXIN
TYPE 9 (PCSK9) EXPRESSION IN HEPATIC HEPG2 CELL LINE IN A SOCS3-DEPENDENT MANNER
M. Ruscica, Ricci, C. Macchi, P. Magni, L. Jingwen, A. Corsini, N. Ferri
(Italy)
337
SaG004 A POTENTIAL ROLE OF CHOLESTEROL UPTAKE CAPACITY, A NEW
MEASURE FOR HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, IN
CORONARY RISK STRATIFICATION
A. Harada, R. Toh, K. Murakami, M. Kiriyama, K. Yoshikawa, T. Kubo,
K. Miwa, Y. Irino, K. Mori, N. Tanaka, T. Ishida, K. Hirata (Japan)
338
SaG005 LOW-DENSITY LIPOPROTEIN UPREGULATE SR-BI THROUGH SP1
SER702 PHOSPHORYLATION IN HEPATIC CELLS
L. Wang, F. Yang, Y. Du, J. Zhang, B. Hong (China)
339
SaG006 SNPS LOCATED IN ABCA1, CETP AND APOA5/A4/C3/A1 ARE
ASSOCIATED WITH PLASMA CHOLESTEROL EFFLUX
C. Talbot, J. Plat, H. Popeijus, A. Ritsch, R. Mensink
340
SaG007
IDENTIFICATION OF A NOVEL APOLIPOPROTEIN THAT FACILITATES
MTP-MEDIATED LIPID TRANSPORT
H. Peng, C.S. Liu, T.Y. Chiu, H.T. Chen, J.J.Y. Yen, H.F. Yang-Yen (Taiwan)
SaG008 BETA CELL-SPECIFIC DELETION OF ABCA1 AND ABCG1 REGULATES
THE INCREASE OF SMALL NUCLEOLAR RNAS IN ADIPOCYTES
F. Tabet, L. Hou, B. Cochran, L.F. Cuesta Torres, P.J. Barter, K.A. Rye
(Australia)
341
342
Easy online submission at: http://ees.elsevier.com/ath
More information on the types of papers we publish and further instructions
for authors can be found at: www.atherosclerosis-journal.com
83
Science at a Glance
Poster #
Poster #
Vascular Biology I
Genetic, Omics and in silico Approaches
Chair: G.R.Y. De Meyer (Belgium)
343
SaG009 HIGH-DENSUTY LIPOPROTEIN PHOSPHOLIPID CONTENT AND
APOLIPOPROTEIN A-I LEVEL ARE DETERMINANTS OF CHOLESTEROL
EFFLUX CAPACITY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA 344
M. Ogura, M. Harada-Shiba (Japan)
SaG010
SaG011
SaG012
SaG013
SaG014
SaG015
SaG016
84
A HIGH-THROUGHPUT SCREENING OF KINASE INHIBITORS IDENTIFIES
A REGULATORY ROLE OF VEGF SIGNALING FOR TRANSENDOTHELIAL
TRANSPORT OF HIGH-DENSITY LIPOPROTEINS
S. Velagapudi, L. Rohrer, A. Von Eckardstein (Switzerland)
346
SMOOTH MUSCLE CELLS PCSK9 KNOCK-OUT EXHIBIT AN IMPAIRED
RESPONSE TO PDGF STIMULATION
S. Marchianò, G. Tibolla, A. Corsini, A.L. Catapano, N. Ferri (Italy)
347
5-METHOXYTRYPTOPHAN REDUCES NEOINTIMA FORMATION
FOLLOWING ARTERIAL INJURY
C.H. Chen, Y.C. Ho, H.H. Ho, C.H. Su, S.F. Yet (Taiwan)
348
SaG019
IMPACT OF FIBRE ORIENTATION IN FIBROUS CAP ON THE
MECHANICAL LOADING IN HUMAN CORONARY ATHEROSCLEROTIC
PLAQUES349
Z. Teng, G. Douglas, A. Brown, M. Sutcliffe, J. Gillard (United Kingdom)
IN VITRO MIGRATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS
(PBMCS) INTO HUMAN HEALTHY AND DISEASED ARTERIES
B. Jakic, C. Krapf, M. Buszko, G. Cappellano, M. Grimm, G. Wick (Austria)
SaG018
345
MITOPHAGY ACTS AS A SAFEGUARD MECHANISM AGAINST HUMAN
VASCULAR SMOOTH MUSCLE CELL APOPTOSIS INDUCED BY
ATHEROGENIC LIPIDS
H. Nahapetyan, A. Swiader, J. Faccini, R. D'Angelo, E. Mucher, M. Elbaz,
P. Boya, C. Vindis (France)
MDM2 E3 LIGASE-MEDIATED UBIQUITINATION AND DEGRADATION OF
HDAC1 IN VASCULAR CALCIFICATION
H. Kook, D.H. Kwon, G.H. Eom, S. Shin, E.M. Kim, Y.U. Lee, N. Choe
(Republic of Korea)
SaG017
350
351
Chair: N. Sanjana (USA)
352
GENE EXPRESSION PROFILES OF RECURRENT ACUTE PANCREATITIS
RISK IN SEVERE HYPERTRIGLYCERIDEMIA
K. Tremblay, D. Gaudet (Canada)
353
EVIDENCE FOR ENHANCED DE NOVO LIPOGENESIS AND
UNCOUPLING OF OBESITY FROM TYPE 2 DIABETES RISK IN THE LOWEXPRESSION VARIANT CARRIERS OF FATTY ACID-BINDING PROTEIN 4
J. Saksi, P. Ijäs, A. Jula, H. Heikkilä, J. Tuimala, O. Dwivedi, T.M. Tuomi,
L. Groop, M. Jauhiainen, P. Kovanen, P. Lindsberg (Finland)
354
THE PREVALENCE OF FAMILIAL HYPERLIPIDAEMIA AND
HYPER-LIPOPROTEIN(A) IN MUTATION-NEGATIVE FAMILIAL
HYPERCHOLESTEROLAEMIA AND ASSOCIATIONS WITH
CARDIOVASCULAR EVENTS
K. Ellis, J. Pang, D. Chan, A. Hooper, D. Bell, J. Burnett, G. Watts
(Australia)
SaG020 THE RS16900627 POLYMORPHISM OF THE RECEPTOR-INTERACTING
PROTEIN 2 (RIP2) GENE IS ASSOCIATED WITH SUBCLINICAL
ATHEROSCLEROSIS. THE GENETICS OF ATHEROSCLEROTIC DISEASE
(GEA) MEXICAN STUDY
G. Vargas-Alarcon, R. Posadas-Sánchez, J. Angeles-Martínez, E. AlvarezLeón, N. Pérez-Hernánez, J.M. Rodríguez-Pérez, J.M. Fragoso,
G. Cardoso, T. Villarreal-Molina, C. Posadas-Romero (Mexico)
SaG021
SaG022
RARE VARIANTS IN ABCG2 IDENTIFIED BY SEQUENCING MAY
INFLUENCE THE LIPID RESPONSE TO ROSUVASTATIN TREATMENT
M. Hu, J. Chan, B. Tomlinson (Hong Kong- China)
CHARACTERISTICS OF HOMOZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA IN SPAIN
R.M. Sánchez-Hernández, M. Stef, S. Perez-Calahorra, F. Almagro,
P. Sáenz-Aranzubía, N. Plana, J.T. Real, F. Blanco-Vaca, J.F. Ascaso,
F. Civeira, M. Pocovi (Spain)
355
356
357
358
SaG023
CLINICAL CHARACTERISTICS AND PREVALENCE OF CARDIOVASCULAR
DISEASE RISK FACTORS IN SUBJECTS SCREENED FOR FAMILIAL
HYPERCHOLESTEROLEMIA - A CROSS SECTIONAL STUDY IN THE
NETHERLANDS359
M.L. Hartgers, J. Besseling, B. Lucius, L. Kutikova, G.K. Hovingh (Netherlands)
SaG024
LOOKS LIKE FH BUT IT'S NOT FH - EXTENDED LIPID PROFILE OF
PAEDIATRIC CLINICAL FH PATIENTS REVEALS A DIFFERENT LIPID
PROFILE IN FH NEGATIVE PATIENTS
A.M. Medeiros, M. Bourbon, P. Aguiar (Portugal)
360
85
Science at a Glance
Poster #
Poster #
CV Risk Factors and Atherosclerosis I
Experimental Cadiovascular Medicine I
Chair: Y. Matsuzawa (Japan)
SaG025
SaG026
SaG027
SERUM PHOSPHATIDYLCHOLINE PLASMALOGEN AND ALKYLPHOSPHATIDYLCHOLINE CONCENTRATIONS ARE INVERSELY
ASSOCIATED WITH MYOCARDIAL INFARCTION INCIDENCE IN PATIENTS
WITH PERIPHERAL ARTERY DISEASE
J. Moxon, R. Jones, G. Wong, D. Liu, J. Weir, R. Behl-Gilhotra, B. Kingwell,
P. Meikle, J. Golledge (Australia)
SaG029
SaG032
86
362
SaG034
363
ANTI-APOLIPOPROTEIN A-1 ANTIBODIES AS A NOVEL
CARDIOVASCULAR RISK FACTOR: RESULTS FROM THE COLAUS STUDY
N. Vuilleumier (Switzerland)
364
REMNANT CHOLESTEROL PREDICTS CARDIOVASCULAR EVENT RISK
IN PATIENTS WITH TYPE 2 DIABETES INDEPENDENTLY FROM THE
BASELINE CORONARY ARTERY DISEASE STATE
C. Saely, D. Zanolin, P. Rein, A. Vonbank, A. Leiherer, A. Muendlein,
H. Drexel (Austria)
SaG030 THE PROSPECTIVE RELATIONSHIPS OF CIRCULATING AND URINARY
CHOLINE METABOLITES WITH INCIDENT TYPE 2 DIABETES AMONG
PATIENTS WITH SUSPECTED STABLE ANGINA PECTORIS
G.F.T. Svingen, H. Schartum-Hansen, E.R. Pedersen, P.M. Ueland,
G.S. Tell, G. Mellgren, P.R. Njølstad, R. Seifert, E. Strand, T. Karlsson,
O.K. Nygård (Norway)
SaG031
SaG033
SERUM ACYLCARNITINES AND RISK OF INCIDENT TYPE 2 DIABETES
IN PATIENTS WITH SUSPECTED STABLE ANGINA PECTORIS - A
PROSPECTIVE COHORT STUDY
E.W. Rebnord, E. Strand, G.F.T. Svingen, P.R. Njølstad, G. Mellgren,
G.S. Tell, R.K. Berge, A. Svardal, O.K. Nygård, E.R. Pedersen (Norway)
SaG028 REDUCTION IN PLASMA CHOLESTEROL EFFLUX CAPACITY FROM
HUMAN MACROPHAGES IS ASSOCIATED WITH THE APPEARANCE OF
CLINICAL FEATURES OF METABOLIC SYNDROME
J. Gall, E. Frisdal, R. Bittar, W. Le Goff, E. Bruckert, P. Lesnik, M. Guerin,
P. Giral (France)
Chair: P. Parini (Sweden)
361
365
366
SaG035
SaG036
SaG037
ASSOCIATIONS OF TRIGLYCERIDES WITH PERCENT BODY FAT IN
ADOLESCENTS: THE PEP FAMILY HEART STUDY
T. Bertsch, G.M. Haas, E. Liepold, P. Schwandt (Germany)
368
HEPATITIS C VIRUS (HCV) AND ATHEROSCLEROSIS RISK: A ROLE FOR
LOW-DENSITY IMMUNE COMPLEXES?
M. Bassendine, S. Nielsen, D. Neely (United Kingdom)
369
HEPATIC MIRNA EXPRESSION PROFILING IN GENETICALLY MODIFIED
MOUSE MODELS OF DIFFERENT ATHEROSCLEROSIS SUSCEPTIBILITY
S. Manzini, M. Busnelli, M. Chiara, C. Parolini, F. Dellera, G.S. Ganzetti,
D.S. Horner, G. Chiesa (Italy)
371
372
ESTRADIOL PROTECTS OVARIECTOMIZED FEMALE RATS AGAINST
FRUCTOSE RICH DIET INDUCED CARDIAC INFLAMMATION
M. Bundalo, M. Zivkovic, G. Koricanac, A. Stankovic (Serbia)
373
IMPACT OF ENDOTHELIAL LIPASE OVEREXPRESSION ON
CHOLESTEROL EFFLUX CAPACITY OF SERUM, APOLIPOPROTEIN
B-DEPLETED SERUM AND HDL
I. Schilcher, A. Hrzenjak, T. Eichmann, T. Stojakovic, H. Scharnagl,
G. Marsche, S. Frank (Austria)
374
SR-BI INVOLVED ON PLASMA HDL2-APOA-I RECIRCULATION TO PREbHDL IN MICE
M. Tsujita, T. Yokota, N. Akita, F.J. Gonzalez, S. Yokoyama (Japan)
375
SaG038 MICE ABUNDANT IN MURICHOLIC BILE ACIDS SHOW RESISTANCE
TO DIETARY INDUCED STEATOSIS, WEIGHT GAIN, AND TO IMPAIRED
GLUCOSE METABOLISM
Y. Bonde, G. Eggertsen, M. Rudling (Sweden)
SaG039
367
THE ROLE OF MICRO RNAS AND THEIR TARGETS IN A CAROTID
ARTERY INTIMAL HYPERPLASIA
Y.U. Lee, N. Choe, E.M. Kim, S. Shin, D.H. Kwon, T. Kook, H. Kook
(Republic of Korea)
370
IMPACT OF LITOMOSOIDES SIGMODONTIS ANTIGEN ON T CELL
DIFFERENTIATION AND ON THE DEVELOPMENT OF INITIAL
ATHEROSCLEROTIC LESIONS IN APOE-KNOCKOUT MICE
C. Kühn, M. Tauchi-Brück, J. Ajendra, A. Hörauf, C. Stumpf,
S. Achenbach, M. Hübner, B. Dietel (Germany)
SaG040 UNSTABLE LDL - NOVEL MECHANISM OF ATHEROGENESIS AND LINK
TO CARDIOVASCULAR DEATHS
M. Ruuth, S.D. Nguyen, T. Vihervaara, T.D. Laajala, M. Uusitupa,
U. Schwab, M. Savolainen, J. Sinisalo, T. Aittokallio, R. Käkelä,
M. Jauhiainen, P. Kovanen, K. Oörni (Finland)
376
377
378
87
Science at a Glance
Poster #
Poster #
Nutrition, Nutraceuticals and Cardiovascular Disease
Pharmacology of Dyslipidemia
Chair: A.H. Lichtenstein (USA)
SaG041
MIDDLE-TERM DIETARY SUPPLEMENTATION WITH RED YEAST RICE
PLUS COENZYME Q10 IMPROVES LIPID PATTERN, ENDOTHELIAL
REACTIVITY AND ARTERIAL STIFFNESS IN MODERATELY
HYPERCHOLESTEROLEMIC SUBJECTS
A. Cicero, M. Morbini, M. Rosticci, S. D'Addato, E. Grandi, C. Borghi (Italy)
SaG042 INCREASED OXIDATIVE STRESS AND IMPAIRED MITOCHONDRIAL
BIOGENESIS AND DYNAMICS ARE IMPROVED BY RICE BRAN
ENZYMATIC EXTRACT DIET SUPPLEMENTATION
C. Perez Ternero, C. Werner, M. Alvarez de Sotomayor, M.D. Herrera,
U. Laufs (Spain)
SaG043
INVESTIGATION OF THE IMPACT OF CROCUS SATIVUS ON THE
METABOLIC PROFILE OF DIABETIC RATS
P. Konstantopoulos, L.M. Korou, I. Vlachos, I. Doulamis, A. Tzani,
S. Fragouli, G. Mastorakos, Ν. Katsilambros, D. Perrea (Greece)
SaG044 LONG-CHAIN METABOLITES OF Α-TOCOPHEROL EMERGE FROM THE
SHADOW OF THEIR PRECURSORS: Α-13’-OH AND Α-13’-COOH AS A
NEW CLASS OF REGULATORY METABOLITES
L. Schmölz, M. Wallert, S. Ciffolilli, S. Kluge, G. Cruciani, M. Glei, O. Werz,
F. Galli, M. Birringer, S. Lorkowski (Germany)
SaG045
CONSUMPTION OF POLYUNSATURATED FAT IMPROVES THE
SATURATED FATTY ACID-MEDIATED IMPAIRMENT OF HDL
ANTIOXIDANT POTENTIAL
A. García León, L. Cedó, J. Metso, D. Santos, J.L. Sánchez-Quesada,
J. Julve, J. Mora-Brugués, M. Jauhiainen, F. Blanco-Vaca, J.C. Escolà-Gil
(Spain)
SaG046 PLASMA LEVELS OF THE PRO-ATHEROGENIC NUTRIENT BIOMARKER
TMAO IS INCREASED BY EXPOSURE TO DIOXIN-LIKE POLLUTANTS
THROUGH UPREGULATION OF FMO3
M. Petriello, J. Hoffman, M. Sunkara, A. Morris, B. Hennig (USA)
SaG047
SOYA-ENRICHED MIXED DIET SIGNIFICANTLY IMPROVES
CARDIOVASCULAR AND METABOLIC RISK FACTORS: A RANDOMIZED
CONTROLLED TRIAL
M. Ruscica, C. Pavanello, B. Morlotti, M. Gomaraschi, C. Vitali, R. Bosisio,
C.R. Sirtori, A. Arnoldi, P. Magni (Italy)
SaG048 PREVALENCE AND 2010-15 SECULAR TRENDS IN SUGAR-SWEETENED
BEVERAGES SALES IN EUROPE AND THE MIDDLE EAST
B. Arsenault, M.R. Taskinen, J.P. Després (Canada)
88
Chair: M. Averna (Italy)
379
380
SaG049 ATTAINMENT OF ACC/AHA RECOMMENDED LDL-C LOWERING WITH
STATIN AND EZETIMIBE STATIN THERAPIES
P. Toth, H. Bays, M. Farnier, E. Jensen, J. Tomassini, A. Polis, J. Foody,
A. Tershakovec (USA)
381
SaG050 EFFICACY AND SAFETY OF PITAVASTATIN IN PAEDIATRIC FH
COMPARED WITH OTHER STATINS FROM COCHRANE DATABASE
M. Harada-Shiba, T. Ohta, A. Ohtake, T. Okada, O. Arisaka, J. Kastelein,
I. Luirink (Japan)
SaG051
382
SaG052
383
SaG053
384
385
386
387
SaG054
SaG055
SaG056
HOW TO IMPROVE THE CHOLESTEROL-LOWERING EFFICACY OF
EZETIMIBE IN STATIN-INTOLERANT PATIENTS IN CLINICAL PRACTICE: A
RETROSPECTIVE STUDY
A. Cicero, M. Morbini, S. D'Addato, F. Fogacci, M. Rosticci, C. Borghi (Italy)
IDENTIFICATION AND MANAGEMENT OF CANADIAN PATIENTS WITH
SYMPTOMS OF STATIN INTOLERANCE: RESULTS FROM A REAL-WORLD
CLINICAL PRACTICE SURVEY
P. Oh, G.K. Hovingh, S.R. Gandra, J. McKendrick, R. Dent, H.M. Wieffer,
A.L. Catapano, R.S. Rosenson, E.S.G. Stroes (Switzerland)
PCSK9 CIRCULATING LEVELS AND CETP PLASMA ACTIVITY ARE
ASSOCIATED INDEPENDENTLY OF LIPID LOWERING THERAPIES
J. Girona, D. Ibarretxe, N. Plana, S. Guaita, N. Amigó, M. Heras, L. Masana
(Spain)
UNDERSTANDING LIPOPROTEIN(A) METABOLISM: REBOUND ANALYSES
OF LIPOPROTEIN(A) AND PCSK9 CONCENTRATIONS FOLLOWING
REGULAR LIPOPROTEIN APHERESIS TREATMENT (THE LIPARE-STUDY)
E. Waldmann, E.M. Ooi, P.H.R. Barrett, D.C. Chan, S.M. Marcovina,
G.F. Watts, K.G. Parhofer (Germany)
DPP4 INHIBITOR, ANAGLIPTIN, AMELIORATES FASTING AND
POSTPRANDIAL HYPERTRIGLYCERIDEMIA
M. Sairyo, D. Masuda, T. Kobayashi, H. Matsuda, T. Okada, R. Kawase,
K. Nakatani, M. Koseki, T. Ohama, M. Nishida, Y. Sakata, S. Yamashita
(Japan)
FAMILIAL HYPERCHOLESTEROLEMIA IN PRIMARY CARE IN GERMANY
- DIABETES AND CARDIOVASCULAR RISK EVALUATION: TARGETS AND
ESSENTIAL DATA FOR COMMITMENT OF TREATMENT (DETECT) STUDY
N. Schmidt, B. Schmidt, A. Dressel, U. Fraass, I. Gergei, J. Klotsche,
L. Pieper, H. Scharnagel, M.E. Kleber, W. März, H.U. Wittchen, T. Grammer
(Germany)
388
389
390
391
392
393
394
395
396
89
Science at a Glance
Poster #
Poster #
Imaging in Vascular Dysfunction and Myocardial Infarction
Chair: W. Koenig (Germany)
SaG057
A NOVEL TC-99M AND FLUORESCENCE LABELED PEPTIDE AS A
MULTIMODAL IMAGING AGENT FOR TARGETING ANGIOGENESIS IN A
MURINE HINDLIMB ISCHEMIA MODEL
D.W. Kim, S.G. Kim, M.H. Kim, C.G. Kim (Republic of Korea)
397
CV Risk Factors and Atherosclerosis II
398
Chair: W. März (Germany)
SaG065
SaG058 REPRODUCIBILITY OF ENDOTHELIAL SHEAR STRESS AND LOW
DENSITY LIPOPROTEIN TRANSPORT MODELING IN COMPUTED
TOMOGRAPHY ANGIOGRAPHIC IMAGING DATA
A. Sakellarios, C.V. Bourantas, S.L. Papadopoulou, T. De Vries,
P.H. Kitslaar, C. Gyrasis, K.K. Naka, S. Veldhof, G.W. Stone, J.H.C. Reiber,
L.K. Michalis, P.W. Serruys, P.J. De Feyter, H.M. Garcia Garcia, D.I. Fotiadis
(Greece)
SaG059
USAGE OF NOVEL HYBRID PIXEL DETECTORS FOR NATIVE
ATHEROSCLEROTIC PLAQUE IMAGING BY HIGH RESOLUTION X-RAY
COMPUTED TOMOGRAPHY
A. Zhemchugov, A. Svetlikov, D. Kozhevnikov, G. Shelkov, S. Urazgildeeva,
V. Gurevich (Russia)
SaG060 COMPOSITION OF CORONARY PLAQUES BY CT ANGIOGRAPHY:
VALIDATION BY NEAR-INFRARED SPECTROSCOPY
J.A. Goldstein, R.D. Madder, S. Dixon (USA)
SaG061
SaG062
SaG063
ACTIVATED-PLATELET TARGETED FIBRINOLYTIC DRUGS: NOVEL
TARGETED-THERANOSTIC MICROBUBBLES FOR SIMULTANEOUS
DIAGNOSIS, TREATMENT AND MONITORING USING MOLECULAR
ULTRASOUND TECHNOLOGY
X. Wang, K. Peter (Australia)
CARDIOVASCULAR EVENTS IN PATIENTS TREATED BY LIPOPROTEIN
APHERESIS (LA) - ANALYSIS OF POSSIBLE REASONS
S. Tselmin, S. Fischer, F. Pistrosch, G. Müller, U. Julius (Germany)
THE RELATIONSHIP BETWEEN INSULIN LIKE GROWTH FACTOR-1
AND CORONARY ARTERY CALCIUM SCORE IN CARDIOVASCULAR
ASYMPTOMATIC ADULT MEN
K.C. Park, M.J. Kim, K.C. Kim, B.H. Choi, K.H. Park, H.C. Cho (Republic of
Korea)
SaG064 2013 ACC/AHA VERSUS 2004 NCEP ATP III GUIDELINES IN THE
PREDICTION OF CORONARY ARTERY CALCIFICATION PROGRESSION
IN A KOREAN POPULATION
C.H. Jung, S. Kim, W.J. Lee, J.Y. Park, C.Y. Park (Republic of Korea)
399
SERUM LEVELS OF ANTI-APOLIPOPROTEIN A-1 IGG ARE ASSOCIATED
WITH LONG-TERM DISABILITY AND CEREBRAL LESION VOLUME IN
ACUTE ISCHEMIC STROKE PATIENTS
406
407
N. Satta, F. Carbone, F. Montecucco, J. Virzi, F. Burger, A. Roth,
G. Roversi, C. Tamborino, I. Casetta, S. Seraceni, A. Trentini, M. Padroni,
F. Dallegri, P. Lalive, F. Mach, E. Fainardi, N. Vuilleumier (Switzerland)
SaG066 GLYCATION OF APOA-I LINKS DIABETES AND CVD
408
J. Domingo-Espin, O. Nilsson-Wolanin, J. Dalla-Riva, K. Bernfur,
M. Lindahl, J. Lagerstedt (Sweden)
400
SaG067
APOLIPOPROTEIN CII AND CIII: PROGNOSTIC MARKERS OF
CARDIOVASCULAR RISK?
409
H. Scharnagl, M.E. Kleber, T.B. Grammer, T. Stojakovic, M.M. Hoffmann,
W. März (Austria)
401
SaG068 SERUM MMP-8 AND TIMP-1 ASSOCIATE WITH INCIDENT CVD EVENTS
AND ALL-CAUSE MORTALITY IN A POPULATION-BASED COHORT
410
I. Kormi, A.S. Havulinna, V. Salomaa, T. Tervahartiala, T. Sorsa,
P.J. Pussinen (Finland)
402
SaG069 PLASMA CONCENTRATIONS OF AFAMIN ARE ASSOCIATED WITH THE
PREVALENCE AND INCIDENCE OF TYPE 2 DIABETES MELLITUS
411
B. Kollerits, C. Huth, S. Kiechl, C. Lamina, C. Meisinger, C. Herder,
L. Kedenko, J. Willeit, B. Thorand, D. Dähnhardt, D. Stöckl, M. Roden,
W. Rathmann, B. Paulweber, A. Peters, H. Dieplinger, F. Kronenberg (Austria)
403
SaG070
OMENTIN-1 AND RISK OF STROKE: RESULTS FROM THE EPIC-POTSDAM
COHORT STUDY
412
J. Menzel, R. Di Giuseppe, R. Biemann, C. Wittenbecher, K. Aleksandrova,
T. Pischon, A. Fritsche, M.B. Schulze, H. Boeing, B. Isermann, C. Weikert
(Germany)
404
SaG071
405
AGE, GENDER AND BLOOD LIPID LEVELS: A CHANCE TO IMPROVE
CARDIOVASCULAR RISK ASSESSMENT
413
W. Balder, J.K. De Vries, I.M. Nolte, J.A. Kuivenhoven, P.W. Kamphuisen
(Netherlands)
SaG072
THE ADDED VALUE OF AORTIC PWV BEYOND TRADITIONAL RISK
FACTORS IN CARDIOVASCULAR RISK STRATIFICATION
414
B. Benczur, R. Bocskei, A. Cziraki, M. Illyes (Hungary)
90
91
Science at a Glance
Poster #
Poster #
Vascular Biology II
Insulin Resistance, Diabetes, Metabolic Syndrome and
Obesity
Chair: H. Stangl (Austria)
SaG073
ENDOTHELIAL DYNAMIC CHANGES IN CHONDROITIN SULFATE AND
DERMATAN SULFATE PROTEOGLYCANS INDUCED BY VERY LOW
DENSITY LIPOPROTEINS
415
Chair: G. Watts (Australia)
416
SaG081
R.E. Oberkersch, Y. Rasente, S. Yuschak, N. Volpi, G. Calabrese
(Argentina)
SaG074
PRO-ATHEROGENIC OXIDIZED-LDL/Β2-GLYCOPROTEIN I COMPLEXES
IN CORONARY ARTERY DISEASE PATIENTS ARE ASSOCIATED WITH
DISEASE SEVERITY
PAI-1 EXPRESSION RENDERS M2 POLARIZED MACROPHAGES
PROTEOLYTICALLY QUIESCENT
417
IN VITRO EVIDENCE OF A PRO-INFLAMMATORY ACTION OF PCSK9 IN
THP-1-DERIVED MACROPHAGES
INCREASED MITOCHONDRIAL ROS ACCELERATE ATHEROSCLEROSIS IN
MITOCHONDRIAL CATALYTIC ENZYME 3 DEFICIENT MICE
COMPARATIVE EFFECT OF SILYMARIN AND SILYBIN TREATMENT
ON INFLAMMATION AND OXIDATIVE STRESS IN TRANSGENIC
SPONTANEOUSLY HYPERTENSIVE RATS OVEREXPRESSING HUMAN
C-REACTIVE PROTEIN
419
PONATINIB AUGMENTS VASOCONSTRICTION AND ATTENUATES
VASORELAXATION IN MOUSE AORTIC RINGS
J. Jalkanen, M. Maksimow, S. Jalkanen, H. Hakovirta (Finland)
92
428
N. García-Casares, J. García-Arnés, A. Gutiérrez-Cardo, J. Rioja,
M.J. Ariza, F. Alfaro, A. Nabrozidis, P. González-Santos (Spain)
SaG085
COMPONENTS OF THE METABOLIC SYNDROME AND RISK OF TYPE 2
DIABETES429
S. Marott, B. Nordestgaard, A. Tybjærg-Hansen, M. Benn (Denmark)
421
SaG086 THE PLASMA PROTEOME OF TANGIER DISEASE PATIENTS REVEALS
PERTURBATIONS OF DIABETIC AND INFLAMMATORY PATHWAYS
430
J. McParland, E. Pashos, D. Rader, M. Cuchel (USA)
SaG087
422
A. Kirsch, R. Kirchmair, S. Frank (Austria)
SaG080 CARDIOVASCULAR RISK FACTORS DIFFER IN INFLAMMATION
PATHOLOGY IN PATIENTS WITH CLINICALLY SYMPTOMATIC LOWER
LIMB ATHEROSCLEROSIS
SaG084 WAIST CIRCUMFERENCE AND BODY MASS INDEX CORRELATE WITH
CEREBRAL GLUCOSE METABOLISM IN THE TEMPORAL LOBE IN
DIABETIC PATIENTS
420
O. Oliyarnyk, H. Malinska, I. Markova, J. Trnovska, V. Skop, L. Kazdova,
R. Vecera, M. Pravenec (Czech Republic)
SaG079
427
S. Afzal, A. Tybjærg-Hansen, G.B. Jensen, B.G. Nordestgaard (Denmark)
S.H. Park, S.K. Hur, J.Y. Yoo, S.J. Jeong, G.T. Oh (Republic of Korea)
SaG078
426
Y. Liu, T. Siahmansur, J.D. Schofield, S. Hama, R. Yadav, S. Adam,
M. France, S. Kwok, R. Donn, A. Stevens, J. Ho, B.J. Ammori, A. Syed,
P.N. Durrington, H. Soran (United Kingdom)
SaG083 BODY MASS INDEX AND MORTALITY OVER 3 DECADES
C. Ricci, A. Corsini, N. Ferri (Italy)
SaG077
SaG082 EFFECTS OF OBESITY AND BARIATRIC SURGERY ON HDL
FUNCTIONALITY AND MICROVASCULAR COMPLICATIONS OF OBESITY
418
P. Hohensinner, J. Baumgartner, B. Ebenbauer, B. Thaler, D. Konstantin,
C. Kaun, S. Stoijkovic, M. Fischer, G. Maurer, K. Huber, J. Wojta (Austria)
SaG076
BARIATRIC SURGERY-INDUCED WEIGHT LOSS IN MORBIDLY OBESE
PATIENTS PROMOTES A FAVORABLE DECREASE IN THE GENE
EXPRESSION OF MARKERS OF SUBCUTANEOUS ADIPOSE TISSUE
HOMEOSTASIS425
J. Julve, E. Pardina, R. Ferrer, J. Rossell, J.A. Baena-Fustegueras,
J.M. Fort, A. Lecube, J. Peinado-Onsurbe (Spain)
L.R. Lopez, K.P. Bliden, R. Chaudhary, R. Damrongwatanasuk, K.E. Guyer,
M.G. Gesheff, C.J. Franzese, U.S. Tantry, P.A. Gurbel (USA)
SaG075
424
423
ROLE OF PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE
9) IN OBESITY AND METABOLIC SYNDROME: BEYOND LDLR TARGETING
431
G. Balzarotti, G. Tibolla, M. Ruscica, M. Stramba-Badiale, A.L. Catapano,
D.G. Norata (Italy)
SaG088 DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND PROTECTION AGAINST
STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS
432
F. Barkas, M. Elisaf, V. Tsimihodimos, H. Milionis (Greece)
93
Science at a Glance
Poster #
Poster #
Hypertension, Liver and Chronic Renal Disease
Experimental Cadiovascular Medicine II
Chair: A. Zambon (Italy)
SaG089 PRO-ATHEROGENIC LIPOPROTEIN PROFILE ASSOCIATED WITH WHITE
MATTER LESIONS IN CHRONIC KIDNEY DISEASE PATIENTS: A 1H-NMR
METABOLOMIC APPROACH
433
SaG097
434
N. Amigó, R. Fuertes, C. Cabré, M. Vinaixa, M. Romeu, M. Muñoz,
M. Giralt, J. Soler, J. Aquilera, M.T. Compte, X. Correig, A. Martínez-Vea
(Spain)
SaG090 ALTERED INFLAMMATORY PARAMETERS AND CHEMERIN LEVELS AFTER
RENAL TRANSPLANTATION
RENAL DISEASE IS ASSOCIATED WITH MODIFIED PON1 DISTRIBUTION
AT HDL SUBCLASSES
M.C. Duta-Mare, B. Radovic, S. Schlager, M. Wegscheider, D. Kolb-Lenz,
T. Madl, S. Stryeck, D. Kratky (Austria)
HEPATIC TRANSCRIPTOMIC SIGNATURES IN A MOUSE MODEL OF THE
METABOLIC SYNDROME
435
SaG099 THE ATHEROPROTECTIVE ACTIVITY OF GANODERMA AND ITS ACTION
MECHANISM IN MICE
STRONGLY INCREASING PREVALENCE OF HYPERTENSION BY
INCREASING OVERWEIGHT IN CHILDREN AND ADOLESCENTS
436
SaG100
SaG101PPARΓ ACTIVATION ATTENUATES OXIDATIVE STRESS AND IMPROVES
CEREBRAL ARTERIES ENDOTHELIAL DYSFUNCTION IN AGING RAT
THROUGH UP-REGULATING UCP2
438
LIVER DISEASE ALTERS HIGH-DENSITY LIPOPROTEIN COMPOSITION,
METABOLISM AND FUNCTION
SaG103
440
94
448
GENETIC CORRELATIONS BETWEEN CIRCULATING MIRNAS AND LIPID
PROFILES REVEAL NOVEL BIOMARKERS OF CVD RISK
449
L. Michael, S. McAhren, S. Kumar, J. Peralta, H. Kulkarni, W. Gerard,
J. Weir, C. Barlow, M. Kowala, P. Meikle, J. Blangero, J. Curran (USA)
M. Trieb, V. Stadlbauer, R. Birner-Gruenberger, G. Marsche (Austria)
N.A. Mohd Kasim, R. Rahmat, S. Abdul Razak, S. Muid, T. Rahman,
H. Nawawi (Malaysia)
EFFECTS OF CHRONIC INFLAMMATION ON MEGAKARYOCYTE AND
PLATELET FUNCTION IN A CONDITIONAL MOUSE MODEL
M. Salzmann, M. Haase, C. Arzt, M. Mussbacher, A. Assinger, J.A. Schmid
(Austria)
439
SaG096 ENHANCED STATUS OF PROTHROMBOGENESIS AND ITS ASSOCIATION
WITH SERUM LDL-C LEVELS IN SUBJECTS WITH FAMILIAL
HYPERCHOLESTEROLAEMIA441
447
P. Wang, G. Cai, F. Wang, P. Zhou, Q. Wang (China)
SaG102
B.M. Choi, Y.O. Kim, H.C. Song, Y.B. Lee (Republic of Korea)
SaG095
THE APOE*3LEIDEN.GK+/- MOUSE AS NOVEL TRANSLATIONAL
MODEL FOR DYSLIPIDEMIA, TYPE 2 DIABETES AND MACROVASCULAR
COMPLICATIONS446
M. Pouwer, S. Heinonen, M. Behrendt, A.C. Andréasson, E. Pieterman,
A. Van den Hoek, W. Jukema, B. Leighton, A.C. Jönsson-Rylander,
H. Princen (Netherlands)
437
G.M. Haas, E. Liepold, T. Bertsch, P. Schwandt (Germany)
SaG094 ASSOCIATION OF CORONARY ARTERY CALCIFICATION AND ARTERIAL
MICRO-CALCIFICATION OF THE VASCULAR ACCESS IN INCIDENT
HEMODIALYSIS PATIENTS
445
F.E. Mo, P.L. Hsu, Y.C. Lin (Taiwan)
D. Nasias, I. Evangelakos, D. Kardassis (Greece)
SaG093
444
S. Kim, S.J. Jeong, G.T. Oh (Republic of Korea)
M. Miljkovic, J. Kotur-Stevuljevic, A. Stefanovic, J. Vekic, A. Zeljkovic,
T. Gojkovic, S. Simic-Ogrizovic, V. Spasojevic-Kalimanovska, Z. JelicIvanovic (Serbia)
SaG092
442
CONSEQUENCES OF LYSOSOMAL ACID LIPASE DEFICIENCY IN
MACROPHAGES443
SaG098 PEROXIREDOXIN 1 HAVE PROTECTIVE ROLE IN THE VASCULAR DISEASE
BY REGULATING MACROPHAGES
R. Szentimrei, M. Harangi, H. Lőrincz, E.V. Varga, A. Szentpéteri, P. Fülöp,
I. Seres, G. Paragh (Hungary)
SaG091
Chair: M. Jauhiainen (Finland)
SaG104
ELEVATED LDL AND OXIDATIVE STRESS CONTRIBUTE TO
ARRHYTHMOGENIC CARDIOMYOPATHY PHENOTYPIC MANIFESTATION
450
L. Arnaboldi, I. Stadiotti, S. Brambilla, G. Milano, A. Scopece, F. Cattaneo,
A. Granata, C. Tondo, A. Corsini, G. Pompilio, E. Sommariva (Italy)
95
Science at a Glance
Poster #
Poster #
Immunity and Atherosclerosis
Emerging Aspects in Pharmacological Treatment of Primary
and Secondary Dyslipidemia
Chair: G. Caligiuri (France)
SaG105
SaG106
A NOVEL MECHANISM OF STATINS IN ATHEROSCLEROTIC AND
IN HIGH-RISK SUBJECTS: MODULATION OF THE ADIPONECTIN
RECEPTOR PATHWAY IN CIRCULATING MONOCYTES
451
Chair: B. Dieplinger (Austria)
K. Gasbarrino, H. Zheng, S.S. Daskalopoulou (Canada)
EFFICACY AND SAFETY OF LONG-TERM COADMINISTRATION OF
FENOFIBRATE AND EZETIMIBE IN PATIENTS WITH COMBINED
HYPERLIPIDEMIA: RESULTS OF THE EFECTL TRIAL
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND THE RISK OF
STROKE IN PATIENTS WITH RHEUMATOID ARTHRITIS
S. Oikawa, S. Yamashita, N. Nakaya, J. Sasaki, S. Kono, G. EFECTL Study
Investigators (Japan)
452
453
Y.R. Chen, H. Fang-I, W. Hsin-Chiao, C. Hung-Yi (Taiwan)
SaG107
THE PROTEIN COMPOSITION OF INTIMA AND MEDIA THORACIC
AORTA LAYERS IN ATHEROSCLEROSIS WITH AUTOANTIGENS
DETECTION AND IDENTIFICATION USING PROTEOMIC TECHNOLOGIES
SaG114
EXPRESSION OF E06, A NATURAL MONOCLONAL ANTIBODY
TARGETED TO OXIDIZED PHOSPHOLIPIDS (OXPL), ATTENUATES THE
PROGRESSION OF AORTIC SCLEROSIS IN AGED HYPERLIPIDEMIC MICE
SaG115
SaG109
CCL22/ MACROPHAGE-DERIVED CHEMOKINE EXPRESSION VIA
HISTAMINE IN THE ATHEROSCLEROSIS
SaG116
SOLUBLE URIC ACID PROMOTES DEVELOPMENT OF
ATHEROSCLEROSIS LESIONS VIA ENHANCEMENT OF INNATE
INFLAMMATION IN MICE
456
SaG117
457
Y. Kimura, T. Yanagida, A. Onda, K. Asako, H. Kikuchi, H. Kono (Japan)
SaG111
PENTRAXIN 3 PLAYS A KEY ROLE IN THE IMMUNOMODULATION OF
DIET INDUCED-OBESITY IN MICE
REGULATORY CD19+CD24HICD38HI B CELLS ARE DECREASED IN
PATIENTS WITH CORONARY ATHEROSCLEROSIS AND HAVE IMPAIRED
INTERLEUKIN-10 PRODUCTION IN RESPONSE TO CPG
463
OMEGA-3 CARBOXYLIC ACIDS IN SEVERE HYPERTRIGLYCERIDEMIA:
EVOLVE II STUDY RESULTS
464
CARDIOVASCULAR EVENT RATES IN HOMOZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA (HOFH): TRIAL ASSESSING LONG-TERM USE
OF PCSK9 INHIBITION IN SUBJECTS WITH GENETIC LDL DISORDERS
(TAUSSIG) STUDY INTERIM RESULTS
465
F. Raal, C. Kurtz, N. Honarpour, L. Tang, E.A. Stein (South Africa)
458
SaG118
A. Moregola, F. Bonacina, U. Guerrini, E. Bonavita, C. Garlanda,
A. Mantovani, A.L. Catapano, G.D. Norata (Italy)
SaG112
PHARMACODYNAMIC RELATIONSHIP BETWEEN PCSK9, ALIROCUMAB,
AND LDL-C LOWERING IN FOUR PHASE 3 ODYSSEY TRIALS WITH/
WITHOUT STATIN BACKGROUND
E. Stroes, T. De Bruin, M. Davidson, H. Yang, M. Kvarnstrom, T. Lundstrom
(Netherlands)
S. Kimura, S. Yamada, H. Noguchi, K.Y. Wang, T. Nakayama (Japan)
SaG110
462
J.G. Robinson, M. Farnier, J.J. Kastelein, E.M. Roth, M.R. Taskinen,
H.M. Colhoun, A. Brunet, A.T. DiCioccio, G. Lecorps, R. Pordy,
M.T. Baccara-Dinet, C.P. Cannon (USA)
455
C. Yeang, M.Y. Hung, J. Pattison, K. Bowden, N. Dalton, K.L. Peterson,
J.L. Witztum, S. Tsimikas, X. Que (USA)
EFFICACY AND SAFETY OF EVOLOCUMAB IN PATIENTS ON HIGH- VS
MODERATE-INTENSITY BACKGROUND STATIN THERAPY
461
H. Soran, A. Lira, R. Dent, I. Bridges, R. Somaratne, M. Koren (United
Kingdom)
454
R. Zhetisheva, V. Naumov, L. Kovalyov, M. Kovalyova, I. Kamenihina,
L. Novikova, M. Shogenova, A. Karpov (Russia)
SaG108
SaG113
460
TRANSITION FROM LDL APHERESIS TO EVOLOCUMAB IN
HETEROZYGOUS FH IS EQUALLY EFFECTIVE IN LOWERING LDL- BUT
WITHOUT LOWERING HDL CHOLESTEROL
466
A. Hovland, K.T. Lappegård (Norway)
SaG119
459
THE IMPACT OF SELECTIVE LDL APHERESIS ON SERUM ADIPOKINE
LEVELS IN PATIENTS WITH HYPERCHOLESTEROLEMIA
467
V.E. Varga, H. Lőrincz, N. Zsíros, P. Fülöp, I. Seres, G. Paragh, J. Balla,
M. Harangi (Hungary)
I.E. Dumitriu, P. Baruah, J.C. Kaski (United Kingdom)
SaG120
THE MECHANISM OF STATIN-INDUCED MODULATION OF VITAMIN D
METABOLISM468
J. Beltowski (Poland)
96
97
Poster #
Vascular Biology III
Chair: J. Herz (USA)
SaG121
ACUTE EXPOSURE TO AIR POLLUTION AGGRAVATES ACUTE
MYOCARDIAL INFARCTION AND SUBSEQUENT ISCHEMIC HEART
FAILURE IN MICE
469
470
D. Wolf, T. Marchini, N. Anto Michel, D. Dürschmied, I. Hilgendorf,
C. Bode, A. Zirlik (Germany)
SaG122
EFFECT OF OMEGA-3 FATTY ACID SUPPLEMENTATION ON ARTERIAL
ELASTICITY IN PATIETNS WITH FAMILIAL HYPERCHOLESTEROLAEMIA
ON STATIN THERAPY
84 EAS CONGRESS
th
May 29 - June 1, 2016
Innsbruck, Austria
471
D. Chan, J. Pang, P.H.R. Barrett, D.R. Sullivan, T.A. Mori, J.R. Burnett,
F.M. Van Bockxmeer, G.F. Watts (Australia)
SaG123
THE ABSENCE OF PCSK9 DETERMINES A LOWER NEOINTIMAL
FORMATION IN RESPONSE TO PERIVASCULAR CAROTID COLLAR
PLACEMENT472
N. Ferri, G. Tibolla, A. Dhyani, R. Baetta, A. Catapano, A. Corsini (Italy)
SaG124
BLOOD LEVEL OF CD45+ PLATELETS AND DEVELOPMENT OF
RESTENOSIS AFTER DRUG-ELUTING STENT IMPLANTATION IN
PATIENTS WITH CORONARY ARTERY DISEASE
473
Z. Gabbasov, S. Kozlov, I. Melnikov, S. Byazrova, O. Saburova (Russia)
SaG125
PLASMA FROM PATIENTS WITH CALCIFIED AORTIC DISEASE TRIGGERS
AN OSTEOBLAST-LIKE PHENOTYPE SWITCH IN HUMAN AORTIC VALVE
INTERSTITIAL CELLS
474
L. Cattan-Lévy, M.P. Jacob-Lenet, M. Dehoux, C. Deschildre, I. Codogno,
M. Morvan, A.T. Gaston, G. Even, J.B. Michel, D. Messika-Zeitoun,
A. Nicoletti, G. Caligiuri, J. Khallou-Laschet (France)
SaG126
A NOVEL PLAYER IN VASCULAR CALCIFICATION: HYPOXIA INDUCES
OSTEOGENIC DIFFERENTIATION AND EXTRACELLULAR MATRIX
MINERALIZATION OF VASCULAR SMOOTH MUSCLE CELLS
475
V. Jeney, B. Enikő, T. Emese, T. Andrea (Hungary)
SaG127
HH RESPONSIVE CELLS CONTRIBUTE TO VSMC ACCUMULATION
FOLLOWING VASCULAR INJURY
476
P. Cahill, E. Fitzpatrick, H. Jay-Christian, S. Diana, R. Hakimjavadi,
E. Redmond (Ireland)
SaG128
METABOLOMIC PROFILING OF ASCENDING THORACIC
AORTIC ANEURYSMS AND DISSECTIONS - IMPLICATIONS FOR
PATHOPHYSIOLOGY AND BIOMARKER DISCOVERY
C. Doppler, K. Arnhard, J. Dumfarth, K. Heinz, K. Danzl, B. Messner,
C. Stern, D. Bernhard (Austria)
98
477
tI
if
h
S
n
io
t
a
t
n
e
s
e
Poster Pr
29–
Sunday, May
0
3
y
a
M
,
y
a
d
n
o
M
Poster Walks – Monday
Board #
Vascular Biology: Endothelium and Smooth Muscle Cells
001
SIGMA-1 RECEPTOR INVOLVEMENT In RHOA/ROCK ACTIVATION AND
ENDOTHELIAL DYSFUNCTION INDUCED BY COCAINE
478
C.G. Saez, M.P. Hernández, K. Pereira-Flores, M. Palominos, A. LeguinaRuzzi, D. Mezzano, J. Pereira (Chile)
002
P38 MITOGEN-ACTIVATED PROTEIn KINASE IS INVOVLED In ARGINASE-IIMEDIATED ENOS-UNCOUPLING In AGING AND OBESITY
479
Y. Yu, J.P. Montani, X. Ming, Z. Yang (Switzerland)
003
SOLUBLE ENDOGLIn EFFECTS ON ENDOTHELIAL CELLS In VITRO
480
M. Varejckova, I. Nemeckova, P. Fikrova, E. Dolezelova, B. Vitverova,
P. Nachtigal (Czech Republic)
004
The RhoGEF TRIO REGULATES ANGIOGENIC SPROUTING THROUGH
VE-CADHERIN481
J. Kroon, I. Timmerman, M. Hoogenboezem, S.A. Van de Pavert,
E.M. Weijers, P. Koolwijk, J.D. Van Buul (Netherlands)
005
IDENTIFICATION Of FLOW-SENSITIVE GENES DURING EMBRYOTIC
VASCULAR DEVELOPMENT
482
C.W. Ni, N. Lawson (United Arab Emirates)
006
The NEURONAL GUIDANCE CUE SEMAPHORIn 3F IS HIGHLY EXPRESSED
BY ENDOTHELIAL CELLS UPON LAMINAR FLOW AND INHIBIT MONOCYTE
MIGRATION483
H. Zhang, R.G. De Bruin, W.M.P.J. Sol, E.P. Van der Veer, B.M. Van den Berg,
T.J. Rabelink, A.J. Van Zonneveld, J.M. Van Gils (Netherlands)
007
SUPPLEMENTATION WITH A COMBINATION Of L-CITRULLINE AND
L-ARGININE RESTORES The PLASMA L-ARGININE CONCENTRATION AND
RETARDS ENDOTHELIAL SENESCENCE
484
T. Hayashi, K. Ina, M. Kuzuya (Japan)
008
FICUS DELTOIDEA ENHANCES EXPRESSION Of ENDOTHELIAL NITRIC
OXIDE SYNTHASE AND REDUCES ENDOTHELIN-1 ON STIMULATED
HUMAN CORONARY ARTERY ENDOTHELIAL CELLS
485
R. Ahmad, T. Rahman, N.A. Mohd Kasim, G.A. Froemming, S. Muid,
N.H. Ismail, A.M. Ali, H. Nawawi (Malaysia)
009
ANTI-OXIDANT PROPERTIES Of FENUGREEK AND SAPONINS, AND
THEIR EFFECTS ON eNOS EXPRESSION ON HUMAN CORONARY ARTERY
ENDOTHELIAL CELLS.
486
R. Ahmad, T. Rahman, G.A. Froemming, H. Nawawi (Malaysia)
101
Board #
Board #
010
020
ANTIOXIDANT PROPERTIES Of SAFFRON AND CROCIn AND THEIR
EFFECTS ON ENDOTHELIAL NITRIC OXIDE SYNTHASE EXPRESSION
In STIMULATED HUMAN CORONARY ARTERY ENDOTHELIAL CELLS
487
R. Ahmad, N.A. Mohd Kasim, T. Rahman, G.A. Froemming, H. Nawawi (Malaysia)
011
GLYCATED LDL INDUCE ENDOPLASMIC RETICULUM STRESS ALONG WITH
The STIMULATION Of VCAM-1 EXPRESSION In HUMAN ENDOTHELIAL
CELLS, AND The ENSUING MONOCYTE ADHESION
ENDOTHELIAL CELL DEATH AND DISASSEMBLY In ATHEROSCLEROSIS
021
488
LEVOROTATORY-AMLODIPINE PLUS FLUVASTATIn CONFER ADDITIVE
EFFECTS ON RETARDING ENDOTHELIUM-MESENCHYMAL TRANSITION
THROUGH SUPPRESSING ROCK1 EXPRESSION
022
489
STUDIES ON The MECHANISM Of ACTION Of The ANTIPROLIFERATIVE
EFFECT Of NO-DONORS FUROXANS In SMOOTH MUSCLE CELLS
023
490
The DIACYLGLYCEROL ACETYLTRANSFERASE INHIBITORS
XANTHOHUMOL AND AMIDEPSINE D REVEAL LIPID SYNTHESIS AS A
PROMOTER Of ANGIOGENESIS
024
491
PROLIFERATION Of ENDOTHELIAL PROGENITOR CELLS BY
11,12-EPOXYEICOSATRIENOIC ACID In I/R INJURED RAT
025
492
HIGH LEVELS Of SOLUBLE ENDOGLIn INDUCE INFLAMMATION AND
OXIDATIVE STRESS In AORTA COMPENSATED WITH PRESERVED NODEPENDENT VASODILATATION MICE FED HIGH FAt DIET
MEMBRANE CONTACT SITES In ENDOTHELIAL CELLS
027
ENDOTHELIAL PROGENITOR CELLS BEFORE AND AFTER TREATMENT
WITH METFORMIn In PATIENTS WITH FAMILIAL COMBINED
HYPERLIPIDEMIA AND INSULIn RESISTANCE
C.O. Aragona, E. Imbalzano, V. Cairo, C. Conte, F. Mamone, A. Lo Gullo,
M.A. Sardo, A. Saitta, G. Mandraffino (Italy)
102
The ASSESSMENT Of VARIANT DOUBLE FILTRATION PLASMAPHERESIS
(DFPP) IMPACT ON The ADHESION MOLECULES CONTENT In STABLE
CORONARY ARTERY DISEASE (CAD) PATIENTS AFTER CORONARY STENTING 501
028
502
The ROLE Of INHIBITORS Of WNT SIGNALING In CARDIOVASCULAR EVENTS 503
The GOOD? The BAD? The UGLY! RETINOIC ACID In MYOCARDIAL
INFARCTION504
ARTERIAL STIFFNESS CORRELATES WITH EXTRACELLULAR MATRIX
TURNOVER In HEART FAILURE WITH PRESERVED EJECTION FRACTION PATIENTS505
M. Martínez-Marin, J. Perez-Calvo, C. Josa-Laorden, I. Lacambra-Blasco,
I. Gimenez-Lopez, J. Rubio-Gracia, V. Garces-Horna, M. Sanchez-Marteles,
F. Ruiz-Laiglesia, P. Samperiz-Legarre, I. Torres-Courchoud, B. AmoresArriaga, R. Martinez-Marin, C. Sanz-Bescos, F. Roncales-Garcia Blanco (Spain)
495
029
496
The EFFECTS Of HIV-INFECTION AND ANTI-RETROVIRAL TREATMENT
ON ENDOTHELIAL FUNCTION In A SOUTH AFRICAN COHORT
K. Danzl (Austria)
494
A. Kivelä, V. Olkkonen (Finland)
019
500
C. Ress, A. Kirschner, M. Paulweber, K. Willeit, L. Kedenko, G. Goebel,
K. Rufinatscha, K. Salzmann, G. Staudacher, H. Tilg, B. Igelseder,
B. Paulweber, S. Kaser (Austria)
493
K. Jezkova, J. Rathouska, I. Nemeckova, P. Fikrova, E. Dolezelova,
M. Varejckova, B. Vitverova, C. Bernabeu, J.M. Novoa, S. Chlopicki,
P. Nachtigal (Czech Republic)
018
ULTRASTRUCTURAL STUDY Of ENDOTHELIUM In ADVANCED CAROTID
ARTERY ATHEROSCLEROSIS
N. Mashele, S. Charania, F. Essop, I. Webster, C. Westcott, N. Goswami, P. De
Boever, T. Nawrot, H. Strijdom (South Africa)
026
S. Kim, J.K. Chae, J.L. Young, Y.S. Kim, S.H. Lee, S.R. Lee, K.S. Rhee, W.H. Kim,
J. Ko (Republic of Korea)
017
499
M. Pyatchenkov, V. Tishko, A. Sokolov (Russia)
K. Astanina, J. Spang, R.T. Hahn, D. Oster, J. Hoppstaedter, A.K. Kiemer
(Germany)
016
The CAPACITY Of EL MODIFIED SERUM / APO B DEPLETED SERUM TO
PROTECT VASCULAR ENDOTHELIAL FUNCTION
A. Evdokimenko, T. Gulevskaya, T. Gulevskaya, S. Scrylev, V. Shchipakin,
M. Tanashyan (Russia)
L. Arnaboldi, M. Lombardi, M. Sinelli, B. Rolando, L. Lazzarato, R. Fruttero,
A. Gasco, A. Corsini (Italy)
015
498
S. Radulović, A. Kirsch, I. Schilcher, M. Lechleitner, C. Nusshold, S. Hallström,
S. Frank (Austria)
A. Cai, L. Liwen, Z. Yingling, C. Jiyan, L. Xida (China)
014
UNDERSTANDING The INTERACTIVE EFFECTS Of DOXORUBICIn AND
RADIOTHERAPY ON ENDOTHELIAL CELL FUNCTION - The ROLE Of JNK
G. Hargrave, M. Boyd, R. Plevin (United Kingdom)
S. Paone, G. Atkin-Smith, R. Tixeira, S. Caruso, L. Jiang, I. Poon, M. Hulett
(Australia)
013
497
N. Grechanyk, A. Filippova, A. Kuryata (Ukraine)
L. Toma, G.M. Sanda, M. Deleanu, C.S. Stancu, A.V. Sima (Romania)
012
ENDOTELIAL DYSFUNCTION, BLOOD LIPID SPECTRUM,LEVEL
Of LEPTIn AND MASS Of BODY In PATIENT WITH CORONARY HEART
DISEASE In COMBINATION WITH HEPATIC STEATOSIS.
BYGLICAN EXPRESSION, ARTERIAL STIFFNESS AND PROATHEROGENIC
PROFILE In FORMER SMOKERS AFTER 1-YEAR SMOKE CESSATION
506
G. Mandraffino, C.O. Aragona, V. Cairo, F. Mamone, A. Lo Gullo, M.A. Sardo,
A. Saitta, E. Imbalzano (Italy)
103
Board #
Board #
030
HIGH, NOT LOW LEVELS Of ENDOGENOUS ENDOSTATIn SERUM LEVELS
PREDICT EVENT-FREE SURVIVAL In PATIENTS WITH PERIPHERAL ARTERIAL
DISEASE507
040
B. Zierfuss, C. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner
(Austria)
041
031
HIGH FRUCTOSE CONSUMPTION IMPAIRS AORTIC FUNCTION AND
METABOLIC PARAMETERS COMPARED TO GLUCOSE In FEMALE RATS
508
042
043
HOMOARGININE: A NEW POTENTIAL AVENUE In The MANAGEMENT
Of NEOINTIMAL HYPERPLASIA?
510
SOLUBLE ST2 IS A NOVEL MARKER Of AORTIC STIFFNESS AND
ARTERIOSCLEROSIS MEASURED BY INVASIVE HEMODYNAMIC STUDY
044
VASCULAR RESPONSES TO INSULIn ARE IMPAIRED AFTER DIET-INDUCED
OBESITY WHEREAS RESPONSES TO IGF-1 ARE MAINTAINED
CARDIOMETABOLIC AND VASCULAR EFFECTS Of TREATMENT WITH A
FIXED-DOSE COMBINATION ANTI-RETROVIRAL DRUG CONTAINING
NUCLEOSIDE AND NON-NUCLEOSIDE REVERSE TRANSCRIPTASE
INHIBITORS (NRTIs AND NNRTIs) In ADULT RATS
045
512
SHORT-TERM AEROBIC EXERCISE IMPROVES AORTIC STIFFNESS
In WOMEN AFTER MENOPAUSE
046
513
EFFECTS Of ADIPONECTIn ON VASCULAR PROPERTIES Of CAROTID
ARTERY ASSOCIATED WITH MATRIX REMODELING
EFFECTS OF OXIDAZED LDL IN M2 MACROPHAGES. IMPLICATIONS IN
ATHEROSCLEROSIS522
HUMAN MACROPHAGES EXPOSED TO OXIDIZED LDL OR TUNICAMYCIN
EXHIBIT INCREASED MMP-9 EXPRESSION, SECRETION AND ACTIVITY BY A
MECHANISM INVOLVING ENDOPLASMIC RETICULUM STRESS
523
G.M. Sanda, M. Deleanu, C.S. Stancu, M. Simionescu, A.V. Sima (Romania)
047
514
515
524
REDUCED DIETARY INTAKE OF TLR2 AND TLR4 STIMULANTS FAVOURABLY
MODIFIES LIPID AND INFLAMMATORY MARKERS OF CARDIOMETABOLIC
RISK IN HEALTHY MEN
525
T. Faraj, C. Erridge (United Kingdom)
049
516
RECOMBINANT DOMAIN V OF BETA(2)-GLYCOPROTEIN I INHIBITS OXLDLINDUCED TF EXPRESSION IN MACROPHAGES
Y. Chi, T. Yu, Q. Liu, J. Qin, J. Li, Y. Chen, M. Li (China)
048
P. Wohlfahrt, J. Pitha, I. Kralova Lesna, O. Auzky, P. Suchanek, P. Stavek
(Czech Republic)
039
521
F. Goncalves, K. Alcantara, V. Moura, P. Nolasco, J. Kalil, M. Hernandez
(Brazil)
H. Strijdom, N. Goswami, P. De Boever, C. Westcott, T. Ogundipe,
F. Everson, A. Genis (South Africa)
038
INTIMA-MEDIA THICKNESS OF THE DESCENDING AORTA IS INFLUENCED
BY AORTIC VALVE DISEASE
Vascular Biology: Macrophages, Inflammation, Immunity
G.K. Povlsen, I. Buza, H. Boonen, J. Worm (Denmark)
037
GENOMIC REARRANGEMENTS In HUMAN ATHEROSCLEROTIC VASCULAR
TISSUES520
511
S.H. Kim, H.L. Kim, W.H. Lim, J.B. Seo, W.Y. Chung, J.H. Zo, H.L. Lee,
M.A. Kim, D.G. Park, G.J. An (Republic of Korea)
036
519
J. Petrini, M. Ring, P. Eriksson, A. Franco-Cereceda, K. Caidahl, M.J. Eriksson
(Sweden)
F. Dellera, G.S. Ganzetti, A. Froio, S. Manzini, M. Busnelli, A. Meinitzer,
G. Chiesa, C. Parolini (Italy)
035
MODIFYING The GUT MICROBIOME WITH POLYPHENOLS AND A
LECTIn LIMITED DIET IMPROVES ENDOTHELIAL FUNCTION
A. Sleptcov, M. Nazarenko, I. Lebedev, N. Skryabin, O. Barbarash, V. Puzyrev
(Russia)
I. Kvetnoi, K. Kozlov, E. Sedova, I. Bolotov, V. Polyakova (Russia)
034
518
S. Gundry (USA)
MECHANICAL CONDITIONS AROUND NEOVESSELS In POPLITEAL
ATHEROSCLEROTIC PLAQUES - AN ANALYSIS USING FINITE ELEMENT
METHOD509
LASER CONFOCAL MICROSCOPY Of ARTERIAL WALL: ROLE
Of SIGNALING MOLECULES In MECHANISMS Of RESTENOSIS
The EFFECT Of HIGH-FAt DIET ON The BARRIER FUNCTIONS AND
INFLAMMATORY STATUS Of HUMAN VASCULAR ENDOTHELIAL CELLS
P. Gorzelak-Pabis, E. Luczak, K. Wojdan, M. Broncel, M. Chalubinski (Poland)
M. Mocan, M. Bogdan, B. Sorin Nicu (Romania)
033
517
P. Risko, J. Pláteník, R. Buchal, J. Potočková, P. Kraml (Czech Republic)
G. Sanguesa, M.D.M. Cascales, S. Shaligram, F. Akther, M. Baena,
R. Rahimian, J.C. Laguna, M. Alegret, N. Roglans (Spain)
032
The LABILE IRON POOL AND PARAMETERS Of ARTERIAL WALL ELASTICITY
THE ROLE OF OXIDIZED LOW-DENSITY LIPOPROTEINS AND
AUTOANTIBODIES TO THEM IN ATHEROGENESIS IN PATIENTS WITH
CORONARY ATHEROSCLEROSIS
526
M. Shogenova, A. Karpov, R. Zhetisheva, V. Masenko, V. Naumov (Russia)
W.C. Tsai, Y.T. Sun (Taiwan)
104
105
Board #
050
CELL-SPECIFIC UPREGULATION OF APOLIPOPROTEIN E GENE
EXPRESSION IN MACROPHAGES BY GLUCOCORTICOIDS
Board #
060
527
V.G. Trusca, E.V. Fuior, I.M. Fenyo, I.F. Tudorache, D. Kardassis,
M. Simionescu, A.V. Gafencu (Romania)
051INTERLEUKIN-27 POLYMORPHISMS ARE ASSOCIATED WITH PREMATURE
CORONARY ARTERY DISEASE AND INSULIN RESISTANCE. THE GENETICS
OF ATHEROSCLEROTIC DISEASE (GEA) MEXICAN STUDY
ENZYMATIC DEGRADATION OF 7-KETOCHOLESTEROL (7-KC), A NEW
STRATEGY FOR THE TREATMENT OF ATHEROSCLEROSIS
061
528
HUMAN MONOCYTE-DERIVED MACROPHAGES FROM CORONARY
ARTERY DISEASE PATIENTS SHOW AN IMPAIRED PHENOTYPE
062
AGE-ALBUMIN REDUCES ABCA-1 CONTENT IN MACROPHAGES BY
INDUCING ITS MODIFICATION BY AGE AND DEGRADATION BY THE
UBIQUITIN-PROTEASOME AND LYSOSOMAL SYSTEM.
063
MONOCYTE ACTIVATION CORRELATES WITH ATHEROGENIC
MITOCHONDRIAL MUTATIONS
530
064
531
065
532
066
067
PRO-INFLAMMATORY GENE EXPRESSION IN ADIPOSE TISSUE IN PATIENTS
WITH ATHEROSCLEROSIS
534
068
RESPONSE GENE TO COMPLEMENT-32 REGULATES TGF-Β
EXTRACELLULAR MATRIX EXPRESSION IN HUMAN AORTIC
ATHEROSCLEROTIC WALL
THE ROLE OF MYELOID DENDRITIC CELLS, CHEMOKINE CCL17 AND
T-CELL RECEPTOR CCR4 IN ATHEROGENESIS
542
THE INFLAMMATORY PROCESS AS A RISK FACTOR OF DEVELOPING
ATHEROSCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS
543
MMP-12 AND TIMPS BEHAVIOUR IN STROKE RELATED TO CAROTID
ARTERY STENOSIS
544
ATHEROSCLEROTIC PATIENTS HAVE M1-SKEWED MONOCYTES:
COMORBIDITIES AND RISK FACTORS CONTRIBUTE
545
H. Williams, V. Patel, G. Cassorla, N. Pertsoulis, S. Li, J. Fletcher, H. Medbury
(Australia)
535
069
S. Cejková, I. Králová Lesná, J. Froněk, A. Králová, R. Poledne (Czech
Republic)
059
541
N. Cifani, F. Del Porto, L. Ferri, M. Proietta, D. Toni, R. Dito, M. De Michele,
A. Falcou, M. Taurino (Italy)
S. Kajani, M. O'Reilly, W. Guo, F. McGillicuddy (Ireland)
058
INTERMEDIATE DENSITY LIPOPROTEIN IS ASSOCIATED WITH MONOCYTE
SUBSET DISTRIBUTION IN PATIENTS WITH STABLE ATHEROSCLEROSIS
I. Starodubtseva (Russia)
FOXO1 AND NF-κB REGULATE CYCLOOXEGENASE-2 EXPRESSION UNDER
LYSOPHOSPHATIDYALCHOLINE TREATMENT IN HUMAN CARDIAC FIBROBLAST 533
DIVERGENT EFFECTS OF SODIUM SALICYLATE ON GLUCOSE METABOLISM
AND REVERSE CHOLESTEROL TRANSPORT IN OBESITY
540
A. Karpov, A. Rvatcheva, M. Shogenova, R. Zhetisheva, V. Masenko,
V. Naumov (Russia)
H.C. Tseng, C.M. Yang (Taiwan)
057
RELATIONSHIP BETWEEN MMP-9, TIMP-1, hs CRP AND THE SEVERITY
OF ATHEROSCLEROTIC CORONARY ARTERY DISEASE
K. Krychtiuk, S. Kastl, T. Pongratz, G. Goliasch, L. Gaspar, G. Maurer,
K. Huber, E. Dostal, S. Pfaffenberger, S. Oravec, J. Wojta, W. Speidl (Austria)
A. Orekhov, N. Nikiforov, N. Elizova, M. Sazonova, A. Zhelankin, I. Sobenin
(Russia)
056
EVALUATION OF MMP-7 AND TIMP-1 IN PATIENTS WITH CORONARY
ATHEROSCLEROSIS539
C.R. Revnic, C. PENA, S. PRADA, F. REVNIC, G. PRADA (Romania)
R. Tallada Iborra, A. Machado-Lima, U. Fabres Machado, L. Rui,
E.R. Nakandakare, S. Yokoyama, M. Passarelli (Brazil)
055
538
C.R. Revnic, C. PENA, S. VOINEA, F. REVNIC, B. PALTINEANU (Romania)
529
S. Eligini, S. Fiorelli, N. Cosentino, V. Cavalca, S. Colli, G. Marenzi, E. Tremoli
(Italy)
054
FEATURES OF CELLULAR AND VASCULAR INFLAMMATORY RESPONSE IN
PATIENTS WITH UNSTABLE ANGINA AND MYOCARDIAL INFARCTION
N. Musikhina, T. Petelina, L. Gapon, O. Irina, V. Kuznetsov (Russia)
I. Perveen, S. Ahmed (Pakistan)
053
537
K. Miura, E. Saita, N. Suzuki, K. Miyata, N. Ikemura, R. Ohmori, Y. Ikegami,
Y. Kishimoto, K. Kondo, Y. Momiyama (Japan)
R. Posadas-Sánchez, N. Pérez-Hernández, J.M. Rodríguez-Pérez,
J. Angeles-Martínez, C. Posadas-Romero, G. Cardoso-Saldaña,
T. Villarreal-Molina, G. Vargas-Alarcón (Mexico)
052
THE ASSOCIATION BETWEEN PLASMA INTERLEUKIN-27 (IL-27) LEVELS
AND THE SEVERITY OR INSTABLITY OF CORONARY ATHEROSCLEROSIS IN
PATIENTS WITH CAD
INCREASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP)
IS ASSOCCIATED WITH INFLAMMATION IN OBESE SUBJECTS
546
M. Malczewska-Malec, M. Malczewska-Malec, A. Polus, J. Goralska,
U. Razny, A. Dembinska-Kiec, B. Solnica (Poland)
536
S.I. Vlaicu, A. Tatomir, D. Boodhoo, A.P. Mekala, C.A. Tegla, V. Rus, H. Rus
(Romania)
106
107
Board #
Board #
070
079
INCREASING B1A LYMPHOCYTES THROUGH APRIL OVEREXPRESSION
IN APOLIPOPROTEIN E-DEFICIENT MICE STABILIZES ADVANCED
ATHEROSCLEROTIC LESIONS BY DECREASING NECROTIC AREA AND
INCREASING SMOOTH MUSCLE CELL CONTENT
071
CYTOMEGALOVIRUS DNA LOAD AND T-LYMPHOCYTES ACTIVATION IN
ATHEROSCLEROTIC PLAQUES
080
548
A. Lebedeva, E. Nikitskaya, O. Ivanova, J.C. Grivel, E. Maryukhnich,
A. Shpektor, E. Vasilieva, L. Margolis (Russia)
072
073
INTERLEUKIN-17-RELATED PATHWAYS ARE INVOLVED IN CAROTID
ATHEROSCLEROSIS, BUT NOT IN STANFORD-A ACUTE AORTIC DISSECTION 549
ROLE OF T HELPER 17 LYMPHOCYTE SUBPOPOLATIONS IN CRITICAL
CAROTID ARTERY STENOSIS
074
INCREASED FREQUENCIES OF CIRCULATING T-HELPERS 17 AND
DIMINISHED REGULATORY T-CELLS TO T-HELPERS 17 RATIO PREDICT
CAROTID ATHEROSCLEROSIS PROGRESSION
550
DECREASED BONE MARROW ACTIVITY MEASURED BY USING
18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY
AMONG PATIENTS WITH CEREBRAL ARTERY ATHEROSCLEROSIS
083
551
084
085
552
086
087
554
HUMAN HERPESVIRUS ACTIVATION IN PATIENTS WITH ACUTE CORONARY
SYNDROME555
E. Nikitskaya, O. Ivanova, M. Elena, G. Jean-Charles, A. Lebedeva,
A. Shpektor, L. Margolis, E. Vasilieva (Russia)
108
THE LEVEL OF NITRIC OXIDE REGULATES LIPOCALIN-2 EXPRESSION
UNDER INFLAMMATORY CONDITION IN RINM5F BETA-CELLS
560
DIFFERENTIAL WHITE BLOOD CELL COUNT AND METABOLIC SYNDROME
IN JAPANESE MEN
561
NON-HDL CHOLESTEROL RELATES TO PRO-INFLAMMATORY STATUS OF
HUMAN VISCERAL ADIPOSE TISSUE
562
EFFECT OF FAT COMPOSITION OF A MEAL ON THE ACUTE POSTPRANDIAL
INFLAMMATORY RESPONSE
563
I. Shapira, O. Raz, S. Berliner (Israel)
A. Dhyani, V.K. Pulakazhi Venu, P. Uboldi, A.F. Muro, A.L. Catapano,
D.G. Norata (Italy)
078
559
R. Poledne, I. Kralova Lesna, A. Kralova, A. Sekerkova, J. Fronek (Czech
Republic)
PSORIASIS AND CORONARY ARTERY DISEASE: THE ROLE OF INFLAMMATION 553
ABSENCE OF FIBRONECTIN-EDA CONTRIBUTES TO SEPSIS OUTCOMES IN
A MURINE MODEL
PATIENTS WITH RHEUMATOID ARTHRITIS SHOWED ALTERED
LIPOPROTEIN PROFILE WITH DYSFUNCTIONAL HIGH-DENSITY
LIPOPROTEINS TO EXACERBATES INFLAMMATION AND
ATHEROSCLEROTIC PROCESS
Y. Ikeda, N. Hisakawa, T. Ohguro, J. Nishiuchi, Y. Kumon (Japan)
P. Altieri, H.L. Banchs, J. Nieves (Puerto Rico)
077
558
S.Y. Chang, Y.H. Jo, M.J. Kim (Republic of Korea)
J.M. Kim, L. Eun Seoung, P. Kwang-Yeol, S. Ju Won, J. Keun-Hwa (Republic
of Korea)
076
REDOX-ACTIVE IRON IN MONOCYTES ISOLATED FROM PATIENTS WITH
CHRONIC CARDIOVASCULAR DISEASE
J.Y. Kim, E.Y. Lee, K.H. Cho (Republic of Korea)
A. Filatova, A. Shchinova, E. Pylaeva, A. Potekhina, A. Osokina, M. Tripoten,
O. Pogorelova, T. Balakhonova, E. Noeva, E. Klesareva, O. Afanasieva,
T. Arefieva (Russia)
075
557
P. Kraml, P. Riško, J. Pláteník, J. Potočková (Czech Republic)
082
M. Proietta, N. Cifani, F. Del Porto, L. Ferri, G. Orgera, S. Perrotta, R. Dito,
L. Tritapepe, M. Iaconi, M. Taurino (Italy)
IDENTIFYING FEATURES OF VASCULAR INFLAMMATORY RESPONSE IN
PATIENTS WITH MYOCARDIAL INFARCTION USING THE SYNTAX SCORE
T. Petelina, N. Musikhina, L. Gapon, I. Osipova, V. Kuznetsov (Russia)
081
F. Del Porto, N. Cifani, L. Ferri, S. Perrotta, R. Dito, M. Iaconi, R. Carletti,
M. Proietta, L. Tritapepe, C. Di Gioia, M. Taurino (Italy)
556
A. Van Dam, S. Bekkering, M. Crasborn, L. Van Beek, S. Van den Berg,
F. Vrieling, S. Joosten, V. Van Harmelen, M. De Winther, E. Lutgens, M. Boon,
N. Riksen, P. Rensen, J. Berbée (Netherlands)
547
K.H. Zheng, S. Bernelot Moens, S.I. Van Leuven, S. Havik, D. Baeten, E. Stroes
(Netherlands)
BACILLE-CALMETTE-GU&EACUTE;RIN LOWERS PLASMA CHOLESTEROL
AND DELAYS ATHEROSCLEROTIC LESION PROGRESSION IN MICE
THE RELATIONSHIP BETWEEN HELICOBACTER PYLORI INFECTION AND
ARTERIAL STIFFNESS IN ADULTS WITH ABNORMAL GASTRIC ENDOSCOPIC
FINDINGS564
K.C. Park, M.J. Kim, K.S. Park, Y.S. Kim, H.C. Cho, H.R. Sung, K.H. Park,
B.H. Choi, K.C. Kim (Republic of Korea)
088
PROTECTIVE EFFECT OF CAROTENOIDS ON CX40 AD CX43 EXPRESSION
IN THE LEFT VENTRICLE OF NORMOTENSIVE WISTAR RATS AFTER
ADMINISTRATION OF LPS
565
K. Frimmel, J. Krizak, B. Liptak, J. Navarova, V. Knezl, E. Breierova,
I. Bernatova, L. Okruhlicova (Slovakia)
109
Board #
Board #
Vascular Biology: Myocardial Infarction, Stroke, Peripheral
Vascular Disease
099
089
EFFECT OF THROMBOLYTIC THERAPY AND PERCUTANEOUS CORONARY
INTERVENTION (PCI) ON INFLAMMATORY MEDIATORS
566
EFFECT OF ENDOVASCULAR TREATMENT AT PATIENTS WITH EARLY
POSTINFARCTION STENOCARDIA
100
101
567
TERMS OF SUCCESS OF REHABILITATION IN PATIENTS WITH MULTIFOCAL
ATHEROSCLEROSIS568
P. Bondarenko, A. Novikova, M. Ivanov, M. Ermina, M. Chvostova,
A. Yadernaya, R. Al-Banna (Russia)
092
INTERSECTED GENES IN HYPERLIPIDEMIA AND CORONARY BYPASS
PATIENTS: FEASIBLE BIOMARKERS FOR CORONARY HEART DISEASE
093
MYOCARDIAL STANNING AFTER THROMBOLYTIC THERAPY FOR ACUTE
MYOCARDIAL INFARCTION.
102
EARLIEST OUTCOMES OF ACUTE CORONARY SYNDROME IN PATIENTS
WITH TYPE 2 DIABETES
103
570
N-ACETYLCYSTEINE IN A COMBINATION THERAPY REDUCES
MYOCARDIAL DAMAGE IN PATIENTS WITH ACUTE CORONARY SYNDROME
AND IMPROVES LEFT VENTRICULAR FUNCTION AFTER PERCUTANEOUS
CORONARY INTERVENTION.
104
571
RELATIONSHIP BETWEEN LIPID DISORDERS AND SEVERITY AND NATURE
OF CORONARY ARTERY LESIONS IN MALE PATIENTS WITH CORONARY
ARTERY DISEASE
105
572
PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS OF HYPERTHYROID
RAT HEART DURING ISCHEMIA REPERFUSION
106
573
ACUTE ARTERIAL OCCLUSION OF APPARENTLY HEALTHY ARTERIES - A
CONCLUSIVE EXPLANATION USING FRACTAL PHYSICS
D. Tesloianu, M. Agop, I. Nedelciuc (Romania)
110
ATHEROSCLEROTIC SOFT PLAQUE REGRESSION USING
TRANSCUTANEOUS LOW-LEVEL COMBINED DUAL-FREQUENCY
SONICATION ACCOMPANIED BY HIGH-DOSE ATORVASTATIN AND PESDA
MICROBUBBLES ADMINISTRATION
580
INDIVIDUAL ATORVASTATIN DOSES TITRATION TO TREATMENT OF
CAROTID PLAQUES IN PATIENTS WITH ARTERIAL HYPERTENSION I-II DEGREE 581
EFFECT OF SHORT-TERM INTENSIVE ROSUVASTATIN THERAPY ON
CAROTID ATHEROSCLEROTIC PLAQUE VOLUME IN VERY HIGH
CARDIOVASCULAR RISK PATIENTS USING THE THREE-DIMENSIONAL
ULTRASOUND582
PLEIOTROPIC EFFECTS OF ANTI-ATHEROSCREROTIC CILOSTAZOL ON
BRAIN OF STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS (SHR-SP) 583
K. Abe, Y. Omote, T. Yamashita, R. Morihara, Y. Nakano, Y. Ohta (Japan)
107
574
C.R. Revnic, C. PENA, F. REVNIC, A.S. NICA, S. PRADA, G. PRADA (Romania)
098
579
Z. Luginova, M. Koshurnikova, E. Solovieva, T. Balakhonova, A. Susekov
(Russia)
V. Kashtalap, O. Barbarash, O. Hryachkova, A. Novitskaya (Russia)
097
CORRELATION OF HIGH-SENSITIVE CRP, CAROTID INTIMA-MEDIA
THICKNESS, AND THE CHRONIC KIDNEY DISEASE OF HEALTHY
RESIDENTS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION
STUDY (KOPS)
N. Balashenka, V. Podpalov (Belarus)
A. Nizomov, B. Toshev, M. Mukhamedova, J. Berdiqulov (Uzbekistan)
096
578
H. Mehrad, M. Mokhtari-Dizaji, H. Ghanaati (Iran)
S. Abdijalilova, M. Kenjaev, L. Botirova, U. Ganiyev, A. Nizomov (Uzbekistan)
095
ASSOCIATION OF BASELINE APOLIPOPROTEIN B AND FRIEDEWALD LDLC
WITH LONG-TERM RE-INFARCTION IN HYPERTRIGLYCERIDEMIC PATIENTS
WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Y. Tanaka, M. Shimizu, N. Furusyo, Y. Kato, J. Hayashi (Japan)
M. Kenjaev, S. Kenjaev, S. Abdijalilova, A. Nizomov (Uzbekistan)
094
577
M. Hermans, A. Van der Laarse, M. Schalij, F. Romijn, N. Smit, Y. Van der
Burgt, W. Jukema, C. Cobbaert (Netherlands)
569
Y. Maneerat, K. Prasongsukarn, S. Benjathummarak, W. Dechkhajorn,
U. Chaisri (Thailand)
VENOUS THROMBOEMBOLISM AND CORONARY SYNDROME
A. Babets, A. KURIATA (Ukraine)
S. Salakhitdinov, M. Kenjaev, S. Abdijalilova, A. Nizomov (Uzbekistan)
091
576
P. Sudjana, F. Nugraha, C. Achmad, A. Purnomowati, T. Aprami (Indonesia)
B. Bagheri, A. Garjani, B. Taherkhanchi, B. Sohrabi, F. Mousavi (Iran)
090
AUTOLYSIS IN CAD STEMI ANTEROSEPTOAPICOLATERAL WALL PATIENT, A
CASE REPORT
ASSOCIATION BETWEEN VO2PEAK AND CLAUDICATION WALKING TIME
MEASURED DURING WALKING ON A TREADMILL AND IN COMMUNITY
SETTINGS OUTDOOR WALK - PILOT STUDY
584
E. Rosłoniec, A. Kulik, J. Trzeciak, P. Mika (Poland)
575
108
EFFECTS OF NORDIC POLE WALKING ON OXIDATIVE STRESS AND
WALKING ABILITIES IN PATIENTS WITH INTERMITTENT CLAUDICATION
585
E. Rosłoniec, M. Więcek, M. Bawelski, M. Maciejczyk, J. Głodzik, P. Mika
(Poland)
111
Board #
Board #
109
120
LOW NUMBER OF CIRCULATING CD34 POSITIVE CELL IS ASSOCIATED
WITH GREATER PROGRESSION OF CORONARY CALCIUM DETERMINED BY
MDCT586
T. Miyoshi, M. Doi, K. Nakamura, H. Ito (Japan)
110
A GIANT LEFT ATRIUM
121
587
ARTERIAL STIFFNESS AS A PREDICTOR OF RECOVERY OF LEFT
VENTRICULAR SYSTOLIC FUNCTION AFTER ACUTE MYOCARDIAL
INFARCTION TREATED WITH PRIMARY PERCUTANEOUS CORONARY
INTERVENTION588
EVALUATION OF CHANGES OF GLOBAL LONGITUDINAL STRAIN IN
PATIENTS WITH STEMI AFTER MYOCARDIAL REVASCULARIZATION
ASSESSMENT OF EFFICIENT REVASCULARIZATION ON DYNAMICS OF
VELOCITY PARAMETERS IN PATIENTS WITH STEMI
122
589
STRUCTURAL AND FUNCTIONAL PROPERTIES OF THE MAJOR ARTERIES
IN PATIENTS WITH CORONARY HEART DISEASE AND HEALTHY SUBJECTS
124
590
LIVER DYSFUNCTION AND 18F-NAF ATHEROSCLEROTIC PLAQUE UPTAKE
- ANALYSIS IN HIGH-CARDIOVASCULAR RISK INDIVIDUALS
591
125
THE RELATIONSHIP BETWEEEN CALCIFIED PLAQUES AND RESTENOSIS
AFTER CAROTID ENDARTERECTOMY
126
ASSOCIATION BETWEEN SERUM ZINC LEVEL AND CAROTID
ATHEROSCLEROSIS WITHOUT PLAQUE
127
594
M. Park (Republic of Korea)
118
PLAQUE CHARACTERISATION AND ANALYSIS IN THE RISK STRATIFYING
PATIENTS WITH SYMPTOMATIC CAROTIS STENOSIS
AREA MEASUREMENT OF CAROTID PLAQUE COMPARING B-MODE,
DOPPLER COLOR AND CONTRAST-ENHANCED ULTRASOUND IMAGING
E. Nyman, D. Vanoli, C. Grönlund, U. Näslund, P. Lindqvist (Sweden)
112
601
LIMITATIONS OF CONTRAST-ENHANCED ULTRASOUND WITH
EVALUATION OF NEOVASCULARISATION IN THE ATHEROSCLEROTIC PLAQUE 602
COMPARISON OF THE RESULTS OF CORONARY ANGIOGRAPHY AND
PARAMETERS OF LOCAL RIGIDITY OF COMMON CAROTID ARTERY IN
PATIENTS WITH CORONARY HEART DISEASE
603
EFFICACY OF SCREENING OF SUBCLINICAL AORTAL ATHEROSCLEROSIS
IN WORKING-AGE POPULATION DEPENDING ON INVESTIGATIONAL
METHODS.604
N. Koziolova, A. Chernyavina (Russia)
128
595
SUBCLINICAL CAROTID AND CEREBRAL ATHEROSCLEROSIS
SCREENING IN WORKING-AGE POPULATION: EFFICACY OF DIFFERENT
INVESTIGATIONAL METHODS.
605
N. Koziolova, A. Chernyavina (Russia)
D. Vanoli, P. Lindqvist (Sweden)
119
NON-INVASIVE HIGH-FREQUENCY ULTRASOUND USING INTIMA
AND INTIMA/MEDIA THICKNESS RATIO (BUT NOT CIMT), CORRECTLY
MONITORED EXPECTED BENEFICIAL VASCULAR EFFECTS OF
MENOPAUSAL HORMONE THERAPY
V. Oleynikov, L. Salyamova, A. Khromova, N. Burko (Russia)
593
H. Katano, K. Yamada, M. Mase (Japan)
117
600
A. Evdokimenko, L. Druina, A. Chechetkin, M. Tanashyan, T. Gulevskaya,
S. Scrylev (Russia)
592
M. Santos, M. Castelo-Branco, R. Silva, A. Gomes, P. Donato, J. Ferreira,
C. Domingues, M. Pego, L. Gonçalves, M.J. Ferreira (Portugal)
116
INVESTIGATION OF PROTOPORPHYRIN IX-MEDIATED SONODYNAMIC
THERAPY ON INTERMEDIATE STAGE ATHEROSCLEROSIS USING A NEW
COMPUTERIZED B- MODE ULTRASOUND ANALYZING METHOD
T. Naessen, M. Larsson (Sweden)
V. Oleynikov, A. Khromova, L. Salyamova (Russia)
115
599
H. Mehrad, M. Farhoudi (Iran)
V. Oleynikov, V. Galimskaya, E. Romanovskaya, I. Avdeeva (Russia)
114
REFERENCE VALUES FOR LOCAL ONE-POINT CAROTID STIFFNESS BY
ECHO-TRACKING IN A LARGE POPULATION OF HEALTHY SUBJECTS
S. Favretto, S. Carerj, J. Jaroch, K. Łoboz-Grudzień, F. Antonini-Canterin,
C. Zito, E. Bossone, M. PIrisi, O. Vriz (Italy)
123
V. Oleynikov, V. Galimskaya, E. Romanovskaya (Russia)
113
QUANTIFICATION OF MICROVESSELS DENSITY IN CAROTID PLAQUE BY
CONTRAST-ENHANCED ULTRASOUND WITH HISTOPATHOLOGIC VALIDATION598
A. Evdokimenko, L. Druina, A. Chechetkin, S. Scrylev, T. Gulevskaya,
M. Tanashyan (Russia)
G. Mandraffino, C.O. Aragona, S. Quartuccio, G. Trapani, A. Saitta,
M. Vatrano, E. Imbalzano (Italy)
112
597
B. Muinjonov, E. Giyazitdinova (Uzbekistan)
Y. Saleh, A. Almaghraby, B. Hammad, M. Elbahey, A. Samoka, A. Ghoneem,
M. Seleem (Egypt)
111
DO STROKE PATIENTS WITH NORMAL CAROTID ARTERIES REQUIRE TEE
FOR EXCLUSION OF RELEVANT AORTIC PLAQUE?
129
596
RETINAL VASCULAR CALIBER, OCULAR BLOOD FLOW AND ENDOTHELIN-1
LEVEL IN BLOOD SERUM IN PATIENTS WITH SUBCLINICAL ATHEROSCLEROSIS606
N. Adzhemian, V. Neroev, T. Kiseleva, M. Ezhov, N. Balatskaya, N. Ilina,
V. Tankovskiy (Russia)
113
Board #
Board #
130
139
INVESTIGATING THE FEASIBILITY OF B-MODE ULTRASONOGRAPHY
ACCOMPANIED BY PESDA MICROBUBBLES ADMINISTRATION FOR
ACCURATE VISUALIZATION OF INTRAPLAQUE NEOVASCULARIZATION
607
SUBCLINICAL ATHEROSCLEROSIS AND COGNITIVE IMPAIRMENT IN
UZBEKISTAN608
140
D. Akramova, A. Umarov (Uzbekistan)
132
THE RELATIONSHIP BETWEEN NONALCOHOLIC HEPATIC STEATOSIS AND
CAROTID ATHEROSCLEROSIS AT THE ELDERLY
133
141
RELATIONSHIP BETWEEN THE CHOLESTEROL AND TRIGLYCERIDE
CONTENT OF LIPOPROTEIN SUBCLASSES AND CAROTID INTIMA MEDIA
THICKNESS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY610
CONFOCAL DUAL-PULSED ELECTROHYDRAULIC SHOCK WAVE THERAPY
ACCOMPANIED BY PESDA MICROBUBBLES AND ATORVASTATIN
ADMINISTRATION REDUCE THE ATHEROSCLEROTIC INTRAPLAQUE
NEOVESSELS IN THE RABBIT CAROTID ARTERY
611
142
RISK FACTORS OF ATHEROSCLEROSIS IN SYSTEMIC LUPUS
ERYTHEMATOSUS WITH THYROID GLAND LESION
144
612
CARDIOVASCULAR MORTALITY AND MORBIDITY IN A GROUP OF
PATIENTS WITH HIV DIAGNOSIS
145
613
ARE CARDIOVASCULAR RISK FACTORS THE NEW THREAT TO HIV PATIENTS?
M. Monsalvo, E. Sifuentes Diaz, A. Caceres Gestoso, P. Perez Guerrero,
I. Tinoco Racero, A. De los Santos Moreno (Spain)
114
DEVELOPMENT OF A NOVEL HOMOGENEOUS ASSAY FOR REMNANT
LIPOPROTEINS620
MOST OF THE HEPATIC TRIGLYCERIDE LIPASE (HTGL) IS BOUND TO
APOE-RICH HDL IN POST-HEPARIN PLASMA
621
NOVEL ROLE OF A TRIGLYCERIDE-SYNTHESIZING ENZYME: DGAT1 AT THE
CROSSROAD BETWEEN TRIGLYCERIDE AND CHOLESTEROL METABOLISM
622
V. Sachdev, C. Leopold, R. Bauer, J.V. Patankar, J. Iqbal, S. Obrowsky,
M. Doktorova, M. Goeritzer, B. Scheicher, D. Kolb, G. Hoefler, A.V. Turnbull,
A. Zimmer, M.M. Hussain, A.K. Groen, D. Kratky (Austria)
614
146
THE ROLE OF ANGPTL3 IN HUMAN LIPOPROTEIN METABOLISM
623
A. Tikka, J. Metso, M. Jauhiainen (Finland)
E. Sifuentes Diaz, M. Monsalvo Hernando, C. Palomar Muñoz, N. Caro
Gomez, E. Lopez Tinoco, R. Toro (Spain)
138
619
K. Nakajima, S. Usui, R. Shinohata, K. Miyashita, S. Imamura, J. Kobayashi,
T. Machida, H. Sumino, M. Murakami (Japan)
R. Sayfutdinov, O. Bugrova, K. Nagornova, M. Dobrolubov, N. Artemova
(Russia)
137
ARTERIAL STIFFNESS IN A BLACK SOUTH AFRICAN COHORT INFECTED
WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV)
N. Satoh, M. Ikaida, Y. Ito (Japan)
E. Berta, M. Harangi, V.E. Varga, H. Lőrincz, I. Seres, E.V. Nagy, G. Paragh,
M. Bodor (Hungary)
136
618
Lipoproteins and Lipid Metabolism: ApoB Containing
Lipoproteins
143
Vascular Biology: Immune Disease and Cardiovascular
Pathologies
EVALUATION OF SERUM CHEMERIN LEVEL IN PATIENTS WITH
HASHIMOTO’S THYROIDITIS
PREVALENCE OF INCREASED ARTERIAL STIFFNESS AND PERIPHERAL
ARTERIAL DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS
C.M. Fourie, J.M. Van Rooyen, H.W. Huisman, C.M. Mels, W. Smith, R. Kruger,
S. Botha, L. Lammertyn, L. Gafane, A.E. Schutte (South Africa)
H. Mehrad, S.A. Seyedikhosroshahi (Iran)
135
617
K. Tziomalos, I. Gkougkourelas, A. Sarantopoulos, E. Bekiari, N. Raptis,
E. Makri, K. Tselios, M. Pantoura, A. Hatzitolios, P. Boura (Greece)
N. Furusyo, M. Shimizu, Y. Kato, Y. Tanaka, J. Hayashi (Japan)
134
PREVALENCE OF INCREASED ARTERIAL STIFFNESS AND PERIPHERAL
ARTERIAL DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
K. Tziomalos, I. Gkougkourelas, A. Sarantopoulos, E. Bekiari, E. Makri,
N. Raptis, K. Tselios, M. Pantoura, A. Hatzitolios, P. Boura (Greece)
609
A. Capisizu, A. Zamfirescu, R. Dascalescu, O. Stanciu, S.M. Aurelian
(Romania)
616
A. Baragetti, M. Magnoni, K. Garlaschelli, L. Grigore, M. Berteotti, I. Scotti,
E. Bozzolo, A. Berti, A.A. Manfredi, E. Ammirati, A.L. Catapano, G.D. Norata
(Italy)
H. Mehrad, M. Mokhtari-Dizaji, H. Ghanaati (Iran)
131
SYSTEMIC LUPUS ERYTHEMATOSUS FLARE-UP IS ASSOCIATED WITH
INCREASED 5-YEARS CAROTID INTIMA-MEDIA THICKNESS PROGRESSION
147
615
ASSOCIATION OF THE POSTPRANDIAL CHYLOMICRON TRIGLYCERIDE/
ApoB INDEX AND CARDIOVASCULAR EVENTS
624
H. Scharnagl, C. Werner, T. Stojakovic, W. März, U. Laufs (Austria)
115
Board #
148
SYSTEMATIC ASSAY OF LIPOPROTEIN LIPASE ACTIVITY AND MASS IN
COHORT OF PATIENTS WITH HISTORY OF TYPE V HYPERLIPIDEMIA
Board #
158
625
O. Marmontel, M. Di Filippo, S. Nony, C. Marcais, C. Caussy, S. Charriere,
A. Sassolas, P. Moulin (France)
149
159
APOLIPOPROTEIN C-III GLYCOFORMS CORRELATE HETEROGENEOUSLY
WITH PLASMA LIPID PROFILE IN SUBJECTS WITH CORONARY ARTERY DISEASE626
160
PLASMA APOLIPOPROTEIN CIII LEVELS AND INCIDENT CORONARY
ARTERY DISEASE RISK: THE EPIC-NORFOLK PROSPECTIVE POPULATION
STUDY.627
14C MIRISTIC ACID AND 3H CHOLESTEROL UPTAKE STUDIES IN AGING
RABBIT AORTA AND HEART MUSCLE.THE IMPACT OF SERUM FACTORS
FROM PATIENTS WITH LIPID METABOLIC DISORDERS
LDL SUBFRACTIONAL ANALYSIS: A LABORATORY DIAGNOSTIC ASSAY IN
PATIENTS WITH CAROTID AND CORONARY ATHEROSCLEROSIS
161
THERMAL STABILITY OF HUMAN PLASMA LDL(-): A PARADOXICAL
BEHAVIOR OF LDL AGGREGATION
162
LIPOPROTEINS FROM CORD BLOOD OF SMALL BABY FOR GESTATIONAL
AGE SHOWED ELEVATED TRIGLYCERIDE AND DIMINISHED APOA-I
CONTENT WITH MORE PRO-ATHEROSCLEROTIC AND PROINFLAMMATORY ACTIVITY
163
629
630
POLOXAMERS INHIBIT ASSOCIATION OF MULTIPLY MODIFIED LDL, BUT
DO NOT REDUCE THEIR ATHEROGENIC POTENTIAL
MULTIPLE MODIFICATION OF LDL CIRCULATING IN BLOOD OF
ATHEROSCLEROTIC PATIENTS
COMPARABILITY STUDY OF CANDIDATE REFERENCE METHODS FOR
LDL-P MEASUREMENTS
N. Clouet Foraison, S. Vaslin-Reimann, C. Cobbaert, P. Gillery, V. Delatour
(France)
116
639
SUBFRACTIONAL DISTRIBUTION OF APO B-CONTAINING LIPOPROTEINS:
A NEW MARKER FOR DETECTION OF INDIVIDUAL CARDIOVASCULAR RISK
640
Lipoproteins and Lipid Metabolism: Lipoprotein
Metabolism
631
165
NOVEL CHIMERAS PROVIDE INSIGHT INTO STRUCTURE/FUNCTION
ACTIVITY IN APOLIPOPROTEIN E3 AND APOLIPOPROTEIN AI
641
632
166
633
642
EFFECTS OF ROSUVASTATIN ON GENE EXPRESSION OF LIVER LDL-R,
PCSK9, SREBP-2, AND LRP1 IN OVARIECTOMIZED RATS SUBMITTED OR
NOT TO VOLUNTARY EXERCISE
643
J.M. Lavoie, E.T. Ngo Sock, G. Mayer (Canada)
167
634
EFFECTS OF TUMOR BEARING ON SERUM AND LIVER LIPID LEVELS
IN SATO LUNG CARCINOMA (SLC)-IMPLANTED RATS: EFFECT OF A
DIFFERENCE IN IMPLANTED CELL NUMBERS
M. Kawasaki (Japan)
A. Orekhov, I. Sobenin, A. Melnichenko (Russia)
157
LIPIDOMICS OF PLASMA, LIVER AND AORTA OF PCSK9-KO MICE
V. Narayanaswami, M. Lek, N. Ibe, W. Beck, J. Bielicki, P. Weers (USA)
A. Melnichenko, N. Elizova, A. Orekhov (Russia)
156
OXIDIZED LOW-DENSITY LIPOPROTEINS AND LECTIN-LIKE OXIDIZED LDL
RECEPTOR-1 ARE POSITIVELY ASSOCIATED TO PCSK9 IN TYPE 2 DIABETES
MELLITUS638
V. Metelskaya, I. Ozerova, N. Gavrilova, E. Yarovaya, S. Boytsov (Russia)
164
S.M. Kim, C. Kyung-Hyun (Republic of Korea)
155
637
G. Chiesa, M. Busnelli, C. Parolini, S. Manzini, G.S. Ganzetti, F. Dellera,
M. Suoniemi, M. Hilvo, R. Hurme, K. Ekroos, C.R. Sirtori, R. Laaksonen (Italy)
628
A. Rull, S. Jayaraman, A. Rivas, M. Pérez Cuellar, J. Ordóñez Llanos,
J.L. Sánchez Quesada, O. Gursky (Spain)
154
STRUCTURAL CHANGES INDUCED BY ACIDIC PH IN HUMAN
APOLIPOPROTEIN B-100
Y. Nekaies, B. Baudin, S. Kalbousi, M. Sakly, N. Attia (France)
N. Gavrilova, V. Metelskaya, I. Ozerova, E. Yarovaya, S. Boytsov (Russia)
153
636
A. Benito-Vicente, J.A. Fernández-Higuero, J.C.G. Milicua, A. Etxebarria,
H. Ostolaza, J.L.R. Arrondo, C. Martin (Spain)
C.R. Revnic, C. Pena, F. Revnic, S. Voinea, B. Paltineanu (Romania)
152
ADIPONECTIN AS A BLOCKER OF OXIDIZED LDL
A. Kakino, Y. Fujita, T. Sawamura (Japan)
J. Van Capelleveen, S.J. Bernelot Moens, X. Yang, N.T. Wareham, K.T. Khaw,
E.S.G. Stroes, J.L. Witztum, G.K. Hovingh, S.M. Boekholdt, S. Tsimikas
(Netherlands)
151
635
L. Cibickova, R. Gasko, H. Vaverkova, D. Karasek (Czech Republic)
C. Chiariello, A. Castagna, N. Martinelli, P. Guarini, M. Manfredi, E. Ranzato,
S. Martinotti, E. Marengo, D. Cecconi, O. Olivieri (Italy)
150
THE DETERMINATION OF APOLIPOPROTEIN B BY CALCULATION AND BY
MEASUREMENT ON SET OF DYSLIPIDEMIC PATIENTS
BLOOD LEVELS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE
9 (PCSK9) IN MEN OF DIFFERENT POPULATION SUBGROUPS AND ITS
RELATIONSHIP WITH UNFAVORABLE LONG-TERM PROGNOSIS
644
K. Astrakova, Y. Ragino, E. Shakhtshneider, S. Astrakov, M. Voevoda (Russia)
117
Board #
168
LDL RECEPTOR (LDLR) EXPRESSION AND FUNCTION IN HUMAN
PANCREATIC BETA CELLS
Board #
179
645
A. Thedrez, R. Scharfmann, P. Parnet, E. Nobécourt, G. Lambert (France)
169
170
HIGH INTAKE OF SODIUM CHLORIDE EXACERBATES DEGRADATION OF
HUMAN LIPOPROTEINS AND IMPAIRMENT OF REPRODUCTIVE CAPACITY
VIA TESTICULAR TOXICITY IN ZEBRAFISH
646
180
E.Y. Lee, K.H. Cho (Republic of Korea)
SPHINGOMYELIN CONTENT OF ERYTHROCYTE MEMBRANES IS IN LINEAR
ASSOCIATION WITH MEMBRANES’ LOADING WITH CHOLESTEROL IN
CORONARY ARTERY DISEASE PATIENTS.
MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN THE ISCHEMIC HEART
647
G. Chalikias, P. Kikas, I. Drosos, M. Pavlaki, A. Thomaidis, S. Konstantinides,
D. Tziakas (Greece)
181
STABLE ISOTOPE KINETIC STUDY OF APOLIPOPROTEIN M IN HEALTHY
SUBJECTS648
M. Croyal, M. Chétiveaux, K. Ouguerram, S. Billon-Crossouard,
E. Nobécourt, M. Krempf (France)
172
HEPATOSTEATOSIS AND ESTROGEN INCREASE APOLIPOPROTEIN O
PRODUCTION IN THE CHICKEN
NORMALIZATION OF LIPOPROTEIN PROFILE DURING PREGNANCY IN
LCAT DEFICIENCY
182
649
CHARGED RESIDUES IN THE C-TERMINAL DOMAIN OF APOLIPOPROTEIN
A-I MEDIATE OLIGOMERIZATION
183
650
EFFECTS OF APOE VARIANTS ON PLTP INTERACTION AND ACTIVATION OF
LOW AND HIGH ACTIVITY FORMS OF PLTP
184
651
HIGH-PERFORMANCE GEL PERMEATION CHROMATOGRAPHY ANALYSIS
DEMONSTRATES ATHEROGENIC PROPERTIES OF LIPOPROTEINS IN
PATIENTS WITH CHOLESTERYL ESTER TRANSFER PROTEIN DEFICIENCY
652
COMPARISON OF FATTY ACID COMPOSITION OF SUBCUTANEOUS,
PERICARDIAL AND EPICARDIAL ADIPOSE TISSUE AND ATRIAL TISSUE IN
PATIENTS WITH HEART DISEASE
653
660
EFFECT OF SALSALATE ON METABOLIC SYNDROME-RELATED
PARAMETERS AND ACTIVITY OF BROWN ADIPOSE TISSUE IN WISTAR AND
HEREDITARY HYPERTRIGLYCERIDEMIC RATS
661
185
SPECIFIC CIRCULATING PHOSPHOLIPIDS, ACYLCARNITINES, AMINO ACIDS
AND BIOGENIC AMINES ARE AEROBIC EXERCISE MARKERS
662
186
HETEROGENEITY OF PLASMA LOW DENSITY LIPOPROTEINS AND
HIGH DENSITY LIPOPROTEINS: SOME GENDER PECULIARITIES IN
SUBFRACTIONAL DISTRIBUTION
663
V. Metelskaya, I. Ozerova, N. Gavrilova, S. Boytsov (Russia)
654
R. Bülow Eschen, J. Gu, J.J. Andreasen, A. Andreasen, S. LundbyeChristensen, E. Berg Schmidt (Denmark)
178
INVESTIGATION OF LPL INDEPENDENT PATHWAYS OF TG-RICH
LIPOPROTEIN METABOLISM IN LPL DEFICIENCY
T. Felder, S. Ring-Dimitriou, S. Auer, S. Soyal, L. Kedenko, M. Rinnerthaler,
J. Cadamuro, E. Haschke-Becher, E. Aigner, B. Paulweber, W. Patsch
(Austria)
T. Okada, T. Ohama, M. Okazaki, H. Matsuda, M. Sairyo, Y. Zhu, R. Kawase,
D. Masuda, M. Koseki, M. Nishida, Y. Sakata, S. Yamashita (Japan)
177
659
V. Skop, J. Trnovska, M. Huttl, H. Malinska, I. Markova, O. Oliyarnyk,
L. Kazdova (Czech Republic)
M. Jauhiainen, I. Dafnis, J. Metso, V. Zannis, A. Chroni (Finland)
176
ATHEROGENIC INDEX OF PLASMA FOR PREDICTION OF FUTURE
CARDIOVASCULAR DISEASE IN PREDIABETES AND DIABETES POPULATION
D. Gaudet, D. Brisson, K. Tremblay (Canada)
P. Weers, V. Narayanaswami, L. Fuentes, J. Horn, R. Ellena, K. Cong (USA)
175
658
P. Regmi, B. Baral, M. Raut, M.P. Khanal (Nepal)
A. Ossoli, E. Hanna, S. Simonelli, R. Mullan, S. Chamney, J. Chestnutt,
F. Stewart, G. Franceschini, L. Calabresi (Italy)
174
COMPLEX PHOSPHOLIPIDS ASSOCIATE WITH ARTERIAL
NOREPINEPHRINE, NON-ESTERIFIED FATTY ACIDS AND HEART RATE,
MARKERS OF SYMPATHETIC NERVE SYSTEM IN METABOLIC SYNDROME
SUBJECTS INDEPENDENTLY OF INSULIN RESISTANCE
657
P. Nestel, N. Straznicky, A. Anwar, M. Pyush, P. Meikle (Australia)
B. Schmidinger, A. Weijler, W.J. Schneider, M. Hermann (Austria)
173
656
G. Speziali, D. Cecconi, N. Martinelli, O. Olivieri, A. Castagna, P. Guarini (Italy)
M. Klevstig, M. Scharin Täng, M. Ståhlman, M. Levin, J. Borén (Sweden)
171
MYRISTIC ACID PLASMA LEVELS ARE STRONGLY CORRELATED WITH
TRIGLYCERIDE AND APOLIPOPROTEIN C-III PLASMA CONCENTRATION IN
A COHORT OF SUBJECTS WITH OR WITHOUT CORONARY ARTERY DISEASE
187
IDENTIFICATION OF A NOVEL LXR TARGET
664
E.C.L. Cook, J.K. Nelson, V. Sorrentino, N. Zelcer (The Netherlands)
DIETARY SATURATED FATTY ACIDS AGGRAVATE PRESSURE OVERLOADINDUCED CARDIOMYOPATHY IN MICE IN THE ABSENCE OF CARDIAC STEATOSIS 655
I. Muthuramu, R. Amin, N. Singh, A. Postnov, O. Gheysens, P. Van Veldhoven,
B. De Geest (Belgium)
118
119
Board #
Board #
Lipoproteins and Lipid Metabolism: Lp(a)
197
188
PROGNOSTIC VALUE OF COMBINED LIPOPROTEIN(A) AND
HOMOCYSTEINE IN ANGIOGRAPHICALLY PROVEN PATIENTS WITH
CORONARY ARTERY DISEASE
665
S.W. Kwon, H.M. Kwon (Republic of Korea)
189
LIPOPROTEIN(A) MEASUREMENT AND ASSOCIATION WITH MEDICAL
HISTORY IN SECONDARY CARE LIPID CLINICS
ELEVATED LIPOPROTEIN(A) AND ISCHEMIC STROKES- A CASE REPORT
198
666
667
199
RATIONALE AND DESIGN OF A CLINICAL TRIAL TO ASSESS LP(A)
LOWERING WITH IONIS-APO(A)-LRX IN PATIENTS UNDERGOING
APHERESIS FOR ELEVATED LP(A) AND RECURRENT CARDIOVASCULAR EVENTS668
PREVALENCE OF LPA SINGLE NUCLEOTIDE POLYMORPHISMS AND
ISOFORMS IN PATIENTS ENROLLED IN A PHASE 2 IONIS-APO(a)Rx
CLINICAL TRIAL
NATURAL TEMPORAL VARIABILITY IN Lp(a) LEVELS IN PATIENTS
ENROLLED IN THE PLACEBO ARMS OF IONIS-APO(a)Rx ANTISENSE
OLIGONUCLEOTIDE CLINICAL TRIALS
200
201
669
202
670
PROGNOSTIC VALUE OF SERUM LIPOPROTEIN(A) LEVELS ON LONGTERM MORTALITY IN A LARGE SAMPLE OF SUBJECTS IN PRIMARY
CARDIOVASCULAR PREVENTION: DATA FROM THE BRISIGHELLA HEART STUDY671
A SYSTEMATIC REVIEW AND META-ANALYSIS COMPARING THE EFFECTS
OF STATINS AND FIBRATES ON PLASMA LIPOPROTEIN(A) LEVELS
203
DEFINING THE MECHANISM OF LIPOPROTEIN(A) [LP(A)] LOWERING BY
ALIROCUMAB IN TRANSGENIC MOUSE MODELS
C. Yeang, P. Miu, S. Green, X. Yang, M.Y. Hung, J.L. Witztum, S. Tsimikas (USA)
THE ROLE OF Lp(a) LEVELS AND APOPROTEIN(a) PHENOTYPE IN THE
DEVELOPMENT OF ATHEROSCLEROSIS IN PATIENTS WITH CORONARY
ARTERY DISEASE
678
LIPOPROTEIN(a) AND T-HELPER CELLS AS INDEPENDENT PREDICTORS
OF RAPID PROGRESSION OF CAROTID ATHEROSCLEROSIS
679
POPULATION AND ASSAY THRESHOLDS FOR THE PREDICTIVE VALUE OF
LIPOPROTEIN(A) FOR RISK OF CORONARY ARTERY DISEASE: THE EPICNORFOLK PROSPECTIVE POPULATION STUDY
680
R. Verbeek, S.M. Boekholdt, R.M. Stoekenbroek, G.K. Hovingh, J.L. Witztum,
N.J. Wareham, M.S. Sandhu, K.T. Khaw, S. Tsimikas (Netherlands)
204
672
A. Sahebkar, L.E. Simental-Mendía, M. Banach, M.C. Serban, G.F. Watts (Iran)
196
677
O. Afanasieva, E. Pylaeva, T. Arefieva, E. Klesareva, M. Afanasieva,
A. Potekhina, A. Shchinova, T. Balakhonova, O. Pogorelova, M. Tripoten,
S. Pokrovsky (Russia)
F. Fogacci, S. D'Addato, A.F.G. Cicero, E. Bertagnin, S. Palmisano,
L. D'Agostini, E. Grandi, M. Giovannini, C. Borghi (Italy)
195
CIRCULATING LIPOPROTEIN (A) [LP(A)] LEVELS AND RISK OF
CARDIOVASCULAR DISEASE: THE ATHEROSCLEROSIS RISK IN
COMMUNITIES (ARIC) STUDY
D. Labudovic, K. Toseska-Trajkovska, S. Alabakovska, J. Bogdanska,
S. Jovanova (FYR Macedonia)
N.J. Viney, S. Marcovina, J. Tami, S. Xia, J.L. Witztum, S. Tsimikas (USA)
194
676
R. Hoogeveen, W. Sun, V. Salim, B. Christie (USA)
E.S. Stroes, F.M. Van der Valk, D. Gaudet, I. Gouni-Berthold, N.P. Riksen,
E. Steinhagen-Thiessen, B. Isermann, B. Nordestgaard, N.J. Viney,
S. Marcovina, S.G. Hughes, J. Tami, S. Xia, J.L. Witztum, S. Tsimikas
(Netherlands)
193
A NOVEL MODIFIED LIPID TETRAD INDEX AS PREDICTOR OF PREMATURE
CORONARY ARTERY DISEASE IN INDIANS
S. Das (India)
P.M. Moriarty, E.S. Thiessen, J.L. Witztum, N.J. Viney, S. Tsimikas (USA)
192
LIPOPROTEIN(a) AND INSULIN RESISTANCE: A POSSIBLE INVERSE
RELATIONSHIP BETWEEN TWO WELL-KNOWN CARDIOVASCULAR RISK
FACTORS675
C.O. Aragona, E. Imbalzano, V. Cairo, F. Mamone, A. Lo Gullo, M.A. Sardo,
A. Saitta, G. Mandraffino (Italy)
P. Moriarty, N. Sehar, L. Denney, F. Perez-Marques, A. Panchal, P. Luna (USA)
191
674
C. Yeang, S. Tsimikas (USA)
K.E. Shipman, A.J. Lawson, W. Alkaaby, A.F. Jones, R. Cramb (United
Kingdom)
190
LIPOPROTEIN(A)-CHOLESTEROL (LP(A)-C) LEVELS DETERMINED BY
VERTICAL AUTO PROFILE (VAP) CORRELATES WEAKLY WITH LP(A)
MASS BUT MODESTLY WITH HDL-C: IMPLICATIONS FOR APPROPRIATE
INTERPRETATION OF CLINICAL DATA
STATUS OF INFLAMMATION, ENDOTHELIAL ACTIVATION AND
PROTHROMBOGENESIS AMONG NEGRITOS AND MALAYS WITH
METABOLIC SYNDROME
681
S.S. Mokhtar, N.A. Mohd Mokhsin, F. Mohd Nor, S.A. Shaari, H. Nawawi,
B.P. Hoh, T. Rahman (Malaysia)
673
205
ELEVATED LIPOPROTEIN(A) LEVELS RESULT IN A HIGH CARDIOVASCULAR
RISK – A PROSPECTIVE ANALYSIS OF A LIPIDOLOGY OUTPATIENTS UNIT
682
U. Schatz, S. Fischer, U. Julius, S.R. Bornstein, S. Tselmin (Germany)
120
121
Board #
206
PROFILE OF CIRCULATING miRNAs IN PATIENT WITH HIGH Lp(a) TREATED
BY LDL/Lp(a) APHERESIS
Board #
215
683
D. Dlouha, J. Pitha, Z. Eretova, O. Viklicky, A. Parikova (Czech Republic)
207
FAMILIAL HYPERCHOLESTEROLEMIA (FH) WITH ELEVATED
LIPOPROTEIN(a) (Lp(a)) LEVELS AND AGGRESSIVE CORONARY HEART
DISEASE: A CASUISTIC APPROACH
LIPOPROTEIN(a) IS A PREDICTOR OF ONE-YEAR VEIN GRAFT
OCCLUSIONS IN STABLE ANGINA PATIENTS RECEIVED LIPOPROTEIN
APHERESIS FOR REFRACTORY HYPERCHOLESTEROLEMIA AFTER
CORONARY ARTERY BYPASS GRAFTING
216
684
217
685
LIPOPROTEIN(A) LEVEL AS A PREDICTOR OF LONG-TERM
CARDIOVASCULAR OUTCOMES AFTER PERCUTANEOUS CORONARY
INTERVENTIONS686
EFFECT OF NIACIN ON LIPOPROTEIN SUBFRACTIONS CONCENTRATION
IN PATIENTS WITH ELEVATED LIPOPROTEIN(a)
218
219
687
220
APOA-I DEPLETION IN CHOW-FED APOEKO MICE SEVERELY WORSENS
CORONARY ATHEROSCLEROSIS DEVELOPMENT
688
221
EVALUATION OF NOVEL APOA-I TWO-SITE IMMUNOASSAYS
689
690
222
J. Lövgren, P. Negi, T. Heikkilä, T. Tallgren, K. Pettersson, M. Jauhiainen,
U. Lamminmäki (Finland)
214
EICOSAPENTAENOIC ACID (EPA) MEMBRANE INCORPORATION REDUCES
ABCA1-DEPENDENT CHOLESTEROL EFFLUX IN UNLOADED AS WELL AS
IN CHOLESTEROL-LOADED PRIMARY HUMAN MACROPHAGES THROUGH
DIFFERENT MECHANISMS
ELEVATED LEVELS OF LECITHIN:CHOLESTEROL ACYLTRANSFERASE (LCAT)
ARE ASSOCIATED WITH REDUCED ATHEROMA BURDEN – AN IVUS STUDY
696
EVALUATION OF HDL CHOLESTEROL EFFLUX CAPACITY (CEC) AFTER
CONSUMPTION OF AN INNOVATIVE PASTA ENRICHED WITH BIOACTIVE
COMPONENTS AND FUNCTIONAL PROBIOTICS
697
AEROBIC EXERCISE TRAINING DOES NOT SYSTEMATICALLY AFFECT
MACROPHAGE GENE EXPRESSION INVOLVED IN REVERSE CHOLESTEROL
TRANSPORT AND CHOLESTEROL EFFLUX IN CETP TRANSGENIC MICE
698
P.R. Pinto, K.S. Silva, D.J. Gomes, A. Machado-Lima, R.T. Iborra, G.S. Ferreira,
E.C.R. Quintao, E.R. Nakandakare, U.F. Machado, M.L.C. Corrêa-Giannella,
S. Catanozi, M. Passarelli (Brazil)
G.S. Ganzetti, M. Busnelli, C. Parolini, S. Manzini, F. Dellera, C.R. Sirtori,
G. Chiesa (Italy)
213
695
E. Cipollari, F. Zimetti, M.P. Adorni, N. Ronda, D. Angelino, N. Pellegrini,
F. Bernini, E. Favari (Italy)
S. Filou, E. Karavia, C. Constantinou, E. Zvintzou, K. Kypreos (Greece)
212
IDENTIFICATION OF A NOVEL UPREGULATOR OF ABCA1 AND SRB1
EXPRESSION WITH THE ACTION OF REGULATING CHOLESTEROL
METABOLISM IN VITRO AND IN VIVO
D. Rhainds, C. Gebhard, M. Cossette, M.C. Guertin, E. Rhéaume, J.C. Tardif
(Canada)
Lipoproteins and Lipid Metabolism: HDL
FUNCTIONAL DIFFERENCES BETWEEN APOLIPOPROTEIN E- AND
APOLIPOPROTEIN A-I- CONTAINING HDL PARTICLES
694
S. Si, Y. Xu, C. Liu, P. Liu, X. Wang, B. Hong (China)
E. Utkina, O. Afanasieva, N. Artemieva, M. Ezhov, I. Adamova,
Y. Berestetskaya, S. Pokrovsky (Russia)
211
INFLAMMATION POTENTLY SUPPRESSES ABCA1-MEDIATED CHOLESTEROL
EFFLUX FROM MACROPHAGES, AND NOT ADIPOCYTES, VIA ACTIVATION
OF JAK/STAT PATHWAY
M. O'Reilly, M. Goodwin, O. Ansmidte, H. Roche, F. McGillicuddy (Ireland)
M. Mitroshkin, M. Ezhov, M. Safarova, O. Afanasieva, Y. Matchin,
S. Pokrovsky (Russia)
210
PROBUCOL OXIDIZED PRODUCTS, SPIROQUINONE AND
DIPHENOQUINONE, PROMOTE REVERSE CHOLESTEROL TRANSPORT IN MICE693
K. Shiotani, E. Yakushiji, M. Ayaori, T. Nishida, S. Takiguchi, H. Uto-Kondo,
M. Sasaki, M. Yogo, T. Komatsu, R. Lu, S. Yokoyama, K. Ikewaki (Japan)
R. Adzhiev, M. Ezhov, O. Afanasieva, S. Pokrovsky (Russia)
209
692
D. Greco, L. Mele, A. Piemontese, S. Battista, A. Poli, F. Bernini, I. Zanotti
(Italy)
A. Dybvig, A. Græsdal (Norway)
208
EFFECTS OF MODERATE AND EXCESS ALCOHOL CONSUMPTION ON THE
REVERSE CHOLESTEROL TRANSPORT IN VIVO
HDL CHOLESTEROL EFFLUX IS NOT PREDICTIVE OF CARDIOVASCULAR
RISK IN DIABETIC PATIENTS ON HEMODIALYSIS
699
C. Kopecky, S. Ebtehaj, B. Genser, C. Wanner, M.D. Saemann, U. Tietge
(Austria)
223
691
XANTHOHUMOL, A PRENYLATED FLAVONOID IN HOPS, PROMOTES
MACROPHAGE REVERSE CHOLESTEROL TRANSPORT IN HAMSTER
700
H. Hirata, H. Uto-Kondo, M. Ogura, M. Ayaori, K. Ikewaki (Japan)
N. Fournier, S. Tardivel, B. Vedie, J.F. Benoist, F. Allaoui, J.L. Paul (France)
122
123
Board #
Board #
224
234
FAT-ACTIVATED ER STRESS INDUCES THE REDUCTION OF ABCG5/8
EXPRESSION IN THE SMALL INTESTINE AND LIVER OF HYPERLIPIDEMIC
HAMSTERS AND THE APPEARANCE OF DYSFUNCTIONAL HDL
701
C.S. Stancu, M.G. Carnuta, G.M. Sanda, L. Toma, M. Deleanu, L.S. Niculescu,
M. Simionescu, A.V. Sima (Romania)
225
ASSOCIATIONS BETWEEN LIPID SUBFRACTIONS AND SERUM
MYELOPEROXIDASE LEVELS IN UNTREATED HYPERLIPIDEMIC PATIENTS
226
ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN SUBCLASSES WITH
CAROTID INTIMA-MEDIA THICKNESS：SHIMANE CoHRE STUDY
702
227
HIGH DENSITY LIPOPROTEINS EXERT PRO-INFLAMMATORY EFFECTS ON
MACROPHAGES VIA PASSIVE CHOLESTEROL DEPLETION AND PKC-NF-KB/
STAT1-IRF1 SIGNALING
703
228
RELATIONSHIP BETWEEN FRAMINGHAM SCORE, HDL-CHOLESTEROL AND
C-REACTIVE PROTEIN AT ELDERLY PATIENTS
704
THE LIPID FRACTIONS AS RISK FACTORS FOR ATHEROSCLEROSIS IN
DIFFERENT AGE GROUPS IN BOSNIAN POPULATION
238
METRICS OF HIGH-DENSITY LIPOPROTEIN FUNCTION AND HOSPITAL
MORTALITY IN ACUTE HEART FAILURE PATIENTS
705
239
706
CAUSAL LINK BETWEEN SERUM AMYLOID A AND OXIDATIVE DAMAGES TO
HIGH-DENSITY LIPOPROTEIN
707
240
241
708
HIGH-DENSITY LIPOPROTEIN (HDL) FUNCTION AND SUBCLASS
DISTRIBUTION IN OBESE AND NORMAL-WEIGHT BLACK AND WHITE
AFRICAN WOMEN.
715
STATUS OF INFLAMMATION AND ENDOTHELIAL ACTIVATION IN SUBJECTS
WITH LOW HIGH DENSITY LIPOPROTEIN CHOLESTEROL AMONG
ABORIGINES IN MALAYSIA
716
EFFECT OF STATINS ON HDL IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS717
242
710
HDL AS A CRUCIAL INDICATOR OF AN EARLY CLINICAL MANIFESTATION
OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH FAMILIAL
HYPERCHOLESTEROLEMIA718
S. Urazgildeeva, M.V. Muzalevskaya, A.V. Tregubov, T.V. Nekrasova,
V.S. Gurevich (Russia)
INFLUENCE OF HDL-CHOLESTEROL LEVELS ON HDL PARTICLES LIPID
COMPOSITION IN HEALTHY INDIVIDUALS. AN NMR-BASED LIPIDOMIC STUDY 709
C. Kostara, V. Tsimihodimos, E. Bairaktari, M. Elisaf (Greece)
233
VITAMIN D STATUS AND HDL FUNCTIONALITY IN HEALTHY PREMENOPAUSAL WOMEN
M. Licona-Rashid, R. Yahya, D. Wattimena, J. Roeters van Lennep,
C. Christoffersen, E. Sijbrands, A. Verhoeven, M. Mulder (Netherlands)
S. Jayaraman, C. Haupt, O. Gursky (USA)
232
A PHASE III MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED
STUDY (TANGO) TO EVALUATE CER-001 ON CAROTID ATHEROSCLEROSIS
(VESSEL WALL AREA) IN PATIENTS WITH FAMILIAL PRIMARY
HYPOALPHALIPOPROTEINAEMIA714
N.A. Mohd Mokhsin, W.N.H. Wan Ahmad, F.H. Sakri, N.A. Mohd Kasim,
N. Mohd Nasir, S. Abdul Razak, M. Md Yasin, A. Mohd Ismail, T. Rahman,
H. Nawawi (Malaysia)
I. Potočnjak, V. Degoricija, M. Trbušić, S. Dokoza Terešak, B. Radulović,
G. Pregartner, B. Andrea, B. Tiran, G. Marsche, S. Frank (Austria)
231
713
F. Zimetti, D. Kocyigit, D. Greco, M.P. Adorni, N. Ronda, K.M. Gurses,
S.H. Oguz, A. Gurlek, L. Tokgozoglu (Italy)
B. Pojskic, E. Stimjanin, L. Pojskic, H. Selimovic, A. Macic-Dzankovic, S. Palo,
I. Sisic (Bosnia and Herzegovina)
230
HDL-SPHINGOMYELIN REDUCTION AFTER WEIGHT LOSS BY AN
ENERGY-RESTRICTED DIET IS ASSOCIATED WITH THE IMPROVEMENT OF
METABOLIC SYNDROME COMPONENTS IN OVERWEIGHT PATIENTS
E. Stroes, R. Benghozi, J.L. Dasseux, J. Genest, H. Ginsberg, C. Keyserling,
E. Leitersdorf, P. Raggi, A. Von Eckardstein (Netherlands)
S. Opris, G. Constantin, M. Grigorie (Romania)
229
712
O. Pérez-Méndez, M. Martínez-Ramírez, M. Madero (Mexico)
237
E. Van der Vorst, K. Theodorou, Y. Wu, M. Hoeksema, P. Goossens,
C. Bursill, L. Huitema, S. Tas, M. Gijbels, K. McDaniels, C.C. Wang, M. Leitges,
T. Lawrence, L. Touqui, J. Plat, M. Van Eck, K.A. Rye, M. De Winther,
E. Biessen, M. Donners (Germany)
ESTIMATION OF HDL ANTIOXIDATIVE ACTIVITY IN SUBJECTS WITH ACUTE
CORONARY SYNDROME
H. Thakkar, V. Vincent, A. Roy, S. Singh, L. Ramakrishnan, A. Singh (India)
236
Y. Notsu, T. Nabika, S. Yano, A. Nagai (Japan)
711
L. Persègol, M. Darabi, C. Dauteuille, M. Lhomme, R. Salvayre, A. NègreSalvayre, S. Monier, A. Kontush (France)
235
A. Szentpéteri, H. Lőrincz, N. Zsíros, V.E. Varga, I. Seres, M. Katkó, P. Fülöp,
G. Paragh, M. Harangi (Hungary)
SMALL, DENSE HDL DISPLAY POTENT VASORELAXING ACTIVITY,
REFLECTING THEIR ELEVATED CONTENT OF S1P
ENDOTHELIAL PROTECTIVE PROPERTIES OF HDL IMPROVE EARLY AFTER
ROUX-EN-Y GASTRIC BYPASS BUT NOT AFTER DIET-INDUCED WEIGHT
LOSS: THE SUPERIOR CARDIOMETABOLIC BENEFITS OF RYGB
719
E. Osto, E. McLoughlin, P. Doytcheva, M. Charakida, L. Van Gaal,
J. Deanfield, T. Lüscher (Switzerland)
N. Woudberg, J. Goedecke, D. Blackhurst, M. Frias, R. James, L. Opie,
S. Lecour (South Africa)
124
125
Board #
Board #
243
253
EFFECTS OF BARIATRIC SURGERY ON HIGH-DENSITY LIPOPROTEIN SUBTYPES720
G. Rega-Kaun, C. Kaun, E. Dostal, S. Oravec, M. Prager, J. Wojta, W. Speidl
(Austria)
244
INTERLEUKIN-6 REDUCES PARAOXONASE-1 ACTIVITY IN A DOSEDEPENDENT MANNER; EVIDENCE FOR A POTENTIAL NOVEL
LIPOPROTEIN-BASED MODULATORY MECHANISM
TERMINALIA ARJUNA MODULATES LIPID EFFLUX AND INFLAMMATION IN
HYPERCHOLESTEROLEMIC RABBITS
730
J. Frutuoso, M. Bourbon (Portugal)
254
CORONARY ARTERY DISEASE AS A RISK FOR DEVELOPING TYPE 2
DIABETES MELLITUS
731
C. Saely, A. Vonbank, P. Rein, D. Zanolin, A. Leiherer, A. Muendlein, H. Drexel
(Austria)
721
A. Abedpour Dehkordi, H. Nayeri, G.A. Naderi, N. Jafari Dinani, M. Boshtam (Iran)
245
THE NEED TO CREATE AWARENESS TOWARDS CHOLESTEROL
255
722
V. Dhawan, R. Rather, D. Trikha (India)
C-REACTIVE PROTEIN SIGNIFICANTLY PREDICTS CARDIOVASCULAR
EVENTS BOTH IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITH AND
IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITHOUT THE METABOLIC
SYNDROME732
A. Vonbank, C. Saely, P. Rein, D. Zanolin, A. Leiherer, H. Drexel (Austria)
256
CVD Risk Factors
246
ELEVATED NEUTROPHILS, MONOCYTES AND WHITE CELL COUNTS IN
PATIENTS WITH MYOCARDIAL INFARCTION COMPARED WITH STABLE
CORONARY ARTERY DISEASE
THE RISK FACTORS OF ATHEROSCLEROSIS IN ROMA POPULATION IN
SOUTH BOHEMIA
723
257
724
258
RISK OF DEMENTIA HOSPITALISATION ASSOCIATED WITH
CARDIOVASCULAR RISK FACTORS IN MIDLIFE AND OLDER AGE: THE
ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY
259
PULSE WAVE VELOCITY IS CORRELATED WITH THE SERUM N-TERMINAL
FRAGMENT OF BRAIN NATRIURETIC PEPTIDE LEVEL INDEPENDENTLY OF
CENTRAL BLOOD PRESSURE AND THE AUGMENTATION INDEX
726
260
ATHEROSCLEROTIC LESIONS OF AORTO-ILIAC SEGMENT AND LONGTERM CONSEQUENCES OF RECONSTRUCTIVE OPERATIONS
261
727
COMBINED EFFECTS OF ADIPONECTIN AND VISCERAL FAT ON THE RISK
OF METABOLIC SYNDROME
THE EFFECT OF MOXONIDINE ON LIPID PROFILE OF PATIENTS WITH
ARTERIAL HYPERTENSION, GRADE 1 AND 2
736
RISK OF INCIDENT HYPERTENSION ACCORDING TO METABOLIC HEALTH
AND OBESITY: DEFINITION OF METABOLIC HEALTH DOES NOT MATTER
737
BRACHIAL-ANKLE PULSE WAVE VELOCITY IS ASSOCIATED WITH
COMPOSITE CAROTID AND CORONARY ATHEROSCLEROSIS IN A MIDDLEAGED ASYMPTOMATIC POPULATION
738
H.J. Joo, S.A. Cho, J.Y. Cho, S. Lee, J.H. Park, S.H. Hwang, S.J. Hong,
C.W. Yu, D.S. Lim (Republic of Korea)
728
A. Kozireva, M. Ivanov, P. Bondarenko, M. Ermina, D. Kozhevnikov,
P. Puzdriak, A. Yadernaya, A. Kebryakov (Russia)
252
735
C.H. Jung, W.J. Lee, J.Y. Park, C.Y. Park, S. Kim (Republic of Korea)
M. Shimizu, N. Furusyo, Y. Kato, Y. Tanaka, J. Hayashi (Japan)
251
AGE-DEPENDENCE OF THE MAGNITUDE OF LIPID PROFILE VARIABLES
RESEMBLANCE BETWEEN FIRST DEGREE RELATIVES IN FAMILIES OF
PATIENTS WITH EARLY CORONARY HEART DISEASE
E. Karlafti, A. Hatzitolios, T. Didangelos, M. Baltatzi, G. Koliakos,
A. Kalkavouri, E. Liorda, V. Chasiotis, C. Savopoulos (Greece)
250
734
M. Konnov, A. Deev, N. Gratsiansky (Russia)
LIPOPROTEIN PHENOTYPE IN NAïVE PATIENTS WITH KLINEFELTER SYNDROME725
A. Antonucci, A. Bonaldo, P. Scarinzi, M. Barichello, P. Bigolin, N. Caretta,
M. Ghezzi, R. Selice, M. Terrin, D. Vianello, R. Marin, A. Ferlin, C. Foresta,
E. Manzato, F. Fabris, S. Bertocco, S. Zambon, A. Zambon (Italy)
249
OVERWEIGHT IN CHILDREN OF PATIENTS WITH EARLY CORONARY HEART
DISEASE: RELATION TO OWN AND PARENTAL CHARACTERISTICS`
M. Konnov, A. Deev (Russia)
V. Adamkova, J. Hubacek, D. Novakova, V. Adamek, V. Lanska, V. Tothova
(Czech Republic)
248
733
I. Trakarnwijitr, B. Li, H. Adams, J. Layland, J. Garlick, A. Wilson (Australia)
247
PRO B-TYPE NATRIURETIC PEPTIDE SIGNIFICANTLY PREDICTS FUTURE
VASCULAR EVENTS IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITH
TYPE 2 DIABETES
729
262
SUSTAINED METABOLIC SYNDROME AFTER LIFESTYLE COUNSELING
WAS ASSOCIATED WITH HIGHER RISK OF SUBCLINICAL CORONARY
ATHEROSCLEROSIS739
H.J. Joo, S.A. Cho, J.Y. Cho, S. Lee, J.H. Park, S.H. Hwang, S.J. Hong,
C.W. Yu, K.J. An, D.S. Lim (Republic of Korea)
K.H. Ha, D.J. Kim, H.C. Kim (Republic of Korea)
126
127
Board #
Board #
263
274
ASSOCIATION OF Pro12Ala PPARγ AND -308G/A TNFα WITH PPARγ AND
TNFα mRNA LEVELS IN VISCERAL ABDOMINAL TISSUE IN FERTILE WOMEN
IN RUSSIA
264
CAN NON-CHOLESTEROL STEROLS AND LIPOPROTEIN SUBCLASSES
DISTRIBUTION PREDICT DIFFERENT PATTERNS OF CHOLESTEROL
METABOLISM AND STATIN THERAPY RESPONSE?
275
SERUM LIPID PROFILE ON ADMISSION FOR ISCHEMIC STROKE/
TRANSIENT ISCHEMIC ATTACK
741
276
DETERMINATION OF FACTORS CONTRIBUTING TO ATHEROSCLEROTIC
DISEASE PROGRESSION IN PATIENTS WITH SYMPTOMATIC PERIPHERAL
ARTERIAL DISEASE (PAD)
277
742
COMPLIANCE INITIATIVES IN MANAGEMENT OF PATIENTS WITH
CORONARY ARTERY DISEASE AND PARKINSONISM SYNDROME
743
HEART RATE TURBULENCE AS A MORTALITY PREDICTOR IN 5 YEARS
STUDY IN PATIENTS WITH CRORONARY HEART DISEASE
279
744
EFFECTS OF ASTHMA SEVERITY ON CHANGE OF PRESSURE OF
PULMONARY ARTERY IN PATIENTS WITH ARTERIAL HYPERTENSION
280
745
CLINICAL CHARACTERISTICS OF PATIENTS ON HEMODIALYSIS WITH
281
746
ASSOCIATIONS BETWEEN OSTEOPOROSIS AND SIGNIFICANT CORONARY
ARTERY DISEASE IN ASYMPTOMATIC POSTMENOPAUSAL WOMEN
747
282
ADJUSTED NECK CIRCUMFERENCE AND METABOLIC SYNDROME:
RESULTS FROM THE BRISIGHELLA HEART STUDY
748
283
NON-CORONARY ATHEROSCLEROSIS PREVALENCE ACCORDING TO THE
DATA OF THE ADULT POPULATION SCREENING
SERUM ENDOSTATIN IS CORRELATED TO RENAL FUNCTION
INDEPENDENTLY OF CAROTID ATHEROSCLEROSIS: RESULTS FROM THE
KYUSHU AND OKINAWA POPULATION STUDY (KOPS)
756
SYSTEMATIC REVIEW OF HERPES ZOSTER AND ITS ASSOCIATION WITH
CARDIOVASCULAR EVENTS
757
EXPOSURE TO CARDIOVASCULAR DISEASE RISK FACTORS IN CHILDHOOD
IS ASSOCIATED WITH INCREASED CAROTID EXTRA MEDIAL THICKNESS IN
ADULTHOOD: THE CHILDHOOD DETERMINANTS OF ADULT HEALTH STUDY
758
CANDIDATE GENE POLYMORPHISMS RELATED TO LIPID AND
CARBOHYDRATE METABOLISM SHOW AN ASSOCIATION WITH RISK
FACTOR COMPONENTS OF THE METABOLIC SYNDROME IN ASIAN INDIANS.
759
284
750
CLINICAL CHARACTERISTICS AND LDL-CHOLESTEROL MANAGEMENT
IN PATIENTS WITH CARDIOVASCULAR EVENT AND/OR DIABETES IN THE
NETHERLANDS760
E. Heintjes, J. Kuiper, B. Lucius, F. Penning-van Beest, L. Kutikova, A. Liem,
R. Herings (Switzerland)
749
E. Bertagnin, S. D'Addato, F. Fogacci, S. Palmisano, L. D’Agostini,
A.F.G. Cicero, M. Giovannini, M. Rosticci, C. Borghi (Italy)
273
755
T. Maistry (South Africa)
S.N. Lee (Republic of Korea)
272
THE ASSOCIATION OF AN ELEVATED SERUM ENDOSTATIN LEVEL AND
CAROTID ATHEROSCLEROSIS: RESULTS FROM THE KYUSHU AND
OKINAWA POPULATION STUDY (KOPS)
H. West, M. Skilton, B. Fraser, T. Dwyer, A. Venn, C. Magnussen (Australia)
N. Aoyama (Japan)
271
754
N. Erskine, H. Tran, L. Levin, C. Ulbricht, R. Goldberg (USA)
A. Odegova, E. Tarlovskaya (Russia)
270
ACCURATE CARDIOVASCULAR EVENT RISK ESTIMATION CAN BE
OBTAINED USING CORONARY ARTERY SCAN
Y. Kato, M. Shimizu, N. Furusyo, Y. Tanaka, J. Hayashi (Japan)
N. Zagidullin, D. Gareeva, I. Lackman, I. Sagitov, S. Zagidullin (Russia)
269
753
Y. Kato, M. Shimizu, N. Furusyo, Y. Tanaka, J. Hayashi (Japan)
A. Shalaeva, N. Dadabaeva, M. Bozorboev, G. Kasimdjanova (Uzbekistan)
268
CHADS2 AND CHA2DS2-VASC SCORES PREDICT CARDIOVASCULAR
DISEASE IN STATIN-TREATED INDIVIDUALS WITHOUT ATRIAL FIBRILLATION
M. Gracia, D. Craiem, A. Simon (Spain)
278
L.P. Zielinski, M.M. Chowdhury, B.P. Worsfold, S.C. Harrison, J.R. Boyle,
P.D. Hayes, P.A. Coughlin (United Kingdom)
267
752
F. Barkas, E. Klouras, G. Liamis, M. Elisaf, E. Liberopoulos (Greece)
T. Vassalo, F. Faria, T. Duarte, I. Colaço, D. Cruz, J.L. Ducla Soares (Portugal)
266
PREVALENCE OF RISK FACTORS AND CARDIOVASCULAR DISEASES IN
EMPLOYEES OF A SINGLE PLANT IN DIFFERENT AGE GROUPS
R. Allanov, R. Rakhimov, E. Shalaeva, N. Dadabaeva (Uzbekistan)
T. Gojković, S. Vladimirov, V. Spasojević-Kalimanovska, A. Zeljković, J. Vekić,
D. Kalimanovska-Oštrić, Z. Jelić-Ivanović (Serbia)
265
751
S. Lee, Y.S. Lee, B. Kim (Republic of Korea)
740
A. Kopytova, T. Usenko, V. Miroshnikova, E. Bazhenova, M. Nikolaev,
A. Panteleeva, I. Semenova, A. Neimark, E. Baranova, S. Pchelina (Russia)
EPICARDIAL FAT THICKNESS IS ASSOCIATED WITH HIGHER VAGAL TONE
WAIST-HIP-RATIO AND 1-YEAR CLINICAL OUTCOME IN PATIENTS WITH
NON-ST-ELEVATION ACUTE CORONARY SYNDROME
761
H.W. Lee, T.J. Hong, J.H. Choi, B.W. Kim (Republic of Korea)
R. Khokhlov, L. Tribuntseva, V. Burlachuk, L. Khokhlov (Russia)
128
129
Board #
Board #
285
295
GLOMERULAR FILTRATION RATE (GFR) MODERATES THE PROTECTIVE
EFFECT OF MEDITERRANEAN DIET AGAINST CARDIOVASCULAR
INCIDENCE: 10-YEAR FOLLOW-UP (2002-12) OF THE ATTICA STUDY
762
E. Georgousopoulou, C. Pitsavos, D. Panagiotakos, C. Chrysohoou,
I. Skoumas, M. Chatzigeorgiou, D. Tousoulis, C. Stefanadis (Greece)
286
PLAQUE CHARACTERIZATION AND REMODELING BY CORONARY
COMPUTED TOMOGRAPHY ANGIOGRAPHY AND CORONARY EVENTS
DURATION OF DIABETES IS AN INDEPENDENT DETERMINANT AND
INTERACTED WITH GENDER FOR ACUTE MYOCARDIAL INFARCTION
296
763
PRESENCE OF CAROTID PLAQUES AND CARDIOVASCULAR DISEASE
EVENTS: A PROSPECTIVE STUDY
297
764
298
TWO-GENERATION CARDIOVASCULAR DISEASE PREVALENCE IN FAMILIAL
R. Mateo-Gallego, S. Perez-Calahorra, M. Laclaustra, N. Plana, C. Lahoz,
J. Pedro-Botet, J.F. Ascaso, A. Vila Belmonte, P. Valdivielso, A. Brea, F. Civeira
(Spain)
290
RAPID RISE IN PREVALENCE OF HYPERTENSION IN YOUNG IN NATIONAL
CAPITAL REGION (NCR) OF DELHI, INDIA
VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL, BLOOD PRESSURE,
AND HEART RATE: THE GAIN IN CONTEXT OF CIRCUMSTANCES
IMPROVING CARDIOVASCULAR PREVENTION IN PATIENTS WITH HIGH
CARDIOVASCULAR RISK THROUGH AN INNOVATIVE APPROACH: “THE
COACHING” CARE MODEL
OVERWEIGHT/OBESITY AND CORONARY HEART DISEASE: AGE
DEPENDENCIES IN METABOLIC MEDIATION
DECREASED SERUM LEVELS OF SOLUBLE DIPEPTIDYL PEPTIDASE IV ARE
ASSOCIATED WITH ALL-CAUSE DEATH IN PATIENTS WITH PERIPHERAL
ARTERIAL DISEASE
M.T. Howanietz, C.T. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner
(Austria)
130
RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS: WHY IS IMPORTANT
TO EVALUATE THIS?
775
COMPARISON OF COMBINED THERAPY OF CAD ACCOMPANIED BY
GASTRODUODENAL PATHOLOGY
776
768
777
HIGH PREVALENCE OF CVD RISK FACTORS AND UNSATISFACTORY
CONTROL OF LDL-C LEVELS IN 40-YEARS-OLD MEN AND 50-YEARS-OLD
WOMEN IN THE CZECH REPUBLIC
778
Z. Chmelik, M. Vrablík (Czech Republic)
302
769
PLASMA METHIONINE IS NOT ASSOCIATED WITH RISK OF ACUTE
MYOCARDIAL INFARCTION IN PATIENTS WITH SUSPECTED STABLE
ANGINA PECTORIS
779
I. Dhar, V. Lysne, P. Ueland, A. McCann, O. Nygård (Norway)
303
THE DIFFERENCE IN BLOOD PRESSURE READINGS BETWEEN ARMS AND
CARDIOVASCULAR RISK: AN URBANITE INDIAN STUDY
780
P. Bhasin, S. Kapoor (India)
770
304
771
INCREASED VISCERAL FAT AND LOWER MUSCLE STRENGTH ASSOCIATED
WITH ACUTE MYOCARDIAL INFARCTION
E. Okuyan, B. Ayca, S. Varol (Turkey)
301
J. Fritz, S. Strohmaier, G. Nagel, H. Concin, H. Ulmer (Austria)
294
299
767
S. Mosteoru, K. Kotseva, O.C. Cosor, L. Gaita, R. Pleava, A. Dumitrescu,
G. Mut-Vitcu, D. Gaita, S. Mancas, D. Wood (Romania)
293
774
M. Parvu, S. Coman, S. Voidazan (Romania)
300
E. Pello, T. Kouznetsova, Y. Nikitin, J. Staessen (Russia)
292
KLOTHO GENE POLYMORPHISMS ARE ASSOCIATED WITH PROGRESSION
OF ATHEROMATOSIS IN PATIENTS WITH CKD. RESULTS OF TWO YEARS
FOLLOW-UP OF THE NEFRONA COHORT
Y. Balandina, Z. Simonova, Y. Tarlovskaya (Russia)
A. Roy, P.A. Praveen, R. Amarchand, D. Prabhakaran, A. Krishnan, K.S. Reddy
(India)
291
773
M. Gracia, A. Betriu, M. Martínez, D. Arroyo, M. Abajo, E. Fernández,
J.M. Valdivielso (Spain)
765
A. Bea, E. Jarauta, R. Mateo-Gallego, S. Perez-Calahorra, V. Marco-Benedi,
I. Lamiquiz-Moneo, L. Baila-Rueda, A. Cenarro, F. Civeira (Spain)
289
ANALYSIS OF THE DIRECT CAUSES OF DEATH IN PATIENTS WITH ACUTE
STEMI TREATED WITH PRIMARY PCI FROM 2005 TO 2014
Y.H. Li, P.T. Lee, T.H. Chao, W.C. Tsai (Taiwan)
Y.D. Jiang (Taiwan)
288
772
M. Schneider, C. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner
(Austria)
S.U. Kwon (Republic of Korea)
287
FACTORS PREDICTING SURVIVAL OVER TWO DECADES OF OBSERVATION
AFTER PERIPHERAL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY: A
RETROSPECTIVE STUDY
ASSOCIATION BETWEEN PREPROCEDURAL NON-HIGH-DENSITY
LIPOPROTEIN CHOLESTEROL LEVELS WITH THE INFLAMMATORY
RESPONSE FOLLOWING ELECTIVE PERCUTANEOUS CORONARY
INTERVENTION781
F. Rached, F. Brito Jr, C. Garzillo, T. Nascimento, M.A. Perin, C.V. Serrano Jr
(Brazil)
131
Board #
305
THE INCIDENCE AND SEVERITY OF ANGINA PECTORIS IN PATIENTS AFTER
ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (OPTIMA II)
Board #
316
782
N. Logunova, Y. Karpov, V. Buza, D. Tomilova (Russia)
306
HYBRID INTERVENTION ON FEMOROPOPLITEAL ARTERIAL SEGMENT IN
COMPARISON WITH CONVENTIONAL SURGICAL TECHNIQUE
307
PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN MIDDLE-AGED
SUBJECTS OF HIGH RISK LITHUANIAN POPULATION
317
MULTIPLE CORONARY FISTULAE INTO LEFT VENTRICLE AS A RARE CAUSE
OF MYOCARDIAL ISCHEMIA
318
785
SUBCLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS IN HYPERTENSIVE
FEMALES WITH RHEUMATOID ARTHRITIS AND ITS RELATIONSHIP WITH
THE ADIPONECTIN LEVEL, INSULIN RESISTANCE, ENDOTHELIAL FUNCTION
319
786
THE PREVALENCE OF CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY
WITH SUBCORTICAL INFARCTS AND LEUCOENCEPHALOPATHY (CADASIL)
IN UZBEKISTAN
320
787
311
7 T MRI REVEALS DIFFUSE IRON DEPOSITION IN PUTAMEN AND CAUDATE
NUCLEUS IN CADASIL
GENDER FEATURES OF MYOCARDIAL INFARCTION AND STROKE RISK IN
GENERAL POPULATION WITH VITAL EXHAUSTION IN RUSSIA / SIBERIA:
WHO PROGRAM MONICA-PSYCHOSOCIAL
795
RELATIONSHIP OF STRESS WITH METABOLIC SYNDROME AND CORONARY
HEART DISEASE IN MIDDLE-AGED POLICE OFFICERS
796
M. Janczura, J. Dropinski, A. Stanisz, K. Kotula-Horowitz, R. Rosa,
T. Domagala (Poland)
O. Sirenko, O. Kuryata, T. Lysunets (Ukraine)
310
794
V. Gafarov, E. Gromova, I. Gagulin, D. Panov, A. Gafarova, M. Voevoda
(Russia)
A. Averkova, K. Savostyanov, D. Zateyshchikov (Russia)
309
OUTDOOR AIR POLLUTION AND ISCHEMIC STROKE SEVERITY: AN
ECOLOGICAL STUDY IN THESSALONIKI
N. Kakaletsis, K. Tziomalos, C. Savopoulos, M. Riga, S. Bouziana, M. Spanou,
S. Kostaki, S. Angelopoulou, K. Karatzas, I.A. Hatzitolios (Greece)
784
S. Kutkiene, M. Petrylaite, Z. Petrulioniene (Lithuania)
308
A. Zotikov, Z. Adyrkhaev, V. Mitish, N. Ascerov, A. Kozhanova, A. Ivandaev,
M. Abdulgamidov, A. Pokrovsky (Russia)
783
P. Puzdriak, V. Shlomin, Y. Didenko, Y. Yurtaev, M. Ivanov, P. Bondarenko,
R. Magomedov (Russia)
PATHOPHYSIOLOGICAL MECHANISMS FOR PRESERVING GRAFT PATENCY
IN PATIENTS WITH COMPROMISED OUTFLOW TRACT AFTER DISTAL
RECONSTRUCTION793
PRELIMINARY RESULTS OF THE EGYPTIAN CARDIOVASCULAR RISK
FACTORS PROJECT:MULTICENTER OBSERVATIONAL STUDY OF THE
PATTERN OF RISK FACTOR PROFILE IN EGYPTIAN PATIENTS WITH ACUTE
CORONARY SYNDROME
797
W. Hamed, A. Reda, A. El-Kersh, A. Shalaby, M. Beshay (Egypt)
788
312
TENASCIN-C DEFICIENCY ATTENUATES ABDOMINAL AORTIC ANEURYSM
FORMATION789
A.K. Schaefer, F. Nagel, P. Kaiser, D. Santer, K. Trescher, A. Kiss, B.K. Podesser
(Austria)
313
A CASE OF FATAL OBSTRUCTIVE SHOCK
790
A. Almaghraby, Y. Saleh, B. Hammad, A. Samoka, M. Elbahey, M. Seleem
(Egypt)
314
CARDIOVASCULAR RISK FACTORS IN WOMEN AND MEN
791
A. Nikolova, M. Milanova (Bulgaria)
315
CAROTID INTIMA-MEDIA THICKNESS AS A PROGNOSTIC RISK MARKER OF
DEMENTIA AT THE ELDERLY
792
R. Dascalescu, A. Zamfirescu, S.M. Aurelian, O. Stanciu, A. Capisizu
(Romania)
132
133
Abstract not Registered
400
THE ZINC-SUPPLEMENTED TO RABBITS FED A HIGH CHOLESTROL DIET
DELAYS THE PROGRESSION OF ATHEROSCLEROSIS
411
798
Y. Al mohy (Kingdom of Saudi Arabia)
401
412
EVALUATION OF THE SAFETY AND EFFICACY OF STATIN IN ELDERLY PATIENTS 799
CD34+ BONE MARROW DERIVED CELLS INHIBIT INTIMAL HYPERPLASIA IN
MOUSE MODEL OF VASCULAR INJURY
ESCHERICHIA COLI LIPOPOLYSACCHARIDE AND CPG MAY AFFECT
ATHEROGENESIS THROUGH THE MODULATION OF ENDOTHELIAL
BARRIER AND TOLEROGENIC PHENOTYPE OF APOLIPOPROTEIN B100PULSED DENDRITIC CELLS
800
MODIFICATIONS OF LOW DENSITY LIPOPROTEIN IN ATHEROSCLEROSIS
413
414
ISCHEMIC HEART DISEASE AND EARLY DIAGNOSIS. STUDY ON THE
PREDICTIVE VALUE OF 2D STRAIN
415
REDUCED AVAILABILITY OF DIETARY CHOLESTEROL IN INFANCY
PROGRAMS THE INTESTINAL CHOLESTEROL ABSORPTION DURING
ADULTHOOD IN MICE
416
803
CARDIOVASCULAR RISK AND PROINFLAMMATORY CYTOKINES IN
PATIENTS WITH METABOLIC SYNDROME
417
IS HIGH-DENSITY LIPOPROTEIN SUITABLE PREDICTOR FOR DEVELOPMENT
OF METABOLIC SYNDROME: A 10-YEAR FOLLOW-UP IN ADULTS
804
VIOLATIONS IN THE LEVEL OF SERUM LIPIDS APPEAR AT ALL PATIENTS
WITH PROSTATITIS THAT IS ASSOCIATED WITH DECREASE IN THE LEVEL
OF THE FREE TESTOSTERONE
805
418
419
ON THE DEVELOPMENT OF ANTI-ATHEROSCLEROTIC DRUGS ON THE
BASIS OF NATURAL PRODUCTS USING CELL CULTURES
IMPACT OF THE LIPID AND ANTHROPOMETRIC PARAMETERS ON THE
LDL(-) AND AUTOANTIBODIES ANTI-LDL(-)
814
LIFESTYLE - THE SILENT KILLER, LEADING TO CARDIOVASCULAR EVENTS
ACROSS CONTINENTS IN YOUNG APPARENTLY HEALTHY INDIANS
815
BURDEN OF CARDIOVASCUlaR RISK IN YOUNG, APPARENTLY HEALTHY
INDIANS IN UK & INDIA. TIME FOR INTERVENTION?
816
420
817
IN VIVO/EX VIVO INTEGRATED IMAGING MODEL FOR CORONARY AND
CAROTID PLAQUE RISK ASSESSMENT: A PROOF OF CONCEPT STUDY
818
G. Pelosi, D. Panetta, A. Sakellarios, N. Filipovic, T. Exarchos, V. Federico,
C. Fiorentini, A. Gennaro, S. Rocchiccioli, P.A. Salvadori, M.G. Trivella,
D. Fotiadis, O. Parodi (Italy)
807
421
808
RELATIONSHIP OF CAROTID AND FEMORAL ARTERY INTIMA-MEDIA
THICKNESS WITH HISTOPATHOLOGIC ARTERIAL ATHEROSCLEROSIS IN
CHRONIC KIDNEY DISEASE
N. Nezami, K. Ghabili, B. Shokouhi, M. Mirchi, M. Gojazadeh, S. Ghorashi,
M.K. Tarzamni (USA)
806
A. Govorin, D. Zaytsev (Russia)
410
813
R. Narain, S. Sharma (United Kingdom)
M. Gharipour, M. Sadeghi, N. Sarrafzadegan (Iran)
409
THE ROLE OF OXIDATIVE STRESS ON AMYLOID-LIKE PROTEIN
FORMATION AND AORTIC VALVE CALCIFICATION
R. Narain, A. Pulikal, S. Sharma (United Kingdom)
R. Dragut, E. Rusu, R. Nan, H. Popescu, F. Rusu, M. Jinga, A. Cursaru,
L. Grosu, G. Radulian (Romania)
408
DYSLIPIDEMIA IN PATIENTS WITH HEART FAILURE AND HYPOTHYROIDISM 812
A.P.Q. Mello, I.T. Silva, N.R.T. Damasceno (Brazil)
L.G. Dimova, J.F. De Boer, T. Plösch, H.J. Verkade, U.J.F. Tietge (Netherlands)
407
811
I. Mamarelis, E. Koutoulakis, C. Kotoulas, V. Mamareli, V. Dritsa,
J. Anastassopoulou (Greece)
802
G. Dattilo, A. Lamari, M. Casale, E. Imbalzano, P. Busacca, C. De Gregorio,
G. Di Bella (Italy)
406
HYPOTHYROIDISM IS THE INDEPENDENT FACTOR OF ATHEROSCLEROSIS
A. Logvinenko (Ukraine)
801
G.I. Constantin, S. Opris (Romania)
405
810
O. Kupchynskaya, N. Tsyrulneva, O. Gulkevych, V. Bezrodnyi, M. Mospan,
A. Logvinenko (Ukraine)
M. Chalubinski, K. Wojdan, E. Luczak, P. Gorzelak, G. Katarzyna, B. Maciej,
G. Adrian, R. Karolina, C. Magdalena, B. Marlena (Poland)
404
Identification of Cofilin-1 Induces G0/G1 Arrest and
Autophagy in Angiotensin-(1-7)-treated Human Aortic
Endothelial Cells from iTRAQ Quantitative Proteomics
W.Y. Lo, H.J. Wang (Taiwan)
S. Ananthaseshan, E. Kurzejamska, M. Lazarczyk, P. Religa (Sweden)
403
809
H. Liu, H. Yongqiang, W. Hongyu, L. Jinbo (China)
R. Alves, C. Gonçalves, N. Borges Jr (Brazil)
402
POSSIBLE ASSOCIATION BETWEEN COMMON CAROTID ARTERY LUMEN
DIAMETER AND VASCULAR FUNCTION IN NATURAL POPULATIONS OF SHE
MINORITY FROM FUJIAN PROVINCE IN CHINA
SYNTAX SCORE AS A MARKER OF PLURIDISTRICTUAL ATHEROSCLEROSIS
819
G. Polizzi, S. Evola, S. Novo, V. Evola (Italy)
S. Jargin (Russia)
134
135
422
PERCUTANEOUS TRANSVENOUS MITRAL COMMISSUROTOMY IN
PATIENTS WITH CALCIFIC MITRAL STENOSIS : IMMEDIATE AND INHOSPITAL CLINICAL, ECHOCARDIOGRAPHIC AND HEMODYNAMIC OUTCOME820
T. Rahman, A.A.S. Majumder, M.Z. Ali (Bangladesh)
423
THE EFFECT OF PINACIDIL ON HUMAN SAPHENOUS VEINS OBTAINED
FROM THE PATIENTS WITH AND WITHOUT DIABETES MELLITUS TYPE 2
821
J. Rajkovic, M. Peric, R. Novakovic, D. Nezic, V. Djokic, V. Zivanovic,
V. Kanjuh, H. Heinle, L. Gojkovic-Bukarica (Serbia)
424
SR-BI antagonises the S1P/S1PR2-mediated pro-inflammatory
effects induced by ox-LDL in HUVECs
84 EAS CONGRESS
th
May 29 - June 1, 2016
Innsbruck, Austria
822
K. Ren, Y.J. Lu, X. Liu, Q.H. Zhang, Z.C. Mo, Z.L. Tang, Y. Jiang, X.S. Peng,
G.H. Yi (China)
425
ApoA-I induces S1P release from endothelial cells through
ABCA1 and SR-BI in a positive feedback manner.
823
K. Ren, X. Liu, R. Suo, S.L. Xiong, Q.H. Zhang, Z.C. Mo, Z.L. Tang, J. Yue,
X.S. Peng, G.H. Yi (China)
426TGF-β down-regulates apolipoprotein M expression via the
TAK1-JNK-c-Jun pathway in HepG2 cells
824
K. Ren, X. Liu, Z.C. Mo, Q.H. Zhang, Z.L. Tang, Y. Jiang, X.S. Peng, G.H. Yi (China)
427
THE HYPERCHOLESTEROLEMIC SWINE MODEL OF ATHEROGENESIS:
STATISTICAL APPROACHES TO MOLECULAR MARKERS AND PLAQUE
MORPHOLOGY ASSOCIATION
825
S. Rocchiccioli, G. Pelosi, A. Cecchettini, E. Capobianco, M.G. Trivella (Italy)
428
A NEW MARKER FOR ST ELEVATION MYOCARDIAL INFARCTION: PRESEPSIN? 826
F.N. Turhan caglar, N. Isikssacan, I. Biyik, F. Akturk, S. Opan, H. Cebe,
I. Ungan, O. Karakaya (Turkey)
429
THE ROLE OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION ON
ENDOTHELIAL CELLS: OXIDATIVE STRESS AND VASCULAR DYSFUNCTION.
827
A. Wanschel, E. Lorza, A. Paiva, J. Stravinsky, D. Gabriel, T. Rentz, D. Guizoni,
A. Davel, A. Salerno, H. Oliveira (Brazil)
430
THE EFFECT OF OXIDIZED CHOLESTEROL ON BARRIER FUNCTIONS
AND IL-10 MRNA EXPRESSION IN HUMAN INTESTINAL EPITHELIUM COCULTURED WITH DENDRITIC CELLS IN THE TRANSWELL SYSTEM
828
K. Wojdan, M. Chalubinski, P. Gorzelak, M. Borowiec, M. Broncel (Poland)
431
IMPROVEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY BY COCONSUMPTION OF HIGH DOSAGE VITAMIN C AND CLOVE VIA CETP INHIBITION 829
J.A. Yoo, K.H. Cho
432
IMPACT OF AN ABDOMINAL AORTIC CALCIFICATION ON THE
MORPHOLOGY OF LOW LIMB ARTERY ATHEROSCLEROSIS
V. Zelinskiy, M. Melnikov, V. Andreev, S. Alexandra (Russia)
136
830
II
t
if
h
S
n
io
t
a
t
n
e
s
Poster Pre
y 31–
Tuesday, Ma
1
e
n
u
J
,
y
a
d
s
e
n
Wed
Poster Walks – tuesday
Board #
Metabolic Abnormalities and Atherosclerosis: Diabetes
001
MODY TYPE DIABETES MELLITUS AND COGNITIVE IMPAIRMENT
831
002
POLYMORPHISM IN GENES INVOLVED IN LIPID METABOLISM IN MODY
PATIENTS832
E. Shakhtshneider, A. Ovsyannikova, A. Kurilshikov, D. Ivanoshchuk,
O. Rymar, Y. Ragino, M. Voevoda (Russia)
003
METABOLIC CONTROL IN TYPE 2 DIABETIC PATIENTS
833
B. Orhan (Turkey)
004
ONE-YEAR RESULTS OF A MULTIDISCIPLINARY SCREENING PROGRAM
FOR DIABETES, CARDIOVASCULAR AND PULMONARY DISEASES AMONG
67-YEARS OLD CITIZENS IN VIBORG MUNICIPAL, DENMARK
834
A. Høgh, M. Dahl, J. S. Lindholt (Denmark)
005
DIFFERENCES IN LIPID PROFILE CONTROL AMONG DIABETIC PATIENTS
AT VERY HIGH CARDIOVASCULAR RISK ACCORDING TO THEIR CLINICAL
FEATURES835
D. García Fuertes, E. Villanueva Fernández, M. Crespín Crespín, F.J. Castillo
Bernal, I. Guerado Espinosa, M.C. Castro Jiménez, A. Rodríguez Cubero
(Spain)
006
FACTORS RELATED TO THE APPEARANCE OF MAJOR EVENTS DURING
FOLLOW-UP OF DIABETIC PATIENTS AT VERY HIGH CARDIOVASCULAR RISK
836
M. Crespín Crespín, D. García Fuertes, E. Villanueva Fernández, F.J. Castillo
Bernal, A. Rodríguez Cubero, I. Guerado Espinosa, M.C. Castro Jiménez
(Spain)
007
CONTROL OF CARDIOVASCULAR RISK FACTORS IN A NON-SELECTED
COHORT OF DIABETIC PATIENTS AT VERY HIGH CARDIOVASCULAR RISK
837
E. Villanueva Fernández, D. García Fuertes, M. Crespín Crespín, F.J. Castillo
Bernal, M.C. Castro Jiménez, A. Rodríguez Cubero, I. Guerado Espinosa
(Spain)
008
THE IMPORTANCE OF HDL CHOLESTEROL LEVELS IN DIABETIC
INDIVIDUALS : 9.2-YEAR SURVEY OF CARDIOVASCULAR EVENTS
838
K. Ina, T. Hayashi, M. Kuzuya (Japan)
009
CONCORDANCE OF GLUCOSE BASED AND OF HbA1c BASED
DIAGNOSES OF DIABETES IN PATIENTS WITH ESTABLISHED CORONARY
ATHEROSCLEROSIS - A COMPARISON BETWEEN MEN AND WOMEN
839
C. Saely, D. Zanolin, P. Rein, A. Vonbank, A. Leiherer, A. Muendlein, H. Drexel
(Austria)
139
Board #
Board #
010
020
ASSOCIATION OF INSULIN RESISTANSE WITH CAROTID INTIMA-MEDIA
THICKNESS AND BRACHIAL FLOW-MEDIATED DILATION IN THE SUBJECTS
WITH METABOLIC SYNDROME
011
ASSOCIATION OF INSULIN RESISTANCE, AS DETERMINED BY
HOMEOSTASIS MODEL ASSESSMENT (HOMA), WITH METABOLIC
SYNDROME AMONG MIDDLE-AGED SUBJECTS
021
012
DYSLIPIDEMIA WITH AND WITHOUT INSULIN RESISTANCE: SIMILARITIES
AND DIFFERENCES
022
013
DYSLIPIDEMIA CONTROL IN TYPE 2 DIABETES: EXPERIENCE OF A
PORTUGUESE CENTRE IN THE LAST DECADE
023
843
J. Sequeira Duarte, C. Tavares Bello, R. Fonseca, R. Ferreira, M. Oliveira,
C. Saraiva, C. Gouveia, F. Santos, J. Azinheira, C. Vasconcelos (Portugal)
014
CORRELATION BETWEEN HOMOCYSTEINE AND TYPE-2 DIABETES
MELLITUS COMPLICATIONSCORRELATION BETWEEN HOMOCYSTEINE
AND TYPE-2 DIABETES MELLITUS COMPLICATIONS
015
SERUM APOLIPOPROTEIN B48 CONCENTRATION IS HIGH IN PATIENTS
WITH IMPAIRED GLUCOSE TOLERANCE AND INCREASES AFTER ORAL
GLUCOSE INGESTION IN PATIENTS WITH DIABETES MELLITUS
016
025
026
027
ALTERATIONS OF METABOLIC PARAMETERS AND ANTIOXIDANT ENZYMES
IN DIABETIC AGING FEMALE RAT BRAIN: NEUROPROTECTIVE ROLE OF
METFORMIN847
CARDIO- AND NEPHROPROTECTIVE EFFECTS OF EZETIMIBE/
SIMVASTATIN COMBINATION IN TYPE 2 DIABETES MELLITUS
028
ROLE OF NEW ADIPOKINES IN THE PATHOGENESIS OF ATHEROSCLEROSIS
IN MORBIDLY OBESE SUBJECTS
A. Gentili, P. Trayhurn, S.Y. Alomar, M.S. Zaibi, S. De Vuono, M.A. Ricci,
A. Alaeddin, D. Siepi, M. Boni, G. Vaudo, G. Lupattelli (Italy)
140
854
BMI IS NOT AN IMPORTANT FACTOR FOR THE DEVELOPMENT OF
SUBCLINICAL ATHEROSCLEROSIS IN ELDERLY DIABETIC SUBJECTS WITH
METABOLIC SYNDROME
855
RESVERATROL AND QUERCETIN PROTECT ISOLATED MOUSE CORPORA
CAVERNOSA FROM IN VITRO-INDUCED DIABETIC ERECTILE DYSFUNCTION
856
DIABETIC VASCULAR DISEASE AND MATURITY-ONSET DIABETES OF THE YOUNG 857
029
848
849
RELATIONSHIP BETWEEN 25 HYDROXY-VITAMIN D AND ANKLE BRACHIAL
INDEX IN TYPE 2 DIABETIC PATIENTS
858
S. Lahiani, I. Oueslati, K. Bouzid, K. Khiari, S. Ghezaiel, H. Ben Ahmed,
H. Belhadj Hassen, H. Baccar, J. Abdelmoula, N. Ben Abdallah (Tunisia)
ANKLE BRACHIAL INDEX IN THE PREDICTION OF CORONARY HEART
DISEASE IN TYPE 2 DIABETIC PATIENTS
859
K. Bouzid, H. Ben Ahmed, I. Oueslati, S. Lahiani, K. Khiari, N. Khessairi,
J. Belagha, S. Ghezaiel, N. Ben Abdallah, H. Baccar, J. Abdelmoula (Tunisia)
R. Sayfutdinov, O. Bugrova, O. Boeva (Russia)
019
EFFECT OF THE EDUCATION IN HOSPITALIZATION OF DIABETIC
INDIVIDUALS FOR DIABETES CONTROL AND PREVENTION OF
COMPLICATIONS AS A TOOL OF HOSPITAL AND CLINIC COOPERATION
J.M. Mafra, G. Gaspar, M. Bourbon (Portugal)
P. Kumar, N. Baquer (India)
018
853
C. Boydens, B. Pauwels, L. Vandendaele, J. Van de Voorde (Belgium)
E. Georgousopoulou, D. Panagiotakos, C. Chrysohoou, I. Skoumas,
A. Laskaris, C. Stefanadis, C. Pitsavos (Greece)
017
SERUM LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED END PRODUCTS
ARE ASSOCIATED WITH RESTENOSIS OCCURRENCE IN PATIENTS WITH
DIABETES MELLITUS AFTER DRUG-ELUTING STENT IMPLANTATION
G. Yoshino, H. Yoshino, T. Ann, K. Kawakami, T. Akiyama, Y. Inoue (Japan)
845
FASTING INSULIN LEVELS PREDICT FATAL CARDIOVASCULAR (CVD)
EVENTS MORE ACCURATELY THAN ANY OTHER MARKER OF GLUCOSE
METABOLISM. THE 10-YEAR FOLLOW-UP OF THE ATTICA STUDY (2002-2012) 846
852
T. Hayashi, K. Ina, M. Kuzuya (Japan)
844
D. Masuda (Japan)
RELATIONSHIP BETWEEN CAROTID ARTERY INTIMA-MEDIA THICKNESS
AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH DIABETES
S. Kozlov, Z. Gabbasov, S. Byazrova, O. Saburova, V. Masenko (Russia)
024
M. Akhvlediani, M. Emukhvari, N. Zabakhidze, T. Kvantaliani (Georgia)
851
V. Vasilkova, T. Mokhort, E. Naumenko (Belarus)
842
I. Pchelin, N. Hudiakova, A. Shishkin, O. Vasilkova (Russia)
SEVERITY OF ATHEROSCLEROTIC LESIONS AND FOOT SYNOVIAL TENDON
COMPLEX INJURY AS FACTORS OF SEPSIS DEVELOPMENT IN PATIENTS
WITH DIABETIC FOOT
E. Shalaeva, B. Janabaev, Q. Matmurotov, U. Kasimov, U. Pulatov,
A. Bobabekov (Uzbekistan)
841
M. Janczura, K. Kotula-Horowitz, T. Iwaniec, A. Stanisz, J. Dropinski,
850
D. Gabrielyan, L. Gabrielyan, A. Artemova, D. Zhokhov, M. Ivanov,
P. Bondarenko, M. Ermina, A. Yadernaya (Russia)
840
T. Domagala, M. Janczura, K. Kotula-Horowitz, J. Dropinski, T. Iwaniec,
J. Zagajewski, A. Stanisz (Poland)
DOES TYPE 2 DIABETES ASSOCIATE ATHEROSCLEROTIC PROCESS?
030
CARDIOVASCULAR EFFECTS OF INCRETINS IN PATIENTS WITH TYPE 1
DIABETES860
M. Arutyunova, A. Glazunova, S. Martynov, I. Klephortova, A. Ilyin,
O. Manchenko, I. Ulianova, M. Shamkhalova, M. Shestakova (Russia)
141
Board #
031
SEVERITY OF CORONARY ARTERY STENOSIS IN PATIENTS WITH CRITICAL
PERIPHERAL ARTERY DISEASE UNDERGOING HIGH AMPUTATION
Board #
041
861
E. Shalaeva, B. Janabaev, B. Babadjanov, Q. Matmurotov, U. Kasimov,
U. Pulatov, A. Bobabekov (Uzbekistan)
032
HIGH PREVALENCE OF NON DIPPERS HYPERTENSIVE DIABETIC PATIENTS:
THE ROLE OF AMBULATORY BLOOD PRESSURE MONITORING IN
EFFECTIVE TREATMENT
THE IMPACT OF BARIATRIC SURGERY ON CARDIOMETABOLIC PROFILE
AND ADIPOKINE LEVELS
042
862
BARIATRIC SURGERY IMPROVES LIPID PROFILE IN MORBIDLY OBESE
PATIENTS BY LOWERING LDL-C AND INCREASING HDL-C AND THE
LARGE HDL-PARTICLES
863
035
EFFECTS OF BARIATRIC SURGERY ON MICROVASCULAR DYSFUNCTION
AND METABOLIC PROFILE IN MORBID OBESITY
FACTORS DETERMINING AND STRATEGIES FOR IMPROVING TREATMENT
ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES MELIITUS: DOCTOR,
COMMUNITY PHARMACIST AND PATIENT PERSPECTIVES. ADHERI2 STUDY.
864
045
PREVALENCE OF 25 HYDROXY-VITAMIN D DEFICIENCY AND ITS
CORRELATION WITH GLYCEMIC CONTROL IN DIABETIC PATIENTS
865
COMBINED DEVELOPMENT OF MACROVASCULAR AND CHRONIC KIDNEY
DISEASE IN TYPE 2 DIABETES ASSOCIATED WITH POLYMORPHISM OF
TNF-α GENE
046
866
047
867
048
868
INCREASED INFLAMMATORY EFFECT ON MONOCYTES OF
ELECTRONEGATIVE LDL AND DECREASED PROTECTION BY HDL FROM
POORLY CONTROLLED TYPE 2 DIABETIC PATIENTS
876
TRANSGENIC OVEREXPRESSION OF THE NRF2 AMELIORATES INSULIN
RESISTANCE AND CHANGES FATTY ACIDS IN MEMBRANE PHOSPHOLIPIDS
IN SPONTANEOUSLY HYPERTENSIVE RATS
877
HYPOLIPIDEMIC THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS:
ANALYSIS TYPICAL APPROACHES
878
049
DIABETES AWARENESS AMONG CORONARY DISEASE PATIENTS DIFFERS
SIGNIFICANTLY BETWEEN MEN AND WOMEN
879
C. Saely, D. Zanolin, A. Vonbank, A. Leiherer, H. Drexel (Austria)
FEATURES OF VASCULAR REMODELING AND METABOLIC DISORDERS IN
PATIENS WITH ESSENTIAL HYPERTENSION AND CONCOMITANT TYPE 2
DIABETES DEPENDING ON GENETIC POLYMORPHISM PPARγ2869
NEUTROPHIL/LYMPHOCYTE RATIO AND VASCULAR INFLAMMATION IN
OBESE WOMEN
875
I. Sapozhnikova, E. Tarlovskaya (Russia)
A. Shalimova, A. Belovol, L. Bobronnikova, M. Kochueva (Ukraine)
040
ASSOCIATION BETWEEN NT-PROBNP AND VISCERAL ADIPOSITY
I. Markova, H. Malinska, O. Oliyarnyk, L. Kazdova, M. Pravenec (Czech
Republic)
O. Vikulova, N. Lebedeva, A. Zheleznyakova, A. Nikitin, M. Shamkhalova,
M. Shestakova (Russia)
039
ASSOCIATION OF DIFFERENT CHOLESTEROL HOMEOSTASIS PATTERNS
WITH ABDOMINAL OBESITY IN PATIENTS WITH CORONARY ARTERY DISEASE 874
M. Estruch-Alrich, I. Miñambres, J.L. Sánchez-Quesada, A. Pérez-Pérez,
J. Ordóñez-Llanos, S. Benítez (Spain)
S. Lahiani, K. Bouzid, I. Oueslati, K. Khiari, N. Bchir, A. Melki, A. Bartkiz,
H. Ben Ahmed, H. Baccar, J. Abdelmoula, N. Ben Abdallah (Tunisia)
038
873
J. Suwa (Japan)
E. Labrador-Barba, A. Hernández-Mijares, M. Rodríguez-de Miguel,
M.J. Faus-Dader, M.L. Orera-Peña, F.J. Alonso Moreno (Spain)
037
CINNAMALDEHYDE ATTENUATES HIGH GLUCOSE-INDUCED OXIDATIVE
STRESS AND ENDOTHELIAL DYSFUNCTION AS AN Nrf2 ACTIVATOR
S. Vladimirov, T. Gojković, V. Spasojević-Kalimanovska, A. Zeljković, J. Vekić,
D. Kalimanovska-Oštrić, Z. Jelić-Ivanović (Serbia)
M. Naeimi Kararoudi, G. Lupattelli, S. Ministrini, V. Bianconi, M.A. Ricci, S. De
Vuono, P. Mariani, A. Moriconi, M. Boni, E. Mannarino, L. Pasqualini (Italy)
036
872
F. Wang, P. Wang, J. Wan, J. Hou, P. Zhou (China)
044
C.A. Kjellmo, T. Nestvold, K.T. Lappegård, A. Hovland, M. Mathisen (Norway)
LpPLA2 IN GESTATIONAL DIABETES MELLITUS - A PROTECTIVE SYSTEM
FOR PLACENTA AND FETUS?
C. Wadsack (Austria)
043
F. Reis de Azevedo Rabello, S. Santoro dos Santos Pereira, M.L. CorrêaGiannella, D. Giannella Neto, E. Sant'Anna Melo, B. Caramelli (Brazil)
034
871
J. Piťha, P. Pithova, P. Stavek, J.A. Hubacek, O. Auzky, T. Neskudla,
T. Pelikanova, M. Kvapil (Czech Republic)
V. Manea, C. Pop, L. Pop (Romania)
033
GENE FOR CONNEXIN 37 IS ASSOCIATED WITH ATHERSCLEROTIC
CHANGES IN WOMEN WITH DIABETES MELLITUS TYPE 2.
050
880
V. Sharma (India)
051
870
INDIAN DIABETES RISK SCORE (IDRS) FOR TYPE 2 DIABETES MELLITUS
SCREENING IN YOUNG ADULTS: EFFECT OF YOGA AND MEDITATION
ASSOCIATION OF RED CELL DISTRIBUTION WIDTH WITH CORONARY
ARTERY DISEASE IN PATIENTS WITH DIABETES IN MULTI-ETHNIC SINGAPORE 881
C. Chiong, Y.J. Chee, X. Gao, R. Dalan (Singapore)
B. Ilincic, M. Djeric, E. Stokic, R. Mijovic, S. Nikolic, Z. Stosic (Serbia)
142
143
Board #
Board #
052
061
PREDICTORS OF 10-YEAR MORTALITY ARE DIFFERENT IN DIABETIC
AND NON-DIABETIC PATIENTS WITH CHRONIC LOWER EXTREMITY
882
T. Mueller, F. Hinterreiter, W. Poelz, M. Haltmayer, B. Dieplinger (Austria)
053
HAND GRIP STRENGTH SIGNIFICANTLY PREDICTS CARDIOVASCULAR
EVENT RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
TELMISARTAN ATTENUATES HYPERGLYCEMIA-AGGRAVATED VCAM1 EXPRESSION AND MONOCYTES ADHESION IN TNFα-STIMULATED
ENDOTHELIAL CELLS BY INCREASING GSK3β-SER9 PHOSPHORYLATION
062
883
GENETIC VARIANTS AND LIPID TRAITS IN THE HONG KONG CHINESE
PATIENTS WITH TYPE 2 DIABETES
063
884
ANTIATHEROGENIC EFFECT OF METFORMIN IN TWO MOUSE LINES WITH
DIFFERENT SUSCEPTIBILITY TO GLUCOSE INTOLERANCE
064
885
065
886
Metabolic Abnormalities and Atherosclerosis: Adipose
Tissue
ADIPOKINES AND CYTOKINES SERUM LEVELS IN CHILDREN AND
ADOLESCENTS AND ITS RELATIONSHIP WITH OBESITY
887
INDUCIBILITY OF TRIGLYCERIDE TURNOVER IN WHITE FAT – A MARKER
OF LEAN PHENOTYPE
888
144
895
EFFECT OF BMI ON EPICARDIAL FAT ,CARDIAC CHAMBERS AND
CORONARY CALCIFICATION CORRELATIONS
896
ARE WE FOLLOWING THE GUIDELINES TO PREVENT CONTRAST INDUCED
ACUTE KIDNEY INJURY? A CLINICAL AUDIT ON PATIENTS WITH CHRONIC
KIDNEY DISEASE(CKD) UNDERGOING CORONARY ANGIOGRAM
897
EFFECT OF RECOMMENDED DIETARY PROTEIN RESTRICTION ON THE
PROGRESSION OF KIDNEY DISEASE
898
C. Visinoni, A. Baragetti, I. Baragetti, C. Biazzi, K. Garlaschelli, L. Grigore,
C. Pozzi, N. Giuseppe Danilo, C. Alberico L (Italy)
889
RELATIONSHIP OF ORPHAN RECEPTOR RORA AND CHOLESTEROL
TRANSPORTERS ABCA1 AND ABCG1 EXPRESSION IN VISCERAL ADIPOSE
TISSUE890
V. Miroshnikova, A. Panteleeva, E. Demina, T. Usenko, E. Bazhenova,
I. Semenova, O. Berkovich, E. Baranova, S. Pchelina (Russia)
OVARIECTOMY AFFECTS SUBSTRATE UTILIZATION IN BROWN ADIPOSE
TISSUE AND INDUCES LIVER DICARBONYL STRESS IN RATS
V. Kanthasamy, S. Gill (United Kingdom)
068
K. Adamcova, P. Flachs, P. Zouhar, K. Bardova, M. Svobodova, P. Janovska,
A. Keenan, L. Madsen, J. Jones, K. Kristiansen, J. Kopecky (Czech Republic)
060
894
Metabolic Abnormalities and Atherosclerosis: Kidney
067
C. Rodriguez-Leal, M. Monsalvo-Hernando, I. Tinoco-Racero, E. Segura,
N. Caro, M. Lagares Carballo, A. Perez, C. Perez, M. Rodriguez -Rosety,
T. Pery, A. Mangas, T. Rocio (Spain)
059
LIPOSOMES FOR MICRORNA DELIVERY TO HUMAN ADIPOCYTES
H. Alnafakh, H. Nafakhi, A. Albasri, A. Almusawi (Iraq)
A. Almusawi, H. Nafakhi, H. Alnafakh, A. Albasri (Iraq)
058
893
J. Trnovska, H. Malinska, V. Skop, L. Kazdova (Czech Republic)
066
EPICARDIAL FAT ,CARDIAC CHAMBERS AND CORONARY CALCIFICATION
IN HYPERTENSIVE PATIENTS
RELATION BETWEEN EPICARDIAL FAT TISSUE AND INFLAMMATORY
MARKERS IN PREGNANTS WITH PREECLAMPSIA
G. Schratter, M. Karbiener, G. Almer, H. Mangge, M. Scheideler, R. Prassl
(Austria)
A. Asai, Y. Shuto, M. Nagao, T. Miyazawa, H. Sugihara, S. Oikawa (Japan)
057
892
H.A. Cakmak, B. Dincgez Cakmak, C. Yayla Abide, E. Inci Coskun, M. Erturk
(Turkey)
M. Hu, C. Tam, W.Y. So, J. Chan, B. Tomlinson, R. Ma (Hong Kong- China)
056
COLD-INDUCED CHANGES IN WHITE ADIPOSE TISSUE OF A/J AND
C57BL/6J MICE
K. Bardova, P. Flachs, K. Adamcova, M. Svobodova, J. Kopecky (Czech Republic)
D.H. Cho, J.E. Lee, K.H. Song (Republic of Korea)
055
891
A. Albasri, H. Nafakhi, A. Almusawi, H. Alnafakh (Iraq)
P. Rein, C. Saely, A. Vonbank, D. Zanolin, A. Leiherer, H. Drexel (Austria)
054
EPICARDIAL FAT AND BMI RELATIONSHIPS WITH CORONARY
ATHEROSCLEROTIC MARKERS IN PATIENTS WITH CORONARY CALCIUM
SCORE >0: THE EFFECT OF AGE AND GENDER
069
VERY MILD RENAL ENDOTHELIAL DAMAGE AND GLOMERULAR
HYPERFILTRATION MAY PRECEDE INCIDENT HYPERTENSION IN THE
JAPANESE GENERAL POPULATION: THE WATARI STUDY
899
M. Munakata, T. Hattori, S. Konno (Japan)
070
EARLY BIOMARKERS OF CHRONIC KIDNEY DISEASE IN DIABETIC PATIENTS
900
Z. Zuraeva, O. Mikhaleva, O. Vikulova, A. Ilyin, M. Shamkhalova,
M. Shestakova (Russia)
145
Board #
071
CHOLESTEROL LEVELS AND GLOMERULAR FILTRATION RATE - IS THERE
ANY ASSOCIATION?
Board #
081
901
J. Frutuoso, M. Bourbon (Portugal)
072
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND CONTRASTINDUCED ACUTE KIDNEY DISEASE IN PATIENTS UNDERGOING
PERCUTANEOUS CORONARY INTERVENTION
EVALUATION OF THE ASSOCIATION OF PLASMA PENTRAXIN 3 LEVELS
WITH TYPE 2 DIABETES AND DIABETIC NEPHROPATHY IN PATIENTS WITH
RENAL FAILURE.
902
075
Metabolic Abnormalities and Atherosclerosis: NASH and
Liver Abnormalities
082
903
P. Miarka, M. Walus-Miarka, D. Fedak, M. Kuzniewski, A. Pietrzycka,
E. Wieczorek-Surdacka, P. Jasik, B. Przepiorkowska-Hoyer, M. Kapusta,
B. Idzior-Walus, W. Sulowicz (Poland)
074
083
CARDIOMETABOLIC RISK IN PATIENTS WITH CHRONIC RENAL DISEASE
RELATED TO HYPERTRIGLYCERIDEMIA-LOW HDL -CHOLESTEROL ASSOCIATION 904
084
CORRELATION OF THYROID STIMULATING HORMONE TO KIDNEY
FUNCTION OF HEALTHY RESIDENTS: RESULTS FROM THE KYUSHU AND
OKINAWA POPULATION STUDY (KOPS)
085
ISHCEMIC PRECONDITIONING IN CONTRAST-INDUCED NEPHROPATHY
PROPHYLACTICS IN PATIENTS WITH MILD CHRONIC KIDNEY FAILUTE
905
CHARACTERISTICS OF LONG-TERM SURVIVORS IN A DIABETIC DIALYSIS
PATIENT COLLECTIVE (4D STUDY)
906
086
EVALUATION OF CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC
KIDNEY DISEASE
087
907
ADULT RELAPSING FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
MAINTAINED IN PARTIAL REMISSION FOLLOWING LIPOPROTEIN
APHERESIS: CASE STUDY
A. Haikal, N. Sehar, L. Denney, P. Moriarty (USA)
146
914
CONTINUOUS GRADING OF EARLY FIBROSIS IN NAFLD USING LABEL-FREE
IMAGING915
THE ROLE OF VITAMIN D3 IN HIGH FAT DIET INDUCED FATTY LIVER
DISEASE AND OBESITY.
916
COMPARATIVE ANALYSIS OF SERUM LIPIDS IN PATIENTS WITH CHRONIC
HEPATITIS C, NONALCOHOLIC FATTY LIVER DISEASE, AND HEALTHY
CONTROLS917
R. Ivanova, I. Valkov, C. Marinova, A. Alexiev, K. Antonov, D. Jelev, L. Mateva
(Bulgaria)
908
088
LIPID-MODIFYING EFFECTS OF CURCUMIN IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
918
Y. Panahi, P. Kianpour, R. Mohtashami, R. Jafari, A. Sahebkar (Iran)
909
089
I. Oueslati, S. Lahiani, K. Bouzid, K. Khiari, H. Kaaroud, E. Elfaleh, A. Bartkiz,
N. Ben Abdallah, J. Abdelmoula (Tunisia)
080
CARDIOMETABOLIC RISK FACTORS IN YOUNG V/S MIDDLE-AGED
PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
R. Kheder, J. Hobkir, M. Browning, C. Stover (United Kingdom)
S. Triebswetter (Germany)
079
913
J. Pirhonen, J. Arola, S. Sädevirta, P. Luukkonen, S.M. Karppinen,
T. Pihlajaniemi, A. Isomäki, M. Hukkanen, H. Yki-Järvinen, E. Ikonen (Finland)
N. Zagidullin, A. Dunaeva, E. Sherbakova, S. Zagidullin (Russia)
078
ASSOCIATION BETWEEN SERUM MONOCYTE CHEMOATTRACTANT
PROTEIN-1(MCP-1) LEVELS, INSULIN RESISTANCE AND SUBCLINICAL
ATHEROSCLEROSIS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS
R. Ivanova, C. Marinova, A. Alexiev, L. Mateva (Bulgaria)
A. Teplov, A. Zotikov, A. Gritskevich, Z. Adyrkhaev, S. Pyanikin, I. Timina,
I. Pyatkova, A. Kozhanova, A. Ivandaev, A. Pokrovsky (Russia)
077
912
N. Leach, S.C. Vesa, T. Alexescu, E. Dronca, V. Negrean, S. Dorel P. (Romania)
R. Toro, I. Tinoco, B. Ruiz-Estevez, C. Rodriguez-Leal, E. Segura, N. Caro,
C. Perez, I. Garcia, D. Gomez -Villarejo, M. Rodriguez-Rosety, M. Lagares,
A. Mangas (Spain)
EX VIVO ORGAN-PRESERVING SURGERY ON KIDNEYS FOR RENAL CELL
CARCINOMA AND RENAL ARTERY ANEURYSMS
APO-B48 IN PATIENTS WITH TYPE 2 DIABETES AND NON-ALKOHOLIC
FATTY LIVER DISEASE
B. Idzior-Waluś, M. Walus-Miarka, A. Trojak, P. Miarka, M. Kapusta (Poland)
Y. Tanaka, M. Shimizu, N. Furusyo, Y. Kato, J. Hayashi (Japan)
076
911
A. Zotikov, A. Gritskevich, Z. Adyrkhaev, I. Timina, I. Pyatkova, V. Cigankov,
A. Varava, A. Kozhanova, A. Ivandaev, M. Demina, A. Pokrovsky (Russia)
Y. Liu, L. Hua-Long, W. Dengxuan, Z. Jianbin, C. Shiqun, D. Chong-Yang,
C. Ping-Yan, T. Ning, C. Ji-Yan (China)
073
SURGICAL TREATMENT OF ANEURYSM AND ARTERIOVENOUS FISTULA OF
RENAL ARTERIES
EFFECTS OF BODY WEIGHT ON HEPATIC STEATOSIS IN ESSENTIAL
HYPERTENSION919
C.H. Chou, W.C. Tsai (Taiwan)
090
910
HEPATIC STEATOSIS IS INDEPENDENTLY ASSOCIATED WITH
ERECTILE DYSFUNCTION: ONE MORE LINK BETWEEN THE LIVER AND
CARDIOVASCULAR RISK?
920
F. Rached, A. Laurinavicius, R. Conceição, R. Santos (Brazil)
147
Board #
Board #
Dyslipidemias: Dyslipidemias, Screening and Treatment
101
091
PREVALENCE OF DIABETES MELLITUS IN PATIENTS WITH FAMILIAL
S. Perez-Calahorra, R. Mateo-Gallego, N. Plana, J.P. Botet-Montoya,
J.F. Ascaso, C. Lahoz, F. Almagro, R.M. Sánchez-Hernández, I. LamiquizMoneo, F. Civeira (Spain)
092
FAMILIAL HYPERCHOLESTEROLEMIA (FH) IN CHILDREN AND
ADOLESCENTS: OPTIMIZATION OF DETECTION FOR EARLY TREATMENT
093
DIAGNOSTIC PERFORMANCE OF VARIOUS FAMILIAL
HYPERCHOLESTEROLAEMIA CRITERIA COMPARED TO THE DUTCH LIPID
CLINIC CRITERIA IN AN ASIAN POPULATION
094
103
104
RETROSPECTIVE OBSERVATIONAL STUDY ON THE DIAGNOSIS AND
THERAPY OF THE FH ON A SAMPLE OF REAL WORLD POPULATION
105
096
INTERNATIONAL COMPARISON OF PRIMARY CARE KNOWLEDGE AND
PRACTICES OF FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
106
926
G.F. Watts (Australia)
097
INTERNATIONAL COMPARISON OF SERVICES AND FACILITIES FOR THE
CARE OF FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
SWITCH TO ROSUVASTATIN VERSUS ADDITION OF EZETIMIBE IN PATIENTS
RECEIVING ATORVASTATIN: EFFECT ON URINE 8-ISOPROSTANE LEVELS
107
927
CASCADE GENETIC SCREENING FOR FAMILIAL HYPERCHOLESTEROLEMIA
IN WEST SIBERIA
108
928
929
LIPID CLINIC EXPERIENCE OF GENOTYPING FOR FAMILIAL
HYPERCHOLESTEROLAEMIA930
K. Shipman, R. Cramb (United Kingdom)
148
FAMILIAL HYPERCHOLESTEROLAEMIA - GEOMAPPING OF THE BASELINE
LDL LEVELS AND CHARACTERISATION OF LDL RECEPTOR MUTATIONS
FOR PATIENTS DIAGNOSED IN THE NORTH WALES SCREENING
PROGRAMME 2010-2015
936
ESTABLISHMENT OF A NATIONWIDE CASCADE SCREENING PROGRAM
AND REGISTER FOR FAMILIAL HYPERCHOLESTROLEMIA IN GERMANY CARE HIGH
937
EPISODIC MEMORY PERFORMANCE IN YOUNG ADULTS WITH FAMILIAL
M. Mauri, N. Cuenca, R.M. Borrallo, E. Romero, J. Ottino, I. García-García,
M.A. Jurado, M. Garolera (Spain)
109
E. Shakhtshneider, K. Makarenkova, D. Ivanoshchuk, P. Orlov, Y. Ragino,
M. Voevoda (Russia)
100
CASE REPORT: HYPERCHOLESTEROLEMIC PATIENT WITH NEW
HOMOZYGOUS LDLR MUTATION AND SEVERE EARLY CORONARY HEART
DISEASE935
N. Schmidt, W. März, T. Grammer (Germany)
E. Klouras, C. Tellis, F. Barkas, E. Liberopoulos, M. Elisaf, A. Tselepis (Greece)
099
934
M. De Soysa, R. Gingell, Y.P. Teoh (United Kingdom)
G.F. Watts (Australia)
098
THE UK PAEDIATRIC FAMILIAL HYPERCHOLESTEROLAEMIA (FH) REGISTER:
PRELIMINARY DATA
T. Grenkowtiz, U. Kassner, N. Buchmann, N. El-Zidy-Ibrahim, D. Spira,
I. Demuth, E. Steinhagen-Thiessen (Germany)
925
C. Garaffa, F. Natale, S. Sperlongano, F. Fimiani, M. Laringe, L. D'Acierno,
E. Garaffa, G. Limongelli, G. Piccinocchi, P. Calabrò (Italy)
933
S. Humphries, J. Cooper, U. Ramaswami (United Kingdom)
S. Sperlongano, C. Garaffa, F. Natale, F. Fimiani, E. Garaffa, L. D'Acierno,
M. Laringe, G. Limongelli, G. Piccinocchi, P. Calabrò (Italy)
095
THE CT CORONARY CALCIUM SCORE IN FAMILIAL
HYPERCHOLESTEROLAEMIA: COMPARISON BETWEEN PATIENTS WITH FH
MUTATIONS AND THOSE WITH NO IDENTIFIED MUTATION
S. Chaudhuri, M. Labib, A. Abeysekera (United Kingdom)
923
DUTCH SCORE AND “CASCADE SCREENING” FOR THE IDENTIFICATION OF
PATIENTS AFFECTED BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 924
SEVERE FAMILIAL HYPERCHOLESTEROLEMIA: PREVALENCE AND
CHARACTERIZATION OF PATIENTS PRESENTING FOR CARDIAC
CATHETERIZATION932
B. Zafrir, C. Shapira, G. Lavie, D.A. Halon, M.Y. Flugelman (Israel)
922
S. Abdul Razak, R. Rahmat, N.A. Mohd Kasim, T. Abdul Rahman, S. Muid,
N. Mohd Nasir, Z. Ibrahim, S. Kasim, H. Nawawi (Malaysia)
931
M. Walus-Miarka, B. Idzior-Walus, D. Czarnecka, M. Kloch-Badełek,
W. Wojciechowska, M. Kapusta (Poland)
102
E. De Faria (Brazil)
CAROTID PLAQUES AND INTIMA-MEDIA THICKNESS - ARE THE SAME RISK
FACTORS IN MEN AND WOMEN WITH FAMILIAL HYPERCHOLESTEROLEMIA?
CARRIERS OF THE LDL RECEPTOR MUTATIONS WITHIN THE EXON 12 IN
GENERAL POPULATION
939
J. Hubacek, A. Fellnerova, D. Dlouha, L. Schwarzova, V. Adamkova (Czech
Republic)
110
TARGETED NEXT-GENERATION SEQUENCING OF THE LDLRAP1 GENE IN
PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
940
D. Ivanoshchuk, E. Shakhtshneider, K. Makarenkova, P. Orlov, Y. Ragino,
M. Voevoda (Russia)
149
Board #
111
112
FH CLINICS - TWO SHORT YEARS OF EXPERIENCE
Board #
941
I. Colaço, T. Vassalo, F. Faria, D. Cruz, J.L. Ducla Soares (Portugal)
D374Y MUTATION IN THE PCSK-9 GENE IN TURKISH PATIENTS WITH
FAMILIAL HYPERCHOLESTEROLEMIA: LONG TERM FOLLOW-UP WITH
GOOD CLINICAL COURSE
ACHIEVEMENT OF EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS)
TARGETS WITH LOMITAPIDE, A MICROSOMAL TRANSFER PROTEIN
INHIBITOR IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH) 942
M. Kayıkcıoglu, E.K. Kocabas, A.T. VARDARLI, Z. EROGLU, H. DOKMEN,
N. SALMAN, S. PAYZIN, L.H. CAN (Turkey)
122
H. Phillips, M. Ager, A. Hutchings (United Kingdom)
113
USING PERCENTILES TO DIAGNOSE FAMILIAL HYPERCHOLESTEROLEMIA
IN PORTUGAL
LOW-DENSITY LIPOPROTEIN GENE SCORE TO IDENTIFY POLYGENIC
FORMS OF FAMILIAL HYPERCHOLESTEROLEMIA IN A SPANISH POPULATION
123
115
GENETIC ANALYSIS OF FAMILIAL HYPERCHOLESTEROLAEMIA IN
IBEROAMERICAN COUNTRIES
124
IDENTIFICATION OF A NEW MUTATION IN THE N-TERMINAL REGION OF
THE APOLIPOPROTEIN B GENE IN FAMILIAL HYPERCHOLESTEROLEMIA
945
125
126
946
PRELIMINARY RESULTS OF RUSSIAN FAMILIAL HYPERCHOLESTEROLEMIA
REGISTRY947
127
CLINICAL CHARACTERISTICS OF COMMON PCSK9 GAIN-OFFUNCTION E32K VARIANT WITH HIGHER TG ELEVATION, AND DOUBLE
HETEROZYGOTES WITH COMMON PCSK9 VARIANTS AND LDLR MUTATIONS 948
PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 (PCSK9) V4I VARIANT
WITH LDLR MUTATIONS MODIFIES THE PHENOTYPE OF HETEROZYGOUS
FAMILIAL HYPERCHOLESTEROLEMIA
128
HEREDITARY DEFECT OF APOLIPOPROTEIN B 100 - ANALYSIS OF GROUP
OF PATIENTS TREATED WITH STANDARD PERORAL LIPID-LOWERING
THERAPY IN ST. ANNE´S UNIVERSITY HOSPITAL BRNO
O. Kyselak, V. Soska (Czech Republic)
150
CONSTRUCTION OF A NEW FAMILIAL HYPERCHOLESTEROLAEMIA
VARIANT DATA BASE: A SYSTEMATIC REVIEW FOR A 2015 UPDATE
955
MOLECULAR BASIS OF FAMILIAL HYPERCHOLESTEROLEMIA IN POLAND
– UPDATE FROM THE POLISH NATIONAL CENTRE OF DIAGNOSTICS AND
TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA
956
MORTALITY OF CARDIOVASCULAR DISEASE IN PATIENTS WITH
GENETICALLY VERIFIED FAMILIAL HYPERCHOLESTEROLEMIA
957
HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH) IN
CHILDREN: AN ITALIAN EXPERIENCE
958
F. Guaraldi, M.D. Di Taranto, C. Giacobbe, G. Fortunato, O. Guardamagna
(Italy)
129
949
130
950
GENETIC ANALYSIS OF FAMILIAL HYPERCHOLESTEROLEMIA IN MEXICO
959
A. Vazquez Cardenas, M.T. Magaña Torres, Y. Sanchez Lopez, T. Hernandez
Flores, A.G. Colima Fausto, J.R. González Garcia, F. Escalante, D. Gonzalez
Marines, C. Aguilar Salinas, M. Bourbon (Mexico)
M. Hori, N. Ohta, A. Takahashi, M. Ogura, H. Makino, T. Tamanaha,
Y. Miyamoto, M. Harada-Shiba (Japan)
120
954
K. Retterstøl, J. Igland, L. Ose, K.B. Holven, T.P. Leren, M.B. Veierød,
L. Mundal (Norway)
A. Nohara, M.A. Kawashiri, H. Tada, M. Yoshida, M. Mori, C. Nakanishi, K. Yagi,
A. Inazu, M. Yamagishi, H. Mabuchi (Japan)
119
GENETIC EPIDEMIOLOGY OF ARH IN SICILY
M. Chmara, M. Zuk, A. Mickiewicz, A. Brandt, K. Chlebus, J. Kubalska,
J. Bautembach-Minkowska, M. Stroniawska-Woźniak, M. BednarskaMakaruk, L. Kłosiewicz-Latoszek, A. Rynkiewicz, M. Mysliwiec, M. Gruchala,
J. Limon, B. Wasag (Poland)
I.V. Sergienko, A.A. Ansheles, A.B. Popova, M.I. Voevoda, V.S. Gurevich,
V.V. Henkel, V.V. Kukharchuk, M.V. Ezhov (Russia)
118
953
S. Azevedo, J.R. Chora, A.C. Alves, A.M. Medeiros, M. Bourbon (Portugal)
M. Abifadel, S. Elbitar, Y. Ghaleb, G. Peloso, N. Stitziel, P. El Khoury, J.P. Rabes,
V. Carreau, E. Bruckert, S. Kathiresan, M. Varret, C. Boileau (France)
117
FIRST PCSK-9 MUTANT PATIENT IN TURKEY
R. Spina, V. Valenti, V. Ingrassia, M.P. La Spada, C. Scrimali, G. Misiano,
D. Noto, O. Palesano, G.I. Altieri, V. Licata, F. Fayer, C.M. Barbagallo,
A.B. Cefalù, M. Averna (Italy)
J. Chora, P. Mata, R. Santos, A. Cárdenas Vázquez, M. Stoll, L. Schreier,
A. Cuevas, A.C. Alves, A.M. Medeiros, L. Perez Isla, C. Jannes, A. Pereira,
N. Dell'Oca, X. Reyes, P. Corral, V. Bañares, T. Magaña-Torres, C. AguilarSalinas, R. Alonso, M. Bourbon (Argentina)
116
952
E. Kaya Kocabas, M. Kayikcioglu, A. Tetik Vardarli, Z. Eroglu (Turkey)
944
J.M. Martín-Campos, J. Julve, N. Plana, R. Figueras, E. Esteve, M. Mauri,
M. Bueno, A. Caixàs, E. Llargués, A. Vila, C. Morales, C. Soler, J. Argimón,
J. Mayos, J. Grau, A. Zamora, L. Matas, L. Vila, L. Masana, F. Blanco-Vaca (Spain)
ATHEROSCLEROSIS IN MONOGENIC FAMILIAL HYPERCHOLESTEROLEMIA
VERSUS POLYGENIC HYPERCHOLESTEROLEMIA
951
M. Sharifi, A. Gallivan, D. Harvey, L. Ka Wah, J. Cooper, M. Futema,
S.E. Humphries, D. Nair (United Kingdom)
943
A. Pereira, A.C. Alves, A.M. Medeiros, C. Mariano, M. Bourbon (Portugal)
114
121
35 YEARS OF EXPERIENCE WITH CHILDREN AFFECTED WITH
HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): A CASE
SERIES OF NINE PATIENTS
960
K. Widhalm, K. Derfler, G. Kostner, O. Helk (Austria)
151
Board #
Board #
131
141
PROGRAM STRATEGIES FOR FAMILIAL HYPERCHOLESTEROLEMIA IN URUGUAY961
M. Stoll, X. Reyes, N. Dell’Oca, F. Machado, A. Ressia, G. Fernandez,
Zelarayán M(1) (Uruguay)
132
EFFECT OF APOE GENOTYPE ON LDL CHOLESTEROL LEVELS IN FH AND
FDB PATIENTS: IS THERE SEX-SPECIFICALLY PROTECTIVE GENOTYPE?
133
GENETIC AND PHENOTYPIC CHARACTERIZATION OF LDLRECEPTOR IN PATIENTS WITH A CLINICAL DIAGNOSIS OF FAMILIAL
HYPERCHOLESTEROLEMIA: TWO NOVEL MUTATIONS
142
134
THE R46L POLYMORPHISM OF PCSK9 GENE AND LIPID PROFILE IN
CAUCASIAN POPULATION OF RUSSIA
143
135
144
FAMILIAL HYPERCHOLESTEROLAEMIA IN PRIMARY CARE: AWARENESS,
KNOWLEDGE AND PRACTICES AMONG PRIMARY CARE DOCTORS IN
MALAYSIA965
136
PERCEPTIONS ON HEALTH COMMUNICATION, SYMPTOMS AND CAUSES
IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA TREATED IN
SPECIALIST CLINICS
137
CARDIOVASCULAR DISEASE RESEARCH BY USING DATA FROM
ELECTRONIC HEALTH RECORDS
146
967
LDL APHERESIS IN CHILDREN WITH HOMOZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA: A CASE SERIES
968
I. Luirink, A. Wiegman, B. Hutten, J. Groothoff (Netherlands)
139
EVALUATION OF PLASMA-FED LIPID APHERESIS IN PATIENTS WITH
HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA.
147
LOMITAPIDE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA FIRST EXPERIENCES IN CLINICAL PRACTICE
A. Vogt (Germany)
152
148
970
975
LONG-TERM TREATMENT WITH EVOLOCUMAB HOMOZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA PATIENTS: RESULTS FROM THE TRIAL
ASSESSING LONG-TERM USE OF PCSK9 INHIBITION IN SUBJECTS WITH
GENETIC LDL DISORDERS (TAUSSIG)
976
LIPID-LOWERING THERAPY AND TARGET ATTAINMENT AMONG
HYPELIPIDEMIC INDIVIDUALS WITH OR WITHOUT FAMILIAL
HYPERCHOLESTEROLEMIA: EVIDENCE FROM A LIPID CLINIC
977
F. Barkas, E. Klouras, T. Dimitriou, G. Liamis, E. Liberopoulos, M. Elisaf
(Greece)
969
P. Downie, G. Bayly, L. Hart, S. Douglas, J. Griffin (United Kingdom)
140
CARDIOVASCULAR DISEASE IN HETEROZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA SUBJECTS ON STATIN TREATMENT
E.A. Stein, T. Sampietro, R. Santos, M. Harada-Shiba, E. Bruckert, D. Blom,
G.K. Hovingh, P. Couture, V. Blaha, M. Farnier, O. Descamps, H. Soran,
S. Kasichayanula, J. Gibbs, C. Kurtz, L. Tang, N. Honarpour, S.M. Wasserman,
F.J. Raal (South Africa)
L. Majnaric, S. Sabanovic (Croatia)
138
ATTAINMENT OF LDL-C TREATMENT TARGET IN FAMILIAL
HYPERCHOLESTEROLEMIA PATIENTS: A THEORETICAL MODEL
EXPLORING EFFICACY OF CURRENT AND NOVEL LIPID LOWERING THERAPIES974
V. Marco-Benedi, S. Perez-Calahorra, N. Plana, J.C. Pedro-Botet, J. Ascaso,
C. Lahoz, F. Almagro, E. Ros, A. Brea, M. Suarez-Tembra, R.M. SanchezHernández, A. Vila Belmonte, F. Civeira (Spain)
966
N.A. Mohd Mokhsin, S. Abdul Razak, A.S. Ramli, M. Md Yasin, N.A. Mohd
Kasim, S.S. Kasim, T. Rahman, H. Nawawi (Malaysia)
973
M.L. Hartgers, J. Besseling, G.K. Hovingh (Netherlands)
145
A.S. Ramli, N.A. Mohd Mokhsin, S. Abdul Razak, M. Md Yasin, Z. Ismail,
N.A. Mohd Kasim, T. Rahman, H. Nawawi (Malaysia)
FUNCTIONAL ANALYSIS OF MUTATIONS LOCATED IN THE LDL RECEPTOR
SIGNAL SEQUENCE CODING REGION
T. Freiberger, J. Pavlouskova, K. Reblova, L. Tichy, L. Fajkusova (Czech
Republic)
964
K. Astrakova, E. Shakhtshneider, D. Ivanoshchuk, Y. Ragino, S. Astrakov,
M. Voevoda (Russia)
STUDY OF APOB MUTATIONS AND FAMILIAL HYPERCHOLESTEROLEMIA
PHENOTYPES972
J. Bassani Borges, G. Medeiros Bastos, T.K. Almendros Afonso, E. Da Silva
Rodrigues, H. Strelow Thurow, T. Dominguez Crespo Hirata, A. Arpad
Faludi, R. Marques Gonçalves, R. Dominguez Crespo Hirata, M. Hiroyuki
Hirata (Brazil)
963
C. Pavanello, C. Tarlarini, S. Penco, L. Calabresi, S. Castelnuovo,
G. Mombelli, C. Sirtori (Italy)
971
I. Lamiquiz Moneo, M.R. Perez-Ruiz, E. Jarauta, M.T. Tejedor, L. Baila-Rueda,
A.M. Bea, R. Mateo-Gallego, A. Cenarro, F. Civeira (Spain)
962
L. Schwarzova, A. Horinek, J. Hubacek, M. Vrablik, T. Freiberger, L. Tichy,
H. Vaverkova, R. Ceska (Czech Republic)
ANALYSIS OF CANDIDATE SINGLE NUCLEOTIDE VARIATIONS ASSOCIATED
WITH POLYGENIC HYPERCHOLESTEROLEMIA IN FAMILIES WITH THE
CLINICAL DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA
INCIDENCE OF CARDIOVASCULAR DISEASE AMONG INDIVIDUALS WITH
AND WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA ATTENDING A LIPID
CLINIC978
F. Barkas, E. Klouras, T. Dimitriou, G. Liamis, M. Elisaf, E. Liberopoulos (Greece)
153
Board #
Board #
149
158
CHANGES IN PLASMA LIPOPROTEIN SUBFRACTIONS IN PATIENTS
WITH POLYGENIC HYPERCHOLESTEROLEMIA, FAMILIAL COMBINED
HYPERLIPOPROTEINEMIA, AND FAMILIAL HYPERCHOLESTEROLEMIA
AFTER ATORVASTATIN
150
PREVALENCE OF DYSLIPIDAEMIA AMONG ADULTS AGED 50-64 YEARS IN
IRELAND: THE IRISH LONGITUDINAL STUDY ON AGEING (TILDA)
C. Boot, E. Holmes, D. Neely, F. Jenkinson, H. Datta, L. Hughes (United
Kingdom)
979
159
980
C. Murphy, E. Shelley, T. Fahey, R.A. Kenny (Ireland)
151
IMPACT OF SOCIAL AND CLINICAL PARAMETERS ON NON-HDL
CHOLESTEROL IN SCHOOL CHILDREN
152
STATIN PRESCRIPTION PATTERNS, ADHERENCE, AND ATTAINMENT
OF CHOLESTEROL TREATMENT GOALS IN CLINICAL CARE IN ELDERLY
WITH HYPERLIPIDEMIA AND CORONARY HEART DISEASE: A RUSSIAN
OBSERVATION STUDY
160
153
STUDY OF THE PREVALENCE OF DYSLIPIDEMIAS IN CHILDREN AND
ADOLESCENTS ATTENDED BY THE NATIONAL HEALTH SYSTEM IN
CAMPINAS - SÃO PAULO - BRAZIL
161
154
162
CLINICAL MANAGEMENT AND QUALITY OF LIFE IN PATIENTS WITH
HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA UNDERGOING LIPIDAPHERESIS IN TURKEY: FIRST RESULTS OF A NATION-WIDE SURVEY (A-HIT
REGISTRY)984
M. Kayıkcıoglu, L. Tokgozoglu, S. Pirildar, M. Yilmaz, L. Kaynar, M. Aktan,
R. Durmus, A. Temizhan, O. Ozcebe, T. Akyol, H. Okutan, S. Sag,
B. Altunkeser, M. Yenercag, E. Kurtoglu, S. Demircioglu, O. Salcioglu,
M. Demir, H. Yilmaz, O. (Turkey)
155
FUNCTIONALLY CHARACTERIZATION OF LDLR MISSENSE ALTERATIONS
FOUND IN CLINICAL FH PATIENTS
GENETIC VARIANTS OF PCSK9 GENE IN CORONARY ARTERY DISEASE
AMONG SOUTH INDIAN PATIENTS
FAMILIAL COMBINED HYPERLIPIDEMIA IN CHILDREN: BIOCHEMICAL
CHARACTERIZATION IN PEDIATRIC AGE
F. Abello, E. Barabesi, A. Bosusco, O. Guardamagna, D. Vianello, A. Zambon
(Italy)
991
CARDIOVASCULAR COMORBIDITIES LINKED TO OBESITY IN FORMER
ATHLETES FROM TRANSYLVANIA
992
V. Negrean, O. Orășan, T. Alexescu, N. Leach, I. Para, M. Milaciu (Romania)
163
164
E_LIPID: CHARACTERIZATION OF THE LIPID PROFILE IN THE PORTUGUESE
POPULATION993
SEVERE HYPERCHOLESTEROLEMIA IN HOSPITAL PRACTICE-SINGLE
CENTRE EXPERIENCE IN SINGAPORE
994
S. Dissanayake, S.P. Li Tin, J.F. Choi Wan, M.S. Wong, S. Tavintharan
(Singapore)
985
165
HIGH PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA IN
ARGENTINA: RESULTS OF THE FIRST DETECTION PROGRAM.
995
P. Corral, G.I. López, A. Cristaldi, J.C. Tuseddo, L. Cacciagiú, G. Berg,
L. Schreier (Argentina)
986
166
M. Ganesan (India)
157
HIGH TRIGLYCERIDES, LOW HDL CHOLESTEROL AND A LOW LDL
CHOLESTEROL PER APOLIPOPROTEIN B RATIO PREDICT INCIDENT
DIABETES IN PATIENTS WITH ESTABLISHED CORONARY ARTERY DISEASE
C. Mariano, M. Antunes, Q. Rato, M. Bourbon (Portugal)
A.C. Alves, S. Azevedo, A. Benito-Vicente, A. Etxebarria, P. Barros,
A.M. Medeiros, C. Martin, M. Bourbon (Portugal)
156
SEARCHING FOR THE ELUSIVE FAMILIAL HYPERCHOLESTEROLAEMIA
GENE MUTATIONS FOR INDEX PATIENTS - USING HISTORICAL
LABORATORY LDL-C RESULTS IN PRIMARY CARE. A NORTH WALES
EXPERIENCE.990
C. Saely, P. Rein, A. Vonbank, D. Zanolin, A. Leiherer, A. Muendlein, H. Drexel
(Austria)
983
E. De Faria, E.I. Gomes, V.H. Zago, E.S. Parra, N.B. Panzoldo, G. Redezuk
(Brazil)
989
Y.P. Teoh, R. Gingell (United Kingdom)
982
M. Bubnova, D. Aronov (Russia)
TREATMENT OF THERAPY-REFRACTORY HYPERCHOLESTEROLEMIA
WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 ANTIBODIES
(PCSK9-I) IN CARDIOVASCULAR HIGH RISK PATIENTS - EFFECTIVITY AND
SAFETY IN CLINICAL ROUTINE
T. Hollstein, D. Spira, N. Buchmann, N. El-Zidy Ibrahim, T. Bobbert,
E. Steinhagen-Thiessen, U. Kassner (Germany)
981
A. Pereira, F. Guarnieri, A.P.Q. Mello, R. Santos Filho, T.L.R. Martinez (Brazil)
VALIDATION OF SERUM ApoB/CHOLESTEROL AND ApoB/NON-HDL
CHOLESTEROL RATIOS AS SCREENING TESTS FOR TYPE III HYPERLIPIDAEMIA 988
987
NETWORK ANALYSIS APPROACH TO FIND NEW CANDIDATE GENES
AND PATHWAYS INVOLVED IN THE PATHOPHYSIOLOGY OF FAMILIAL
N. Rossi, M. Bourbon, F. Enguita (Portugal)
167
PARAMETRES OF ARTERIAL REMODELING IN FAMILAL
HYPERCHOLESTEROLEMIA PATIENTS
997
V. Korneva, T. Kuznettsova (Russia)
154
155
Board #
Board #
Dyslipidemias: Treatment
178
168
EFFECTS OF DIFFERENT DOSES OF ATORVASTATIN ON PLATELET
AGGREGATION, ENDOTHELIAL FUNCTION, LEVELS OF SEROTONIN,
ANGIOTENSIN II, BLOOD PRESSURE, CEREBRAL BLOOD FLOW IN
HYPERTENSIVE PATIENTS WITH HYPERLIPIDEMIA
EFFECT OF STATIN ON FASTING BLOOD SUGAR LEVEL; COMPARISONS OF
KINDS OF STATINS AND ASSOCIATED PARAMETERS
998
179
999
DIFFERENT ROLE OF ACHIEVED LDL-CHOLESTEROL AND HS-CRP
LEVEL IN FUTURE CARDIOVASCULAR DISEASE OUTCOMES IN NONPERCUTANEOUS CORONARY INTERVENTION PATIENTS WITH ONGOING
STATIN THERAPY OF MODERATE INTENSITY
180
1000
M.H. Hyun, E. Lee, B.G. Choi, H.S. Seo, J.O. Na, C.U. Choi, H.E. Lim, J.W. Kim,
S.W. Rha, E.J. Kim, C.G. Park, D.J. Oh (Republic of Korea)
171
172
181
173
COMPARISON OF LIPID MANAGEMENT BETWEEN ELDERLY AND NONELDERLY PATIENTS WITH AND WITHOUT CORONARY HEART DISEASE (CHD) 1002
STATIN ESCAPE PHENOMENON: DOES IT REALLY EXIST? EVIDENCE FROM
A LIPID CLINIC
EFFECTS OF LOW-DOSE VS. MODERATE-DOSE PITAVASTATIN ON LONGTERM CARDIOVASCULAR EVENTS IN KOREAN PATIENTS WITH CORONARY
ARTERY DISEASE REQUIRING STENT IMPLANTATION: PROSPECTIVE,
3-YEAR FOLLOW-UP TRIAL
183
1003
GENE VARIANTS ASSOCIATED WITH STATIN-INDUCED MYOPATHY:
DETERMINATION IN A CZECH POPULATION
184
1004
THE SAFETY OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE
ONE YEAR PERSISTENCE OF ATORVASTATIN AND AMLODIPINE FIXED
DOSE COMBINATION VERSUS ATORVASTATIN THERAPY
TESTOSTERONE UNDECANOATE IMPROVES LIPID PROFILE IN PATIENTS
WITH TYPE 1 DIABETES AND HYPOGONADOTROPHIC HYPOGONADISM.
RESULTS FROM TEST-T1D RANDOMIZED CLINICAL TRIAL.
1012
EFFECT OF TOCILIZUMAB ON CARDIAC BIOMARKERS HIGH-SENSITIVITY
TROPONIN T AND NT-PROBNP IN RHEUMATOID ARTHRITIS: POST HOC
ANALYSIS OF A RANDOMISED CONTROLLED TRIAL
1013
186
1006
CCAAT/ENHANCER BINDING PROTEIN DELTA CONTRIBUTES TO AN
EARLIER PHASE OF PRO-INFLAMMATORY RESPONSE IN DOXORUBICIN
RELATED CARDIOMYOPATHY
1014
EFFECT OF ENDOTOXIN AND NATURAL CAROTENOIDS ON AORTIC
ENDOTHELIAL TIGHT JUNCTIONS´ OCCLUDIN EXPRESSION
1015
J. Krizak, K. Frimmel, E. Breierova, R. Sotnikova, J. Navarova, I. Bernatova,
L. Okruhlicova (Slovakia)
1005
EFFECT OF DHA/EPA SUPPLEMENTATION ON ENDOTHELIAL DAMAGE
MARKERS. THE BIOCLAIMS STUDY
1016
J. Góralska, M. Malczewska-Malec, U. Razny, A. Zdzienicka, A. Gruca,
A. Chabowski, M. Sanak, A. Dembinska-Kiec, B. Solnica (Poland)
Y.K. Cho (Republic of Korea)
177
1011
J.T. Wen, L.W. Hsu, P.Y. Liu (Taiwan)
185
J. Petrkova, L. Kocourkova, V. Zizkova, M. Taborsky, M. Petrek (Czech Republic)
176
THE EFFECTS OF ALIROCUMAB ON LDL CHOLESTEROL LEVELS IN
PATIENTS RECEIVING STATINS
P. Welsh, K. Tuckwell, N. Sattar (United Kingdom)
D.S. Lim, H.J. Kim, Y.C. Kim, B.G. Kang, S.M. Jeon, S.J. Hong, J.Y. Cho,
S.H. Lee, H.J. Joo, J.H. Park, C.W. Yu (Republic of Korea)
175
1010
J.J. Chillarón, J. Pedro-Botet, M. Fernández-Miró, M. Albareda, L. Vila,
D. Benaiges, J.A. Flores Le-Roux (Spain)
F. Barkas, E. Klouras, T. Dimitriou, M. Elisaf, E. Liberopoulos (Greece)
174
EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION OF OLMESARTAN
MEDOXOMIL AND ROSUVASTATIN IN KOREAN PATIENTS WITH
HYPERTENSION AND DYSLIPIDEMIA
H. Habibinejad (Iran)
182
N. Kume, R. Shimizu, H. Torii, D. Yasuda, Y. Hiraoka, T. Hashida (Japan)
1009
S.H. Kim, H.L. Lee, W.H. Lim, H.L. Kim, J.B. Seo, W.Y. Chung, J.H. Zo,
M.A. Kim, H.S. Kim (Republic of Korea)
COMPARISON THE EFFECT ON FASTING BLOOD SUGAR BETWEEN
ATORVASTATIN, ROUSUVASTATIN AND PITAVASTATIN IN KOREAN
POPULATION1001
Y.S. Lee, Y.W. Park, S.P. Hong, J.B. Lee, J.K. Ryu, J.Y. Choi, K.S. Kim (Republic
of Korea)
THE EFFICACY OF EVOLOCUMAB AND OTHER LIPID-LOWERING
THERAPIES (LLT) FOR THE MANAGEMENT OF LOW DENSITY LIPOPROTEIN
CHOLESTEROL (LDL-C): A SYSTEMATIC REVIEW AND NETWORK METAANALYSIS (NMA)
G. Worthy, S.R. Gandra, I. Bridges, G. Worth, R. Dent, L.I. Cheng, C. Forbes,
S. Deshpande, J. Ross, J. Kleijnen, E.S.G. Stroes (Netherlands)
C.J. Kim, M.A. Kim (Republic of Korea)
170
1008
K. Kotula-Horowitz, M. Janczura, T. Iwaniec, R. Rosa, J. Zagjewski,
M. Bubnova, D. Aronov, E. Semenova (Russia)
169
IMPACT OF FENOFIBRATE THERAPY ON ENDOTHELIAL FUNCTION IN THE
SUBJECTS WITH METABOLIC SYNDROME
1007
G. Simonyi, F. Tamás (Hungary)
156
157
Board #
Board #
187
197
IN VITRO PHARMACOLOGICAL EVALUATION OF MULTITARGET
THROMBOXANE PROSTANOID RECEPTOR/ COX-2 AGENTS: A POSSIBLE
STRATEGY TO SOLVE THE CARDIOVASCULAR ISSUES OF COXIBS
1017
M. Hoxha, C. Buccellati, V. Capra, C. Cena, A. Sala, M. Bertinaria, G. Rovati
(Italy)
188
M. Eriksson, O. Ahmed, U. Gustafsson, K. Littman, S. Sahlin, C. Pramfalk,
P. Parini (Sweden)
THE USE OF N-ACETYLCYSTEINE IN PATIENTS WITH ACUTE CORONARY
SYNDROME AND DIASTOLIC LEFT VENTRICULAR DYSFUNCTION, IN
ACCORDANCE WITH THE LEVEL OF HIGH-SENSITIVITY C-REACTIVE
PROTEIN.1018
A. Nizomov, B. Toshev, J. Berdiqulov (Uzbekistan)
189
THREE TIMES A WEEK AND FIVE TIMES A WEEK WALKING EXERCISE
FREQUENCIES ARE EQUALLY EFFECTIVE IN IMPROVING WALKING
CAPACITY IN EXPERIMENTAL PERIPHERAL ARTERY DISEASE
198
SONODYNAMIC THERAPY OF THE RABBIT CAROTID ARTERY NEOINTIMAL
HYPERPLASIA USING LOW- LEVEL COMBINED ELECTROHYDRAULIC
SHOCK WAVES AND ULTRASONIC WAVES ACCOMPANIED BY
PROTOPORPHYRIN IX ADMINISTRATION
199
1019
1020
H. Mehrad, B. Mahvi (Iran)
191
A NOVEL COMPOUND (D-47), THE HYPOLIPIDEMIC EFFECTS AND THE
MECHANISM IN AN ANIMAL MODEL OF HYPERCHOLESTEROLEMIA
(WHHLMI RABBIT)
192
193
Dyslipidemias: Coagulation
201
NOVEL ROLE OF BERBERINE IN LOX1-MEDIATED ENDOTHELIAL DYSFUNCTION 1022
A. Cicero, C. Caliceti, P. Rizzo, R. Ferrari, F. Fortini, G. Aquila, J. Shehu,
E. Leoncini, L. Zambonin, B. Rizzo, M. Guardigli, A. Roda, S. Hrelia (Italy)
R. Somerville, K. Viljoen, S. McKey, A. Shrivastava, J. Mehegan, R. Segurado,
C. Murrin, C. Kelleher (Ireland)
1023
202
DOWN-REGULATION OF THE CHEMOKINE (C-C MOTIF) RECEPTOR 9
(CCR9) CONTRIBUTES TO THE ATHEROSCLEROSIS-LOWERING ACTIVITY
OF THE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR CAPTOPRIL
INCIDENCE OF VALVULAR HEART DISEASE AFTER COMBINATION OF
DOPAMIN AGONISTS WITH STATINS
203
1024
HYPOLIPIDEMIC EFFECT OF RHEOPHERESIS AND RESTORATION OF
RETINAL PHOTORECEPTOR JUNCTION
1032
PLATELET-ASSOCIATED TISSUE FACTOR AS A NEW MECHANISM INVOLVED
IN THE PROTHROMBOTIC PHENOTYPE OF STABLE ANGINA PATIENTS
WITH TYPE-2 DIABETES MELLITUS (T2DM)
1033
L. Rossetti, P. Canzano, M. Mapelli, D. Trabattoni, F. Santilli, G. Davì, A. Lualdi,
E. Tremoli, M. Camera (Italy)
1025
E. Giyazitdinova, B. Muinjonov, G. Rakhimbayeva, Y. Musayeva (Uzbekistan)
196
ADJUSTING FOR THE INFLUENCE OF THE HEMATOCRIT LEVEL IMPROVES
THE PROGNOSTIC VALUE OF THE VERIFYNOW P2Y12 ASSAY
1031
J.W. Suh, Y.G. Kim, Y.S. Cho, T.J. Youn, I.H. Chae (Republic of Korea)
J. Abd Alla, A. Langer, U. Quitterer (Switzerland)
195
PLASMA ADVANCED OXIDIZED PROTEIN PRODUCTS PROMOTE PLATELETENDOTHELIAL CROSSTALK AND ENDOTHELIAL TISSUE FACTOR EXPRESSION1030
G. Marsche, A. Heinemann, L. Pasterk (Austria)
1021
A. Pokrovskiy, A. Zotikov, V. Kulbak, E. Burtceva (Russia)
194
STATIN THERAPY REDUCES PHOSPATE LEVELS IN DIALYSIS PATIENTS:
RESULTS FROM THE EPIDEMIOLOGICAL VITAMIN K ITALIAN STUDY (VIKI
STUDY)1029
PLASMA FIBRINOGEN IS AN IMPORTANT CLINICAL MARKER FOR
PROSPECTIVE ALL-CAUSE MORTALITY IN THE LIFEWAYS CROSSGENERATION COHORT STUDY
EXPERIENCE OF TAKAYASU`S ARTERITIS SURGICAL TREATMENT
1028
C. Panzavolta, L. Benvegnù, A. Aghi, M. Biolo, S. Giannini, M. Noale,
G. Tripepi, M. Plebani, N. Veronese, P. Messa, M. Rossini, M. Gallieni, S. Sella,
F. Fabris, E. Manzato, L. Previato, S. Bertocco, A. Zambon, M. Fusaro,
S. Zambon (Italy)
200
S. Tamura, Y. Yu, T. Nakagawa, R. Nagasaka, T. Tsunoda, K. Ogawa, M.O. Tori,
T. Koike, M. Shiomi (Japan)
CROSS-CLASS SERINE PROTEASE INHIBITOR SERP-2 BLOCKS LIVER
ISCHEMIA REPERFUSION INJURY
S. Ambadapadi, H. Chen, J. Fuentes, S. Morshed, J. Davids, B. Marques,
A. Lucas (USA)
M. Pellegrin, J. Lavier, K. Bouzourene, L. Mazzolai (Switzerland)
190
REMNANT CHOLESTEROL REDUCTION BY EZETIMIBE AND SIMVASTATIN
DOES NOT AFFECT BILIARY LIPID CONCENTRATION IN GALLSTONE
PATIENTS1027
1026
204
IMPACT OF TYPE-2 DIABETES MELLITUS (T2DM) ON THE PLATELET
TRANSCRIPTOME PROFILE IN STABLE ANGINA (SA) PATIENTS
1034
L. Rossetti, M. Brambilla, P. Canzano, L. Piacentini, E. Bono, M. Mapelli,
D. Trabattoni, A. Lualdi, G. Colombo, E. Tremoli, M. Camera (Italy)
M. Blaha, E. Rencova, H. Langrova, M. Lanska, A. Stepanov, V. Blaha (Czech
Republic)
158
159
Board #
Board #
205NTEGRIN αΙΙbβ3 AS POTENTIAL BIOMARKER OF HIGH ON-TREATMENT
PLATELET REACTIVITY TO CLOPIDOGREL IN PATIENTS WITH AN ACUTE
CORONARY SYNDROME
214
1035
A. Gkourogianni, M. Tsoumani, I. Ntallas, D. Tsoukatos, I. Goudevenos,
A. Tselepis (Greece)
206
THE COMBINATION OF N-ACETYLCYSTEINE WITH FIBRINOLYTIC THERAPY
IN PATIENTS WITH ACUTE CORONARY SYNDROME.
215
1036
216
FEASIBILITY OF TARGETING THROMBUS USING FOCUSEDELECTROHYDRAULIC SHOCK WAVES ACCOMPANIED BY
SIMULTANEOUSLY B-MODE ULTRASOUND IMAGING IN THE RABBIT
MODEL OF COMMON CAROTID ARTERY ATHEROTHROMBOTIC OCCLUSION1037
NON-INVASIVE TREATMENT OF THE RABBIT CAROTID ARTERY
ATHEROTHROMBOTIC OCCLUSION USING COMBINED Nd:YAG
LASER AND PULSED- FOCUSED ULTRASOUND ACCOMPANIED BY
THROMBOLYTIC AGENT ADMINISTRATION
PROTHROMBOTIC PHENOTYPE IN HYPERTENSION: CONTRIBUTION
OF MEGAKARYOCYTE- AND PLATELET-ASSOCIATED TISSUE FACTOR
EXPRESSION IN STROKE-PRONE RATS
217
SILENCING ANTICOAGULANT PROTEIN C CAUSES SPONTANEOUS
ATHEROTHROMBOSIS IN APOE KNOCKOUT MICE
VASCULAR AGE - A HELPFUL TOOL IN ASSESSING CARDIOVASCULAR RISK
1046
REMOTE ISCHEMIC PRECONDITIONING AND ENDOTHELIAL FUNCTION IN
HEALTHY VOLUNTEERS
1047
N. Ryazankina, M. Vagida, V. Manchurov, A. Lebedeva, A. Arakelyan,
J.C. Grivel, L. Margolis, E. Vasilieva, A. Shpektor (Russia)
218
1038
THE ENDOTHELIAL FUNCTION IMPROVEMENT ON STATIN THERAPY
IN TYPE 2 DIABETES ASSOCIATED WITH TNFα G(308)A AND G(238)A
POLYMORPHIC MARKERS
1048
N. Lebedeva, O.K. Vikulova, A.G. Nikitin, M.S. Shamkhalova, M.V. Shestakova
(Russia)
1039
219
M. Brambilla, P. Gelosa, L. Rossetti, L. Castiglioni, P. Canzano, S. Luigi,
E. Tremoli, M. Camera (Italy)
210
1045
A. Dumitrescu, S. Mosteoru, L. Gaita, R. Pleava, D. Gaita (Romania)
H. Mehrad, A. Akrami (Iran)
209
THE PROGNOSTIC IMPORTANCE OF ENDOTHELIAL DYSFUNCTION IN
METABOLIC SYNDROME WITH CORONARY ARTERY DISEASE
T. Ueda (Japan)
H. Mehrad (Iran)
208
1044
N. Burko, L. Salyamova, Y. Tomashevskaya, V. Oleynikov (Russia)
A. Nizomov (Uzbekistan)
207
INFLUENCE OF CARBOHYDRATE METABOLISM DISORDERS ON
STRUCTURAL AND FUNCTIONAL PROPERTIES OF THE LARGE ARTERIES IN
PATIENTS WITH TYPE 2 DIABETES MELLITUS
BENEFICIAL EFFECT OF AZILSARTAN AND AMLODIPINE ON ENDOTHELIAL
FUNCTION IN HYPERTENSIVE PATIENTS
1049
T. Nishida, M. Ayaori, K. Shiotani, H. Uto-Kondo, M. Sasaki, T. Komatsu,
Y. Endo, M. Ito, M. Ishizuka, M. Sakurada, K. Ikewaki (Japan)
1040
220
A.B. Ouweneel, M. Heestermans, R.A.F. Verwilligen, M. Van Eck, B.J.M. Van
Vlijmen (Netherlands)
CIRCULATING PROGENITOR CELLS IN HYPERTENSIVE SUBJECTS:
EFFECTIVENESS OF A TREATMENT WITH OLMESARTAN IN
IMPROVING CELL NUMBER AND MIRS PROFILE BESIDES EXPECTED
PHARMACOLOGICAL EFFECTS
1050
G. Mandraffino, C.O. Aragona, E. Imbalzano, V. Cairo, F. Mamone,
M.A. Sardo, A. Saitta (Italy)
Dyslipidemias: Endothelial Dysfunction
211
LOW-FLOW MEDIATED CONSTRICTION INCORPORATED INDICES AS
INDICATORS OF CARDIOVASCULAR RISK IN SMOKERS
1041
221
N. Norioka, Y. Takemoto, M. Kobayashi, A. Makuuchi, J. Yoshikawa,
Y. Yamazaki, Y. Kamiyama, T. Shuto, M. Yoshiyama (Japan)
212
ENDOTHELIAL SHEAR RATE IN PATIENTS WITH CAROTID ATHEROSCLEROSIS 1042
V. Genkel, A. Salashenko, O. Alekseeva, M. Denisenko, I. Shaposhnik (Russia)
213
Genetics, Nutrition, Biomarkers: Genetics, Gene Regulation
ANALYSIS OF BIOLOGICAL, STRUCTURAL AND FUNCTIONAL MARKERS
OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ARTERIAL
HYPERTENSION, TREATED WITH ANGIOTENSIN-CONVERTING ENZYME
(ACE) INHIBITORS
1051
P. Downie, G. Bayly (United Kingdom)
222
1043
A CASE OF SEVERE CHYLOMICRONAEMIA SYNDROME, IN A PATIENT
WITH NORMAL LIPOPROTEIN LIPASE ACTIVITY, DUE TO A PREVIOUSLY
UNIDENTIFIED MUTATION IN THE GPIHBP1 GENE
MOLECULAR ANALYSIS OF GENES INVOLVED IN LIPOPROTEIN LIPASE
DEFICIENCY IN SLOVAK PATIENTS WITH FAMILIAL CHYLOMICRONEMIA
1052
D. Gabcova, D. Stanikova, M. Huckova, V. Bzduch, J. Stanik, I. Klimes,
K. Raslova, D. Gasperikova (Slovakia)
M. Andor, V. Buda, C. Cristescu, M. Voicu, L. Suciu, C. Muntean, M. Tomescu
(Romania)
160
161
Board #
223
DISSECTION OF CLINICAL AND GENE EXPRESSION SIGNATURES OF
FAMILIAL VS MULTIFACTORIAL CHYLOMICRONEMIA
Board #
234
1053
D. Gaudet, D. Brisson, K. Tremblay (Canada)
224
225
A NOVEL HOMOZYGOUS MUTATION IN GPD1 LEADING TO SEVERE
HYPERTRIGLYCERIDEMIA1054
THE GG GENOTYPE OF VITAMIN D METABOLISM-RELATED GENE DHCR7
rs12785878 IS MORE PREVALENT IN THE INDIANS AND ASSOCIATED WITH
HIGHER OXIDATIVE STRESS INDEX IN SINGAPORE
IDENTIFICATION AND CHARACTERIZATION OF TWO NOVEL MUTATIONS
IN THE LPL GENE CAUSING TYPE I HYPERLIPOPROTEINEMIA
R. Dalan, H. Liew, L.L. Goh, X. Gao, D. Chew, B.O. Boehm (Singapore)
STATINS UPREGULATE microRNA-122 IN HepG2 CELLS
227
THE HYPERTRIGLYCERIDEMIC EFFECT OF APOC3 3'UTR VARIANT SST1 IS
NOT MEDIATED BY A HEPATIC OR INTESTINAL MIRNA REGULATION
235
1055
236
237
1057
PLASMA LIPOPROTEINS OF PATIENTS WITH GENETIC LAL DEFICIENCY
ARE ENRICHED IN CHOLESTERYL ESTERS: RELEVANCE OF CHOLESTEROL
ESTERIFICATION BY LCAT
238
1058
M. Gomaraschi, L. Arnaboldi, F. Abello, C. Pavanello, F. Zimetti, E. Favari,
L. Calabresi, O. Guardamagna (Italy)
229
LYSOSOMAL ACID LIPASE DEFICIENCY IN GREECE: A RARE INBORN ERROR
OF METABOLISM PRESENTING WITH DYSLIPIDAIMIA AND LIVER DISEASE
230
WILL FAMILIAL HYPERCHOLESTEROLAEMIA COHORTS HIDE MANY MORE
LISOSOMAL ACID LIPASE DEFICIENCY PATIENTS?
1059
231
SCREENING OF LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS WITH
SEVERE DYSLIPIDEMIA AND PREMATURE CORONARY HEART DISEASE
232
GENETIC VARIANTS OF ABO BLOOD GROUP WITH CORONARY ARTERY
DISEASE AMONGST INDIANS
241
1061
GPER P.P16L POLYMORPHISM IS NOT ASSOCIATED WITH ALTERED LIPID
PHENOTYPES AND CIMT PROGRESSION- A PLIC STUDY
242
1062
A. Dhyani, A. Baragetti, K. Garlaschelli, F. Pellegatta, L. Grigore, D. G.Norata,
A.L. Catapano (Italy)
162
1069
GENETIC DETERMINATION OF THE ATHEROSCLEROTIC PLAQUE STABILITY 1070
MAY THE TRANSCRIPTIONAL ACTIVITY OF TRANSFORMING GROWTH
FACTOR BETA 1 GENE BE A MARKER FOR EARLY STAGES FOR CORONARY
ATHEROSCLEROSIS?1071
ASSOCIATION OF SERUM CAROTENOID CONCENTRATION WITH SINGLE
NUCLEOTIDE POLYMORPHISMS IN APOE, BCMO1, NPC1L1, CD36, GSTP1,
ABCG5, FABP1, FABP2 AND LIPC GENES1072
A. Mazeikiene, D. Karciauskaite, N. Burokiene, Z. Daunoravicius,
Z.A. Kucinskiene, V. Kucinskas (Lithuania)
243
1063
PHENOTYPE OF VULNERABLE ATHEROSCLEROTIC PLAQUES SHOWS
STRONG ASSOCIATION WITH SINGLE NUCLEOTIDE POLYMORPHISM
ALLELES OF COMMON RISK VARIANTS FOR CORONARY ARTERY DISEASE
J. Dąbek, M. Bałys, J. Piotrkowicz, J. Głogowska-Ligus, Z. Gąsior (Poland)
P. Chawla, T. Ashavaid, C. Ponde, R. Rajani, A. Deshpande, R. Sawant (India)
233
1068
I. Goncharova, M. Golubenko, O. Makeeva, V. Kashtalap, N. Tarasenko,
A. Markov, V. Puzyrev (Russia)
1060
O. Azevedo, N. Marques, H. Antunes, P. Azevedo, M. Oliveira, D. Bento,
J. Guedes, B. Marmelo, R. Faria, E. Correia (Portugal)
Rs6922269 MARKER AT THE MTHFD1L GENE PREDICT CARDIOVASCULAR
MORTALITY IN MALES AFTER ACUTE CORONARY SYNDROME
R. Furtmair, C. Kuehn, C. König, A. Ekici, L. Klinghammer, S. Achenbach,
A. Reis, M. Tauchi, B. Dietel (Germany)
240
J.R. Chora, A.C. Alves, A.M. Medeiros, C. Mariano, G. Loubarinhas, A. Guerra,
H. Mansilha, M. Bourbon (Portugal)
SINGLE NUCLEOTIDE POLYMORPHISMS AT THE HYDROXY-METHYLGLUTARYL-COA REDUCTASE GENE LOCUS SIGNIFICANTLY PREDICT
CARDIOVASCULAR EVENTS IN CORONARY PATIENTS WITH TYPE 2 DIABETES 1067
J. Hubacek, V. Stanek, R. Poledne, V. Adamkova, J. Pitha (Czech Republic)
239
E. Drogari, V. Mollaki, H. Christomanou, K. Stamatelopoulos, N. Manolaki
(Greece)
1066
A. Leiherer, A. Muendlein, C. Saely, E. Kinz, P. Rein, A. Vonbank,
P. Fraunberger, H. Drexel (Austria)
M. Dancer, C. Marcais, C. Caussy, M. Di filippo, P. Moulin, S. Charrière (France)
228
ASSOCIATION OF THE HETEROPLASMY LEVEL OF MUTATION IN GENE
MT-CYB WITH CAROTID ATHEROSCLEROSIS IN WOMEN
1065
V. Sinyov, M. Sazonova, M. Chicheva, N. Nikitina, I. Sobenin, A. Orekhov
(Russia)
1056
A. Etxebarria, X. Moreno, A. Benito-Vicente, S. Jebari, U. Galicia, H. Ostolaza,
C. Martin (Spain)
1064
T. Chia-Yin, C. Hung-Yi, H. Fang-I (Taiwan)
J. Levels, R. Piña-Aguilar, J. Peter, G.M. Dallinga-Thie (Netherlands)
P. Pingitore, S.M. Lepore, C. Pirazzi, R.M. Mancina, B.M. Motta, L. Valenti,
K.E. Berge, K. Retterstøl, T.P. Leren, O. Wiklund, S. Romeo (Sweden)
226
NFE2L2 RS2364723 CC GENOTYPE SIGNIFICANTLY INCREASED THE
RISK OF CARDIOVASCULAR DISEASE: A CASE-CONTROL STUDY IN AN
ARSENIASIS-ENDEMIC AREA IN TAIWAN
A TOOL FOR QUANTITATIVE MEASUREMENT OF PROATHEROGENIC
HETEROPLASMIC MUTATIONS OF MITOCHONDRIAL DNA
1073
I. Sobenin, K. Mitrofanov, A. Orekhov (Russia)
163
Board #
Board #
244
253
CREATION OF CYBRID LINES OF MONOCYTE ORIGIN WITH HIGH
HETEROPLASMY LEVEL FOR MITOCHONDRIAL GENOME MUTATION
M.1555G>A1074
M. Sazonova, V. Sinyov, A. Ryzhkova, T. Shkurat, N. Demakova, N. Nikitina,
I. Sobenin, A. Orekhov (Russia)
245
DETECTION OF THRESHOLD HETEROPLASMY LEVEL OF mtDNA IN
LYPOFIBROUS PLAQUES OF HUMAN AORTIC INTIMA
PROATHEROGENIC MUTATIONS OF MITOCHONDRIAL DNA IN PATIENTS
1075
MITOCHONDRIAL DNA MUTATIONS ASSOCIATED WITH CAROTID
ATHEROSCLEROSIS: NGS DATA
255
1076
ROLES OF ORPHAN NUCLEAR RECEPTORS IN CARDIAC HYPERTROPHY
1077
ROLE OF GENETIC POLYMORPHISMS AT THE ADIPONECTIN GENE IN
REGULATION OF ADIPONECTIN GENE EXPRESSION AND CIRCULATING
ADIPONECTIN LEVELS
257
1078
1085
DNA METHYLATION AND COPY NUMBER EVENTS IN ATHEROSCLEROTIC
LESIONS1086
GENE THERAPY: CASE STUDY ON THE FIRST LIPOPROTEIN LIPASE
DEFICIENCY PATIENT TREATED WITH ALIPOGENE TIPARVOVEC IN GERMANY 1087
U. Kassner, T. Hollstein, M. Wühle-Demuth, I. Demuth, E. SteinhagenThiessen (Germany)
258
1079
L. Kedenko, W. Patsch, I. Kedenko, S.M. Patsch, S. Coassin, F. Kronenberg,
F. Krempler, B. Paulweber, C. Lamina (Austria)
250
ENDOTOXIN STRESS-INDUCED APOLIPOPROTEIN E GENE
DOWNREGULATION IN MACROPHAGES IS REDUCED BY METFORMIN
M. Nazarenko, A. Markov, A. Sleptcov, I. Lebedev, N. Skryabin, O. Barbarash,
V. Puzyrev (Russia)
G.H. Eom, D.H. Kwon, S. Shin, Y.U. Lee, E. Kim, N. Choe, Y.S. Nam, H. Kook
(Republic of Korea)
249
1084
E.V. Fuior, S. Stavri, V.G. Trusca, I.F. Tudorache, M. Simionescu, D. Kardassis,
A.V. Gafencu (Romania)
256
I. Sobenin, A. Zhelankin, Z. Khasanova, V. Orekhova, A. Orekhov, A. Postnov
(Russia)
248
DOES THE GENE EXPRESSION OF NUCLEAR FACTOR KAPPA B IN PATIENTS
WITH EARLY STAGES OF CORONARY ATHEROSCLEROSIS DIFFERS FROM
HEALTHY INDIVIDUALS
J. Dąbek, M. Bałys, J. Głogowska-Ligus, J. Piotrkowicz, Z. Gąsior (Poland)
I. Sobenin, M. Sazonova, V. Orekhova, A. Zhelankin, A. Orekhov, A. Postnov
(Russia)
247
1083
E. Coskunpinar, H.A. Cakmak, A.K. Kalkan, N. Ozan Tiryakioglu, T. Araz,
Z. Ongen (Turkey)
254
A. Ryzhkova, M. Sazonova, V. Sinyov, E. Galitsyna, V. Barinova, N. Nikitina,
I. Sobenin, A. Orekhov (Russia)
246
IS PLASMA MICRORNA-1909-5p A NEW POTENTIAL BIOMARKER FOR
ACUTE MYOCARDIAL INFARCTION
MAJOR ADIPOKINES AND -420 C>G RESISTIN GENE POLYMORPHISHM AS
PREDICTORS OF ACUTE ISCHEMIC STROKE SEVERITY AND IN-HOSPITAL
OUTCOME1088
S. Bouziana, K. Tziomalos, A. Goulas, T.A. Vyzantiadis, A. Panderi,
A. Hatzitolios (Greece)
LOW LDL-CHOLESTEROL, PCSK9 AND HMGCR GENETIC VARIATION, AND
RISK OF NEURODEGENERATIVE DISEASE: A MENDELIAN RANDOMIZATION
STUDY1080
259
PPAR-ALPHA GENE HAPLOTYPES, ARSENIC EXPOSURE AND RISK OF
CARDIOVASCULAR DISEASE
1089
F.I. Hsieh, S.H. Lin, C.F. Huang, H.Y. Chiou (Taiwan)
M. Benn, B. Nordestgaard, R. Frikke-Schmidt, A. Tybjærg-Hansen (Denmark)
251
252
RELATIONSHIP BETWEEN CIRCULATING microRNA-30c WITH
LIPOPROTEINS, THEIR CIRCULATORY TRAFFICKING AND EFFECT OF STATINS 1081
Genetics, Nutrition, Biomarkers: Nutrition
R. Sodi, J. Eastwood, L. Denby, I. Godber, M. Caslake, C.J. Packard (United
Kingdom)
260
HYPERGLYCEMIA INCREASES MICRORNAS IN CIRCULATING HDL FROM
ACUTE CORONARY SYNDROME PATIENTS AND MODULATES MIRNA
PROCESSING MACHINERY IN HUMAN MACROPHAGES
L.S. Niculescu, N. Simionescu, G.M. Sanda, M.G. Carnuta, C.S. Stancu,
A.C. Popescu, R.M. Popescu, A. Vlad, D.R. Dimulescu, M. Simionescu,
A.V. Sima (Romania)
164
ABNORMAL BALGHAM MUNZIQ, A UIGHUR HERBAL MEDICINE FORMULA,
HAS BEEN RECENTLY SHOWN TO POSSESS EXTENSIVE CARDIOVASCULAR
PHARMACOLOGICAL ACTIVITIES
1090
D. Xilifu, A. Nurmuhammat, U. Halmurat (China)
1082
261
EFFECTS OF RAMADAN FASTING ON BIOLOGICAL PARAMETERS IN
PATIENTS WITH CARDIOVASCULAR RISK FACTORS
1091
K. Bouzid, W. Hmaidi, Y. Molahedh, H. Ben Ahmed, A. Bartkiz, H. Baccar,
J. Abdelmoula (Tunisia)
165
Board #
262
INCREASING ADHERENCE OF CONSUMERS TO DIET & LIFESTYLE
CHANGES TO LOWER (LDL) CHOLESTEROL: THE ACT STUDY
Board #
272
1092
T.E. SIALVERA, P. Farajian, E.A. Trautwein, A. Papadopoulou, S. Efstathiou,
G. Goumas, I. Dimakopoulos, K. Papavasiliou, A. Koutsouri, A. Zampelas
(Greece)
263
NUTRITIONAL MODULATION OF THE TOXICITY OF ENVIRONMENTAL
POLLUTANTS: IMPLICATIONS IN ATHEROSCLEROSIS
DIETARY POLYUNSATURATED FATTY ACID AND FRAMINGHAM RISK
SCORE : ANALYSIS OF THE KOREA NATIONAL HEALTH AND NUTRITION
EXAMINATION SURVEY (KNHAENS 2013)
1093
273
VITAMIN D STATUS AND BIOMARKERS OF ENDOTHELIAL ACTIVATION IN
OBESE INDIVIDUALS
274
1094
EFFECTS OF VITAMIN E OR LIPOIC ACID SUPPLEMENTATION ON FASTING
OXYPHYTOSTEROL CONCENTRATIONS IN SUBJECTS WITH IMPAIRED
GLUCOSE TOLERANCE OR TYPE II DIABETES
1095
275
276
EFFECTIVENESS OF A LOW GLYCEMIC INDEX SOLUBLE PLANT POWDER, AS
A LOW-CALORIE REPLACEMENT MEAL, IN OVERWEIGHT AND OBESE PATIENTS1097
SUSTAINED NUTRITIONAL COUNSELING IMPROVES DIETARY INTAKE IN
PARENTS AND THEIR CHILDREN OVER 5 YEARS: THE PEP FAMILY HEART
STUDY1098
P. Schwandt, E. Liepold, M. Heinzel-Gutenbrunner, T. Bertsch, G.M. Haas
(Germany)
269
SPANISH OBESE CHILDREN AND BIOCHEMICAL PARAMETERS : NONHEALTHY NUTRITIVE PATTERNS
LONG-TERM MAGNESIUM SUPPLEMENTATION IMPROVES ARTERIAL
STIFFNESS IN OVERWEIGHT AND OBESE ADULTS: A RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED INTERVENTION STUDY
1099
271
THIRTEEN YEAR FOLLOWUP OF MANAGING PATIENTS WITH KNOWN
CORONARY ARTERY DISEASE USING A LECTIN-LIMITED, HIGH DOSE
OLIVE OIL AND POLYPHENOL RICH DIET
1105
PLASMA PLANT STEROLS AND PLANT STEROL INTAKE VARY ACROSS
PLANT-BASED DIETARY PATTERNS AMONG ADULTS FROM NORTH AMERICA 1106
LOW-FAT DIETARY TREATMENT ENRICHED WITH SOY PROTEIN
IN CHILDREN AFFECTED WITH HETEROZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA: RESULTS FROM A RANDOMIZEDCONTROLLED PILOT STUDY
1107
ANGIOGRAPHIC AND ANTIOXIDANT CHANGES AFTER SUPPLEMENTATION
WITH HERACLEUM PERSICUM EXTRACT: RESULTS OF A RANDOMIZED
CONTROLLED TRIAL
1108
A. Sahebkar, Y. Panahi, H. Taghipour (Iran)
279
DO DIET AND EXERCISE INFLUENCE IN AN ATHLETIC POPULATION?: NEW
CLUES OF THE ENTERO-INSULAR AXIS
1109
C. Rodriguez-Leal, V. Aragon, I. Tinoco-Racero, E. Segura, B. Ruiz-estevez,
E. Sanchez-Orellana, C. Perez, M. Monsalvo Hernando, N. Caro, A. Perez,
I. Garcia-Campanario, A. Mangas, R. Toro (Spain)
1100
280
P.J. Joris, J. Plat, S.J.L. Bakker, R.P. Mensink (Netherlands)
HAZELNUT-ENRICHED DIET IMPROVES LIPID PROFILE, FATTY ACID
COMPOSITION OF ERYTHROCYTES MEMBRANE AND MARKERS OF
OXIDATIVE STRESS IN CHILDREN WITH PRIMARY DYSLIPIDEMIA: A
RANDOMIZED CONTROL TRIAL
O. Helk, K. Widhalm (Austria)
278
C. Rodriguez-Leal, B. Ruiz-Estevez, E. Segura, I. Tinoco-Racero, N. Caro,
C. Perez, I. Garcia-Campanario, A. Perez, M. Quezada-Feijoo, A. Mangas,
R. Toro (Spain)
270
1104
D. Luetjohann, K. Jaceldo-Siegl, R. Sirirat, E. Haddad (Germany)
277
R. Volpe, A. Bianco, F. Pacioni, E. Schiavetto (Italy)
268
PLASMA FAT-SOLUBLE VITAMIN AND CAROTENOID CONCENTRATIONS
AFTER PLANT STEROL AND PLANT STANOL ESTER CONSUMPTION –
A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
V. Deon, C. Del Bo', A. Bosusco, S. Vendrame, M. Porrini, P. Simonetti,
O. Guardamagna, P. Riso (Italy)
1096
S. Baumgartner, R.P. Mensink, G. Haenen, A. Bast, C. Binder, O. Bekers,
C. Husche, D. Lütjohann, J. Plat (Netherlands)
267
1103
S. Baumgartner, R. Ras, E. Trautwein, R.P. Mensink, J. Plat (Netherlands)
B. Ilincic, E. Stokic, M. Djeric, N. Eremic, D. Popovic, Z. Stosic (Serbia)
266
PLANT STANOL SUPPLEMENTATION LOWERS CETP-MASS, BUT NOT
CETP-ACTIVITY, IN HEALTHY SUBJECTS
C. Talbot, J. Plat, A. Ritsch, R. Mensink (Netherlands)
N.S. Joo, B. Choi, S.I. Jung (Republic of Korea)
265
1102
G. Chiva-Blanch, V. Bratseth, K. Laake, P. Myhre, H. Arnesen, S. Solheim,
E. Berg-Schmidt, L. Badimon, I. Seljeflot (Spain)
B. Hennig, M. Petriello (USA)
264
SERUM CONTENT OF OLEIC ACID IS ASSOCIATED WITH HIGHER
PLATELET-, ENDOTHELIAL- AND LEUKOCYTE-DERIVED CIRCULATING
MICROPARTICLES IN NORWEGIAN NORMOLIPIDEMIC ELDERLY PATIENTS
AFTER AN ACUTE MYOCARDIAL INFARCTION
EVALUATION OF ACTUAL CONSUMPTION OF PULSE REDUCING DRUGS IN
PATIENTS AFTER ACUTE CORONARY SYNDROME
1110
T. Chudinovskikh, E. Tarlovskaya (Russia)
1101
S. Gundry, J. Epstein (USA)
166
167
Board #
281
EFFECTS OF RAMADAN FASTING ON CLINICAL AND BIOCHEMICAL
PARAMETERS FOR TYPE 2 DIABETICS
Board #
291
1111
K. Bouzid, Y. Molahedh, W. Hmaidi, N. Mchirgui, A. Bartkiz, E. Talbi,
N. Ben Abdallah, A. Bahlous, J. Abdelmoula (Tunisia)
282
COMPARISON OF EFFECTS OF DIABETIC ENTERAL NUTRITION AND
STANDARD ENTERAL NUTRITION ON POSTPRANDIAL LEVEL OF GLYCEMIA,
FREE FATTY ACIDS AND GLUCAGON-LIKE PEPTIDE-1.
REGULATION OF HYPOTHALAMIC GENE EXPRESSION BY DNA
METHYLATION IS INFLUENCED BY PARENTAL DIET DURING PREGNANCY
AND LINKED TO OFFSPRING'S RISK OF OBESITY
292
INORGANIC NITRATE DOES NOT AFFECT GLUCOSE AND INSULIN
REGULATION BUT LOWERS OXIDATIVE STRESS IN OBESE ADULTS DURING
ACUTE HYPERGLYCAEMIA
1112
293
1113
EFFECT OF DIFFERENT ORAL GLUCOSE LOADS ON THE ANTIOXIDANT,
INFLAMMATORY AND PLATELET RESPONSE OF HEALTHY VOLUNTEERS
294
1114
INCREASED BILE ACID AND CHOLESTEROL SYNTHESES AND PCSK9
IN MORBID OBESITY ARE RAPIDLY NORMALIZED FOLLOWING ACUTE
CALORIC RESTRICTION
295
1115
SUPPRESSION OF DNA DAMAGE BY DIETARY SUPPLEMENT WHICH
CONTAINS PLANT EXTRACTS: A RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED TRIAL
296
1116
IMPACT OF OIL AND PROTEINS DERIVED FROM ANTARCTIC KRILL ON
ATHEROSCLEROSIS DEVELOPMENT IN APOEKO MICE
THE IMPACT OF DIETARY SUPPLEMENTATION OF VERNONIA CALVOANA
LEAVES ON SERUM LIPID PROFILE AND HAEMATOLOGICAL INDICES IN
ALBINO WISTAR RATS
1124
FERULIC ACID FROM RICE BRAN ENZYMATIC EXTRACT IS RESPONSIBLE
FOR ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITIES
1125
POTENTIAL PROTECTIVE EFFECTS OF DUNALIELLA SALINA ON DEHPINDUCED MMP-2 AND MMP-9 EXPRESSION VIA MAPK, ERK1/2, AKT, AND
NF-κB PATHWAYS IN VASCULAR SMOOTH MUSCLE CELLS
1126
M.F. Shih, J.Y. Cherng (Taiwan)
297
298
1118
RiBOSE-CYSTEINE INCREASES GLUTATHIONE-BASED ANTIOXIDANT
STATUS AND REDUCES ATHEROSCLEROSIS IN apoE-DEFICIENT MICE
1127
S. McCormick, T. Kader, C. Porteous, G. Jones, N. Dickerhof (New Zealand)
1117
L. Gavriil, C. Argyrou, I. Malagaris, E. Fragopoulou (Greece)
288
1123
C. Perez Ternero, B. Bermudez Pulgarin, A. Macia, M.J. Motilva,
M.D. Herrera, M. Alvarez de Sotomayor (Spain)
S. Straniero, F. Rosqvist, D. Edholm, M. Sundbom, U. Risérus, M. Rudling
(Sweden)
287
LIQUID FRUCTOSE SUPPLEMENTATION IN WESTERN DIET-FED C57BL/6N
MICE CAUSES LIVER CHOLESTEROL LOADING WITHOUT CHANGING
CALORIE INTAKE AND BODY WEIGHT
G. Egbung, I. Atangwho (Nigeria)
A. Mikellidi, D. Papadopoulou - Pozatzidou, E. Bachti, C. Xenaki,
S. Antonopoulou, C. Demopoulos, T. Nomikos (Greece)
286
1122
M. Baena, G. Sangüesa, M. González, M. Alegret, N. Roglans, J.C. Laguna
(Spain)
A. Ashor (United Kingdom)
285
LOW-SALT DIET INDUCES ATHEROSCLEROSIS INDEPENDENT OF
LOWERING BLOOD PRESSURE IN HYPERTENSIVE MICE
S. Catanozi, F. Fusco, D. Gomes, K. Bispo, V. Toledo, D. Barbeiro,
V. Capelozzi, L. Furukawa, A.P. Velosa, W. Teodoro, J. Heimann, E. Quintao,
M. Passarelli, E. Nakandakare (Brazil)
I. Khurana, A. Kaspi, M. Ziemann, T. Block, T. Connor, B. Spolding, A. Cooper,
P. Zimmet, A. El-Osta, K. Walder (Australia)
284
1121
J. Dienova, K. Frimmel, L. Okruhlicova (Slovakia)
J. Visek, A. Ticha, L. Sobotka, V. Blaha (Czech Republic)
283
ENDOTOXIN AND OMEGA-3 FATTY ACIDS EFFECTS ON ENDOTHELIAL
OCCLUDIN EXPRESSION IN RAT HEART
ANTIPLATELET EFFECT OF THE MAIN TRITERPENOIDS OF AN OLIVE LEAF
EXTRACT1128
M. Tsoumani, V. Kontogianni, T. Kellici, T. Mavromoustakos, I. Gerothanassis,
A. Tzakos, A. Tselepis (Greece)
C. Parolini, F. Dellera, G.S. Ganzetti, S. Manzini, M. Busnelli, M.S. Ramsvik,
B. Bjorndal, I. Bruheim, R.K. Berge, G. Chiesa (Italy)
289
INVESTIGATION OF CHIOS MASTIC GUM EFFECT ON METABOLIC PROFILE
IN STREPTOZOTOCIN-INDUCED DIABETIC MICE
1119
A. Tzani, I. Georgiadis, L.M. Korou, P. Konstantopoulos, G. Agrogiannis,
I. Vlachos, I. Doulamis, N. Katsilambros, D. Perrea (Greece)
290
ANTI-HYPERLIPIDEMIC POTENTIAL OF EMBLICA OFFICINALIS IN HIGH FAT
FED RATS: UP-REGULATION OF PPARS
1120
B. Variya, S. Patel, A. Bakrania (India)
168
169
Board #
Board #
Genetics, Nutrition, Biomarkers: Biomarkers
309
299
URINARY LIVER-TYPE FATTY ACID-BINDING PROTEIN IS ASSOCIATED
WITH AORTIC STIFFNESS IN MALE CORONARY ARTERY DISEASE PATIENTS
300
IMPACT OF ALKALINE PHOSPHATASE ON IN-HOSPITAL MORTALITY AND
1-YEAR CLINICAL OUTCOME IN PATIENTS WITH ST-SEGMENT ELEVATION
MYOCARDIAL INFARCTION UNDERWENT PRIMARY PERCUTANEOUS
CORONARY INTERVENTION
310
THE GENERATION OF MALONDIALDEHYDE-POSITIVE MICROVESICLES
311
1130
LEUKOARAIOSIS IS UNRELATED TO CAROTID STENOSIS OR RISK FACTORS
FOR ATHEROSCLEROSIS
1131
312
VARIABILITY AND TEMPORAL TREND OF VICORDER-ESTIMATED PULSE
WAVE VELOCITY
313
314
EVALUATION OF OXIDATIVE STRESS INDEX AND ITS CORRELATION WITH
TRADITIONAL CARDIOVASCULAR RISK FACTORS, INFLAMMATION AND
CAROTID INTIMA MEDIA THICKNESS IN DIABETES AND HEALTHY SUBJECTS 1134
PLASMA ARGININE/ADMA RATIO IS A SENSITIVE RISK MARKER FOR
ATHEROSCLEROSIS: SHIMANE CoHRE STUDY
306
316
THE ALANINE AMINOTRANSFERASE/ ASPARTATE AMINOTRANSFERASE
RATIO PREDICTS FUTURE CARDIOVASCULAR EVENTS IN PATIENTS WITH
ESTABLISHED CORONARY ARTERY DISEASE AND HOMA INSULIN RESISTANCE1136
307
IMPACT OF AGE ON THE CARDIOVASCULAR EVENT RISK CONFERRED BY
HbA1c IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE
ProBNP STRONGLY PREDICTS FUTURE MACROVASCULAR EVENTS IN
ANGIOGRAPHIED CORONARY PATIENTS WITH AS WELL AS IN THOSE
WITHOUT TYPE 2 DIABETES
317
1137
1143
STATUS OF NOVEL CARDIOVASCULAR RISK FACTOR AND
CARDIOVASCULAR DISEASE RISK IN AN URBAN DELHI POPULATION-A
PILOT STUDY
1144
THE ATHEROGENIC PROFILE – PREDOMINANT LIPOPROTEIN PROFILE IN
CARDIOVASCULAR DISEASE
1145
IMPACT OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN
AND NEUTROPHIL COUNTS IN THE LUDWIGSHAFEN RISK AND
CARDIOVASCULART HEALTH STUDY
1146
INCREASED LEVELS OF YKL-40 ARE ASSOCIATED WITH ALL-CAUSE
MORTALITY IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE
1147
C.T. Herz, M.L. Tscharre, C. Höbaus, G. Pesau, F. Obendorf,
R. Koppensteiner, G.H. Schernthaner (Austria)
318
1138
BRANCHED-CHAIN AMINO ACID PROFILES INDICATE CARDIO METABOLIC
RISK INDEPENDENT OF BODY MASS INDEX
R. Woitas, H. Scharnagl, M.E. Kleber, G.E. Delgado, T.B. Grammer, M. Pichler,
B.K. Krämer, W. März, T. Stojakovic (Austria)
A. Vonbank, C. Saely, D. Zanolin, P. Rein, A. Leiherer, H. Drexel (Austria)
308
1142
S. Prof. Dr. Oravec, K. Dr. Gruber, A. Prof. Dr. Dukat, P. Ass. Prof. Gavornik,
L. Ass. Prof. Gaspar, E. Dr. Dostal (Slovakia)
1135
S. Yano, Y. Notsu, A. Nagai, T. Nabika (Japan)
NITRIC OXIDE-RELATED CARDIOVASCULAR RISK FACTORS IN PATIENTS
WITH MAJOR DEPRESSION
V. Sharma, R. Shahrawat (India)
315
R. Dalan, H. Liew, L.L. Goh, X. Gao, D.E. Chew, B.O. Boehm, M.K.S. Leow
(Singapore)
305
1141
S. Zelzer, A. Meinitzer, D. Enko, G. Almer, R. Prassl, H. Mangge (Austria)
1133
A.K. Mistri, P. Connell, T. Robinson (United Kingdom)
304
THE INVERSE ASSOCIATION BETWEEN PLASMA ENDOGLIN LEVELS AND
THE SEVERITY OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH
STABLE CAD
A. Meinitzer, S. Zelzer, H. Mangge, G. Almer, R. Prassl, O. AmouzadehGhadikolai, C. Robier, A. Baranyi (Austria)
1132
303
1140
E. Saita, K. Miura, N. Suzuki, K. Miyata, N. Ikemura, R. Ohmori, Y. Ikegami,
Y. Kishimoto, K. Kondo, Y. Momiyama (Japan)
F. Puhm, T. Afonyushkin, C. Binder (Austria)
302
SIMPLE MORTALITY PROGNOSTIC RISK CALCULATOR FOR PATIENTS WITH
ACUTE CORONARY SYNDROME
N. Zagidullin, E. Travnikova, B. Zagidullin, R. Zulkarneev, S. Zagidullin (Russia)
P.C. Oh, K. Woong Chol, M. Jeonggeun, S. Jon, P. Hyun Woo, J. Ho-Jun,
K. Tae-Hoon, P. Sang-Don, K. Sung Woo, S. Soon Yong, L. Kyounghoon,
H. Seung Hwan, A. Taehoon, S. Eak Kyun (Republic of Korea)
301
1139
F. Byazrova, V. Lopukhova, V. Buza, K. Zykov, Y. Karpov (Russia)
1129
K. Paapstel, M. Zilmer, J. Eha, K. Tootsi, A. Piir, J. Kals (Estonia)
THE LEVEL OF EOSINOPHIL CATIONIC PROTEIN IS CORRELATE WITH
SEVERITY OF CORONARY ATEROSCLEROSIS
RELATIONSHIP OF INFLAMMATORY BIOMARKERS, PTX3 WITH SEVERITY OF
1148
K. Igari (Japan)
P. Rein, C. Saely, A. Vonbank, D. Zanolin, A. Leiherer, H. Drexel (Austria)
170
171
Board #
319
GALECTIN 3 AND THE REMODELING OF ARTERIAL WALL IN PATIENTS
Board #
329
1149
V. Ionin, D. Brovin, E. Bazhenova, T. Karonova, E. Polyakova, O. Belyaeva,
E. Baranova, E. Shlyachto (Russia)
320
RELATION OF PLASMA COPEPTIN LEVELS AND WAIST CIRCUMFERENCE
IN NON-DİABETIC ACUTE ST-SEGMENT ELEVATION MYOCARDİAL
INFARCTION PATIENTS
321
1150
322
AORTIC VALVE STENOSIS IN ASSOCIATION WITH INFLAMMATORY
PROCESS AND BIOCHEMICAL MARKERS.
331
ASSOCIATIONS OF LIPOCALIN 2 WITH MARKERS OF INFLAMMATION AND
OXIDANT STATUS IN OBESE NON-DIABETIC PATIENTS
332
FIRST TRIMESTER SERUM CONCENTRATIONS OF AFAMIN ARE
ASSOCIATED WITH THE DEVELOPMENT OF PREECLAMPSIA AND
GESTATIONAL DIABETES MELLITUS IN PREGNANT WOMEN
1152
333
1153
IS RED BLOOD CELL GLUTATHIONE A BETTER MARKER FOR CORONARY
ARTERY DISEASE THAN PLASMA GLUTATHIONE?
1154
CHANGES BRAIN NATRIURETIC PEPTIDE (BNP) LEVELS IMPROVE
RISK PREDICTION OF SHORT-TERM MORTALITY FOLLOWING ACUTE
MYOCARDIAL INFARCTION COMPARED TO GRACE SCORE: A BRASILIA
HEART STUDY SUBANALYSIS
1155
334
335
1156
GENETIC DETERMINANTS CONTROLLING LIPID DEPOSITS IN DIFFERENT
WILD TYPE STRAINS OF ZEBRAFISH (DANIO RERIO)1157
CELL-DERIVED MICROPARTICLES AS MARKERS OF ENDOTHELIAL
FUNCTION, INFLAMMATION AND COAGULATION IN PATIENTS WITH SLEEP
APNEA-HYPOPNEA SYNDROME: A SYSTEMATIC REVIEW
BLOOD PRESSURE FLUCTUATIONS AS A LEADING LINK IN THE
DEVELOPMENT OF COMPLICATIONS OF ATHEROSCLEROSIS
1163
ACC/AHA GUIDELINES SUPERIOR TO ESC/EAS GUIDELINES FOR PRIMARY
PREVENTION WITH STATINS: THE COPENHAGEN GENERAL POPULATION
STUDY1164
PREDICTING THE IMPACT OF THE ORIGINAL AND GENERIC
ROSUVASTATIN ON DIRECT MEDICAL COSTS FOR SECONDARY
PREVENTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
1165
A. Merezhanova, E. Tarlovskaya, B. Nechaeva, A. Semenkin, S. Malchikova
(Russia)
336
K. Vishnolia, K. Tarhbalouti, P. Ciba, C. Kruse, Z. Aherrahrou, J. Erdmann
(Germany)
328
1162
M.B. Mortensen, B.G. Nordestgaard, S. Afzal, E. Falk (Denmark)
L.S. Carvalho, L.A. Bogniotti, O.L. Almeida, J.C. Quinaglia e Silva, L. Trindade,
G. Oliveira, A. Sposito (Brazil)
327
BIOMARKER DISCOVERY BY PLASMA PROTEOMICS IN FAMILIAL LMNA
DILATED CARDIOMYOPATHY
Genetics, Nutrition, Biomarkers: Guidelines and
Miscellaneous
A. Lima, R. Ferin, E. Santos, A. Fontes, S. Ferreira, C. Almeida, D. Martins,
J. Baptista, M.L. Pavão (Portugal)
326
1161
A. Kebryakov, P. Bondarenko, M. Ermina, M. Ivanov, N. Koplyarova,
A. Yadernaya, A. Mishchenko (Russia)
A. Tramontana, B. Dieplinger, G. Stangl, E. Hafner, H. Dieplinger (Austria)
325
CAROTID ATHEROSCLEROSIS IN A VERY ELDERLY POPULATION: ROLE OF
AGEING AND OTHER CARDIOVASCULAR RISK FACTORS
I. Izquierdo, D. De Gonzalo-Calvo, V. Llorente-Cortes, I. Rosa, R. Brugada,
C. Oscar, A. Perez-Serra, J. Broncano, A. Luna, J. Vazquez-Alfageme,
J.R. Gonzalez-Juanatey, A. Mangas, A. Garcia, R. Toro (Spain)
P. Fülöp, H. Lőrincz, S. Somodi, M. Harangi, I. Seres, G. Paragh (Hungary)
324
1160
F. Spannella, F. Giulietti, G. Cocci, P. Giordano, M. Ricci, E. Espinosa,
R. Sarzani (Italy)
J. Lūriņš, A. Visocka, V. Mackēvičs, P. Tretjakovs (Latvia)
323
THE NUMBER OF REQUESTS FOR HIGH SENSITIVE TROPONIN I
MEASUREMENT AND THE NUMBER OF PATIENTS DIAGNOSED WITH
ACUTE MYOCARDIAL INFARCTION
L. Majnaric, M. Mikic, S. Bekic, S. Guljas (Croatia)
CORRELATION OF PIGMENT EPITHELIUM-DERIVED FACTOR WITH
OXIDATIVE AND INFLAMMATORY MARKERS IN OBESE, NON-DIABETIC
PATIENTS1151
I. Juhász, I. Seres, A. Szentpéteri, E.V. Varga, S. Somodi, P. Fülöp, H. Lőrincz,
G. Paragh (Hungary)
1159
J. Bogdanska, D. Labudovic, S. Alabakovska, S. Cekovska, K. Tosheska
Trajkovska, S. Jovanova (FYR Macedonia)
330
K. Cosansu, A. Turer Cabbar, H.A. Cakmak (Turkey)
ANTIOXIDANT ENZYMES IN PATIENTS WITH ATHEROSCLEROSIS
APPLICATION OF A MULTILEVEL HIERARCHICAL MODEL TO CORRELATE
TOTAL CHOLESTEROL IN EIGHT DIFFERENT SETTINGS
1166
337
1158
PROPOSAL OF A NEW APPROACH TO ACCESS CHOLESTEROL RANGES
ACCORDING TO DIFFERENT CONDITIONS
1167
A.J. Vallejo-Vaz, R. Muñoz-Hernández, J. Villar, P. Stiefel (United Kingdom)
172
173
Board #
338
PREDICTING FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS’ QUALITY
OF LIFE AND SELF-ASSESSED HEALTH: ILLNESS BELIEFS, BELIEFS ABOUT
MEDICATION, AND HEALTH LITERACY
Abstract not Registered
1168
400
M. Hagger, J. Pang, G.F. Watts (Australia)
339
METABOLIC DISTURBANCES AND RISK OF CANCER IN THE 25 YEARS
FOLLOW-UP OF THE "VENTIMIGLIA HEART STUDY" EPIDEMIOLOGICAL
PROJECT.1169
ESTRADIOL TREATMENTS CHANGE THE LIPID PROFILE IN NATURALLY
MENOPAUSAL RATS FROM DIFFERENT AGE GROUPS: A THERAPEUTIC
POTENTIAL DRUG FOR ATHEROSCLEROSIS
401
HYPONATREMIA : A RISK FACTOR OF OVERT HEPATIC ENCEPHALOPATHY
402
1170
EFFECTS OF OSTEOPATHIC MANIPULATIVE TREATMENT ON VASCULAR
AND AUTONOMIC FUNCTIONS IN HEART PATIENTS: A RANDOMIZED,
CLINICAL TRIAL
1171
F. Amatuzzi, A. Guervazoni, V. Marães, K. Bousquet, F. Stauffer, M.A. Catai,
G. Chiappa, S. Thomaz, C. Nakata, R. Jácomo, M. Lucena, G. Cipriano
Jr. (Brazil)
S. Khedher, A. Maoui, K. Bouzid, S. Lahiani, A. Bartkiz, M. Salem,
342
403
HYPONATREMIA, A PREDICTING FACTOR OF MORTALITY IN CIRRHOTIC
PATIENT1172
K. Bouzid, S. Khedher, A. Maoui, S. Lahiani, A. Bartkiz, M. Salem,
343
ANDROGEN-DEPRIVATION THERAPY-INDUCED ATHEROSCLEROSIS
IN PROSTATE CANCER: DIFFERENCES BETWEEN GNRH-AGONIST AND
ANTAGONIST1173
RELIABILITY ASSESSMENT OF DETERMINATION OF PROCALCITONIN IN
PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS : ABOUT TWO CASES
A. Bartkiz, K. Bouzid, S. Ghezaiel, S. Lahiani, S. Hammami, E. Talbi,
A. Zannouri, M. Omrane, S. Barbouche, J. Abdelmoula (Tunisia)
1176
APPLANATION TONOMETRY PROPOSE DIFFERENT PHYSIOLOGIC
MECHANISMS IN CHAGASIC VERSUS ISCHEMIC HEART FAILURE
1177
1178
A. Lima, J. Vilela-Martin, L. Giollo, A.P. Silva, M.E. Otto, S. Marianne,
V. Maldaner, G. Chiappa, G. Cipriano, F. Amatuzzi, G. Cipriano Jr (Brazil)
404
W. Duivenvoorden, S. Hopmans, G. Werstuck, J. Pinthus (Canada)
344
RELATIONSHIP BETWEEN CAROTID INTIMA-MEDIA THICKNESS AND THE
WEIGHT GAIN
T. Alexescu, I. Cheta, M. Handru, V. Negrean, L. Ciumarnean, I. Para
(Romania)
P. Kumar, N. Baquer (India)
341
1175
Z. Aktop, E. Coskun (Turkey)
D. Noto, A.B. Cefalù, C.M. Barbagallo, A. Giammanco, F. Fayer, O. Palesano,
G.I. Altieri, R. Spina, V. Valenti, M. Pagano, G. Cavera, M.R. Averna (Italy)
340
WHAT WOULD YOU DO IF YOU WERE WITH AN EMBRYO-LIKE GIANT
THROMBUS IN THE LEFT VENTRICLE: CASE REPORT
PREVALENCE OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
AND IMPACT ON ACHIEVEMENT OF LIPID TARGETS DURING CARDIAC
PREVENTION AND REHABILITATION PROGRAMMES IN ITALY: THE
HEREDITY REGISTRY
1179
M. Ambrosetti, P. Faggiano, P.L. Temporelli, R. Griffo, R. Pedretti (Italy)
405
PEDIATRIC IMT ASSESSMENT
1180
E. Barabesi, O. Guardamagna, F. Abello (Italy)
1174
406
RISK FACTORS FOR DEVELOPING DRUG-RELATED PROBLEMS IN PATIENTS
WITH CARDIOVASCULAR DISEASES ATTENDING GONDAR UNIVERSITY
HOSPITAL, ETHIOPIA
1181
A. Bhagavathula, O. Abubeker, A. Elnour, A. Shehab (Ethiopia)
407
CLINICAL UTILITY OF DABIGATRAN IN UNITED ARAB EMIRATES. A
PHARMACOVIGILANCE STUDY
1182
A. Shehab, A. Elnour, A. Bhagavathula, S. Al Nuaimi (United Arab Emirates)
408
A MUFA RICH-DIET MAY REDUCE LIVER FAT CONTENT IN TYPE 2 DIABETES
PATIENTS THROUGH AN ENHANCED POSTPRANDIAL FAT OXIDATION
1183
L. Bozzetto, G. Costabile, G. Annuzzi, D. Luongo, D. Naviglio, V. Cicala,
M. Giorgini, C. Piantadosi, E. Griffo, P. Cipriano, A. Giacco, A. Rivellese (Italy)
409
AN ASSOCIATION STUDY OF EARLY-LIFE ARSENIC EXPOSURE ON THE RISK
OF HYPERTENSION, HYPERGLYCEMIA, AND HYPERLIPIDEMIA
1184
H.Y. Chiou, S.Y. Kuo, F.I. Hsieh (Taiwan)
174
175
410
NOVEL EFFECTS OF SARCOPENIC OSTEOARTHRITIS ON METABOLIC
SYNDROME AND INSULIN RESISTANCE: THE NATIONAL SURVEY
421
1185
S.M. Chung, M.H. Hyun, H.S. Seo, D.J. Oh, C.G. Park, S.W. Rha, E.J. Kim,
H.E. Lim, J.W. Kim, C.U. Choi, J.O. Na, S.K. Lee (Republic of Korea)
411
412
THE EXPRESSION OF MIR-125A-3P IN PERIPHERAL BLOOD
MONONUCLEAR CELLS OF PATIENTS WITH CORONARY HEART DISEASE
1186
H.L. Dai, X.L. Yin, J. Xiao, X.F. Guang (China)
CARDIOVASCULAR DISEASE RISK ASSESSMENT: TRIGLYCERIDE/
HIGH-DENSITY LIPOPROTEIN VERSUS METABOLIC SYNDROME
CRITERIARUNNING TITLE: CVD RISK ASSESSMENT: TG/HDL VERSUS METS
ENDOTHELIAL VASCULAR MOTOR FUNCTION IN ARTERIAL HYPERTENSIVE
PATIENTS1187
M. Gharipour, M. Sadeghi, P. Nezafati, N. Sarrafzadegan (Iran)
ROSUVASTATIN COMPARED TO ATORVASTATIN ON LIPID PROFILE AND
APOLIPOPROTEIN LEVELS IN DYSLIPIDEMIC PATIENTS WITH ELEVATED
LIPOPROTEIN (a)
422
423
RESPONSE TO AN ORAL FAT LOAD WITH A NON DAIRY CHEESE CREAM
CONTAINING FERMENTED SOYBEAN EXTRACT SOY COMPARED TO A
DAIRY CHEESE IN HEALTHY SUBJECTS
424
1188
EFFECTS OF A NON DAIRY CHEESE CREAM CONTAINING FERMENTED
SOYBEAN EXTRACT ON LIPID PROFILE AND LIPOPROTEINS IN
DYSLIPIDEMIC PATIENTS
425
1189
EVALUATION OF LIPID-LOWERING THERAPYPREFACINGACUTE
CORONARY SYNDROME AND FATSDEPENDING ON CARDIOVASCULARRISK
GROUP OF PATIENTS WITH ATRIAL FIBRILLATION
1190
426
1191
RENOPREDICT: MULTIPLE BIOMARKER APPROACH TO IMPROVE THE
PREDICTION OF MORTALITY IN DIALYSIS PATIENTS
427
1192
PROGRANULIN MAY BE A BIOMARKER OF PERIPHERAL ATHEROSCLEROTIC
DISEASE1193
E. El Eter, H. Al Zamil, L. Al Dokhi, M. Al Omran (Egypt)
419
MATERNAL ENDOTHELIUM AND RISKS OF DEVELOPING
CARDIOVASCULAR DISORDERS
RELATIONSHIP BETWEEN THE LOCATION OF LESION AND THE
ASSOCIATED ARRHYTHMIAS AND CONDUCTION ABNORMALITIES IN
PATIENTS WITH MYOCARDIAL INFARCTION
428
ABNORMAL METABOLIC CONDITIONS ARE INDEPENDENT RISK FACTORS
FOR INCREASED ARTERIAL STIFFNESS INDEPENDENT OF AGE AND
BLOOD PRESSURE
1201
THE RATIO OF SKELETAL MUSCLE MASS TO VISCERAL FAT AREA IS A MAIN
DETERMINANT LINKING CIRCULATING IRISIN TO METABOLIC PHENOTYPE 1202
1194
1203
RESPIRATORY FUNCTION OF LUNGS AT ISCHEMIC HEART DISEASE
PATIENTS CONCOMITANT WITH TYPE 2 DIABETES MELLITUS
1204
S. Murtazaev, A. Mansurov, N. Sharapov, K. Khalikulov (Uzbekistan)
430
1195
PLATELET RELEASE REACTIONS ARE MODIFIED IN VITAMIN D DEFICIENCY
L. Kasatkina, I. Trikash (Ukraine)
429
A. Fatima (Pakistan)
420
CLINICAL OUTCOMES OF MULTI-VESSEL CORONARY ARTERY SPASM ARE
COMPARABLE TO SINGLE VESSEL SPASM ON RECOMMENDED OPTIMAL
MEDICAL TREATMENTS: KOREA VASOSPASTIC ANGINA REGISTRY DATA
ANALYSIS1200
Y.C. Hwang, P. Cheol-Young, Y. Byung-Soo (Republic of Korea)
C. Drechsler, W. März, V. Krane, B. Kollerits, F. Kronenberg, C. Wanner (Germany)
418
1199
S.H. Han, H. Hyo Sang, O. Pyung Chun, K. Kwang Kwon (Republic of Korea)
Y. Dorofeeva, E. Tarlovskaya, S. Malcnikova (Russia)
417
THE MOST COMMON CARDIOVASCULAR RISK FACTORS IN
ADOLESCENTS SIGNIFICANT FOR DEVELOPMENT OF CARDIOVASCULAR
DISEASES IN ADULTHOOD
S.H. Han, O. Pyoung Chun, S. Dong Il, H. Sung Ho, A. Youngkeun, P. Keun
Ho, K. Dong Soo, Y. Tae Hyun, C. Dong Ju, S. Jung Won, K. Hyuck Moon,
L. Byoung Kwon, G. Hyeon Gheol, R. Seung Woon, J. Sang Ho, B. Sang
Hong (Republic of Korea)
G. Derosa, D. Romano, A. D'Angelo, P. Maffioli (Italy)
416
1198
G. Grujic Ilic (Serbia)
415
CARDIOVASCULAR RISK IN CHILDREN: THE CLINICAL RELEVANCE OF
EARLY AND TIMELY STRATIFICATION AND TREATMENT
1197
I. Gomes, B. Cardoso, P. Loureiro, M. Bourbon, F. Pinto (Portugal)
414
1196
B. Gaye, P. Boutouyrie, G. Parati, M.C. Perier, F. Thomas, C. Guibout,
B. Pannier, X. Jouent, J.P. Empana (France)
N. Demikhova, O. Chernatskaya, Y. Smiianova, O. Smiianova,
L. Vynnychenko (Ukraine)
413
ASSOCIATION OF IDEAL CARDIOVASCULAR HEALTH WITH SUBCLINICAL
VASCULAR STRUCTURE FUNCTION AND ELASTICITY IN THE COMMUNITY.
THE PARIS PROSPECTIVE STUDY 3
FREQUENCY OF STATIN DOWNTITRATION DURING OPEN LABEL
EVOLOCUMAB TREATMENT IN THE OSLER-2 STUDIES
1205
M. Koren, Y. Ma, R. Somaratne, M. Bolognese (USA)
U. Ganiev, S. Khaitov, M. Kenjaev (Uzbekistan)
176
177
431
HIGH LYMPHOCYTES AND LOW MEAN CORPUSCULAR VOLUME ARE
ASSOCIATED WITH DIABETES, TRIGLYCERIDE-TO-HIGH-DENSITYLIPOPROTEIN RATIO AND METABOLIC SYNDROME, IN PATIENTS AT HIGH
RISK OF CORONARY ARTERY DISEASE
442
432
NUMBER OF BLOOD PRESSURE MEASUREMENTS NEEDED TO ESTIMATE
LONG TERM VISIT-TO-VISIT SYSTOLIC BLOOD PRESSURE VARIABILITY FOR
PREDICTING 10-YEAR CARDIOVASCULAR RISK
443
433
444
PLASMA TRIMETHYLLYSINE, TRIMETHYLAMINE-N-OXIDE, CARNITINE AND
INCIDENT MYOCARDIAL INFARCTION IN PATIENTS WITH STABLE ANGINA
PECTORIS1208
K.H. Løland, H. Olset, G.F.T. Svingen, H. Schartum-Hansen, E.K. Pedersen,
E. Strand, P.M. Ueland, A. Svardal, Ø. Bleie, J.E. Nordrehaug, O. Nygård (Norway)
434
435
445
IMPACT OF INSULIN RESISTANCE ON CARDIAC AND VASCULAR FUNCTION 1209
G. Manno, S. Novo, R. Russo, D. Buccheri, S. Dell'Oglio, P. Morreale,
G. Vitale, G. Novo (Italy)
Y.R. Sigurðardóttir, B.R. Stefánsdóttir, T. Aspelund, G. Þorgeirsson,
V. Guðnason, L.B. Kristinsdóttir, K. Andersen (Iceland)
446
1210
NIGELLA SATIVA AND THYMOQUINONE REDUCE GENE AND PROTEIN
EXPRESSION OF INTERLEUKIN-6 VIA NUCLEAR FACTOR KAPPA B PATHWAY
438
447
1211
OXIDATIVE-ANTIOXIDATIVE CHANGES OF LDL, CORONARY HEART
DISEASE, SOME ATHEROSCLEROSIS RISK FACTORS AND 7-YEAR
UNFAVORABLE LONG-TERM RESULTS IN MEN POPULATION OF NOVOSIBIRSK1212
N. Soltani, M. Fazali, F. Kharazmi, M. Kamran (Iran)
ALCOHOL AND PREMATURE CARDIOVASCULAR MORTALITY IN BELARUS
LEG MINUS ARM PULSE WAVE VELOCITY MEASURED WITH A NEW DEVICE
CORRELATES WITH CAROTID FEMORAL PULSE WAVE VELOCITY
LEG MINUS ARM PULSE WAVE VELOCITY MEASURED WITH A NEW DEVICE
CORRELATES WITH CORONARY CALCIUM SCORE
1220
1221
448
1213
449
1214
THE LEADING RISK FACTORS FOR DEVELOPMENT OF MYOCARDIAL
INFARCTION IN ELDERLY PATIENTS
1223
1224
I. Sukmanova, I. Zheltova (Russia)
450
GENDER-SPECIFIC RISK FACTORS OF MYOCARDIAL INFARCTION
1225
I. Sukmanova, I. Suspitsyna (Russia)
1215
451
1216
1222
K. Sirojiddin, D. Alimov, B. Mukhamedova, M. Kenjaev, R. Rakhimova
(Uzbekistan)
ISCHEMIC HEART DISEASE MORTALITY AND ALCOHOL CONSUMPTION IN
THE FORMER SOVIET REPUBLICS: A COMPARATIVE ANALYSIS OF TRENDS
S. Rico Martin, J.F. Sánchez Muñoz-Torrero, J.F. Calderón García, J.M. De
Nicolás Jiménez (Spain)
441
EFFECTS OF HIGH-DOSE ATORVASTATIN PRETREATMENT ON
MYOCARDIAL STUNNING IN PATIENTS WITH ST-SEGMENT ELEVATION
MYOCARDIAL INFARCTION
EFFECT OF LOX1 RECEPTOR GENE EXPRESSION BY ORAl MgSO4
ADMINISTRATION TO CONTROL ATHEROSCLEROSIS IN STZ-INDUCED
DIABETIC RAT
Y. Razvodovsky (Belarus)
440
ASSESSMENT OF THE RISK OF PERIPHERAL ARTERIAL DISEASE IN PATIENTS
WITH CORONARY ARTERY DISEASE
Y. Ragino, Y. Polonskaja, S. Malyutina, M. Voevoda (Russia)
Y. Razvodovsky (Belarus)
439
1219
K. Sirojiddin, A. Alavi, M. Kenjaev (Uzbekistan)
F. Mohtar, H. Nawawi, T. Rahman, G.R.A. Froemming (Malaysia)
437
CAROTID INTIMAL-MEDIAL THICKNESS ,PREVALENCE OF DOCUMENTED
CORONARY AND CEREBRAL VASCULAR ATHEROSCLEROTIC DISEASES
IN PATIENTS WITH ABDOMINAL AORTIC ANEURISM AND AORTO-ILIAC
OCCLUSIVE DISEASE
ENDOTHELIAL FUNCTION ASSESSED BY PERIPHERAL ARTERIAL
TONOMETRY IS NOT RELATED TO CARDIOVASCULAR RISK SCORE IN
HEALTHY SUBJECTS
ASSOCIATION OF CAROTID ATHEROSCLEROSIS WITH CORONARY ARTERY
DISEASE: A RETROSPECTIVE STUDY OF 589 PATIENTS
1218
N. Sharashidze, I. Botchorishvili, Z. Pagava (Georgia)
D. Migliorino, A. Mignano, S. Evola, G. Novo, E. Corrado, S. Novo (Italy)
436
ASSOCIATION BETWEEN 677C>T POLYMORPHISM WITHIN
METHYLENETETRAHYDROFOLATE REDUCTASE GENE AND POSTSTROKE
HEMIPARESIS IN POLISH PEDIATRIC PATIENTS
B. Sarecka-Hujar, I. Kopyta, I. Zak, E. Emich-Widera (Poland)
1207
H.M. Lim, Y.C. Chia, S.M. Ching (Malaysia)
1217
T. Ristic, V. Djordjevic, V. Cosic (Serbia)
1206
B. LI, I. Trakarnwijitr, H. Adams, J. Layland, J. Garlick, A. Wilson (Australia)
THE ROLE OF TRACKING OF BCL-2 AND CASPASE-3 ACTIVITY IN PLAQUE
EVOLUTION IN ISCHEMIC HEART DISEASE PATIENTS
THE ROLE OF PSYCHOSOMATIC FACTORS AND HYPODYNAMIA IN THE
DEVELOPMENT OF MYOCARDIAL INFARCTION IN MIDDLE AND ELDERLY
WOMEN1226
I. Suspitsyna, I. Sukmanova (Russia)
J.F. Sanchez Munoz-torrero, S. Rico Martin, J.M. De Nicolas Jimenez,
J.F. Calderon Garcia (Spain)
178
179
452
EFFECT OF ALPHA-LIPOIC ACID SUPPLEMENTATION ON OXIDATIVE
STRESS MARKERS AND ANTIOXIDATIVE DEFENSE IN PATIENTS WITH
DIABETIC NEUROPATHY
1227
F. Sztanek, I. Seres, H. Lőrincz, A. Molnár, G. Paragh (Hungary)
453
COMPARISON OF EFFECTIVENESS OF DIFFERENT ANTIPLATELET DOSES
OF ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROME
1228
T.S. Tan Kurklu (Turkey)
454
PREVALENCE OF FAMILIAL HYPERCHOLESTEROLAEMIA IN PATIENTS WITH
ISCHEMIC STROKE OR HIGH-RISK TIA
84 EAS CONGRESS
th
May 29 - June 1, 2016
Innsbruck, Austria
1229
T. Toell, L. Mayer, K. Willeit, M. Knoflach, S. Kiechl, J. Willeit (Austria)
455
Integrative Analysis of Gene Expression Network for
Atherosclerosis-related disease and Nutraceuticals
Supplements1230
L. Torres, A. Obregon-Gonzalez, V. Padilla-Mata (Mexico)
456
EVALUATING MONITORED LEVELS OF TOTAL CHOLESTEROL AND
APPLICATION OF LIPID-LOWERING THERAPY IN PATIENTS WITH DIABETES
MELLITUS AND ISCHEMIC HEART DISEASE IN AN ACTUALLY AMBULATORY
PRACTICE1231
F. Valikulova, I. Fomin, A. Vaysberg, E. Gurvich, M. Boldina (Russia)
s
r
o
th
u
A
f
Index o
180
INDEX
A
Aguilar-Salinas, C.
945
Ali, M.Z.
820
Abajo, M.
774
Aherrahrou, Z.
1 157
Alimov, D.
1 222
Abd Alla, J.
1 024
Ahmad, R.
Alkaaby, W.
666
Abdelmoula, J.
858, 859,
867, 909, 1
091, 1 111,
1 171, 1 172,
1 174
485, 486,
487
Allanov, R.
752
Ahmed, O.
89, 1 027
Allaoui, F.
691
Ahmed, S.
529
Allen, R.
268
Aigner, E.
662
Almaghraby, A.
587, 790
Abdijalilova, S.
567, 570, 571
Aikawa, E.
42, 93
Almagro, F.
358, 921, 975
Abdul Rahman, T.
923
Aikawa, M.
42
Almeida, C.
1 155
Abdul Razak, S.
441, 716,
923, 965,
966
Aittokallio, T.
378
Almeida, O.L.
1 156
Ajendra, J.
377
972
Akhvlediani, M.
844
Almendros Afonso,
T.K.
Abdulgamidov, M.
793
Akin, I.
274
Almer, G.
Abe, K.
583
Akita, N.
375
894, 1 142,
1 143
Abedpour
Dehkordi, A.
721
Akiyama, T.
855
almusawi, A.
887, 891, 896
987, 1 058,
1 180
1 038
887, 891, 896
Abello, F.
Akrami, A.
alnafakh, H.
Akramova, D.
608
Alomar, S.Y.
849
Aktan, M.
984
866
Akther, F.
508
Alonso Moreno,
F.J.
Aktop, Z.
1 175
Alonso, R.
945
akturk, F.
826
Alshehry, Z.
314
Akyol, T.
984
Alt, K.
223
Al Dokhi, L.
1 193
Altamura, S.
102
al mohy, Y.
798
Altieri, G.I.
954, 1 169
Al Nuaimi, S.
1 182
Altieri, P.
553
Al Omran, M.
1 193
Altunkeser, B.
984
Al Zamil, H.
1 193
Alvarez de
Sotomayor, M.
381, 1 125
Abeysekera, A.
933
Abifadel, M.
946
Abubeker, O.
1 181
Achenbach, S.
377, 1 069
Achmad, C.
576
Adam, S.
426
Adamcova, K.
889, 892
Adamek, V.
724
Adamkova, V.
724, 939, 1
068
Adamova, I.
687
Al-Banna, R.
568
Alvarez-León, E.
356
Adams, H.
723, 1 206
Alabakovska, S.
678, 1 159
Alvarez-Llamas, G.
129
Adamski, J.
290
Alaeddin, A.
849
Alves, A.C.
Adorni, M.P.
697, 715
Alain, V.D.
283
Adrian, G.
801
Alavi, A.
1 221
943, 945,
955, 985, 1
060
Adyrkhaev, Z.
793, 906, 911
Albareda, M.
1 012
Alves, R.
799
Adzhemian, N.
606
Albasri, A.
Amadio, P.
222
Adzhiev, R.
685
891, 896,
887
Amarchand, R.
767
Alberico L, C.
898
Amatuzzi, F.
1 177, 1 178
Alcantara, K.
522
Ambadapadi, S.
107, 1 028
AldamizEchevarria, G.
129
Ambrosetti, M.
1 179
Amigó, N.
393, 434
Afanasieva, M.
679
Afanasieva, O.
551, 679,
685, 686,
687
Afonyushkin, T.
1 131
Alegret, M.
508, 1 123
Amin, R.
126, 655
Afzal, S.
427, 1 164
Aleksandrova, K.
412
Ammirati, E.
616
Ager, M.
942
Alekseeva, O.
1 042
Ammori, B.J.
426
Aghi, A.
1 029
Alexandra, S.
830
Amores-Arriaga, B.
505
AGOP, M.
575
Alexescu, T.
82
AmouzadehGhadikolai, O.
1 142
Agrawal, D.
913, 992, 1
176
Agrogiannis, G.
1 119
Alexiev, A.
914, 917
An, G.J.
512
Aguiar, P.
360
Alfaro, F.
428
An, K.J.
739
Aguilar Salinas, C.
959
Ali, A.M.
485
Ananthaseshan, S.
800
183
INDEX
184
Anastassopoulou,
J.
813
Anđelković, K.
122
Andersen, K.
450, 491, 1
058
Averna, M.
11, 121, 232,
388, 954
Baptista, J.
1 155
Bayly, G.
969, 1 051
Berbée, J.
90, 556
Baquer, N.
847, 1 170
Bays, H.
389
Berdiqulov, J.
Arnesen, H.
1 102
572, 1 018
Averna, M.R.
1 169
Barabesi, E.
987, 1 180
Bazhenova, E.
Berestetskaya, Y.
687
477
Ayami, S.
63
Baragetti, A.
Berg Schmidt, E.
654
Arnoldi, A.
386
Ayaori, M.
Bchir, N.
867
Berg-Schmidt, E.
1 102
1 043
Arola, J.
915
693, 700, 1
049
238, 616,
898, 1 063
740, 890, 1
149
1 220
Arnhard, K.
Andersen, O.M.
332
Andor, M.
Baragetti, I.
898
Bea-Sanz, A.M.
115
707
Aronov, D.
982, 998
777
995
Andrea, B.
Ayca, B.
Berg, G.
Baral, B.
659
Bea, A.
765
475
Arpad Faludi, A.
972
1 061
1 055
Andrea, T.
Azevedo, O.
Berge, K.E.
Barale, C.
276
Bea, A.M.
971
654
Arrondo, J.L.R.
637
1 061
363, 1 118
Andreasen, A.
Azevedo, P.
Berge, R.K.
Baranova, E.
Beacham, L.
61
Arroyo, D.
774
955, 985
244
654
Azevedo, S.
Bergheanu, S.
Andreasen, J.J.
740, 890, 1
149
Becher, B.
127
446
Arsenault, B.
119, 387
843
Barany, P.
47
307
Andréasson, A.C.
Azinheira, J.
Bergthaler, A.
Becher, T.
274
830
Arsiwala, T.
127
Baranyi, A.
1 142
890
Andreev, V.
B
Berkovich, O.
Beck, W.
641
356, 528
Artemieva, N.
687
861
Barbagallo, C.M.
954, 1 169
563
Angeles-Martínez,
J.
Babadjanov, B.
Berliner, S.
956
850
Babets, A.
577
Barbarash, O.
Angelin, B.
336
Artemova, N.
613
Baccar, H.
Beer, J.H.
127
Arutyunova, M.
860
1 122
494
697
Barbeiro, D.
Bernabeu, C.
Angelino, D.
858, 859,
867, 1 091
520, 573, 1
086
Bermudez
Pulgarin, B.
1 125
Artemova, A.
BednarskaMakaruk, M.
Begum, H.
223
794
Arzt, C.
448
Barbieri, S.
222
565, 1 015
Angelopoulou, S.
463
Bernatova, I.
Behl-Gilhotra, R.
362
855
Asai, A.
886
1 174
81, 106, 547
Ann, T.
Barbouche, S.
Bernelot Moens, S.
Asaji, M.
63
Bardova, K.
889, 892
1 096
947
1 102
Bekers, O.
Ansheles, A.A.
Badimon, L.
Bernelot Moens,
S.J.
627
1 183
1 115
446
Annuzzi, G.
Bachti, E.
Behrendt, M.
Asako, K.
457
Barichello, M.
725
425
617, 618
Bernfur, K.
408
694
Ascaso, J.
975
BaenaFustegueras, J.A.
Bekiari, E.
Ansmidte, O.
Barinova, V.
1 075
Bekic, S.
1 160
Bernhagen, J.
291
Anto Michel, N.
224, 470
Ascaso, J.F.
358, 766, 921
Baena, M.
508, 1 123
Barkas, F.
Bekkering, S.
106, 270, 556
Bernhard, D.
477
Antonini-Canterin,
F.
599
Ascerov, N.
793
Baeten, D.
547
432, 753,
928, 977,
978, 1 003
Belagha, J.
859
Bernini, F.
692, 697
204
Berrougui, H.
110
Antonopoulou, S.
1 115
Antonov, K.
917
Antonucci, A.
725
Antunes, H.
1 061
Antunes, M.
993
Anwar, A.
658
Aoyama, N.
747
Ass. Prof. Gavornik, 1 145
P.
Aprami, T.
576
Asselbergs, F.W.
240
Aquila, G.
1 022
Asset, G.
246
Aquilera, J.
434
Assinger, A.
448
Aragon, V.
1 109
Assmann, G.
66
Aragona, C.O.
496, 506,
588, 675, 1
050
Astanina, K.
492
Astrakov, S.
644, 964
Astrakova, K.
644, 964
Atanasovska, B.
113
Atangwho, I.
1 124
Atkin-Smith, G.
489
Attia, N.
638
Auer, S.
662
Aurelian, S.M.
609, 792
Auwerx, J.
127
Auzky, O.
515, 871
Avdeeva, I.
590
Averkova, A.
785
Arakelyan, A.
1 047
Araz, T.
1 083
Arca, M.
121
Arefieva, T.
551, 679
Ares Jr., M.
269
Argimón, J.
944
Argyrou, C.
1 117
Arisaka, O.
390
Ariza, M.J.
428
Armitage, J.M.
51
Arnaboldi, L.
Baccara-Dinet,
M.T.
Ashavaid, T.
1 062
Baetta, R.
472
Barlow, C.
314, 449
Belevich, I.
Ashford, M.
289
Bagheri, B.
566
Barnes, E.
314
Belhadj Hassen, H.
858
Berta, E.
612
Ashor, A.
1 114
Bahlous, A.
1 111
Barrett, P.H.R.
394, 471
Bell, D.
355
Bertaccini, D.
283
869
Bertagnin, E.
671, 749
Aspelund, T.
1 220
Baila-Rueda, L.
115, 765, 971
Barros, P.
985
Belovol, A.
Ass. Prof. Gaspar,
L.
1 145
Bairaktari, E.
709
Bartelt, A.
48
Beltowski, J.
468
Berteotti, M.
616
Bakker, L.
90
Barter, P.
119
Beltrami-Moreira,
M.
93
Berti, A.
616
Bertinaria, M.
1 017
Belyaeva, O.
1 149
Bertocco, S.
725, 1 029
Ben Abdallah, N.
858, 859,
867, 909,
1 111
Bertolini, S.
121
Bertsch, T.
858, 859,
867, 1 091
368, 438, 1
098
Beshay, M.
797
Benaiges, D.
1 012
Besseling, J.
99, 359, 974
Benczur, B.
414
Betriu, À.
774
Benghozi, R.
714
Bezrodnyi, V.
811
Benítez, S.
876
Bhagavathula, A.
1 181, 1 182
Benito-Vicente, A.
637, 985, 1
056
Bhasin, P.
780
Bianco, A.
1 097
569
Bianconi, V.
865
Biazzi, C.
898
123, 429, 1
080
Bielicki, J.
641
Biemann, R.
412
Biessen, E.
704
Biessen, E.A.L.
269
Bigolin, P.
725
Bakker, S.J.L.
1 100
Barter, P.J.
342
Bakrania, A.
1 120
Bartkiz, A.
Balakhonova, T.
551, 582, 679
867, 909, 1
091, 1 111,
1 171, 1 172,
1 174
Balandina, Y.
776
Balashenka, N.
581
Bartolini-Gritti, B.
307
Balatskaya, N.
606
Baruah, P.
40, 459
Balder, W.
413
Bassani Borges, J.
972
Bassendine, M.
369
Balla, J.
467
Ballantyne, C.
61
Bast, A.
1 096
Baltatzi, M.
736
Battista, S.
692
Ben Ahmed, H.
Balu, N.
248
Baudin, B.
638
Bałys, M.
1 071, 1 084
Bauer, R.
622
Balzarotti, G.
431
Baumann, S.
274
Benjathummarak,
S.
Ban, Z.
285
Baumgartner, J.
418
Benn, M.
Banach, M.
259, 672
Baumgartner, S.
1 096, 1 104
Bañares, V.
945
956
Banchs, H.L.
553
BautembachMinkowska, J.
Bao, W.
119
Bawelski, M.
585
Benoist, J.F.
691
Bento, D.
1 061
Benvegnù, L.
1 029
185
INDEX
Bilgic, E.
294
Billon-Crossouard,
S.
648
Boutouyrie, P.
1 196
Buchal, R.
517
Calabrò, P.
924, 925
Castagna, A.
626, 656
Bouziana, S.
794, 1 088
Buchmann, N.
935, 989
1 216, 1 215
Castelnuovo, S.
963
Bouzid, K.
858, 859,
867, 909, 1
091, 1 111,
1 171, 1 172,
1 174
Buda, V.
1 043
Calderón García,
J.F.
Binder, C.
1 096, 1 131
Bonde, Y.
376
Binder, C.J.
36, 39, 307
Boni, M.
849, 865
Bueno, M.
944
Caliceti, C.
1 022
Castiglioni, L.
1 039
Buerger, C.
305
Caligiuri, G.
451, 474
Castillo Bernal, F.J.
Biolo, M.
1 029
Bono, E.
1 034
Bugrova, O.
613, 848
Calosing, C.
118
835, 836,
837
BirnerGruenberger, R.
440
Bonora, E.
312
Boodhoo, D.
536
Bouzourene, K.
1 019
Bujo, H.
330
Camejo, G.
47
Bowden, K.
455
Bülow Eschen, R.
654
Camera, M.
Castro Jiménez,
M.C.
835, 836,
837
Boya, P.
346
Bundalo, M.
373
1 033, 1 034,
1 039
Birringer, M.
383
Boon, M.
90, 111, 556
Bispo, K.
1 122
Boonen, H.
513
Catai, M.A.
1 177
Boyd, M.
498
Bürger, C.
128
CAN, L.H.
951
Catanozi, S.
Bittar, R.
365
Boosani, C.
82
698, 1 122
Boydens, C.
856
Burger, F.
407
Catapano, A.
biyik, I.
826
Boot, C.
988
Boyle, J.R.
743
Burko, N.
603, 1 044
Boytsov, S.
629, 640,
663
Burlachuk, V.
750
Burnett, J.
355
Bozorboev, M.
744
16, 19, 24,
26, 30, 132,
250, 252,
256, 258,
315, 321, 324,
472
Björkbacka, H.
290
Borén, J.
Bjorndal, B.
1 118
241, 10, 43,
647
Blackhurst, D.
710
Borges Jr, N.
799
Blaha, M.
1 026
Borggrefe, M.
274
Burnett, J.R.
471
976, 1 026,
1 112
Borghi, C.
380, 391,
671, 749
Bozzetto, L.
1 183
Catapano, A.L.
Burokiene, N.
Bozzolo, E.
616
682
Brænne, I.
240
Borowiec, M.
828
Brambilla, M.
222, 238,
347, 392,
431, 458,
554, 616, 1
063
358, 384,
944
Bornstein, S.R.
Blangero, J.
449
Borrallo, R.M.
938
Blauw, L.
113
Borst, J.
Bleie, Ø.
1 208
Bliden, K.P.
Block, T.
Blaha, V.
Blanco-Vaca, F.
Bondarenko, P.
Castelo-Branco, M. 592
CANET-SOULAS, E. 292
Cannon, C.P.
463
Canton, G.
248
Cantor, R.M.
241
Canzano, P.
1 033, 1 034,
1 039
1 072
Cao, L.L.
94
Bursill, C.
704
Capelozzi, V.
1 122
Burtceva, E.
1 023
1 034, 1 039
Capisizu, A.
609, 792
Busacca, P.
803
Brambilla, S.
450
Capobianco, E.
825
Busnelli, M.
Cattan-Lévy, L.
474
Brandon, J.
95
Cappellano, G.
351
Cattaneo, F.
450
305
956
1 017
Caussy, C.
625, 1 057
721
Brandt, A.
Capra, V.
Boshtam, M.
131, 372, 511,
639, 689,
1 118
1 102
Cavalca, V.
530
386
Bratseth, V.
863
Bosisio, R.
351
Caramelli, B.
417
Buszko, M.
Brea, Á.
975, 766
407
Cavalot, F.
276
74, 322
113
Carbone, F.
1 113
Buurman, W.
Breierova, E.
565, 1 015
Buza, I.
513
Cavera, G.
1 169
88
Buza, V.
782, 1 139
Cárdenas Vázquez, 945
A.
cebe, H.
826
1 139
Cardoso-Saldaña,
G.
528
Cecchettini, A.
825
Cardoso, B.
1 198
Cecconi, D.
626, 656
Cedó, L.
384
Cefalù, A.B.
121, 954, 1
169
Čejková, S.
535
Cekovska, S.
1 159
Cena, C.
1 017
Cenarro, A.
115, 202,
765, 971
Blom, D.
976
Bossano Prescott,
E.
Bobabekov, A.
851, 861
Bossone, E.
Bobbert, T.
989
Bosusco, A.
987, 1 105
Bridges, I.
462, 1 009
Byazrova, F.
Bobronnikova, L.
869
Bot, I.
307
Brisson, D.
660, 1 053
Byazrova, S.
473, 853
Bocskei, R.
414
Botchorishvili, I.
781
Byoung Kwon, L.
1 200
Cardoso, G.
356
Bode, .
224
921
Brix, S.
285
1 202
Cardouat, G.
281
Bode, C.
306, 470
Botet-Montoya,
J.P.
Byung-Soo, Y.
Broncano, J.
1 162
Bzduch, V.
1 052
Carerj, S.
599
Botha, S.
619
Broncel, M.
518, 828
C
Caretta, N.
725
Botirova, L.
571
Brouwer, I.
56
Cabré, C.
434
Carey, A.
223
995
Carletti, R.
549
Carmeliet, P.
27, 140
Carnuta, M.G.
701, 1 082
Cermenati, G.
267
Caro Gomez, N.
614
Ceska, R.
962
Caro, N.
888, 904, 1
099, 1 109
Chabowski, A.
1 016
Chae, I.H.
1 032
Chae, J.K.
493
Chaisri, U.
569
Chalikias, G.
657
Chalubinski, M.
518, 801, 828
Chamney, S.
650
Chan, D.
355, 471
Chan, D.C.
394
Chan, J.
357, 885
Bodor, M.
612
Boehm, B.O.
1 065, 1 134
Boeing, H.
412
Boekholdt, S.M.
119, 627, 680
Boeva, O.
848
Bogdan, M.
509
Bogdanska, J.
678, 1 159
Bogniotti, L.A.
1 156
Boileau, C.
946
Boldina, M.
1 231
Bolognese, M.
1 205
Bolotov, I.
510
Bonacina, F.
222, 458
Bonaldo, A.
725
Bonavita, E.
458
599
1 219
Brenner, M.B.
Brito Jr, F.
Bottazzi, B.
222
Brovin, D.
1 149
Cacciagiú, L.
Bottiglieri, T.
277
Brown, A.
349
615
Boucher, P.
283
Brown, M.J.
207
Caceres Gestoso,
A.
Boudes, P.
244
Brown, M.S.
134
Cadamuro, J.
662
Cahill, P.
476
cai, A.
490
Cai, G.
447
Carreau, V.
946
Caidahl, K.
521
Caruso, D.
267
Cairo, V.
496, 506,
675, 1 050
Caruso, S.
489
Carvalho, L.S.
1 156
Casale, M.
803
Cascales, M.D.M.
508
Boudier, C.
283
Browning, M.
916
Boulanger, C.M.
200
Bruckert, E.
Boura, P.
617, 618
1, 53, 69,
229, 244,
365, 946,
976
Bourantas, C.V.
399
Bourbon, M.
360, 730,
857, 901,
943, 945,
955, 959,
985, 993,
996, 1 060,
1 198
Bousquet, K.
186
568, 728,
783, 850, 1
163
1 177
Brugada, R.
1 162
Bruheim, I.
1 118
Caixàs, A.
944
Brunet, A.
463
Cakmak, H.A.
Bubnova, M.
982, 998
893, 1 083,
1 150
Buccellati, C.
1 017
Calabrese, G.
Buccheri, D.
1 209
Calabresi, L.
416
Casetta, I.
407
47, 121, 650,
963, 1 058
Caslake, M.
1 081
Cassorla, G.
545
187
INDEX
Chan, K.C.
247
Chlebus, K.
956
Chang, S.Y.
560
Chlopicki, S.
494
Channon, K.
62
Chmara, M.
956
544, 549,
550
Corrado, E.
1 210
Corral, P.
945, 995
D’Angelo, A.
1 188, 1 189,
1 190
de Gonzalo Calvo,
D.
Ciffolilli, S.
383
Corrao, G.
911
202
261
D’Angelo, R.
346
Corrêa-Giannella,
M.L.
863
D’Erasmo, L.
121
De Gonzalo-Calvo, 1 162
D.
D’Agostini, L.
749
de Graaf, J.
244, 270
698
da Silva Rodrigues,
E.
972
de Gregorio, C.
803
615
Chao, T.H.
773
Chmelik, Z.
778
Cigankov, V.
Chapman, J.
4, 8, 213
Cho, D.H.
884
Cioroch, M.
62
404, 564
Cipollari, E.
697
Cho, J.Y.
738, 739, 1
004
Cipriano Jr, G.
1 178
Corrêa-Giannella,
M.L.C.
Cipriano Jr., G.
1 177
Correia, E.
1 061
Dąbek, J.
1 071, 1 084
De los Santos
Moreno, A.
Cho, K.H.
559, 646,
829
Cipriano, G.
1 178
Correig, X.
434
Dadabaeva, N.
744, 752
De Meyer, G.R.Y.
198, 201, 343
Cipriano, P.
1 183
Corsini, A.
Dafnis, I.
652
De Michele, M.
544
Cho, S.A.
738, 739
Ciumarnean, L.
1 176
Dahl, M.
834
de Mutsert, R.
113, 293
Cho, Y.K.
1 006
472, 337,
347, 419,
450, 491
Dähnhardt, D.
411
1 216, 1 215
Cho, Y.S.
1 032
Dai, H.L.
1 186
De Nicolás
Jiménez, J.M.
Choe, N.
350, 371, 1
078
Dalan, R.
881, 1 065,
1 134
de Roos, A.
113, 293
De Soysa, M.
936
Charakida, M.
188
Cifani, N.
719
Charania, S.
502
Charrière, S.
625, 1 057
Chasiotis, V.
736
Chatzigeorgiou, M.
762
Cho, H.C.
Chatzizisis, Y.
93
Chaudhary, R.
417
Chaudhuri, S.
933
Chawla, P.
1 062
Chechetkin, A.
598, 602
Choi Wan, J.F.
994
Chee, Y.J.
881
Choi, B.
Chen, C.H.
348
Chen, H.
107, 1 028
Chen, H.T.
341
Chen, Y.
524
Chen, Y.R.
453
Cheng, L.I.
1 009
Cheol-Young, P.
115, 202,
358, 765,
766, 921,
971, 975
Cosansu, K.
1 150
Cosentino, N.
530
Cosic, V.
1 217
Clapp, W.
107
Coskun, E.
1 175
Dalla-Riva, J.
408
De Vries, J.K.
413
1 094
Clara, J.
48
Coskunpinar, E.
1 083
Dallegri, F.
407
de Vries, T.
399
Choi, B.G.
1 000
Clouet Foraison, N. 634
Cosor, O.C.
769
Dallinga-Thie, G.
97, 260, 331
De Vuono, S.
849, 865
Choi, B.H.
404, 564
Coassin, S.
1 079
Cossette, M.
696
Dallinga-Thie, G.M. 286, 1 054
de Winther, M.
556, 704
Choi, B.M.
439
Cobbaert, C.
578, 634
Costabile, G.
1 183
Dalton, N.
455
Deanfield, J.
719
120, 1 000,
1 185
Cocci, G.
1 161
Coughlin, P.A.
743
814
Dechkhajorn, W.
569
Cochran, B.
342
Couture, P.
976
417
Deev, A.
734, 735
Choi, J.H.
761
Codogno, I.
474
Craiem, D.
754
Dancer, M.
1 057
Degoricija, V.
707
1 202
Choi, J.Y.
1 001
Colaço, I.
742, 941
Cramb, R.
666, 930
Danielsson, A.
290
Dehoux, M.
474
Chernatskaya, O.
1 187
Choi, M.H.
120
Cole, A.
93
Crasborn, M.
556
Danzl, K.
477, 504
Del Bo’, C.
1 105
Cherng, J.Y.
1 126
Choi, Y.J.
244
Colhoun, H.
308, 310
Darabi, M.
104, 711
82
604, 605
Chong-Yang, D.
902
Colhoun, H.M.
246, 463
835, 836,
837
Del Core, M.
Chernyavina, A.
Crespín Crespín,
M.
Chestnutt, J.
650
Chora, J.
945
959
1 176
Chora, J.R.
955, 1 060
995
609, 792
544, 549,
550
Cristaldi, A.
Dascalescu, R.
Cheta, I.
Colima Fausto,
A.G.
267
676
Del Porto, F.
Crestani, M.
Das, S.
1 043
452
634
Cristescu, C.
Daskalopoulou,
S.S.
Delatour, V.
530
Delbridge, L.
223
488, 523, 701
Choi, C.U.
Civeira, F.
Damasceno, N.R.T.
Chétiveaux, M.
648
Chou, C.H.
919
Colli, S.
Chew, D.
1 065
Chowdhury, M.M.
743
Colombo, G.
1 034
Croce, K.
93
Dasseux, J.L.
714
Deleanu, M.
Chew, D.E.
1 134
Christen, T.
293
Coman, S.
775
Croyal, M.
648
Datta, H.
988
Delgado-Coello, B. 64
chi, Y.
524
Christie, B.
677
Compte, M.T.
434
Cruciani, G.
383
Dattilo, G.
803
Delgado, G.E.
1 146
Chia-Yin, T.
1 064
Christoffersen, C.
717
Conceição, R.
920
Cruz, D.
742, 941
Daunoravicius, Z.
1 072
Dell’Oca, N.
945
Chia, Y.C.
1 207
Christomanou, H.
1 059
Concin, H.
770
Cuchel, M.
430
Dauteuille, C.
104, 711
Dell’Oglio, S.
1 209
Chiappa, G.
1 177, 1 178
Chroni, A.
652
Cong, K.
651
Cuenca, N.
938
Davel, A.
827
Dell’Oca, N.
961
Chiara, M.
372
Chrysohoou, C.
762, 846
Connell, P.
1 133
Cuesta Torres, L.F.
342
Davì, G.
1 033
Dellera, F.
1 113
Cuevas, A.
945
131, 372, 511,
639, 689,
1 118
Chiariello, C.
626
Chuang, C.K.
210
Connor, T.
Davids, J.
1 028
Chicheva, M.
1 066
Chudinovskikh, T.
1 110
Conrad, D.H.
307
Curran, J.
449
Davidson, M.
464
Chung, S.M.
1 185
705
Cursaru, A.
805
1 074
131, 372, 511,
639, 689,
1 118
Constantin, G.
Demakova, N.
Chiesa, G.
de Boer, H.
269
512, 1 010
Constantin, G.I.
802
Cutuli, L.
222
546, 1 016
Chung, W.Y.
de Boer, J.F.
804
Dembinska-Kiec,
A.
Chvostova, M.
568
Constantinou, C.
688
Czarnecka, D.
931
De Boever, P.
502, 514
DeMicco, D.
119
Ciba, P.
1 157
CONTAMIN, H.
292
Cziraki, A.
414
de Bruin, R.G.
269, 483
Demikhova, N.
1 187
Cibickova, L.
635
Conte, C.
496
D
de Bruin, T.
464
Demina, E.
890
Cicala, V.
1 183
Cook, E.
209
D’Acierno, L.
924, 925
De Fabiani, E.
267
Demina, M.
911
Cicero, A.
380, 391, 1
022
Cook, E.C.L.
664
D’Addato, S.
De Faria, E.
922, 983
Demir, M.
984
Cooper, A.
1 113
380, 391,
671, 749
de Feyter, P.J.
399
Demircioglu, S.
984
671, 749
Cooper, J.
934, 952
De Geest, B.
126, 655
Demopoulos, C.
1 115
Chillarón, J.J.
1 012
Ching, S.M.
1 207
Chinnasamy, P.
94
Chiong, C.
881
Chiou, H.Y.
1 089, 1 184
Chiu, T.Y.
341
Chiva-Blanch, G.
1 102
Cicero, A.F.G.
D’Agostini, L.
671
189
INDEX
Demuth, I.
935, 1 087
Dixon, S.
401
Dritsa, V.
813
El Khoury, P.
946
Esteve, E.
944
Fellin, R.
121
Denby, L.
1 081
Djaramshi, A.
269
Drogari, E.
1 059
El-Kersh, A.
797
Estruch-Alrich, M.
876
Fellnerova, A.
939
Dengxuan, W.
902
Djeric, M.
870, 1 095
Dronca, E.
913
El-Osta, A.
Etxebarria, A.
527
1 042
Djokic, V.
821
Dropinski, J.
Ferin, R.
1 155
Denney, L.
667, 910
Djordjevic, V.
1 217
796, 840,
841
637, 985, 1
056
Fenyo, I.M.
Denisenko, M.
35, 239, 265,
1 113
El-Zidy Ibrahim, N.
989
Eun Seoung, L.
552
Ferlin, A.
725
Dent, R.
392, 462, 1
009
Dlouha, D.
683, 939
Drosos, I.
657
El-Zidy-Ibrahim, N.
935
Evangelakos, I.
437
312
Dobrolubov, M.
613
Druina, L.
598, 602
Elbahey, M.
587, 790
Evdokimenko, A.
Deon, V.
1 105
Doganci, S.
294
Du, X.J.
223
Elbaz, M.
346
500, 598,
602
FernandezHernando, C.
960
Doi, M.
586
Du, Y.
339
Elbitar, S.
946
Even, G.
474
FernándezHiguero, J.A.
637
Derfler, K.
Derosa, G.
1 188, 1 189,
1 190
DOKMEN, H.
951
Duarte, T.
742
Elena, M.
555
Everson, F.
514
Dokoza Terešak, S.
707
742, 941
Elfaleh, E.
909
Evola, S.
819, 1 210
Fernández-Miró,
M.
1 012
Ducla Soares, J.L.
269
Eligini, S.
530
Evola, V.
819
774
622
Duijs, J.
Fernández, E.
Doktorova, M.
Duivenvoorden, W.
1 173
477
Dumitrescu, A.
769, 1 046
606, 685,
686, 687
267
796, 840,
841, 1 008
Dumfarth, J.
Ferrari, A.
Domagala, T.
432, 709,
753, 928,
977, 978, 1
003
961
480, 494
818
Fernandez, G.
Dolezelova, E.
Exarchos, T.
Ferrari, R.
1 022
Domingo-Espin, J.
408
Dumitriu, I.E.
40, 459
947
Ferreira, G.S.
698
Elizova, N.
532, 632
Domingues, C.
592
Dunaeva, A.
907
F
Ferreira, J.
592
Ellena, R.
651
Dominguez
Crespo Hirata, R.
972
Dunaway, C.
94
531
Ferreira, M.J.
592
Ellis, K.
355
Fabres Machado,
U.
Durmus, R.
984
Ferreira, R.
843
Elnour, A.
1 181, 1 182
Fabris, F.
725, 1 029
Durrington, P.N.
426
Ferreira, S.
1 155
Emese, T.
475
Faccini, J.
346
Dürschmied, D.
470
Ferrer, R.
425
Emich-Widera, E.
1 218
Fagg, W.S.
269
Duta-Mare, M.C.
443
Ferri, L.
Emma, K.
47
Faggiano, P.
1 179
544, 549,
550
Dwivedi, O.
354
Empana, J.P.
1 196
Fahey, T.
980
Ferri, N.
Dwyer, T.
758
Emukhvari, M.
844
Fainardi, E.
407
337, 347, 419,
472
Dybvig, A.
684
Endo, Y.
1 049
Fajkusova, L.
973
Figueras, R.
944
480, 494
Descamps, O.
976
Deschildre, C.
474
Deshpande, A.
1 062
Deshpande, S.
1 009
Després, J.P.
3, 7, 212, 214,
387
Dhar, I.
779
Dhawan, V.
722
Dhyani, A.
472, 554, 1
063
Dominguez
Crespo Hirata, T.
972
803
Donato, P.
592
Di Bella, G.
DI CATALDO, V.
292
Dong Il, S.
1 200
Di Filippo, M.
1 057, 625
Dong Ju, C.
1 200
di Gioia, C.
549
Dong Soo, K.
1 200
di Giuseppe, R.
412
Doni, A.
222
Donn, R.
426
Di Taranto, M.D.
958
Diana, S.
476
DiCioccio, A.T.
463
Dickerhof, N.
1 127
Didangelos, T.
736
Didenko, Y.
783
Dienova, J.
1 121
Dieplinger, B.
460, 882,
1 154
Dieplinger, H.
704
Doppler, C.
477
Dorel P., S.
913
Dorofeeva, Y.
1 191
Dostal, E.
541, 720
Douglas, G.
62, 349
Douglas, S.
969
Doulamis, I.
382, 1 119
Downie, P.
969, 1 051
Ezhov, M.V.
Engberg, S.
209
Falcou, A.
544
Eak Kyun, S.
1 130
Enguita, F.
996
Falk, E.
1 164
Filatova, A.
551
Eastwood, J.
1 081
Enikő, B.
475
Fang-I, H.
453, 1 064
Filipovic, N.
818
Ebenbauer, B.
418
Enko, D.
1 143
Faraj, T.
525
Filippova, A.
497
Ebtehaj, S.
47, 699
Eom, G.H.
350, 1 078
Farajian, P.
1 092
Filou, S.
688
Eckardt, K.U.
278
epstein, J.
1 101
Farhoudi, M.
600
Fimiani, F.
924, 925
Edelberg, J.
246
Erdmann, J.
240, 1 157
Faria, F.
742, 941
Fiorelli, S.
530
Edholm, D.
1 116
Eremic, N.
1 095
Faria, R.
1 061
Fiorentini, C.
818
Edsfeldt, A.
290
Eretova, Z.
683
Farinaro, E.
67
Fiorino, E.
267
EFECTL Study
Investigators, G.
461
Eriksson, M.
89, 1 027
Farnier, M.
Fischer, A.
333
Eriksson, M.J.
521
246, 389,
463, 976
Fischer, A.W.
88
1 194
Fischer, M.
418
377, 1 069
Doytcheva, P.
719
Efstathiou, S.
1 092
Dikkers, A.
47
Dr. Dostal, E.
1 145
Egbung, G.
1 124
Dimakopoulos, I.
1 092
Dr. Gruber, K.
1 145
Eggertsen, G.
376
Dimitriou, T.
977, 978, 1
003
Dragut, R.
805
Eha, J.
1 129
Drechsler, C.
1 192
Ehrenborg, E.
Dimova, L.G.
804
Dressel, A.
396
Dimulescu, D.R.
1 082
Drettwan, D.
Dincgez Cakmak,
B.
893
Drexel, H.
Dissanayake, S.
994
544, 549,
550
Ezhov, M.
Fikrova, P.
Dietel, B.
Dito, R.
190
17, 23, 31,
411, 1 154
Donners, M.
E
Elisaf, M.
Eriksson, P.
521
Fatima, A.
Ermina, M.
568, 728,
850, 1 163
Faus-Dader, M.J.
866
Fischer, S.
403, 682
Faussner, A.
305
Fiser, A.
94
EROGLU, Z.
953, 951
Favari, E.
697, 1 058
Fitzpatrick, E.
476
203
Erridge, C.
525
Favretto, S.
599
Flachs, P.
889, 892
Eichmann, T.
374
90
Erskine, N.
757
Fayer, F.
954, 1 169
Fletcher, J.
545
Eichmann, T.O.
284
366, 731,
732, 733,
839, 879,
883, 991, 1
067, 1 136, 1
137, 1 138
Erturk, M.
893
fazali, M.
1 223
1 012
Ekici, A.
1 069
Escalante, F.
959
Febbraio, M.
223
Flores Le-Roux,
J.A.
Ekroos, K.
131, 275, 639
Escolà-Gil, J.C.
384
Fedak, D.
903
Flugelman, M.Y.
932
El Asmar, Z.
283
Espinosa, E.
1 161
Federico, V.
818
Fogacci, F.
391, 671, 749
El Bounkari, O.
291
Essop, F.
502
Felder, T.
662
Föger, B.
219
El Eter, E.
1 193
Fomin, I.
1 231
191
INDEX
Fonseca, R.
843
Fuentes, L.
651
Garaffa, C.
924, 925
Genser, B.
699
Fontes, A.
1 155
Fuertes, R.
434
Garaffa, E.
924, 925
Gentili, A.
849
Foody, J.
389
Fuior, E.V.
527, 1 085
Garces-Horna, V.
505
Georgiadis, I.
1 119
Forbes, C.
1 009
Fujita, Y.
636
García Fuertes, D.
725
Fülöp, P.
435, 467,
702, 1 151,
1 153
835, 836,
837
Georgousopoulou,
E.
762, 846
Foresta, C.
Garcia Garcia, H.M. 399
Gerard, W.
449
García León, A.
384
Gerdes, N.
128, 305
García-Arnés, J.
428
Gergei, I.
396
GarciaCampanario, I.
1 099, 1 109
Gerothanassis, I.
1 128
Gesheff, M.G.
417
García-Casares, N.
428
Ghabili, K.
García-García, I.
938
Garcia-Vaz, E.
114
Fort, J.M.
425
Fortini, F.
1 022
Fortunato, G.
958
Foryst-Ludwig, A.
285
Fotiadis, D.
818
1 069
Furukawa, L.
1 122
Furusyo, N.
579, 610,
727, 755, 756,
905
Fotiadis, D.I.
399
Fourie, C.M.
619
Fusaro, M.
1 029
Fournier, N.
691
Fusco, F.
1 122
Fraass, U.
396
Futema, M.
952
Fragopoulou, E.
1 117
G
Fragoso, J.M.
356
Gabbasov, Z.
473, 853
Fragouli, S.
382
Gabcova, D.
1 052
France, M.
426
Gabriel, D.
827
Franceschini, G.
650
Gabrielyan, D.
850
Franck, G.
93
Gabrielyan, L.
850
Franco-Cereceda,
A.
521
Gaetano, C.
Frank, S.
192
Furtmair, R.
374, 422,
499, 707
Franz, R.
48
Franzese, C.J.
417
Frascaroli, C.
276
Fraser, B.
758
Fraunberger, P.
1 067
Freiberger, T.
962, 973
Frias, M.
710
Fried, S.
281
Frikke-Schmidt, R.
237, 1 080
Frimmel, K.
565, 1 015,
1 121
Garcia, A.
1 162
Garcia, I.
904
Gareeva, D.
745
Giyazitdinova, E.
597, 726, 787,
788, 831,
979, 1 025,
1 132
Gonzalez-Calero,
L.
129
GonzalezJuanatey, J.R.
1 162
Gkougkourelas, I.
617, 618
1 035
González-Santos,
P.
428
Gkourogianni, A.
Glazunova, A.
860
Gonzalez, F.J.
375
Glei, M.
383
González, M.
1 123
Glerup, S.
332
Goodwin, M.
694
Głodzik, J.
585
Goossens, P.
704
817
Głogowska-Ligus,
J.
1 071, 1 084
Góralska, J.
546, 1 016
Ghaleb, Y.
946
Gordts, P.
44, 46
Godber, I.
1 081
Ghanaati, H.
580, 607
Gorzelak-Pabis, P.
518
Göderle, L.
307
Gharipour, M.
1 197, 806
Gorzelak, P.
801, 828
Goebel, G.
503
Gheysens, O.
655
Goswami, N.
502, 514
Goedecke, J.
710
Ghezaiel, S.
858, 859,
1 174
Gottschling, K.
333
Goedeke, L.
312
Goudevenos, I.
1 035
Goeritzer, M.
284, 622
Goulas, A.
1 088
Goettsch, C.
42
Goumas, G.
1 092
Goh, L.L.
1 065, 1 134
Gouni-Berthold, I.
669
Gojazadeh, M.
817
Gouveia, C.
843
Gojkovic-Bukarica,
L.
821
Govorin, A.
807
Gojković, T.
436, 741, 874
Gracia, M.
754, 774
Goldberg, R.
757
Græsdal, A.
684
Goldstein, J.A.
401
Graham, I.
319
Goliasch, G.
541
Graier, W.F.
284
Golledge, J.
362
Grallert, H.
313
Golubenko, M.
1 070
Grammer, T.
396, 937
Gomaraschi, M.
47, 386, 1
058
Grammer, T.B.
409, 1 146
Granata, A.
450
380, 671
Garjani, A.
566
Garlanda, C.
222, 458
Ghezzi, M.
725
Garlaschelli, K.
238, 616,
898, 1 063
Ghoneem, A.
587
Ghorashi, S.
817
Garlick, J.
723, 1 206
218, 221
Ghosh Laskar, M.
336
Garnier, J.M.
283
Gafane, L.
619
Giacco, A.
1 183
Garolera, M.
938
Gafarov, V.
795
Giacobbe, C.
958
Garzillo, C.
781
Gafarova, A.
795
Giammanco, A.
1 169
Gasbarrino, K.
452
Gafencu, A.V.
527, 1 085
Giannella Neto, D.
863
Gasco, A.
491
Gagulin, I.
795
Giannini, S.
1 029
Gąsior, Z.
1 071, 1 084
Gaita, D.
769, 1 046
Gibbs, J.
976
Gasko, R.
635
Gaita, L.
769, 1 046
Gieger, C.
313
Gaspar, G.
857
Galabova, G.
245
Gijbels, M.
704
Gaspar, L.
541
Galicia, U.
1 056
Gilham, D.
118
Gasperikova, D.
1 052
Galimskaya, V.
589, 590
Gill, S.
897
Gomes, A.
592
Grandi, E.
Gast, K.B.
293
Gomes, D.
1 122
735
1 075
349
Gratsiansky, N.
Galitsyna, E.
Gillard, J.
Gaston, A.T.
474
Gomes, D.J.
698
944
365
634
Grau, J.
Gall, J.
Gillery, P.
Gaudet, D.
505
Gomes, E.I.
983
497
114
Gimenez-Lopez, I.
Grechanyk, N.
Gallagher, J.
59, 244, 247,
300, 353,
660, 669, 1
053
Gingell, R.
936, 990
Gomes, I.
1 198
Greco, D.
692, 715
Ginsberg, H.
714
Gomes, M.
270
Green, S.
673
Gautier, E.L.
104
Giollo, L.
1 178
904
Grenkowtiz, T.
935
Gavriil, L.
1 117
Giordano, P.
1 161
Gomez -Villarejo,
D.
Greter, M.
127
114
Greve, J.W.
113
Frisdal, E.
365
Galli, F.
383
Fritsch, H.
22
Gallieni, M.
1 029
Fritsche, A.
412
Gallivan, A.
952
Fritz, J.
770
Galy, B.
102
Froemming, G.A.
485, 486,
487
Gandra, S.R.
392, 1 009
Ganesan, M.
986
Froemming, G.R.A.
1 211
Ganiev, U.
Froio, A.
511
Froněk, J.
562, 535
Fruttero, R.
491
Frutuoso, J.
730, 901
Fu, J.
5, 9, 113
Fuentes, J.
1 028
629, 640,
663
Giorgini, M.
1 183
Gomez, M.F.
Giovannini, M.
671, 749
Gonçalves, C.
799
Griffin, J.
969
Gaye, B.
1 196
247
GONCALVES, F.
522
Griffo, E.
1 183
1 195
Gipe, D.A.
Gebhard, C.
696
Griffo, R.
1 179
571
365
290
Ganiyev, U.
Giral, P.
Gonçalves, I.
GELOEN, A.
292
592
Grigore, L.
131, 372, 511,
639, 689,
1 118
434
Gonçalves, L.
Ganzetti, G.S.
Giralt, M.
Gelosa, P.
1 039
Girona, J.
393
Goncharova, I.
1 070
238, 616,
898, 1 063
Genest, J.
714
Giulietti, F.
1 161
959
Grigorie, M.
705
881, 1 065,
1 134
Genis, A.
514
238, 898
Grimm, M.
351
Genkel, V.
1 042
Giuseppe Danilo,
N.
González Garcia,
J.R.
Gonzalez Marines,
D.
959
Gritskevich, A.
906, 911
Grivel, J.C.
548, 1 047
Gao, X.
Gapon, L.
538, 557
Gavrilova, N.
Gennaro, A.
818
193
INDEX
Groen, A.K.
210, 622
Gurvich, E.
1 231
Harvey, D.
952
Hernandez, M.
522
Hong, S.P.
1 001
Huisman, H.W.
619
Gromova, E.
795
Gustafsen, C.
332
662
Hernández, M.P.
478
Hong, T.J.
761
Huitema, L.
704
Grönlund, C.
596
Gustafsson, P.
203
Haschke-Becher,
E.
Herrera, M.D.
381, 1 125
hongyu, W.
809
Hukkanen, M.
915
Groop, L.
354
Gustafsson, U.
1 027
Hashida, T.
1 002
Herz, C.
507, 772
481
Hulett, M.
489
Groothoff, J.
968
428
Hatsukami, T.
248
Herz, C.T.
771, 1 147
Humphries, S.
238, 934
Grosu, L.
805
Gutiérrez-Cardo,
A.
Hoogenboezem,
M.
Hattori, T.
899
Herz, J.
Hoogeveen, R.
677
Humphries, S.E.
952
Gruca, A.
1 016
Guyer, K.E.
417
Hatzitolios, A.
Hooper, A.
355
Hung-Yi, C.
453, 1 064
Gruchala, M.
956
Gyrasis, C.
399
617, 618, 736,
1 088
41, 91, 283,
469
Hetjens, S.
274
Hopmans, S.
1 173
290
H
794
455, 673
Grufman, H.
Hatzitolios, I.A.
Hung, M.Y.
Heywood, S.
223
Hoppstaedter, J.
492
1 199
Ha, K.H.
729
708
82
Grujic Ilic, G.
Haupt, C.
Hunter, W.
Hiebert, S.W.
267
Hörauf, A.
377
285
Haas, G.M.
Hilgendorf, I.
949
Havulinna, A.S.
410
Hurme, R.
275, 639
654
224, 306,
470
Hori, M.
Gu, J.
368, 438, 1
098
547
420
Grune, J.
Havik, S.
Hur, S.K.
Horinek, A.
962
393
448
Hayashi, J.
Hilvo, M.
131, 275, 639
Horn, J.
651
1 011
Hinterreiter, F.
882
1 096
1 186
Habibinejad, H.
Husche, C.
Guang, X.F.
Horner, D.S.
372
Hippe, D.
248
249
958
1 106
Husebye, E.S.
Guaraldi, F.
Haddad, E.
579, 610,
727, 755, 756,
905
47
Guaita, S.
Haase, M.
Hurt-Camejo, E.
Host, L.
283
958, 987, 1
058, 1 105,
1 180
1 096
Hiraoka, Y.
1 002
622
Guardamagna, O.
Haenen, G.
Hussain, M.M.
Hottiger, M.O.
127
Haerdtner, C.
306
743
700
42
Hayes, P.D.
Hirata, H.
Hutcheson, J.
Hou, J.
873
Hafner, E.
1 154
83
338
942
He, B.
Hirata, K.
Hutchings, A.
Hou, L.
342
88, 331, 333,
334
972
411
Heeren, J.
Hiroyuki Hirata, M.
Huth, C.
Hovingh, G.K.
Hisakawa, N.
561
119, 286,
359, 392,
627, 680,
974, 976
Hutten, B.
968
Huttl, M.
661
Huynh, K.
314
Hovingh, K.
331
Hwang, S.H.
738, 739
Hovland, A.
466, 864
Hwang, Y.C.
1 202
Howanietz, M.T.
771
Hyeon Gheol, G.
1 200
Hoxha, M.
1 017
Hyo Sang, H.
1 201
Hrelia, S.
1 022
Hyuck Moon, K.
1 200
Hryachkova, O.
573
Hyun Woo, P.
1 130
374
Hyun, M.H.
1 000, 1 185
484, 838,
854
Guardigli, M.
1 022
Hagemeyer, C.
223, 273
Guarini, P.
626, 656
Hagger, M.
1 168
Guarnieri, F.
981, 1 166,
1 167
Hahn, R.T.
492
Heestermans, M.
1 040
Hjellestad, I.D.
249
Haikal, A.
910
Heikkilä, H.
354
Hmaidi, W.
1 091, 1 111
Hakimjavadi, R.
476
Heikkilä, T.
690
Ho-Jun, J.
1 130
Hakovirta, H.
423
Heimann, J.
1 122
Ho, H.H.
348
Hale, A.
62
Hein, L.
306
Ho, J.
426
Halliday, C.
118
Heine, M.
88, 333
Ho, Y.C.
348
Hallström, S.
499
Heinemann, A.
1 030
Höbaus, C.
Halmurat, U.
1 090
Heinle, H.
821
507, 771, 772,
1 147
Halon, D.A.
932
Heinonen, S.
446
Hobbs, H.
32
Hrzenjak, A.
916
Hsieh, F.I.
1 089, 1 184
I
71
Hsin-Chiao, W.
453
Iaconi, M.
549, 550
105, 1 014
IBAROLLA, D.
292
Guðnason, V.
1 220
Guedes, J.
1 061
Guerado Espinosa,
I.
835, 836,
837
Guerin, M.
365
Guerra, A.
1 060
Guerrasio, A.
276
Guerrini, U.
458
Guertin, M.C.
696
Guervazoni, A.
1 177
Guibout, C.
1 196
Guillas-Baudouin,
I.
104
Guizoni, D.
827
Han, S.H.
Gulevskaya, T.
500, 500,
598, 602
Guljas, S.
1 160
Gulkevych, O.
811
Gunasekar, P.
82
Gundry, S.
519, 1 101
Guo, W.
534
Gurbel, P.A.
417
Haltmayer, M.
882
Heintjes, E.
760
Hobkir, J.
Hama, S.
426
Heinz, K.
477
Hoefer, I.
Hamed, W.
797
1 098
Hoefler, G.
284, 622
Hsu, L.W.
Hoeke, G.
90
Hsu, P.L.
445
Ibarretxe, D.
393
357, 885
Ibe, N.
641
Hammad, B.
587, 790
HeinzelGutenbrunner, M.
Hammami, S.
1 174
Helk, O.
960, 1 107
Hoeksema, M.
704
Hu, M.
317, 326
Hua-Long, L.
902
Iborra, R.T.
698
385
Huang, C.F.
1 089
Ibrahim, Z.
923
Hubacek, J.
724, 939,
962, 1 068
Idzior-Waluś, B.
903, 931, 912
Igari, K.
1 148
Hubacek, J.A.
871
Igelseder, B.
503
Huber, K.
418, 541
Igland, J.
957
Hübner, M.
377
Ijäs, P.
354
Huby, T.
104
Ikaida, M.
620
Huckova, M.
1 052
Ikeda, Y.
561
Hudiakova, N.
842
Ikegami, Y.
537, 1 141
Hughes, A.D.
312
Ikemura, N.
537, 1 141
Hughes, L.
988
Ikewaki, K.
Hughes, S.G.
669
693, 700, 1
049
Hui, D.
331
Ikhlef, S.
110
1 200, 1 201
Henkel, V.V.
947
Hoes, A.A.W.
Handru, M.
1 176
Hennig, B.
385, 1 093
Hoffman, J.
Hanna, E.
650
Henstridge, D.
223
Hoffmann, M.M.
409
121, 344,
390, 949,
976
Hentze, M.W.
102
Hofker, M.
113
Heras, M.
393
Høgh, A.
834
Herder, C.
411
Hoh, B.P.
681
Harada, A.
338
Heredero, A.
129
Hohensinner, P.
418
Harangi, M.
435, 467,
612, 702, 1
153
Herings, R.
760
Hollstein, T.
989, 1 087
Hermann, M.
649
Holmes, E.
988
578
Holven, K.B.
957
Harada-Shiba, M.
Gurevich, V.
400
Hargrave, G.
498
Hermans, M.
Gurevich, V.S.
718, 947
Harrison, S.C.
743
Hernandez Flores,
T.
959
HernándezMijares, A.
866
Gurlek, A.
194
Hayashi, T.
715
Hart, L.
969
Gurses, K.M.
294, 715
Hartgers, M.L.
359, 974
Gursky, O.
630, 708
Hartvigsen, K.
307
Honarpour, N.
465, 976
Hong, B.
339, 695
Hong, S.J.
738, 739, 1
004
195
INDEX
Ikonen, E.
915
Jalkanen, S.
423
Jones, A.F.
666
Kalkavouri, A.
736
Kastelein, J.
119, 244, 390
Khan, F.
114, 289
Ilina, N.
606
James, R.
710
Jones, G.
1 127
122
Kastelein, J.J.
463
Khanal, M.P.
659
Ilincic, B.
870, 1 095
Janabaev, B.
851, 861
Jones, J.
889
Kalminaovska
Oštrić, D.
Kastl, S.
541
Kharazmi, F.
1 223
Illyes, M.
414
Janczura, M.
Jones, R.
362
Kals, J.
1 129
Katano, H.
593
Khasanova, Z.
1 077
Ilyin, A.
860, 900
796, 840,
841, 1 008
446
Kamenihina, I.
454
Katarzyna, G.
801
Khaw, K.T.
627, 680
Imamura, S.
621
Jänis, M.
131
Jönsson-Rylander,
A.C.
Kamiyama, Y.
1 041
Kathiresan, S.
946
Kheder, R.
916
Imbalzano, E.
496, 506,
588, 675,
803, 1 050
Jannes, C.
945
Jonung, T.
249
Kammoun, H.
223
Katkó, M.
702
Khedher, S.
1 171, 1 172
Janovska, P.
889
Joo, H.J.
Kamphuisen, P.W.
413
Kato, Y.
859
765, 971
Kamran, M.
1 223
Ina, K.
484, 838,
854
808
Joo, N.S.
1 094
Khiari, K.
Jargin, S.
Kang, B.G.
1 004
579, 610,
727, 755, 756,
905
Khessairi, N.
Jarauta, E.
738, 739, 1
004
858, 859,
867, 909
599
106, 270
Kang, D.O.
120
Katsilambros, N.
1 119
948
Jaroch, J.
Joosten, L.
Inazu, A.
Khokhlov, L.
750
556
Kanjuh, V.
821
Katsilambros, Ν.
382
893
903
Joosten, S.
Inci Coskun, E.
Jasik, P.
Khokhlov, R.
750
48
Kanthasamy, V.
897
Kaudewitz, D.
312
954
Khoury, É.
247
Jørgensen, A.B.
237
780
275
855
Kapoor, S.
Kauhanen, D.
Inoue, Y.
Khromova, A.
591, 603
Joris, P.J.
1 100
903, 912, 931
418, 720
1 149
Kapusta, M.
Kaun, C.
Ionin, V.
623, 111, 286,
354, 378,
384, 442,
652, 690
Jörg, H.
Ingrassia, V.
Jauhiainen, M.
Khurana, I.
239, 1 113
Josa-Laorden, C.
505
karakaya, O.
826
Kawakami, K.
855
Kianpour, P.
918
Jouent, X.
1 196
Kararigas, G.
76
Kawasaki, M.
642
Kiechl, S.
Jovanova, S.
678, 1 159
Karasek, D.
635
Kawase, R.
63, 395, 653
312, 411, 1
229
Ju Won, S.
552
Karatzas, K.
794
Kawashiri, M.A.
948
Kiemer, A.K.
492
Juhász, I.
1 151
Karavia, E.
688
Kaya Kocabas, E.
953
Kikas, P.
657
Jukema, J.W.
245, 269,
293
Karbiener, M.
894
Kaya, E.
294
Kikuchi, H.
457
Karciauskaite, D.
1 072
Kayikcioglu, M.
953
Kim, B.
751
Kardassis, D.
130, 206,
437, 527, 1
085
Kayıkcıoglu, M.
951, 984
Kim, B.W.
761
Kaynar, L.
984
Kim, C.G.
398
Kazan, H.
269
Kim, C.J.
999
Kazdova, L.
421, 661,
877, 895
Kim, D.J.
729
Kim, D.W.
398
622
Jay-Christian, H.
476
Irina, O.
538
Jayaraman, S.
630, 708
Irino, Y.
338
Jazet, I.
90
Isermann, B.
412, 669
Jean-Charles, G.
555
Ishida, T.
338
Jebari, S.
Ishizuka, M.
1 049
Jelev, D.
isikssacan, N.
826
Jelić Ivanović, Z.
Ismail, N.H.
485
Jelić-Ivanović, Z.
Ismail, Z.
965
Isomäki, A.
Iqbal, J.
917
122
Jukema, W.
113, 446, 578
436, 741, 874
Jula, A.
354
Jeney, V.
475
Julius, U.
403, 682
915
Jenkinson, F.
988
Julve, J.
Kari, A.
220
Ito, H.
586
Jensen, E.
389
384, 425,
944
Karimova, M.
209
Ito, M.
1 049
Jensen, G.B.
427
Jumaa, H.
307
Karlafti, E.
736
Kebryakov, A.
728, 1 163
620
332
Jung Won, S.
1 200
1 078
Ito, Y.
Jensen, S.L.
Kim, E.
Karlsson, T.
367
Kedenko, I.
1 079
Ivandaev, A.
793, 906, 911
Jenty, M.
283
Jung, C.H.
405, 737
Kim, E.J.
Karolina, R.
801
Kedenko, L.
120, 1 000,
1 185
Ivanoshchuk, D.
832, 929,
940, 964
Jeon, S.M.
1 004
Jung, S.I.
1 094
Karonova, T.
1 149
411, 503,
662, 1 079
Kim, E.M.
350, 371
Jeong, S.J.
420, 444
Juno, C.
245
Karpe, F.
85, 86, 89
Keenan, A.
889
Kim, H.C.
729
568, 728,
783, 850, 1
163
Jeonggeun, M.
1 130
Jurado, M.A.
938
Karpov, A.
Kelleher, C.
1 031
Kim, H.J.
1 004
Jezkova, K.
494
Justiniano, H.
283
454, 526,
542
Kellici, T.
1 128
Kim, H.K.
120
Ji-Yan, C.
902
K
Karpov, Y.
782, 1 139
Kenjaev, M.
Kim, H.L.
512, 1 010
Jianbin, Z.
902
Ka Wah, L.
952
Karppinen, S.M.
915
Kim, H.S.
1 010
Jiang, L.
489
Kaaroud, H.
909
Kasatkina, L.
1 203
567, 570, 571,
1 195, 1 221,
1 222
552
822, 824
Kader, T.
1 127
Kaser, S.
503
570
Kim, J.M.
Jiang, Y.
Kenjaev, S.
764
Kaiser, P.
789
Kashtalap, V.
573, 1 070
980
Kim, J.W.
Jiang, Y.D.
Kenny, R.A.
jinbo, L.
809
Kajani, S.
534
Kasichayanula, S.
976
Kerr, A.
62
120, 1 000,
1 185
Kershaw, E.
285
Kim, J.Y.
559
Kessler, T.
240
Kim, K.C.
404, 564
Keun Ho, P.
1 200
Kim, K.S.
1 001
Keun-Hwa, J.
552
Kim, M.A.
512, 999, 1
010
Keyserling, C.
714
Kim, M.H.
398
Khaitov, S.
1 195
Kim, M.J.
Khalikulov, K.
1 204
404, 560,
564
Khalil, A.
110
Kim, N.H.
120
Khallou-Laschet, J.
474
Ivanov, M.
Ivanova, O.
548, 555
Ivanova, R.
914, 917
Iwaniec, T.
840, 841, 1
008
Izquierdo, I.
1 162
J
Jaceldo-Siegl, K.
1 106
Jinga, M.
805
Kakaletsis, N.
794
Kasim, S.
923
Jacob-Lenet, M.P.
474
Jingwen, L.
337
Käkelä, R.
378
Kasim, S.S.
966
Jacobs, F.
126
Jiyan, C.
490
Kakino, A.
636
Kasimdjanova, G.
744
Jácomo, R.
1 177
Jo, Y.H.
560
Kalbousi, S.
638
Kasimov, U.
851, 861
Jafari Dinani, N.
721
Johansson, J.
118
Kalil, J.
522
Kaski, J.C.
40, 459
918
Jokitalo, E.
204
741, 874
Kaspi, A.
1 113
Jakic, B.
351
Joksić, J.
122
KalimanovskaOštrić, D.
Kassner, U.
Jalkanen, J.
423
Jon, S.
1 130
Kalkan, A.K.
1 083
935, 989, 1
087
Jafari, R.
196
1 056
197
INDEX
Kim, S.
198
405, 444,
493, 737
Kobayashi, J.
621
Koshurnikova, M.
582
Kruse, C.
1 157
Kyounghoon, L.
1 130
Larsson, M.
601
Kobayashi, M.
1 041
Kostaki, S.
794
Krychtiuk, K.
541
Kypreos, K.
688
Laskaris, A.
846
Kim, S.G.
398
Kobayashi, T.
63, 395
Kostara, C.
709
Kubalska, J.
956
Kyselak, O.
950
Lass, A.
284
Kim, S.H.
512, 1 010
Kocabas, E.K.
951
Kostner, G.
135, 263, 960
Kubo, T.
338
Kyung-Hyun, C.
631
Laufs, U.
50, 381, 624
Kim, S.M.
631
Kochueva, M.
869
Kotoulas, C.
813
Kucinskas, V.
1 072
L
Laura, T.
118
Kim, W.H.
493
Kocourkova, L.
1 005
Kotseva, K.
73, 116, 769
Kucinskiene, Z.A.
1 072
La Spada, M.P.
954
Lauridsen, B.
211
Kim, Y.C.
1 004
Kocyigit, D.
294, 715
1 069
Laajala, T.D.
378
Laurila, P.P.
111
1 032
Koenig, W.
397
796, 840,
841, 1 008
Kuehn, C.
Kim, Y.G.
Kotula-Horowitz,
K.
Kühn, C.
377
Laake, K.
1 102
Laurinavicius, A.
920
Kim, Y.O.
439
Kofoed, K.
211
436
Kuiper, J.
307, 760
Laakso, M.
241
LAVENNE, F.
292
Kim, Y.S.
493, 564
Koike, T.
1 021
Kotur-Stevuljevic,
J.
Lavie, G.
932
Kolb-Lenz, D.
443
813
131, 275, 639
456
241, 287, 331,
413
Laaksonen, R.
Kimura, S.
Koutoulakis, E.
Kuivenhoven, J.A.
Lavier, J.
1 019
457
Kolb, D.
622
1 092
933
Kimura, Y.
Koutsouri, A.
Labib, M.
Kukharchuk, V.V.
947
Lavoie, J.M.
643
223, 314, 362
Koliakos, G.
736
768
866
Kingwell, B.
Kouznetsova, T.
Labrador-Barba, E.
Kulbak, V.
1 023
Lawrence, T.
704
285
Kollerits, B.
411, 1 192
454
678, 1 159
Kintscher, U.
Kovalyov, L.
Labudovic, D.
Kulik, A.
584
666
Komatsu, T.
693, 1 049
454
Lawson, A.J.
1 067
Kovalyova, M.
505
Kinz, E.
Kulikowski, E.
118
Lacambra-Blasco,
I.
422
Kondo, K.
537, 1 141
Kulkarni, H.
449
Lackman, I.
745
Layland, J.
723, 1 206
Kiriazis, H.
223
König, C.
1 069
65, 96, 111,
230, 354,
378
482
Kirchmair, R.
Kovanen, P.
Lawson, N.
Kumar, P.
847, 1 170
Laclaustra, M.
766
Lazarczyk, M.
800
Kiriyama, M.
338
Konno, S.
899
Kovanen, P.T.
204
Kumar, S.
449
888
Lazzarato, L.
491
Kirsch, A.
422, 499
Konnov, M.
734, 735
Kowala, M.
449
Kume, N.
1 002
Lagares Carballo,
M.
503
Kono, H.
457
Kozhanova, A.
793, 906, 911
Kumon, Y.
561
904
292
Kirschner, A.
Lagares, M.
LE BARS, D.
606
Kono, S.
461
Kozhevnikov, D.
400, 728
Kuo, S.Y.
1 184
408
293
Kiseleva, T.
Lagerstedt, J.
le Cessie, S.
537, 1 141
Konstantin, D.
418
Koziolova, N.
604, 605
Kupchynskaya, O.
811
508, 1 123
104, 365
Kishimoto, Y.
Laguna, J.C.
Le Goff, W.
789
Konstantinides, S.
657
Kozireva, A.
728
KURIATA, A.
577
Lebedev, I.
520, 1 086
Kiss, M.
307
382, 1 119
Kozlov, K.
510
Kurilshikov, A.
832
Lebedeva, A.
Kitslaar, P.H.
399
Konstantopoulos,
P.
Kozlov, S.
473, 853
Kurtoglu, E.
984
858, 859,
867, 909, 1
171, 1 172,
1 174
913, 992
Kiss, A.
Lahiani, S.
Leach, N.
548, 555, 1
047
Kivelä, A.
495
Kontogianni, V.
1 128
Králová Lesná, I.
515, 562, 535
Kurtz, C.
465, 976
Lahoz, C.
766, 921, 975
Lebedeva, N.
868, 1 048
Kjellmo, C.A.
864
Kontush, A.
104, 711
Králová, A.
562, 535
Kuryata, A.
497
Lai, H.Y.
105
Lechleitner, M.
499
Kleber, M.E.
396, 409, 1
146
Kooijman, S.
111, 210
Krämer, B.K.
1 146
Kuryata, O.
786
Lalive, P.
407
Lecorps, G.
463
Kook, H.
350, 371, 1
078
Kraml, P.
517, 558
Kurzejamska, E.
800
Lamari, A.
803
Lecour, S.
710
Krane, V.
1 192
Kutikova, L.
359, 760
Lamb, H.
113
Lecube, A.
425
Krapf, C.
351
kutkiene, S.
784
Lamb, H.J.
293
Lee, E.
1 000
279, 284,
335, 443,
622
Kuznetsov, V.
538, 557
Lambert, G.
119, 209, 645
Lee, E.M.
120
Kuznettsova, T.
997
LAMBERTON, F.
292
Lee, E.Y.
559, 646
Kuzniewski, M.
903
Lamina, C.
411, 1 079
Lee, H.L.
512, 1 010
Kuzuya, M.
484, 838,
854
Lamiquiz Moneo, I.
971
Lee, H.W.
761
Lamiquiz-Moneo, I. 115, 765, 921
Lee, J.B.
1 001
Kleijnen, J.
1 009
Klephortova, I.
860
Kook, T.
371
Klesareva, E.
551, 679
Koolwijk, P.
481
Klevstig, M.
647
Kopecky, C.
699
Klimes, I.
1 052
Kopecky, J.
889, 892
Klinghammer, L.
1 069
Koplyarova, N.
1 163
Krempf, M.
648
Kloch-Badełek, M.
931
Koppensteiner, R.
Krempler, F.
1 079
Klopfleisch, R.
285
507, 771, 772,
1 147
Krishnan, A.
767
Kvantaliani, T.
844
Lee, J.E.
884
956
294
619
KłosiewiczLatoszek, L.
Kopru, C.
Lammertyn, L.
Kristensen, T.
211
Kvapil, M.
871
Kopyta, I.
1 218
Lamminmäki, U.
690
Lee, P.T.
773
Kristiansen, K.
889
Kvarnstrom, M.
464
Klotsche, J.
396
Kopytova, A.
740
Landlinger, C.
245
Lee, S.
738, 739, 751
Kristinsdóttir, L.B.
1 220
Kvetnoi, I.
510
Klouras, E.
753, 928,
977, 978, 1
003
Korbelius, M.
335
Langer, A.
1 024
Lee, S.H.
493, 1 004
Krizak, J.
565, 1 015
Kwang Kwon, K.
1 201
Koren, M.
462, 1 205
Langrova, H.
1 026
Lee, S.K.
1 185
Kronenberg, F.
Kwang-Yeol, P.
552
Koricanac, G.
373
Langslet, G.
244
Lee, S.N.
748
Kwok, S.
426
Korkusuz, P.
294
Lanska, M.
1 026
Lee, S.R.
493
Kwon, D.H.
Kormi, I.
410
18, 28, 241,
278, 295,
309, 411, 1
079, 1 192
350, 371, 1
078
Lanska, V.
724
Lee, S.Y.
120
Korneva, V.
997
Lappegård, K.T.
466, 864
Lee, W.J.
405, 737
Korou, L.M.
382, 1 119
Laringe, M.
924, 925
Lee, Y.B.
439
Koseki, M.
63, 395, 653
Larsson, L.
89
Lee, Y.S.
751, 1 001
Kluge, S.
383
Knezl, V.
565
Knoflach, M.
1 229
Ko, A.
241
Ko, J.
493
Kratky, D.
Kroon, J.
81, 481
Krott, L.M.
88
Kruger, R.
619
Kwon, H.M.
665
Kwon, S.U.
763
Kwon, S.W.
665
199
INDEX
Lee, Y.U.
350, 371, 1
078
Lim, H.M.
1 207
Lim, W.H.
512, 1 010
Leguina-Ruzzi, A.
478
Lima, A.
1 155, 1 178
Lehti, S.
204
Limon, J.
956
Leighton, B.
446
Limongelli, G.
924, 925
Leiherer, A.
366, 731,
732, 733,
839, 879,
883, 991, 1
067, 1 136, 1
137, 1 138
Lin, S.H.
1 089
Lin, Y.C.
445
Lindahl, M.
408
Leitersdorf, E.
714
Leitges, M.
704
Lek, M.
641
Leoncini, E.
1 022
Leopold, C.
622
Leow, M.K.S.
1 134
Lepore, S.M.
1 055
Leren, T.P.
957, 1 055
Lesnik, P.
104, 365
Letourneur, D.
79, 271
Levels, J.
1 054
Levin, L.
757
Levin, M.
647
Ley, K.
38, 125
Lhomme, M.
104, 711
Li Tin, S.P.
994
LI, B.
723, 1 206
306
Lindholm, B.
47
Lindholt, J.S.
834
435, 467,
612, 702, 1
151, 1 153,
1 227
Machado, U.F.
698
Machida, T.
621
Malinska, H.
421, 661,
877, 895
Margolis, L.
548, 555, 1
047
Macia, A.
1 125
Mallat, Z.
307
mariani, P.
865
Macic-Dzankovic,
A.
706
Malyutina, S.
1 212
Marianne, S.
Lorkowski, S.
383
1 178
Mamareli, V.
813
Mariano, C.
Lorza, E.
827
Maciej, B.
801
Mamarelis, I.
813
943, 993, 1
060
Loßnitzer, D.
274
Loubarinhas, G.
1 060
Maciejczyk, M.
585
Mamone, F.
496, 506,
675, 1 050
Marin, R.
725
Marinova, C.
Loureiro, P.
1 198
914, 917
Lövgren, J.
690
Lu, R.
693
Lu, Y.J.
822
Mackēvičs, V.
1 152
MacRae, L.
268
Mancas, S.
769
Markov, A.
1 070, 1 086
Madder, R.D.
401
Manchenko, O.
860
Markova, I.
421, 661, 877
Madero, M.
713
Manchurov, V.
1 047
Markus, H.
48
Madl, T.
443
Mancina, R.M.
1 055
Marlena, B.
801
Mandraffino, G.
496, 506,
588, 675, 1
050
Marmelo, B.
1 061
Marmontel, O.
625
Maroto, A.S.
129
Marott, S.
429
972
Lindqvist, P.
595, 596
Lualdi, A.
1 033, 1 034
Lindsberg, P.
204, 354
Lucas, A.
107, 1 028
284
Liorda, E.
736
MadreiterSokolowski, C.T.
Lucena, M.
1 177
Liptak, B.
565
Madsen, L.
889
Lucius, B.
359, 760
Lira, A.
462
Madsen, P.
332
Luczak, E.
518, 801
Lisa M., C.
48
Maegdefessel, L.
264, 266
Ludger, S.
48
Littman, K.
1 027
Maffioli, P.
Luetjohann, D.
1 106
1 188, 1 189,
1 190
Liu, C.
695
Luginova, Z.
582
Mafra, J.M.
857
Liu, C.S.
341
Luigi, S.
1 039
959
Liu, D.
362
Luirink, I.
390, 968
Magaña Torres,
M.T.
liu, H.
809
Luna, A.
1 162
Magaña-Torres, T.
945
Liu, J.
248
Luna, P.
667
Magdalena, C.
801
Liu, P.
695
654
Magné, J.
203
Liu, P.Y.
105, 1 014
LundbyeChristensen, S.
Magni, P.
Liu, Q.
524
Lundstrom, T.
464
Liu, X.
822, 823,
824
Luongo, D.
1 183
Lupattelli, G.
Liu, Y.
426, 902
Manea, V.
862
Maneerat, Y.
569
Manfredi, A.A.
616
Marques
Gonçalves, R.
Manfredi, M.
626
Marques, B.
1 028
Mangas, A.
888, 904, 1
099, 1 109,
1 162
Marques, N.
1 061
Marsche, G.
374, 440,
707, 1 030
944
Mangels, N.
333
Mangelsdorf, D.
139
Martín-Campos,
J.M.
Mangge, H.
894, 1 142,
1 143
Martin-Lorenzo, M. 129
337, 386
Mannarino, E.
865
Magnoni, M.
616
Manno, G.
Magnussen, C.
758
Manolaki, N.
849, 865
Magomedov, R.
783
Lūriņš, J.
1 152
Mahvi, B.
Martin, C.
637, 985, 1
056
1 209
Martin, R.
244
1 059
Martinelli, N.
626, 656
Manolio, T.
34
1 020
Martínez-Marin, M.
505
Mansilha, H.
1 060
Martinez-Marin, R.
505
Martínez-Ramírez,
M.
713
Li, J.
524
Li, M.
524
Li, S.
545
Liwen, L.
490
Li, Y.
278
Lüscher, T.
719
Mai, A.
267
Llargués, E.
944
Mansurov, A.
1 204
Li, Y.H.
773
Lüscher, T.F.
127
Maistry, T.
759
Llorente-Cortés, V.
1 162, 202
Mantovani, A.
222, 458
Li, Z.
273
Lutgens, E.
967, 1 160
496, 506,
675
128, 302,
303, 305,
556
Majnaric, L.
Lo Gullo, A.
Manzato, E.
434
820
121, 725, 1
029
Martínez-Vea, A.
Majumder, A.A.S.
Martinez, L.O.
101, 281
Makarenkova, K.
929, 940
Martínez, M.
774
Makeeva, O.
1 070
Martinez, P.J.
129
Makino, H.
949
131, 372, 511,
639, 689,
1 118
Makri, E.
617, 618
Maoui, A.
1 171, 1 172
Martinez, T.L.R.
423
1 033, 1 034
981, 1 166,
1 167
Maksimow, M.
Mapelli, M.
1 177
626
1 041
Marães, V.
Martinotti, S.
Makuuchi, A.
1 117
625, 1 057
1 155
Malagaris, I.
Marcais, C.
Martins, D.
1 165
347
860
Malchikova, S.
Marchianò, S.
Martynov, S.
1 191
470
548
Malcnikova, S.
Marchini, T.
Maryukhnich, E.
546, 546, 1
016
Marco-Benedi, V.
115, 765, 975
März, W.
396, 406,
409, 624,
937, 1 146,
1 192
Liamis, G.
753, 977, 978
Libby, P.
93, 306
Lo, W.Y.
810
Lütjohann, D.
1 096
Liberopoulos, E.
753, 928,
977, 978, 1
003
Łoboz-Grudzień,
K.
599
Luukkonen, P.
915
Lysne, V.
779
Logunova, N.
782
Licata, V.
954
Lysunets, T.
786
Logvinenko, A.
811, 812
Lichtenstein, A.H.
2, 6, 379
M
Løland, K.H.
1 208
Licona-Rashid, M.
717
Lombardi, M.
491
Liem, A.
760
Long, R.
267
Liepold, E.
368, 438, 1
098
Liew, H.
1 065, 1 134
Lim, D.S.
738, 739, 1
004
Lim, H.E.
200
Lindau, A.
Lőrincz, H.
1 000, 1 185
Ma, R.
885
Ma, X.
83
Ma, Y.
1 205
Manzini, S.
Lopez Tinoco, E.
614
Maas, R.
278
López, G.I.
995
Mabuchi, H.
948
Marcovina, S.
669, 670
Lopez, L.R.
277, 417
MalczewskaMalec, M.
Macchi, C.
337
394
1 139
1 178
Marcovina, S.M.
Lopukhova, V.
Maldaner, V.
Mach, F.
58, 60, 407
626
Mas-Oliva, J.
64
209
42
Marengo, E.
Loregger, A.
Maldonado, N.
Machado-Lima, A.
531, 698
Malik, V.
216
Marenzi, G.
530
Masana, L.
121, 393, 944
Machado, F.
961
Mase, M.
593
201
INDEX
Masenko, V.
526, 542,
853
Medeiros Bastos,
G.
972
Mashele, N.
502
Medeiros, A.M.
Masson, G.
93
Mastorakos, G.
382
Masuda, D.
395, 653,
845
Mata, P.
945
Matas, L.
944
Matchin, Y.
686
Mateo-Gallego, R.
115, 765, 766,
921, 971
Mateva, L.
Mathisen, M.
864
Matikainen, N.
241
Matmurotov, Q.
851, 861
Matsuda, H.
395, 653
Matsuzawa, Y.
20, 361
Matter, C.M.
127
Matz L., R.
Maurer, G.
Mauri, M.
202
914, 917
283
418, 541
938, 944
Mavromoustakos,
T.
1 128
Mawson, T.
93
Mayer, G.
643
Mayer, L.
1 229
Mayos, J.
944
Mayr, M.
312
Mazeikiene, A.
1 072
Mazzolai, L.
1 019
Mc Crimmon, R.
114
Mehegan, J.
Mehrad, H.
Meikle, P.
Meiler, S.
Meinitzer, A.
Mieth, M.
278
Migliorino, D.
1 210
360, 943,
945, 955,
985, 1 060
Mignano, A.
1 210
Mijovic, R.
870
1 031
Mika, P.
580, 600,
607, 611, 1
020, 1 037,
1 038
223, 314,
362, 449,
658
441, 485,
487, 716,
923, 965,
966
Motazacker, M.M.
241, 286, 331
N
Motilva, M.J.
1 125
Na, J.O.
1 000, 1 185
Motta, B.M.
1 055
Nabika, T.
703, 1 135
681, 716,
965, 966
Moulin, P.
242, 625, 1
057
Nabrozidis, A.
428
584, 585
Mohd Mokhsin,
N.A.
Nachtigal, P.
480, 494
Mikellidi, A.
1 115
Mohd Nasir, N.
716, 923
Moura, V.
522
Naderi, G.A.
721
Mikhaleva, O.
900
Mohd Nor, F.
681
Mousavi, F.
566
865
Mikic, M.
1 160
Mohtar, F.
1 211
Moxon, J.
362
Naeimi Kararoudi,
M.
Milaciu, M.
992
Mohtashami, R.
918
Mucher, E.
346
Naessen, T.
601
Milano, G.
450
Mokhort, T.
852
Muckenthaler, M.
102
Nafakhi, H.
887, 891, 896
Milanova, M.
791
Mokhtar, S.S.
681
Mueller, P.
95
Nagai, A.
703, 1 135
882
Nagao, M.
886
366, 731,
839, 991, 1
067
Nagasaka, R.
1 021
Nagel, F.
789
Nagel, G.
770
Nagornova, K.
613
Nagy, E.V.
612
Nahapetyan, H.
346
Nahon, K.
90
Nahrendorf, M.
93
Nair, D.
952
Najib, S.
281
Naka, K.K.
399
Nakagawa, T.
1 021
Nakajima, K.
621
Nakamura, K.
586
Nakandakare, E.
1 122
Nakandakare, E.R.
531, 698
Nakanishi, C.
948
Nakano, Y.
583
Nakata, C.
1 177
Nakatani, K.
395
Nakaya, N.
461
Nakayama, T.
456
Nam, Y.S.
1 078
Nan, R.
805
Narain, R.
815, 816
Narayanaswami, V.
641, 651
Nascimento, T.
781
Nasias, D.
437
Näslund, U.
596
Natale, F.
924, 925
Naumenko, E.
852
Naumov, V.
454, 526,
542
Navarova, J.
565, 1 015
Naviglio, D.
1 183
128, 305
Milicua, J.C.G.
637
Mokhtari-Dizaji, M.
580, 607
Mueller, T.
511, 1 142,
1 143
Milionis, H.
432
Molahedh, Y.
1 091, 1 111
Muendlein, A.
Miljkovic, M.
436
Mollaki, V.
1 059
Meisinger, C.
411
Miller, D.
61
Molnár, Á.
1 227
Meitinger, T.
240
Miñambres, I.
876
Mombelli, G.
963
Mekala, A.P.
536
Ming, X.
479
Momiyama, Y.
537, 1 141
Mele, L.
692
Minicocci, I.
121
Monier, S.
711
Melki, A.
867
Ministrini, S.
865
614, 1 109
Mellett, N.
314
Minniti, M.E.
47
Monsalvo
Hernando, M.
Mellgren, G.
363, 367
Mintz, G.S.
83
888
Mello, A.P.Q.
814, 981, 1
166, 1 167
Miranda, M.
127
MonsalvoHernando, M.
Monsalvo, M.
Melnichenko, A.
632, 633
Melnikov, I.
473
Melnikov, M.
830
Mels, C.M.
619
Méndez-Acevedo,
K.
64
Mensink, R.
340, 1 103
Mensink, R.P.
103, 1 096, 1
100, 1 104
Mirchi, M.
817
Miroshnikova, V.
740, 890
Mishchenko, A.
1 163
Misiano, G.
954
Mistri, A.K.
1 133
Mitish, V.
793
Mitro, N.
267
Mitrofanov, K.
1 073
Mitroshkin, M.
686
673
537, 1 141
Mc Neilly, A.
114
Menzel, J.
412
Miu, P.
McAhren, S.
449
Merezhanova, A.
1 165
Miura, K.
Messa, P.
1 029
Miwa, K.
338
Miyamoto, Y.
949
Miyashita, K.
621
McCann, A.
779
McCormick, S.
112, 1 127
277
Messika-Zeitoun,
D.
474
McCullough, P.A.
McDaniels, K.
704
Messner, B.
477
Miyata, K.
537, 1 141
McGillicuddy, F.
534, 694
Metelskaya, V.
Miyazawa, T.
886
Mchirgui, N.
1 111
629, 640,
663
Miyoshi, T.
586
McKendrick, J.
392
McKey, S.
1 031
McLoughlin, E.
719
McParland, J.
430
McWherter, C.
244
Md Yasin, M.
716, 965, 966
Meakin, P.
289
Medbury, H.
545
Mohd Kasim, N.A.
Metso, J.
Mezzano, D.
384, 623,
652
478
Miarka, P.
903, 912
Michael, L.
449
Michalis, L.K.
399
Michel, J.B.
474
Michell, D.
268
Mickiewicz, A.
956
Mlih, M.
283
Mo, F.E.
445
Mo, Z.C.
822, 823,
824
Muid, S.
441, 485,
923
Muinjonov, B.
597, 726, 787,
788, 831,
979, 1 025,
1 132
Mukhamedova, B.
1 222
Mukhamedova, M.
572
615
Mulder, M.
717
Montani, J.P.
479
Mullan, R.
650
Montecucco, F.
407
Müller, G.
403
Mora-Brugués, J.
384
Munakata, M.
899
Morales, C.
944
Mundal, L.
957
Morbini, M.
380, 391
Mundra, P.
314
Moregola, A.
458
1 158
Moreno, X.
1 056
MuñozHernández, R.
Mori, K.
338
Muñoz, M.
434
Mori, M.
948
Muntean, C.
1 043
Mori, T.A.
471
Moriarty, P.
667, 910
Moriarty, P.M.
668
Moriconi, A.
865
Morihara, R.
583
Morlotti, B.
386
Morreale, P.
1 209
Morris, A.
95, 385
Morshed, S.
107, 1 028
Mortensen, M.B.
1 164
Morvan, M.
474
Mocan, M.
509
Moschen, A.R.
312
Moeton, M.
209
Moschetta, A.
205, 208
Mohd Ismail, A.
716
Mospan, M.
811
Mosteoru, S.
769, 1 046
Mostoslavsky, R.
127
Muntoni, S.
121
Murakami, K.
338
Murakami, M.
621
Muro, A.F.
554
Murphy, C.
980
Murrin, C.
1 031
Murtazaev, S.
1 204
Musayeva, Y.
1 025
Musikhina, N.
538, 557
Mussbacher, M.
448
Mut-Vitcu, G.
769
Muthuramu, I.
126, 655
Muxel, R.
241
Muzalevskaya, M.V.
718
Myhre, P.
1 102
Mysliwiec, M.
956
203
INDEX
Nawawi, H.
Nikolic, S.
870
Nurmuhammat, A.
1 090
Olkkonen, V.
111, 286, 495
P
Nikolova, A.
791
Nussbaum, K.
127
Olset, H.
1 208
Paapstel, K.
1 129
Nilsen, R.M.
249
Nusshold, C.
499
Omote, Y.
583
Pacifico, A.
121
Nygård, O.
275, 779, 1
208
Omrane, M.
1 174
Pacioni, F.
1 097
Onda, A.
457
Packard, C.
49
Ongen, Z.
1 083
Packard, C.J.
1 081
Ooi, E.M.
394
Padilla-Mata, V.
1 230
Öörni, K.
47, 100, 204,
378
Padroni, M.
407
Parikova, A.
683
Parini, P.
47, 89, 203,
370, 1 027
Park, C.G.
120, 1 000,
1 185
Park, C.Y.
405, 737
Park, D.G.
512
Park, J.H.
738, 739, 1
004
502
Nilsson-Wolanin,
O.
408
Nawrot, T.
Nayeri, H.
721
Nilsson, J.
290
Nygård, O.K.
363, 367
Nazarenko, M.
520, 1 086
Nilsson, S.K.
88
Nyman, E.
596
Nechaeva, B.
1 165
Ning, T.
902
O
NEDELCIUC, I.
575
Nishida, M.
63, 395, 653
O’Reilly, M.
534, 694
Pagano, M.
1 169
693, 1 049
Obendorf, F.
1 147
opan, S.
826
405, 737
369, 988
Nishida, T.
Park, J.Y.
Neely, D.
Pagava, Z.
1 219
Oberkersch, R.E.
416
Opie, L.
710
404, 564
690
561
Park, K.C.
Negi, P.
Nishiuchi, J.
Pagel, P.
90
711
Oppitz-Plörer, C.
21
Paiva, A.
827
Opris, S.
705, 802
Park, K.S.
564
913, 992, 1
176
ObregonGonzalez, A.
1 230
Negrean, V.
567, 570, 571,
572, 1 018,
1 036
404, 564
Nègre-Salvayre, A.
Nizomov, A.
Park, K.H.
Obrowsky, S.
335, 622
Pajukanta, P.
241
363, 367
992
594
Njølstad, P.R.
Orășan, O.
Park, M.
Odegova, A.
746
Palesano, O.
954, 1 169
1 029
541, 720
420
Noale, M.
Oravec, S.
Park, S.H.
Ogawa, K.
1 021
Palmen, J.
238
645, 648
630
1 001
Nobécourt, E.
Ordóñez Llanos, J.
Park, Y.W.
Ogundipe, T.
514
Palmisano, S.
671, 749
645
Noels, H.
291
Ordóñez-Llanos, J. 876
Parnet, P.
Ogura, M.
Palo, S.
706
Palomar Muñoz, C. 614
Parolini, C.
Noguchi, H.
456
Oguz, S.H.
715
Nohara, A.
948
Oh, D.J.
522
120, 1 000,
1 185
131, 372, 511,
639, 689,
1 118
Nolasco, P.
532, 632,
633, 1 066,
1 073, 1 074,
1 075, 1 076,
1 077
818
551
Orekhov, A.
Parodi, O.
Noeva, E.
344, 700,
949
Neimark, A.
204
441, 485,
486, 487,
681, 716,
923, 965,
966, 1 211
740
Nekaies, Y.
638
Nekrasova, T.V.
718
Nelson, J.
209
Nelson, J.K.
664
Nemeckova, I.
480, 494
Neroev, V.
606
Neskudla, T.
871
Nestel, P.
314, 658
Nestvold, T.
864
Netea, M.
106, 270
Neville, M.
89
Nezafati, P.
1 197
Nezami, N.
817
Nezic, D.
821
Ngo Sock, E.T.
643
Nguyen, S.D.
204, 378
Ni, C.W.
482
Palominos, M.
478
Palotie, A.
241
PALTINEANU, B.
539, 628
Parra, E.S.
983
420, 444
Orekhova, V.
1 076, 1 077
Panagiotakos, D.
762, 846
Parvu, M.
775
Nolte, I.M.
413
Oh, G.T.
Nony, S.
625
Oh, P.
392
Orera-Peña, M.L.
866
Panahi, Y.
918, 1 108
Pashos, E.
430
431, 554
Oh, P.C.
1 130
Orgera, G.
550
Panchal, A.
667
Pasqualini, L.
865
222, 301,
458, 616,
1063
Ohama, T.
395, 653
Orhan, B.
833
Panderi, A.
1 088
Passarelli, M.
Ohguro, T.
561
Orlov, P.
929, 940
Panetta, D.
818
531, 698, 1
122
Ohmori, R.
537, 1 141
Oscar, C.
1 162
Pang, J.
1 030
949
957
355, 471, 1
168
Pasterk, L.
Ose, L.
Pasterkamp, G.
311
Ohta, T.
390
Osipova, I.
557
Pannier, B.
1 196
Patankar, J.V.
622
Ohta, Y.
583
Osokina, A.
551
Panov, D.
795
Patel, M.
104
390
Ossoli, A.
650
Panteleeva, A.
740, 890
Patel, S.
1 120
461, 886
Oster, D.
492
Pantoura, M.
617, 618
Patel, V.
545
1 029
Patsch, S.M.
1 079
Norata, D.G.
Norata, G.D.
Nordestgaard, B.
Nordestgaard, B.G.
75, 211, 227,
237, 254,
429, 669, 1
080
123, 427, 1
164
Ohta, N.
Ohtake, A.
Oikawa, S.
63, 390, 395,
653
Osto, E.
719
Panzavolta, C.
Ostolaza, H.
637, 1 056
Panzoldo, N.B.
983
Patsch, W.
662, 1 079
Okazaki, M.
653
Ottino, J.
938
Paone, S.
489
Pattison, J.
455
Okruhlicova, L.
565, 1 015,
1 121
Otto, M.E.
1 178
1 115
PATURET, A.
292
Oueslati, I.
858, 859,
867, 909
Papadopoulou Pozatzidou, D.
Paul, J.L.
691
Papadopoulou, A.
1 092
Paulweber, B.
68, 272, 411,
503, 662, 1
079
Paulweber, M.
503
Pauwels, B.
856
Pavanello, C.
121, 386,
963, 1 058
Pavão, M.L.
1 155
Pavlaki, M.
657
425
Pavlouskova, J.
973
394
PAYZIN, S.
951
NICA, A.S.
574
Nordrehaug, J.E.
1 208
Nicholls, S.
61
Norioka, N.
1 041
Nicoletti, A.
474
Noto, D.
Niculescu, L.S.
701, 1 082
121, 954, 1
169
Nielen, T.
270
Notsu, Y.
703, 1 135
Nielsen, S.
369
Novakova, D.
724
Okutan, H.
984
Nieves, J.
553
Novakovic, R.
821
Okuyan, E.
777
Ouguerram, K.
648
Papadopoulou, S.L. 399
Nikiforov, N.
532
Novikova, A.
568
Oldoni, F.
331
Ouweneel, A.B.
1 040
Papavasiliou, K.
1 092
Nikitin, A.
868
Novikova, L.
454
Oleynikov, V.
Ovsyannikova, A.
832
Para, I.
992, 1 176
Nikitin, A.G.
1 048
Novitskaya, A.
573
Paragh, G.
Nikitin, Y.
768
1 209, 1 210
Ozan Tiryakioglu,
N.
1 083
Novo, G.
589, 590,
591, 603, 1
044
1 156
Nikitina, N.
1 066, 1 074,
1 075
Novo, S.
Oliveira, G.
Ozcebe, O.
984
Oliveira, H.
827
Ozerova, I.
Novoa, J.M.
494
1 196
548, 555
843, 1 061
Parati, G.
Nikitskaya, E.
Oliveira, M.
629, 640,
663
435, 467,
612, 702, 1
151, 1 153,
1 227
Nikkola, E.
241
Ntallas, I.
1 035
Olivieri, O.
626, 656
Ozmen, F.
294
Pardina, E.
740
Nugraha, F.
576
421, 661, 877
Ozsvar-Kozma, M.
307
Parhofer, K.G.
Nikolaev, M.
Oliyarnyk, O.
819, 1 209,
1 210
Okada, T.
205
INDEX
Pchelin, I.
842
Pchelina, S.
740, 890
Pedersen, E.K.
1 208
Pedersen, E.R.
363, 367
Pedrelli, M.
47, 203
Pedretti, R.
1 179
Pedro-Botet, J.
766, 1 012
Pedro-Botet, J.C.
975
888, 1 099,
1 109
Pingitore, P.
1 055
Polyakova, E.
1 149
Pinthus, J.
1 173
Polyakova, V.
510
Proietta, M.
544, 549,
550
Perez, C.
888, 904, 1
099, 1 109
Pinto, F.
1 198
Pompilio, G.
450
Peric, M.
821
Pinto, P.R.
698
Ponde, C.
1 062
Perier, M.C.
1 196
Pintus, P.
121
Pongratz, T.
541
Perin, M.A.
781
Piotrkowicz, J.
1 071, 1 084
Poon, I.
489
Perkmann, T.
307
PIRAQUIVE
AGUDELO, J.
292
Pop, C.
862
Perrea, D.
382, 1 119
Pop, L.
Pirazzi, C.
1 055
Perrotta, S.
549, 550
Pirhonen, J.
286, 915
Persègol, L.
711
Pirildar, S.
984
Ragino, Y.
644, 832,
929, 940,
964, 1 212
PrzepiorkowskaHoyer, B.
903
Pu, J.
83
Rahimian, R.
508
Rahman, T.
Puhm, F.
1 131
441, 485,
486, 487,
681, 716,
820, 965,
966, 1 211
Pujato, M.
94
862
Pulakazhi Venu,
V.K.
554
Popeijus, H.
340
Pulatov, U.
851, 861
Popeijus, H.E.
103
Rahmat, R.
441, 923
Rainer, S.
Pulikal, A.
335
815
Rajani, R.
1 062
Pego, M.
592
Peinado-Onsurbe,
J.
425
290
1 082
871
Persson, A.
Popescu, A.C.
Pelikanova, T.
PIrisi, M.
599
Purnomowati, A.
576
821
1 063
545
805
Pellegatta, F.
Pertsoulis, N.
Popescu, H.
Rajkovic, J.
Pischon, T.
412
Pussinen, P.J.
410
1 025
Pellegrin, M.
1 019
529
1 082
Rakhimbayeva, G.
Perveen, I.
Popescu, R.M.
Pistrosch, F.
403
Puzdriak, P.
728, 783
752
697
888
947
Pellegrini, N.
Pery, T.
Popova, A.B.
Rakhimov, R.
Piťha, J.
Puzyrev, V.
Popovic, D.
1 095
1 222
Pello, E.
768
121
520, 1 070,
1 086
Rakhimova, R.
Pes, G.
515, 683, 1
068, 871
871
906
712
Pithova, P.
Pyanikin, S.
818, 825
1 147
247, 463
Pelosi, G.
Pesau, G.
Pordy, R.
Ramakrishnan, L.
762, 846
501
934
Pitsavos, C.
Pyatchenkov, M.
946
538, 557
1 105
Peloso, G.
Petelina, T.
Porrini, M.
Ramaswami, U.
Plana, N.
906, 911
356, 528
Pylaeva, E.
551, 679
965, 966
273, 402
Posadas-Romero,
C.
Ramli, A.S.
Peter, K.
Peters, A.
313, 411
1 200
1 118
963
Pyoung Chun, O.
Ramsvik, M.S.
Penco, S.
358, 393,
766, 921,
944, 975
Pyatkova, I.
539, 540,
574, 628
1 054
1 127
312
Peter, J.
Porteous, C.
Ramirez, C.M.
356, 528
Petersen, C.M.
332
1 201
626
341
Pyung Chun, O.
Ranzato, E.
Peng, H.
Posadas-Sánchez,
R.
822, 823,
824
Peterson, K.L.
455
Postnov, A.
Ras, R.
1 104
Petrek, M.
1 005
655, 1 076,
1 077
658
617, 618
Peng, X.S.
Pyush, M.
Raptis, N.
Rasente, Y.
416
Petrides, F.
119
Pláteník, J.
517, 558
Potekhina, A.
Raslova, K.
1 052
Petriello, M.
385, 1 093
Pleava, R.
769, 1 046
Rather, R.
722
Petrini, J.
521
Plebani, M.
Rathmann, W.
411
Petrkova, J.
1 005
Rathouska, J.
494
petrulioniene, Z.
Rato, Q.
993
Raut, M.
659
PENA, C.
Penning-van
Beest, F.
760
Peralta, J.
449
Pereira-Flores, K.
478
Pereira, A.
943, 945,
981, 1 166,
1 167
Plat, J.
103, 340,
704, 1 096,
1 100, 1 103,
1 104
Q
551, 679
Qin, J.
524
Potočková, J.
517, 558
Quartuccio, S.
588
1 029
Potočnjak, I.
707
Que, X.
455
Plevin, R.
498
Pouwer, M.
245, 446
1 099
784
Plösch, T.
804
Povlsen, G.K.
513
Quezada-Feijoo,
M.
784
Pocovi, M.
358
Pozzi, C.
898
1 156
petrylaite, M.
Quinaglia e Silva,
J.C.
Pereira, J.
478
Pettersson, K.
690
Podesser, B.K.
789
Prabhakaran, D.
767
Quintao, E.
1 122
Ray, K.
61
Pérez Cuellar, M.
630
Pfaffenberger, S.
541
Podpalov, V.
581
PRADA, G.
540, 574
Quintao, E.C.R.
698
Ray, K.K.
253
Perez Guerrero, P.
615
Pfeiffer, L.
313
Poelz, W.
882
PRADA, S.
540, 574
Quitterer, U.
1 024
Raz, O.
563
Perez Isla, L.
945
Phillips, H.
942
Pogorelova, O.
551, 679
Prager, M.
720
Qureshi, A.R.
47
Razny, U.
546, 1 016
Perez Ternero, C.
381, 1 125
Piacentini, L.
1 034
Poirier, S.
98
Pramfalk, C.
89, 1 027
R
Razvodovsky, Y.
1 213, 1 214
Piantadosi, C.
1 183
Pojskic, B.
706
Prasongsukarn, K.
569
Raal, F.
465
Real, J.T.
358
Piccinocchi, G.
924, 925
Pojskic, L.
706
Prassl, R.
Raal, F.J.
976
Reaven, P.D.
45, 117
Pichler, M.
1 146
Pokrovskiy, A.
1 023
199, 894, 1
142, 1 143
Reblova, K.
973
692
Pokrovsky, A.
793, 906, 911
767
269, 483
Piemontese, A.
Praveen, P.A.
Rabelink, T.J.
Rebnord, E.W.
363
396
Pokrovsky, S.
707
781, 920
Reda, A.
797
316, 318, 325
Pregartner, G.
Rached, F.
Piepoli, M.
679, 685,
686, 687
421, 877
946
Pieper, L.
Pravenec, M.
RABES, J.P.
Prehn, C.
290
Reddy, K.S.
767
446
535, 562, 1
068
430
Pieterman, E.
Poledne, R.
Rader, D.
Previato, L.
1 029
Radovic, B.
284, 443
Redezuk, G.
983
Poli, A.
692
Princen, H.
446
Radulian, G.
805
Redmond, E.
476
Radulović, B.
707
Redpath, G.
112
Radulović, S.
499
Rega-Kaun, G.
720
Radwan, M.
82
Regmi, P.
659
Raggi, P.
714
Reiber, J.H.C.
399
Reim, S.
128
Perez-Calahorra, S. 115, 358, 765,
766, 921,
975
206
Perez, A.
Perez-Calvo, J.
505
Pérez-Hernández,
N.
528
Pérez-Hernánez,
N.
356
Perez-Marques, F.
667
Pieterman, E.J.
245
Pérez-Méndez, O.
713
Pietrzycka, A.
903
Pérez-Pérez, A.
876
Pihlajaniemi, T.
915
Perez-Ruiz, M.R.
971
Piir, A.
1 129
Perez-Serra, A.
1 162
Piña-Aguilar, R.
1 054
Ping-Yan, C.
902
Polis, A.
389
Princen, H.M.G.
245
Polizzi, G.
819
Prins, J.
269
Polonskaja, Y.
1 212
Prof. Dr. Dukat, A.
1 145
Prof. Dr. Oravec, S.
1 145
Polus, A.
546
207
INDEX
Rein, P.
366, 731,
732, 733,
839, 883,
991, 1 067,
1 136, 1 137,
1 138
Rioja, J.
428
Rosa, I.
1 162
Ryzhkova, A.
Ripatti, S.
111, 235, 236
Rosa, R.
796, 1 008
S
Risérus, U.
1 116
Rosendaal, F.
113
Sabanovic, S.
Reis de Azevedo
Rabello, F.
863
Reis, A.
1 069
Reischl, E.
313
Reiz, B.
Salyamova, L.
591, 603, 1
044
Sardo, M.A.
496, 506,
675, 1 050
967
Salzmann, K.
503
Sarecka-Hujar, B.
1 218
448
Sarrafzadegan, N.
806, 1 197
Riško, P.
517, 558
Rosendaal, F.R.
293
Saburova, O.
473, 853
Salzmann, M.
Riso, P.
1 105
Rosenson, R.S.
392
Sachdev, V.
622
Samani, N.J.
240
Sarzani, R.
1 161
Ristic, T.
1 217
Rosłoniec, E.
584, 585
Sadeghi, M.
806, 1 197
Samoka, A.
587, 790
Sasaki, J.
461
Samperiz-Legarre,
P.
505
Sasaki, M.
693, 1 049
Sasiela, W.
247
Sampietro, T.
976
Sasiela, W.J.
246
Sanak, M.
1 016
Sassolas, A.
625
Sanchez Lopez, Y.
959
Satoh, N.
620
Sánchez MuñozTorrero, J.F.
1 216, 1 215
Satta, N.
407
Sánchez Quesada,
J.L.
630
Sattar, N.
1 013
Sausen, G.
93
Savolainen, M.
378
Savopoulos, C.
736, 794
Savostyanov, K.
785
Sawamura, T.
636
Sawant, R.
1 062
Sayfutdinov, R.
613, 848
Sazonova, M.
532, 1 066,
1 074, 1 075,
1 076
Scarinzi, P.
725
Schaefer, A.K.
789
Schaeffer, C.
283
Schalij, M.
578
Schaltenberg, N.
48
Scharfmann, R.
645
Scharin Täng, M.
647
Scharnagel, H.
396
Scharnagl, H.
374, 409,
624, 1 146
Schartum-Hansen,
H.
367, 1 208
Schatz, U.
682
Schauer, S.
284
Scheicher, B.
622
Scheideler, M.
894
Scheja, L.
88, 108
Schernthaner, G.H.
507, 771, 772,
1 147
Schiavetto, E.
1 097
Schiffmann, R.
277
Schilcher, I.
374, 499
Schlager, S.
284, 443
Schlein, C.
88
Schmid, J.A.
448
Schmidinger, B.
649
109, 340, 1
103
Rosqvist, F.
1 116
Sädevirta, S.
915
Ross, J.
1 009
Saely, C.
Rivas, A.
630
240
Rossell, J.
425
Rivellese, A.
1 183
Religa, P.
800
Rossetti, L.
Rizzo, B.
1 022
1 033, 1 034,
1 039
Ren, K.
822, 823,
824
Rizzo, P.
1 022
Rossi, N.
996
366, 731,
732, 733,
839, 879,
883, 991, 1
067, 1 136, 1
137, 1 138
Robier, C.
1 142
Rossini, M.
1 029
Saemann, M.D.
699
Robinson, J.G.
246, 463
Rosticci, M.
380, 391, 749
358
Robinson, T.
1 133
Roth, A.
407
Sáenz-Aranzubía,
P.
Rocchiccioli, S.
818, 825
Roth, E.M.
463
Saez, C.G.
478
Roche, H.
694
Rothe, M.
285
Safarova, M.
686
Rocio, T.
888
Rotllan, N.
312
Sag, S.
984
Roda, A.
1 022
Rovati, G.
1 017
Sagitov, I.
745
Roden, M.
411
Roversi, G.
407
Saheb, S.
Rodriguez -Rosety, 888
M.
Roy, A.
712, 767
Sahebkar, A.
Rubio-Gracia, J.
505
Rodríguez Cubero,
A.
835, 836,
837
Rudling, M.
336, 376,
1 116
Rodríguez-de
Miguel, M.
866
Rodriguez-Leal, C.
888, 904, 1
099, 1 109
Rencova, E.
1 026
Renker, M.
274
Rensen, P.
90, 111, 113,
556
Rensen, P.C.N.
210, 293
Rensen, S.
113
Rentz, T.
827
Ress, C.
503
Ressia, A.
961
Retterstøl, K.
957, 1 055
Revnic, C.R.
539, 540,
574, 628
REVNIC, F.
Reyes, X.
Rha, S.W.
208
1 074, 1 075
539, 540,
574, 628
945, 961
Ritsch, A.
120, 1 000,
1 185
Rodríguez-Pérez,
J.M.
356, 528
Rhainds, D.
696
904
Rhéaume, E.
696
Rodriguez-Rosety,
M.
Rhee, K.S.
493
106, 121, 717
Riascos-Bernal, D.
94
Roeters van
Lennep, J.
Ricci, .
337
Rogers, M.
Ricci, C.
419
Roglans, N.
Ricci, M.
1 161
Ricci, M.A.
Rus, V.
536
42
Ruscica, M.
337, 386, 431
508, 1 123
Russo, I.
276
Rohrer, L.
345
Russo, R.
1 209
849, 865
Rolando, B.
491
Rusu, E.
805
Richart, A.
223
Romano, D.
Rusu, F.
805
Rico Martin, S.
1 215, 1 216
Rutten, J.
270
Riesmeyer, J.
61
Ruuth, M.
378
Riga, M.
794
Rvatcheva, A.
542
Riksen, N.
106, 270, 556
Ryan, R.O.
87, 288
Riksen, N.P.
669
Ryazankina, N.
1 047
Ring-Dimitriou, S.
662
Ring, M.
521
Roncales-Garcia
Blanco, F.
505
Rye, K.A.
104, 119,
342, 704
Ringdal Pedersen,
E.
275
Ronda, N.
697, 715
Rinnerthaler, M.
662
Ros, E.
975
434
Romijn, F.
578
Sahlin, S.
1 027
Sanda, G.M.
Sairyo, M.
395, 653
488, 523,
701, 1 082
537, 1 141
Sandhu, M.S.
680
496, 506,
588, 675, 1
050
Sang Ho, J.
1 200
Sang Hong, B.
1 200
Sang-Don, P.
1 130
1 109, 904,
1 099
536
Romeu, M.
384, 876
Ruiz-Estevez, B.
Rus, H.
938
Sánchez-Quesada,
J.L.
Saitta, A.
61
Romero, E.
672, 918, 1
108
531
Ruotolo, G.
1 055
1 109
244
Sanchez-Orellana,
E.
503
630
Romeo, S.
505
Rui, L.
Rull, A.
589, 590
Sanchez-Marteles,
M.
Rufinatscha, K.
505
Romanovskaya, E.
975, 358, 921
Saita, E.
Ruiz-Laiglesia, F.
1 188, 1 189,
1 190
SánchezHernández, R.M.
Sakata, Y.
63, 395, 653
Sangüesa, G.
508, 1 123
Sakellarios, A.
399, 818
Sanjana, N.
262, 352
Sakly, M.
638
Sant’Anna Melo, E.
863
Sakri, F.H.
716
Santer, D.
789
Saksi, J.
354
Santer, P.
312
Sakurada, M.
1 049
Santilli, F.
1 033
Sala, A.
1 017
Salakhitdinov, S.
567
Santoro dos Santos 863
Pereira, S.
Salashenko, A.
1 042
Santos Filho, R.
Salatzki, J.
285
Salcioglu, O.
984
Saleh, Y.
587, 790
Salem, M.
1 171, 1 172
Salerno, A.
827
Salim, V.
677
Salinas, M.
93
SALMAN, N.
951
410
818
Rymar, O.
832
Salomaa, V.
Rynkiewicz, A.
956
Salvadori, P.A.
Ryu, J.K.
1 001
Salvayre, R.
711
981, 1 166,
1 167
Santos, D.
384
Santos, E.
1 155
Santos, F.
843
Santos, M.
592
Santos, R.
920, 945,
976
Sanz-Bescos, C.
505
Sapozhnikova, I.
878
Saraiva, C.
843
Sarantopoulos, A.
617, 618
209
INDEX
Schmidt, B.
396
Schmidt, N.
396, 937
Schmitz, C.
291
Schmölz, L.
383
Sergienko, I.V.
947
Schneider, M.
278, 772
Serrano Jr, C.V.
781
Schneider, W.
241
Serruys, P.W.
SERUSCLAT, A.
Schneider, W.J.
133, 649
Schnitzler, J.
81
Schoepf, U.J.
274
Schofield, J.D.
426
Scholler, E.
283
Seung Hwan, H.
Seung Woon, R.
435, 467,
612, 702, 1
151, 1 153,
1 227
Shimizu, M.
579, 610,
727, 755, 756,
905
1 223
Stanikova, D.
1 052
Simonova, Z.
776
Somaratne, R.
462, 1 205
Stanisz, A.
Simonyi, G.
1 007
Somerville, R.
1 031
796, 840,
841
491
Sommariva, E.
450
Stankovic, A.
373
543
292
Shiomi, M.
1 021
Singh, A.
712
Somodi, S.
1 151, 1 153
693, 1 049
Singh, N.
655
Song, H.C.
439
Staudacher, G.
503
930
Singh, S.
712
Song, K.H.
884
Stauffer, F.
1 177
666
Sinisalo, J.
378
Soon Yong, S.
1 130
Stavek, P.
515, 871
Shiqun, C.
902
Sinke, R.
331
Sopic, M.
122
Stavri, S.
1 085
Shiri-Sverdlov, R.
113
Sinyov, V.
426, 462,
976
Stef, M.
358
Stefan K., N.
48
1 130
1 200
Seyedikhosroshahi, 611
S.A.
Shiotani, K.
Shipman, K.
Shipman, K.E.
Shishkin, A.
842
412
Shakhtshneider, E.
644, 832,
929, 940,
964
Shiue, L.
269
Shkurat, T.
1 074
Shalaby, A.
797
Shlomin, V.
783
Shalaeva, A.
744
Shlyachto, E.
1 149
Shalaeva, E.
752, 851, 861
Shogenova, M.
454, 526,
542
Shokouhi, B.
817
Shpektor, A.
548, 555, 1
047
Schwarzova, L.
939, 962
Shaligram, S.
508
Scopece, A.
450
Shalimova, A.
869
Scotti, I.
616
Shamkhalova, M.
Scrimali, C.
954
860, 868,
900
500, 598,
602
Soltani, N.
Starodubtseva, I.
Schulze, M.B.
Scrylev, S.
1 105
Sinelli, M.
1 144
368, 438, 1
098
1 052
Simonetti, P.
621
681
378
415
Stanik, J.
Shinohata, R.
Shahrawat, R.
Schwab, U.
Stangl, H.
582
399
Shaari, S.A.
619
546, 1 016
Solovieva, E.
350, 371, 1
078
945, 995
33, 240
Solnica, B.
650
Shin, S.
894
Schutte, A.E.
754
Simonelli, S.
1 002
Schreier, L.
Schunkert, H.
Simon, A.
Shimizu, R.
Schratter, G.
Schwandt, P.
210
Seres, I.
Shamkhalova, M.S.
1 048
Shapira, C.
932
Sedova, E.
510
Shapira, I.
563
Segura, E.
888, 904, 1
099, 1 109
Shaposhnik, I.
1 042
Sharapov, N.
1 204
Segurado, R.
1 031
Sharashidze, N.
1 219
Sehar, N.
667, 910
Sharifi, M.
952
Seifert, R.
367
SHARMA, M.
112
Sekerkova, A.
562
Sharma, S.
815, 816
Seleem, M.
587, 790
Sharma, V.
880, 1 144
Selice, R.
725
Sharpe, L.
209
Selimovic, H.
706
Shchinova, A.
551, 679
Seljeflot, I.
1 102
Shchipakin, V.
500
Sella, S.
1 029
Shehab, A.
1 181, 1 182
Semenkin, A.
1 165
Shehu, J.
1 022
Semenova, E.
998
Shelkov, G.
400
Semenova, I.
740, 890
Shelley, E.
980
Seo, H.S.
120, 1 000,
1 185
Sheng, Q.
268
Sherbakova, E.
907
Seo, J.B.
512, 1 010
Shestakova, M.
Sequeira Duarte, J.
843
860, 868,
900
Seraceni, S.
407
Shestakova, M.V.
1 048
Serban, M.C.
672
Shih, M.F.
1 126
1 066, 1 074,
1 075
Soran, H.
Sirenko, O.
786
Sorin Nicu, B.
509
Stefanadis, C.
762, 846
Sirirat, R.
1 106
Soronen, J.
111
Stefanovic, A.
436
Sirojiddin, K.
1 221, 1 222
Sorrentino, V.
664
Stefánsdóttir, B.R.
1 220
Sironi, M.
222
Sorsa, T.
410
Stein, E.A.
465, 976
Sirtori, C.
121, 963
Soska, V.
950
Steinberg, A.
244
Sirtori, C.R.
131, 386,
639, 689
Sotnikova, R.
1 015
Soyal, S.
662
SteinhagenThiessen, E.
669, 935,
989, 1 087
Sisic, I.
706
Soyal, T.
294
Stender, S.
211
Skeldal, S.
332
Spang, J.
492
Stenvinkel, P.
47
1 031
Skilton, M.
758
Spannella, F.
1 161
Stepanov, A.
1 026
Shuto, T.
1 041
Škop, V.
421, 661, 895
Spanou, M.
794
Stern, C.
477
Shuto, Y.
886
Skoumas, I.
762, 846
122
Stevens, A.
426
Si, S.
695
Skroblin, P.
312
Spasojević
Kalimanovska, V.
Stewart, F.
650
Siahmansur, T.
426
Skryabin, N.
520, 1 086
436, 741, 874
Steyrer, E.
328
SIALVERA, T.E.
1 092
Sleptcov, A.
520, 1 086
SpasojevićKalimanovska, V.
Stiefel, P.
1 158
Sibinga, N.
94
Smiianova, O.
1 187
Speidl, W.
541, 720
Stimjanin, E.
706
Siebel, A.
223
Smiianova, Y.
1 187
Sperlongano, S.
924, 925
Stitziel, N.
946
Siepi, D.
849
Smit, N.
578
Speziali, G.
656
Stivala, S.
127
Sifuentes Diaz, E.
614, 615
Smith, W.
619
Spina, R.
954, 1 169
Stöckl, D.
411
Sigurðardóttir, Y.R.
1 220
Smyth, S.
95
Spira, D.
935, 989
Stoekenbroek, R.M. 680
Sijbrands, E.
717
So, W.Y.
885
Spitz, C.
128, 305
Stoijkovic, S.
418
Silva, A.P.
1 178
Sobenin, I.
Spolding, B.
1 113
Stojakovic, T.
Silva, I.T.
814
Sposito, A.
1 156
374, 409,
624, 1 146
Silva, K.S.
698
532, 633, 1
066, 1 073, 1
074, 1 075, 1
076, 1 077
Stadiotti, I.
450
Stokic, E.
870, 1 095
Silva, R.
592
Sobotka, L.
1 112
Stadlbauer, V.
440
Stoll, M.
945, 961
Sima, A.V.
488, 523,
701, 1 082
Söderlund, S.
241
Staessen, J.
768
Stone, G.W.
399
Sodi, R.
1 081
Staffler, G.
245
Stosic, Z.
870, 1 095
Simental-Mendía,
L.E.
672
Søfteland, E.
249
Ståhlman, M.
647
Stover, C.
916
566
Stramba-Badiale,
M.
431
314
Sohrabi, B.
1 059
Simes, J.
Stamatelopoulos,
K.
Simic-Ogrizovic, S.
436
Sokolov, A.
501
Stanciu, O.
609, 792
Strand, E.
Simionescu, M.
523, 527, 701,
1 082, 1 085
Sol, W.M.P.J.
483
Stancu, C.S.
363, 367, 1
208
Soler, C.
944
488, 523,
701, 1 082
Straniero, S.
1 116
434
Stanek, V.
1 068
Straußfeld, E.
291
1 102
Stangl, G.
1 154
Stravinsky, J.
827
Shrivastava, A.
Simionescu, N.
1 082
Soler, J.
Simmelbauer, A.
102
Solheim, S.
211
INDEX
Straznicky, N.
Svobodova, M.
889, 892
Strelow Thurow, H. 972
Swartz, E.
93
Strijdom, H.
502, 514
Sweeney, M.
118
Stroes, E.
13, 77, 81,
106, 299,
464, 547, 714
Swiader, A.
822, 823,
824
Thedrez, A.
645
Theodorou, K.
704
Tankovskiy, V.
606
Thiersé, D.
283
346
Tantry, U.S.
417
Thiessen, E.S.
14, 668
Swier, V.
82
Tarasenko, N.
1 070
Torres-Courchoud, 505
I.
Thomaidis, A.
657
277
244, 696
1 230
Swift, C.
Tardif, J.C.
Torres, L.
Thomas, F.
1 196
93
Tardivel, S.
691
Thomaz, S.
1 177
ToseskaTrajkovska, K.
678
Swirski, F.
Swirski, F.K.
306
Tarhbalouti, K.
1 157
Thompson, P.
314
1 159
770
Syed, A.
426
Tarlarini, C.
963
Thorand, B.
411
Tosheska
Trajkovska, K.
956
Sysi-Aho, M.
275
Tarlovskaya, E.
Thymiakou, E.
130
Toshev, B.
Szentimrei, R.
435
746, 878, 1
110, 1 165,
1 191
Tibolla, G.
347, 431, 472
776
Ticha, A.
Tartari, S.
222
Tichy, L.
Tarzamni, M.K.
817
Tietge, U.
Tas, S.
704
Stroes, E.S.
669
Stroes, E.S.G.
392, 627, 1
009
Strohmaier, S.
StroniawskaWoźniak, M.
212
658
Szentpéteri, A.
435, 702,
1 151
Tang, Z.L.
Toro, R.
614, 904, 1
099, 1 109,
1 162
Trzeciak, J.
584
Tsai, W.C.
516, 773, 919
Tscharre, M.L.
1 147
Tschöp, M.
298
Tselepis, A.
928, 1 035,
1 128
Tselios, K.
617, 618
Tselmin, S.
403, 682
Tseng, H.C.
533
572, 1 018
Tsiantoulas, D.
307
Toth, P.
389
Tsimihodimos, V.
432, 709
1 112
Tothova, V.
724
Tsimikas, S.
962, 973
Touqui, L.
704
47, 699
Tousoulis, D.
762
455, 627,
668, 669,
670, 673,
674, 680
Tietge, U.J.F.
804
Trabattoni, D.
1 033, 1 034
Tsoukatos, D.
1 035
84, 217
Tikka, A.
623
Tragante do Ó, V.
240
Tsoumani, M.
1 035, 1 128
111, 241, 387,
463
Tilg, H.
312, 503
Trakarnwijitr, I.
723, 1 206
Tsujita, M.
375
Timina, I.
906, 911
Tramontana, A.
1 154
Tsunoda, T.
1 021
Stryeck, S.
443
Stulnig, T.
231
Stumpf, C.
377
Sztanek, F.
Su, C.H.
348
T
Suarez-Tembra, M.
975
Ta, H.
273
Suchanek, P.
515
Tabet, F.
119, 342
Suciu, L.
1 043
Taborsky, M.
1 005
Sudjana, P.
576
Tada, H.
948
Tatomir, A.
536
Timmerman, I.
481
Tran, H.
757
Tsyrulneva, N.
811
Sugihara, H.
886
Tae Hyun, Y.
1 200
Tauchi-Brück, M.
377
Tinoco Racero, I.
615
Trapani, G.
588
Tubeuf, E.
104
Suh, J.W.
1 032
Tae-Hoon, K.
1 130
Tauchi, M.
1 069
Tinoco-Racero, I.
Trautwein, E.
1 104
Tuckwell, K.
1 013
Suhre, K.
297
Taehoon, A.
1 130
Taurino, M.
Trautwein, E.A.
1 092
Tudorache, I.F.
527, 1 085
Sukhova, G.
93
Taghipour, H.
1 108
544, 549,
550
888, 1 099,
1 109
Tinoco, I.
904
Travnikova, E.
1 140
Tuimala, J.
354
Sukmanova, I.
1 224, 1 225,
1 226
Taherkhanchi, B.
566
Tavares Bello, C.
843
Tiran, B.
707
Trayhurn, P.
849
Tuomi, T.M.
354
Takahashi, A.
949
Tavintharan, S.
994
Tishko, V.
501
Trbušić, M.
707
Turer Cabbar, A.
1 150
Sullivan, D.
314
Takemoto, Y.
1 041
Tawakol, A.
78, 80
Titze, J.M.
54, 55
Tregubov, A.V.
718
turhan caglar, F.N.
826
Sullivan, D.R.
471
Takiguchi, S.
693
TBA,
320, 433
Titze, S.
278
Tremblay, K.
Turnbull, A.V.
622
Sulowicz, W.
903
Talbi, E.
1 111, 1 174
Tegla, C.A.
536
Tixeira, R.
489
353, 660, 1
053
621
Talbot, C.
340, 1 103
Tejedor, M.T.
971
Toell, T.
1 229
Sun, J.
248
Tallada Iborra, R.
531
Tell, G.
275
Toh, R.
338
222, 530, 1
033, 1 034,
1 039
995
Sumino, H.
Tremoli, E.
Tuseddo, J.C.
Tybjærg-Hansen,
A.
237, 211, 427,
429, 1 080
Sun, W.
677
Tallgren, T.
690
Tell, G.S.
363, 367
Tokgözoglu, L.
407
Tzakos, A.
1 128
516
Talmud, P.J.
238
Tellis, C.
928
Trescher, K.
789
Tzani, A.
382, 1 119
Sundbom, M.
1 116
Talukdar, S.
88
Temizhan, A.
984
72, 255, 294,
296, 715,
984
Trentini, A.
Sun, Y.T.
1 152
Tziakas, D.
657
Sung Ho, H.
1 200
Tam, C.
885
Temporelli, P.L.
1 179
Tziomalos, K.
Sung Woo, K.
1 130
Tam, L.
62
Teng, Z.
349
617, 618, 794,
1 088
Sung, H.R.
564
Tamanaha, T.
949
Teodoro, W.
1 122
Sunkara, M.
385
Tamás, F.
1 007
Teoh, Y.P.
936, 990
1 227
Tarlovskaya, Y.
Taskinen, M.
Taskinen, M.R.
Suo, R.
823
Tamborino, C.
407
Teplov, A.
906
Suoniemi, M.
639
Tami, J.
669, 670
Terrand, J.
283
Susekov, A.
582
Tamura, S.
1 021
Terrin, M.
725
Suspitsyna, I.
1 225, 1 226
Tan Kurklu, T.S.
1 228
Tershakovec, A.
389
Sutcliffe, M.
349
Tanaka, N.
338
Tervahartiala, T.
410
Suwa, J.
875
Tanaka, Y.
579, 610,
727, 755, 756,
905
Tesloianu, D.
575
Suzuki, N.
537, 1 141
Svardal, A.
363, 1 208
Svetlikov, A.
400
Svingen, G.F.T.
363, 367, 1
208
Tanashyan, M.
Tang, L.
500, 598,
602
465, 976
Tesmenitsky, Y.
93
Tetik Vardarli, A.
953
Thakkar, H.
712
Thaler, B.
418
Toledo, V.
1 122
Tretjakovs, P.
Toma, L.
488, 701
Tribuntseva, L.
750
Tomas, L.
290
Trieb, M.
440
Tomashevskaya, Y.
1 044
Triebswetter, S.
908
Tomassini, J.
389
Trikash, I.
1 203
Tomescu, M.
1 043
Trikha, D.
722
Tomilova, D.
782
Trindade, L.
1 156
Tomlinson, B.
357, 885
Tripepi, G.
1 029
Tondo, C.
450
Tripoten, M.
551, 679
Toni, D.
544
Tritapepe, L.
549, 550
Tonkin, A.
314
Trivella, M.G.
818, 825
Tootsi, K.
1 129
Trnovska, J.
421, 661, 895
Tori, M.O.
1 021
Trojak, A.
912
Torii, H.
1 002
Trompet, S.
293
Trusca, V.G.
527, 1 085
U
Uboldi, P.
554
Ueda, T.
1 045
Ueland, P.
779
Ueland, P.M.
367, 1 208
Ulbricht, C.
757
Ulianova, I.
860
Ulmer, H.
770
Umarov, A.
608
ungan, I.
826
Urazgildeeva, S.
400, 718
Usenko, T.
740, 890
Usui, S.
621
213
INDEX
Utermann, G.
234
van Tuijl, J.
106
Vesa, S.C.
913
Utkina, E.
687
Van Veldhoven, P.
655
Vianello, D.
725, 987
Uto-Kondo, H.
693, 700, 1
049
van Vlijmen, B.J.M.
1 040
Uusitupa, M.
378
V
Vickers, K.
268
van Zonneveld, A.J. 269, 483
Vihervaara, T.
275, 378
Vandendaele, L.
856
Viklicky, O.
683
Vanoli, D.
595, 596
Vikulova, O.
868, 900
Vrablík, M.
366, 731,
732, 733,
839, 879,
883, 991, 1
067, 1 136, 1
137, 1 138
Watts, G.F.
394, 471,
672, 926,
927, 1 168
Witztum, J.L.
455, 627,
668, 669,
670, 673,
680
Weber-Boyvat, M.
286
Weber, C.
128, 305
Wohlfahrt, P.
515
Weber, J.
127
Woitas, R.
243, 962, 778
1 146
502
Wojciechowska, W. 931
641, 651
Wojdan, K.
518, 801, 828
418, 541, 720
Vagida, M.
1 047
Varava, A.
911
Vikulova, O.K.
1 048
Vrieling, F.
556
Webster, I.
Valdivielso, J.M.
774
Varbo, A.
123
Vila Belmonte, A.
766, 975
Vriz, O.
599
Weers, P.
Valdivielso, P.
766
VARDARLI, A.T.
951
Vila, À.
944
Vuilleumier, N.
364, 407
Wegscheider, M.
443
Wojta, J.
Vila, L.
944, 1 012
Vujic, N.
284, 335
224, 470
480, 494
481
Wolf, D.
Varejckova, M.
Weijers, E.M.
Vilela-Martin, J.
1 178
Vynnychenko, L.
1 187
314, 362
435, 1 151
649
Wong, G.
Varga, E.V.
Weijler, A.
Viljoen, K.
1 031
Vyzantiadis, T.A.
1 088
994
467, 612, 702
412
Wong, M.S.
Varga, V.E.
Weikert, C.
W
362, 449
Wong, N.
118
835, 836,
837
Weir, J.
769
Valenti, L.
1 055
Valenti, V.
954, 1 169
Valikulova, F.
1 231
Valkov, I.
917
Vargas-Alarcón, G.
356, 528
Vallejo-Vaz, A.J.
1 158
Variya, B.
1 120
Villanueva
Fernández, E.
Varol, S.
777
Villar, J.
Varret, M.
946
Villarreal-Molina, T. 356, 528
Vasconcelos, C.
843
Vinaixa, M.
Vasilieva, E.
548, 555, 1
047
Vincent, V.
Vinchi, F.
102
842
Vindis, C.
346
van Beek, L.
556
van Bockxmeer,
F.M.
471
van Buul, J.D.
481
van Capelleveen, J. 286, 331, 627
van Dam, A.
556
van de Pavert, S.A.
481
Vasilkova, V.
852
Van de Voorde, J.
856
Vaslin-Reimann, S.
634
van den Berg, B.M.
483
Vassalo, T.
van den Berg, S.
556
Vasudevan, A.
van den Hoek, A.
446
Vatrano, M.
van den Munckhof, 270
I.
van der Burgt, Y.
578
van der Hoorn,
J.W.A.
245
van der Krieken,
S.E.
103
van der Laarse, A.
578
van der Tuin, S.
113
van der Valk, F.M.
214
Vonbank, A.
669
van der Veer, E.
269
van der Veer, E.P.
483
van der Vorst, E.
704
Van Eck, M.
704, 1 040
van Esch, H.
269
Van Gaal, L.
215, 719
van Gils, J.
269
van Gils, J.M.
483
van Harmelen, V.
556
van Kooten, C.
269
van Leuven, S.I.
547
van Rooyen, J.M.
619
van Tits, L.J.
127
Vasilkova, O.
Viney, N.J.
1 158
434
712
668, 669,
670
62
Welsh, P.
1 013
Wood, D.
872
Wen, J.T.
1 014
Woong Chol, K.
1 130
Wahl, S.
313
Werner, C.
381, 624
Worm, J.
513
Wakefield, D.
107
Werngren, O.
203
Worsfold, B.P.
743
313
Werstuck, G.
1 173
Worth, G.
1 009
Walder, K.
1 113
Werz, O.
383
Worthmann, A.
48
Waldmann, E.
394
West, H.
758
Worthy, G.
1 009
383
Westcott, C.
502, 514
Woudberg, N.
710
903, 912, 931
Whittaker, A.
273
Wu, Y.
704
Wick, G.
351
Wühle-Demuth, M. 1 087
Widhalm, K.
960, 1 107
X
Wade-Martins, R.
Wadsack, C.
Waldenberger, M.
Wallert, M.
Walus-Miarka, M.
742, 941
Virzi, J.
407
Visek, J.
1 112
Wan Ahmad,
W.N.H.
716
277
588
Vishnolia, K.
1 157
Wan, J.
873
Więcek, M.
585
Xenaki, C.
1 115
849
Visinoni, C.
898
Wang, A.
248
903
Xia, S.
669, 670
Vaverkova, H.
635, 962
Visocka, A.
1 152
Wang, C.C.
704
WieczorekSurdacka, E.
Xiao, J.
1 186
Vaysberg, A.
1 231
Vitale, G.
1 209
Wang, F.
447, 873
Wieffer, H.M.
392
Xida, L.
490
Vitali, C.
386
Wang, H.J.
810
Wiegman, A.
968
Xilifu, D.
1 090
Vitverova, B.
480, 494
Wang, J.M.
105
Wigren, M.
290
Xiong, S.L.
823
Wiklund, O.
136, 225,
251, 1 055
Xu, Y.
695
312, 411, 1
229
Yadav, R.
426
Yadernaya, A.
568, 728,
850, 1 163
Vaudo, G.
Vazquez Cardenas, 959
A.
VazquezAlfageme, J.
1 162
Vivanco, F.
129
Wang, K.Y.
456
Vlachos, I.
382, 1 119
Wang, L.
339
Vecera, R.
Vedie, B.
421
Vlad, A.
1 082
Wang, P.
447, 873
691
Vladimirov, S.
741, 874
Wang, Q.
447
Veierød, M.B.
957
Willeit, K.
503, 1 229
Vlaicu, S.I.
536
Wang, X.
402, 695
Vekić, J.
436, 741, 874
Willeit, P.
312
Voevoda, M.
644, 795,
832, 929,
940, 964,
1 212
Wang, Y.
113, 210
Yagi, K.
948
293
Wanner, C.
699, 1 192
Willems van Dijk,
J.A.P.
Yahya, R.
717
Wanschel, A.
827
Willems van Dijk, K. 113, 210
Yakushiji, E.
693
947
680
Willenborg, C.
240
593
Voevoda, M.I.
Wareham, N.J.
Yamada, K.
970
627
William, K.
248
456
Vogt, A.
Wareham, N.T.
Yamada, S.
1 043
956
Williams, H.
545
948
Voicu, M.
Wasag, B.
Yamagishi, M.
Voidazan, S.
775
Wasiak, S.
118
Wilson, A.
723, 1 206
Yamashita, S.
63, 395, 461,
653
VOINEA, S.
539, 628
Wasserman, S.M.
976
Wilson, R.
313
Yamashita, T.
583
Volpe, R.
1 097
Waters, D.
119
Winkels, H.
128, 305
Yamazaki, Y.
1 041
Volpi, N.
416
Wattimena, D.
717
Wittchen, H.U.
396
Yanagida, T.
457
von Eckardstein, A.
257, 327, 329,
345, 714
Watts, G.
355, 424
Wittenbecher, C.
412
Yang-Yen, H.F.
341
Yang, C.M.
533
Velagapudi, S.
345
Veldhof, S.
399
Velosa, A.P.
1 122
Vendrame, S.
1 105
Venn, A.
758
Verbeek, R.
680
Verhoeven, A.
717
Verkade, H.J.
804
Veronese, N.
1 029
VERSET, M.
292
Verweij, S.
81, 106
Verwilligen, R.A.F.
1 040
Willeit, J.
Y
215
216
Yang, F.
339
Yurtaev, Y.
783
Zhang, J.
339
Yang, H.
464
Yuschak, S.
416
Zhang, P.
83
Yang, L.
95
Yvant-Charvet, L.
124, 304
Zhang, Q.H.
Yang, X.
627, 673
Z
822, 823,
824
Yang, Z.
479
Zabakhidze, N.
844
Zhao, S.
268
Yano, S.
703, 1 135
Zafrir, B.
932
Zhelankin, A.
Yarovaya, E.
629, 640
Zagajewski, J.
840
532, 1 076,
1 077
Yasuda, D.
1 002
Zagidullin, B.
1 140
Zheleznyakova, A.
868
Yayla Abide, C.
893
Zagidullin, N.
1 224
Yeang, C.
455, 673, 674
745, 907, 1
140
Zheltova, I.
Zhemchugov, A.
400
Zagidullin, S.
745, 907, 1
140
Zheng, H.
452
Zheng, K.H.
547
Zagjewski, J.
1 008
Zhetisheva, R.
Zago, V.H.
983
454, 526,
542
Zaibi, M.S.
849
Zhokhov, D.
850
Zak, I.
1 218
Zhou, P.
447, 873
12, 226, 725,
987, 1 029
Zhu, W.
268
Zhu, Y.
653
121, 725, 1
029
Zhuang, L.
210
Zielinski, L.P.
743
Yen, J.J.Y.
341
Yenercag, M.
984
Yersal, N.
294
Yet, S.F.
348
Yi, C.
210
Yi, G.H.
822, 823,
824
Zambon, A.
Yilmaz, H.
984
Yilmaz, M.
984
Yin, X.
312
Zambonin, L.
1 022
Yin, X.L.
1 186
Ziemann, M.
1 113
Zamfirescu, A.
609, 792
Yingling, Z.
490
Zierfuss, B.
507
Zamora, A.
944
Yki-Järvinen, H.
915
Zilmer, M.
1 129
Zampelas, A.
1 092
Ylä-Herttuala, S.
37
Zimetti, F.
Zampetaki, A.
312
697, 715, 1
058
Yogo, M.
693
Zannis, V.
652
Zimmer, A.
622
Yokota, T.
375
Zannouri, A.
1 174
Zimmermann, R.
282, 284
Yokoyama, S.
375, 531, 693
Zanolin, D.
Zimmet, P.
1 113
yongqiang, H.
809
Zirlik, A.
Yoo, J.A.
829
224, 306,
470
Yoo, J.Y.
420
Zito, C.
599
Yoshida, M.
948
366, 731,
732, 733,
839, 879,
883, 991, 1
136, 1 137,
1 138
Zivanovic, V.
821
Yoshikawa, J.
1 041
Zanotti, I.
692
Zivkovic, M.
373
Yoshikawa, K.
338
Zateyshchikov, D.
785
Zizkova, V.
1 005
Yoshino, G.
855
Zaytsev, D.
807
Zo, J.H.
512, 1 010
Yoshino, H.
855
Zdzienicka, A.
1 016
Zotikov, A.
Yoshiyama, M.
1 041
Zechner, R.
92, 137
793, 906,
911, 1 023
Youn, T.J.
1 032
Zelarayán M
961
Zouhar, P.
889
467, 702
Zambon, S.
Young, J.L.
493
Zelcer, N.
209, 664
Zsíros, N.
Youngkeun, A.
1 200
Zelinskiy, V.
830
Zuk, M.
956
Yu, C.W.
738, 739, 1
004
Zeljković, A.
436, 741, 874
Zulkarneev, R.
1 140
Zelzer, S.
1 142, 1 143
Zuraeva, Z.
900
Zeng, L.
240
Zvintzou, E.
688
Zerr, A.
283
Zykov, K.
1 139
483
Þorgeirsson, G.
1 220
Νomikos, T.
1 115
Yu, T.
524
Yu, Y.
479, 1 021
Yuan, C.
248
Yue, J.
823
Zhang, H.
84 EAS CONGRESS
th
May 29 - June 1, 2016
Innsbruck, Austria
Recognition,
s and
t
n
e
m
e
g
d
e
l
w
Ackno
t
r
o
pp
u
S
l
a
i
c
r
Comme
84 EAS CONGRESS
th
ACKNOWLEDGEMENTS
PCSK9 inhibitors: a conversation
on selecting the right patients
CORPORATE PARTNERS
gold Level Corporate Partner
Programme
Chair: Alberico Catapano, Italy
Welcome and introduction
Who is at greatest unmet need?
Clinical perspective
How effective are PCSK9 inhibitors
in reducing LDL-C?
Alberico Catapano, Italy
Michel Farnier, France
Panel
Panel
Which patients find it hardest to achieve
recommended LDL-C levels?
- Familial hypercholesterolaemia
- Statin intolerance: gaUSS-3 data
Will lowering LDL-C with PCSK9
inhibitors reduce CV risk?
Closing Q&a and panel discussion
Chair’s summary and close
Silver Level Corporate Partner
Bronze Level Corporate Partners
Panel
Panel
joint Bronze partners
Lu
nc
218
hb
ag
sw
ill b
ep
rov
Amgen (Europe) GmbH
Dammstrasse 23
CH-6300 Zug
Switzerland
www.amgen.com
ide
d
© 2016 Amgen Inc. All rights reserved.
EUHQ-NP-145-0216-125392a
219
84 EAS CONGRESS
th
ACKNOWLEDGEMENTS
The Organising Committee and the EAS Executive Committee would like to express their
gratitude and acknowledgement to the following companies for their generous support in
the 84th EAS Congress:
EXHIBITORS
Platinum sponsors
gold sponsors
silver sponsors
sponsors
220
221
84 EAS CONGRESS
th
Industry supported sessions
12:30-13:30
Carl von Rokitansky (Brussel)Hall
13:00-14:30
Nikolai N. Anitschkow (Tirol) Hall
Meet the Experts The Medical Puzzle of HoFH PCSK9 inhibitors: a conversation on
selecting the right patients
Chairperson: Chairperson: Alberico Catapano, Italy
Cesare Sirtori, Italy
•
Jeanine Roeters Van Lennep, The Netherlands
•
Claudia Stefanutti, Italy
•
Marcello Arca, Italy
16:00-17:30
13:00 - Welcome and introduction
13:05 - Who is at greatest unmet need?
Nikolai N.Anitschkow (Tirol) Hall
13:15 - Clinical perspective
Panel
13:20 - How effective are PCSK9 inhibitors in reducing LDL-C?
MOVING PCSK9 INHIBITION FORWARD:
The Future of Evidence-Based CV Outcomes in High-Risk Primary and
Secondary Prevention Patients
Panel
Chairperson: Jean-Claude Tardif, Canada
13:45 - Statin intolerance: GAUSS-3 data
16:00 - Welcome and Introductions
Jean-Claude Tardif, Canada
Panel
16:05 - Case-Based Approach to Identifying High-Risk Primary and Secondary Prevention
Patients
14:05 - Will lowering LDL-C with PCSK9 inhibitors reduce CV risk?
16:25 - Current Guidelines for High-Risk Patients: The Need for Evidence-Based Decision
Making to Address Remaining Unmet Need
G Kees Hovingh, The Netherlands
Which patients find it hardest to achieve recommended LDL-C levels?
13:35 - Familial hypercholesterolaemia
14:15 - Closing Q&A and panel discussion
Panel
14:25 - Chair’s summary and close
16:45 - Cardiovascular Risk Reduction With PCSK9 Inhibition: Evidence-Based Long-Term
CV Outcomes
Jean-Claude Tardif, Canada
17:05 - Panel discussion/Q&A
222
223
84 EAS CONGRESS
th
13:00-14:30
Karl Landsteiner (Innsbruck) Hall
LDL-Cholesterol Update 2016
Chairpersons: Lale Tokgözoglu, Turkey
Pepe Zamorano, Spain
13:00 -Welcome and Introduction – What’s Hot 2016
Lale Tokgözoglu, Turkey
13:10 - The Clinical Reality – Attaining Treatment Targets in 2016
13:00-14:30
Karl Landsteiner (Innsbruck) Hall
PCSK9 therapeutics – can we redefine the clinical management of
hypercholesterolemia?
Chairperson: John Chapman, France
13:00 - Introduction
John Chapman, France
13:20 -What Do Recent Combination Studies Teach Us? – The Most Recent Insights
Peter Toth, USA
13:05 - PCSK9 therapeutics – the evidence so far
Eli Roth, USA
13:45 -Novel Findings on Genetics and Mendelian Randomization
Heribert Schunkert, Germany
13:25 - PCSK9 therapeutics – early insights from the correlation between LDL-C
and cardiovascular events
Kausik Ray, UK
14:00 - The Role of Combination Therapy – Defining Treatment Options for the Individual
Patient
14:15 - Panel Discussion
13:45 - PCSK9 therapeutics - what do we have yet to learn?
Ulrich Laufs, Germany
14:05 - Panel Discussion and Q&A
Eli Roth, USA
Kausik Ray, UK
Ulrich Laufs, Germany
14:25 - Closing remarks
224
225
84 EAS CONGRESS
th
14:00-14:45 Nikolai N.Anitschkow (Tirol) Hall
Special Lecture: Novel Concept and Clinical Proof to Address Unmet
Medical Needs for the Treatment
of Rasidual Vascular Risk
Chairpersons:
Jean-Charles Fruchart, France
14:00 Welcome and Introduction
14:05 Novel generation of Peroxisome Proliferator-Activated Receptor alpha (PPARα)
agonists: selective PPARα modulator (SPPARMα)
14:25 Clinical proof of concept of SPPARMα developed to be more effective and less
harmful
Shun Ishibashi, Japan
14:10-14:55
Carl von Rokitansky (Brussel) Hall
CETP inhibition – what’s hot in 2016?
Chairperson: Alberico Catapano, Italy
14:10 Opening by the chair
14:15 The pharmacologic basis: Recent insights into kinetics
Gisette Reyes-Soffer, USA
14:25 Facts, Findings & Expectations
Ulf Landmesser, Germany
14:35 Is there a need for a new small molecule?
Wouter Jukema, The Netherlands
14:45 Round Table, Q&A
14:05-14:50 Wilhelm Auerswald (Strassburg) Hall
MeEt the Expert:
Introducing Sebelipase alfa, a novel treatment for LAL-D
A case-based meet-the-expert session chaired by Professor Thomas Stulnig
Experts will present cases on Lysosomal Acid Lipase Deficiency including early treatment
results with Sebelipase alfa.
226
227
84 EAS CONGRESS
th
Educational Grant
Exhibition Information
The following session is supported by an Educational Grant.
EXHIBITION MAP
N. Anitschkow Hall
18:40-19:40
Keynote Lecture
Supported by Amgen, AstraZeneca, MSD, Pfizer, Regenron and Sanofi.
Chair: Alberico Catapano (Italy)
Chair: Wolfgang J. Schneider (Austria)
18:40 How genes control cholesterol
Michael S. Brown (USA)
EXHIBITORS LIST
Company Name
22
Alexion Pharma
2
Amgen
18
Denka Seiken
European Atherosclerosis Society
228
Booth #
Akcea Therapeutics
8
10 and 25
European FH Patient Network
5
FH SCORE
23
Fujifilm VisualSonics
12
Immuno-Biological Laboratories
7
Kaneka Pharma Europe
6
Meda Pharma
17
Merck MSD
1
Mercodia
24
Nebion
4
Numares Health
9
Randox
21
Sanofi Regeneron
20
Wisepress Medical Bookshop
26
229
84 EAS CONGRESS
th
List of Sponsors,
Supporters & Exhibitors
Aegerion
YOU’VE ONLY JUST
ARRIVED & ALREADY
WE’RE THINKING OF
YOUR NEXT TRIP
As the official airline network for EAS 2016, we’d like to
thank you for choosing the Star Alliance network and hope
that all goes really well for you here today.
Whilst you concentrate on the day’s events, we hope you’ll
consider us the next time you need to attend a conference.
With over 18,500 flights a day to 1,330 airports across
192 countries, our 28 member airlines will extend a wide
choice of flights to any future conference you’re planning
to attend. And no matter which of those airlines’ frequent
flyer programmes you belong to, you can earn and redeem
miles across all of them.
Aegerion Pharmaceuticals Inc
One Main St, Suite 800
Cambridge
MA 02142
USA
http://www.aegerion.com
Aegerion Pharmaceuticals, headquartered in Cambridge, Massachusetts, is a
biopharmaceutical company dedicated to the development and commercialization of
innovative therapies for patients with debilitating rare diseases. The Company was founded
in 2005 with an initial focus of bringing new therapies to patients with severe lipid disorders
and is now focused on research, development, commercialization of orphan drugs for the
treatment of debilitating rare diseases.
Akcea Therapeutics
55 Cambridge Parkway, Suite 100
Cambridge
02142
USA
Booth #: 22
http://www.akceatx.com
Akcea Therapeutics is a development and commercialization company focused on
transforming the lives of patients with serious cardiometabolic lipid disorders. Established
as a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., Akcea’s portfolio spans
multiple targets and disease states using advanced RNA-targeted antisense therapeutics.
Akcea’s investigational pipeline includes novel drugs designed to reduce several lipid
risk factors, including LDL-Cholesterol, apoC-III, triglycerides and Lp(a). Volanesorsen,
Akcea’s most advanced investigational drug, is in Phase 3 trials for ultra-orphan lipid
disorders characterized by extremely high triglycerides and apoC-III, including familial
chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL). www.akceatx.com.
So the next time you want to concentrate all your energies
on your conference, we hope you’ll decide to leave the
travel arrangements to us.
www.staralliance.com
Information correct as of 03/2016
230
231
84 EAS CONGRESS
th
Alexion Pharma
AstraZeneca Giesshübelstrasse 30
Zürich
8045
Switzerland
Booth #: 02
http://www.alexionpharma.eu
Alexion is a global biopharmaceutical company focused on developing and delivering lifetransforming therapies for patients with devastating and rare diseases. Patients with these
life-threatening diseases often have no effective treatment options, and they and their
families suffer with little hope. Our goal is to deliver medical breakthroughs where none
currently exist. We are driven because we know people’s lives depend on our work.
SE-43183 Mölndal,
Pepparedsleden 1
Sweden
www.AstraZeneca.com
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the
discovery, development and commercialisation of prescription medicines, primarily for the
treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology,
infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
AMGEN
DAMMSTRASSE 23
ZUG
6300
Switzerland
Booth #: 23
http://www.amgen.com
Amgen’s Commitment to Cardiovascular Disease Amgen is dedicated to addressing
important scientific questions to advance care and improve the lives of patients with
cardiovascular disease. Amgen has built a robust cardiology pipeline in an effort to address
a number of today’s important unmet patient needs, such as high cholesterol and heart
failure. About Amgen Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people’s lives. Amgen has grown to be the world’s largest
independent biotechnology company, reaching millions of patients around the world.
Amgen EU HQ
Dammstr. 23
Zug
6301
Switzerland
Booth #: 18
http://www.amgen.com
Amgen’s Commitment to Cardiovascular Disease Amgen is dedicated to addressing
important scientific questions to advance care and improve the lives of patients with
cardiovascular disease. Amgen has built a robust cardiology pipeline in an effort to address
a number of today’s important unmet patient needs, such as high cholesterol and heart
failure. About Amgen Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people’s lives. Amgen has grown to be the world’s largest
independent biotechnology company, reaching millions of patients around the world.
232
BASF
Carl-Bosch-Strasse 38
Ludwigshafen,Rhineland-Palatinate
Germany
website: http://www.basf.cm
www.newtrition.com
BASF’s Nutrition & Health division develops, produces and markets a comprehensive range
of products and services for the human and animal nutrition, pharmaceutical as well as
flavor and fragrance industries. The division strives to contribute to a better life through
improving the nutrition, health and wellbeing of people across the world. Important human
nutrition products are vitamins and carotenoids, plant sterols, emulsifiers and omega-3 fatty
acids. Its feed additives such as vitamins, carotenoids, enzymes and organic acids make
Nutrition &Health a worldwide leader for the animal nutrition market. The division provides
the pharmaceutical industry with active ingredients such as caffeine and ibuprofen, as well
as excipients and custom synthesis services. Furthermore, it produces aroma ingredients
such as citral, geraniol and L-menthol for the flavor and fragrance industry.
Denka Seiken Co., Ltd
Nihonbashi Mitsui Tower, 2-1-1 Nihonbashi-Muromachi
Tokyo
103-8338
Japan
Booth #: 08
http://denka-seiken.jp
Denka Seiken offers assays directly quantifying (without any sample pretreatment) lipid
subfractions, and also latex-enhanced turbidimetric immunoassays for specific protein
biomarkers to be run on automated chemistry analyzers. The range of lipid subfraction
assays includes small dense LDL, HDL3, Remnant Lipoproteins and Triglycerides in LDL
particles. The latex-enhanced turbidimetric immunoassays are available for Adiponectin,
Lp(a), Cystatin C, hsCRP, RF, Myoglobin, IgE, Ferritin, etc.
233
84 EAS CONGRESS
th
European Atherosclerosis Society
Mässans gata 18/ Box 5243
Gothenburg
40224
Sweden
Booth #: 10
http://www.eas-society.org
Advancing and exchanging knowledge of the causes, natural history, treatments and
prevention of atherosclerotic disease.
FH Europe
7 North Road
Maidenhead
SL6 1PE
UK
Booth #: 05
http://www.fheurope.net
FH Europe is the European FH Patient Network, consisting of 20 European patient
organisations. We actively work to secure early identification and diagnosis of FH patients
to prevent early cardiovascular disease. Our vision is to identify all FH patients across
Europe and for them to be optimally treated in order they may live a full and healthy life.
We were founded in 2015 and have successfully achieved a number of activities, including
launching a Call to Action at the European Parliament in Brussels, we contributed to videos
and articles about FH, attended health care professional meetings to raise awareness of the
network and held a meeting of all countries to share best practice.
FUJIFILM VisualSonics
3080 Yonge Street Suite 6100
Toronto
M4N3N1
Canada
Booth #: 12
http://www.visualsonics.com
FUJIFILM VisualSonics, Inc is the undisputed world leader in high-resolution, microultrasound systems designed for cardiovascular research. Our Vevo systems operate at
10-70 MHz, achieving up to 30 μm resolution, 5-10 times higher than any other ultrasound
system. Our small animal handling platforms captures key physiological parameters
including temperature, respiration, ECG and heart rate. These are integrated in real-time
with echo images and data. VisualSonics platforms combine high-resolution, real-time, in
vivo imaging at reasonable cost with ease-of-use and quantifiable results.
234
Immuno-Biological Laboratories Co.,
Ltd. (IBL)
1091-1 Naka Aza-Higashida,
Fujioka-Shi, Gunma
375-0005
Japan
Booth #: 07
http://www.ibl-japan.co.jp/en/
“LipoSEARCH” is a sophisticated comprehensive lipoprotein profiling service (using HPLCbased system) that can deliver a reliable and promising complete set of data on Cholesterol
and Triglyceride profiled in 4 major classes (CM, VLDL, LDL and HDL) and 20 subclasses
classified by particle size. In addition, it also can deliver number of the particles that is
recognized as an important factor in recent international research of atherosclerosis and
dyslipidemia. The proprietary system and service ”LipoSEARCH” is operated and provided by
Skylight Biotech Inc. who is owned by Immuno-Biological Laboratories Co., Ltd. located in
Japan.
Kaneka Pharma Europe N.V.
Frankfurter Straße 80-82
Eschborn
65760
Germany
Booth #: 06
http://www.kanekapharma.com
Kaneka Corporation is touching the lives of people all over the world with infinite
possibilities of chemistry. By further enhancing our key of highly innovative technology
in producing medical devices and building blocks for active pharmaceutical ingredients
(API), macromolecules, fermentation and bioscience, Kaneka is exploring new possibilities
beyond the traditional boundaries of chemistry. Kaneka Pharma Europe N.V. (KPE) is the
independent subsidiary responsible for the European market. Lipoproteinapheresis (Lp(a),
LDL), in which Kaneka is one of the pioneers since 1989, is beside the interventional
products one of KPE’s main business.
235
84 EAS CONGRESS
th
KOWA
6-29, Nishiki 3-chome, Naka-ku, Nagoya, Aichi 460-8625
Nagoya
460-8625
Japan
http://www.kowa.co.jp/eng/
Kowa Company, Ltd. (Kowa) is a privately held multinational company headquartered in
Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing
and trading activities in the fields of pharmaceuticals, life science, information technology,
textiles, machinery and various consumer products. Especially, the pharmaceutical field
is positioned as the key business segment; prescription (ethical drug), Over-the-Counter
(OTC) / Consumer Healthcare / Dietary supplement and Medical equipment. Moreover, the
pharmaceutical R&D division is focused on research and development for cardiovascular
therapeutics (dyslipidemia, type 2 diabetes and atherosclerosis), ophthalmology and antiinflammatory agents. To visit Kowa Company, Ltd.’s website, please visit www.kowa.co.jp/
eng
Mercodia AB
Sylveniusgatan 8A
Uppsala
75450
Sweden
Booth #: 24
http://www.mercodia.com
Mercodia AB is a Swedish biotech company focusing on the development of immunoassays
for research within the field of metabolic disorders. Our assays are applicable to both
animal and human models and are used for research ranging from basic scientific studies to
large pre-clinical and clinical phase trials. The company was founded in 1991 and is today
a world-leading supplier of products to all major international markets. More than ninety
percent of our production is exported from our facilities in Uppsala to approximately 100
different countries around the world.
MSD
MEDA PHARMA S.P.A.
Via Valosa di Sopra, 9
Monza
20900
Italy
Booth #: 17
http://www.meda.se
Meda is a leading international pharma company with a broad product portfolio. The
nutraceuticals developed fall into the same therapeutic categories in which Meda has a
wealth of experience. The cardiovascular area of nutraceuticals is represented by Armolipid
product line (patented), dietary supplements with natural substances for the control of
lipids when integrated in an adequate diet for such purposes. The ingredients of Armolipid
line derive from high quality natural extracts with very well documented activity. The
production process follows pharmaceutical quality standards, every product is clinically
tested and the results of clinical trials published in peer-reviewed international medical
journals.
236
2000 Galloping Hill Road
Kenilworth
07033
USA
Booth #: 01
http://www.msd.com
Today’s MSD is a global healthcare leader working to help the world be well. MSD is known
as Merck in the United States and Canada. Through our prescription medicines, vaccines,
biologic therapies, and consumer care and animal health products, we work with customers
and operate in more than 140 countries to deliver innovative health solutions. We also
demonstrate our commitment to increasing access to healthcare through far-reaching
policies, programs and partnerships. MSD. Be well. For more information, visit www.msd.com
Mylan
Building 4 Trident Place Mosquito Way
Hatfield
AL10 9UL
UK
http://www.mylan.com/
Mylan is one of the world’s leading global pharmaceutical companies. Our medicines include
generic and brand name products in a variety of dosage forms and therapeutic categories,
such as difficult-to-manufacture injectables, transdermal patches and HIV/AIDS antiretroviral
therapies. The company has innovative research and development capabilities and is one of
the world’s largest active pharmaceutical ingredient manufacturers. Mylan applies one global
quality standard to all of our medications regardless of where they are produced.
Creating better health for a better world. That’s what inspires Mylan in our mission to
provide quality healthcare to the world’s 7 billion people, one person at a time.
237
84 EAS CONGRESS
th
numares AG
Randox Biosciences
Am BioPark 9
Regensburg
93053
Germany
Booth #: 09
http://www.numares.com
numares HEALTH develops innovative, in vitro diagnostic (IVD) tests running exclusively
on the AXINON® System. AXINON® relies on numares’ proprietary MGS® technology for
generating reproducible, quality controlled metabolic information using nuclear magnetic
resonance (NMR) spectroscopy. The AXINON® software makes this information based on
disease-specific metabolic profiles easily accessible for in vitro diagnostics. The integration
of different tests into one system makes AXINON® a highly flexible tool for various
diagnostic questions. The new IVD test lipoFIT-S100 (CE) determines clinically proven
lipoprotein parameters such as LDL-P and sdLDL in high throughput. Further tests for
various indications (e.g. nephrology, oncology) are in development.
55 Diamond Road
Crumlin
BT29 4QY
UK
Booth #: 21
http://www.randoxbiosciences.com/
Randox Biosciences is dedicated to improving health worldwide through scientific
discovery, drug development and diagnostics. We offer a range of molecular products
that provide diagnostic, prognostic and predictive solutions across a variety of disease
areas including cardiology (cardiac risk prediction) and inherited disease. Our Familial
Hypercholesterolemia Arrays l & ll enable the simultaneous detection of 40 FH-causing
mutations within the LDLR, ApoB and PCSK9 genes. Utilising our award winning Biochip
Array Technology for multi-analyte screening of biological samples, our assays provide a
complete patient profile from a single sample for rapid, accurate diagnosis.
Raisio
REGENERON
P.O. Box 101,
FI-21201 Raisio,
Finland
Website: www.raisio.com
Benecol® - proven to reduce cholesterol
Raisio Group is an expert in plant-based nutrition with strong international and local
food brands. Benecol® is the expert brand in cholesterol reduction and a pioneer in the
cholesterol lowering functional food category.
Raisio Group produces the unique cholesterol-lowering ingredient, Plant stanol ester, and
licenses the Benecol brand worldwide. Benecol products are manufactured and sold by
local food companies in 30 countries on five continents.
Over 70 clinical studies support the use of Benecol as an effective, easy and safe dietary
tool to lower LDL-cholesterol. The cholesterol-lowering effect of Benecol is additive to
those of a healthy diet and statin medication.
777 Old Saw Mill River Road
Tarrytown, NY
10591
USA
Booth #: 20
http://www.regeneron.com
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company
based in Tarrytown, New York that discovers, invents, develops, manufactures, and
commercializes medicines for the treatment of serious medical conditions. Regeneron
commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory
condition and has product candidates in development in other areas of high unmet
medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain and
infectious diseases.
SANOFI
54, av. La Boétie
Paris
75008
France
Booth #: 20
http://en.sanofi.com/
Sanofi, an integrated global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of
healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative
drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY)
238
239
84 EAS CONGRESS
th
84th European Atherosclerosis Society Congress
Wisepress Medical Bookshop
25 High Path
London
SW19 2JL
UK
Booth #: 26
http://www.wisepress.com
Wisepress.com, Europe’s leading conference bookseller, has a range of books and journals
relevant to the themes of the meeting. In addition to attending 200 conferences per year,
Wisepress has a comprehensive medical and scientific bookshop online with great offers.
Follow us on Twitter for the latest news @WisepressBooks.
MEET-THE-EXPERT SESSION
Introducing Sebelipase alfa,
a novel treatment for LAL-D
Placing the spotlight on Lysosomal Acid Lipase Deficiency
A case-based Meet-the-Expert session chaired by
Professor Thomas Stulnig (Vienna, Austria)
Experts will present cases on Lysosomal Acid Lipase Deficiency
including early treatment results
31 May 2016; 14:05–14:50
Wilhelm Auerswald (Strassburg) Hall,
Congress und Messe Innsbruck, Innsbruck, Austria
240
EMEA/UNB-LAL/16/0054
241
84 EAS CONGRESS
th
notes
242
243
84 EAS CONGRESS
th
notes
244
245
84 EAS CONGRESS
th
notes
246
247
notes
EAS INTERNATIONAL EVENING
The EAS International Evening Networking event in Innsbruck will take place at
Congress Park Igls
Tuesday, May 31, 2016 at 19:30
Tickets are subject to availability and can be purchased at the registration desk.
Transportation
Buses will leave from the front of the Congress Centre at 18:45
We look forward to welcoming you
248

84th EAS CONGRESS

Transcription

Similar documents

Le nuove Linee guida neLLa prevenzione cardiovascoLare: aLLa

PHYTOBALNEOTHERAPY (“HAY BATHS”) : BETWEEN TRADITION

Il cardiologo clinico

Presentazione standard di PowerPoint

Presentazione di PowerPoint

Di Minno: Panoramica delle malattie

Adolescenti e chirurgia estetica: considerazioni etiche e

La cura del Diabete in Ospedale: il paziente con insufficienza renale

Diapositiva 1 - Terapia Intensiva dell`età Pediatrica (0

I Nuovi Anticoagulanti orali (NAO) nel trombo

Holoprosencephaly